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Fatty	   acid-­‐2	   hydroxylase	   (FA2H)	   is	   a	   43	   kDa	   transmembrane	   protein	   residing	   in	   the	   endoplasmic	  
reticulum.	  As	  a	  monooxygenase	  it	  is	  responsible	  for	  the	  alpha–hydroxylation	  of	  fatty	  acids,	  which	  are	  
later	   incorporated	   into	   sphingolipids,	   thereby	   generating	   2-­‐OH	   sphingolipids.	   FA2H	   and	   2-­‐OH	  
sphingolipids	   show	   a	   quite	   ubiquitous	   tissue	   distribution,	   with	   high	   amounts	   detectable	   in	   brain,	  
spinal	   cord,	   skin,	   testis,	   ovary,	   kidney,	   stomach	   and	   intestine.	   Especially	   important	   is	   their	   role	   in	  
myelin,	   where	   up	   to	   60%	   of	   the	   total	   amount	   of	   galactoylceramide	   and	   sulfatide	   are	   alpha-­‐
hydroxylated.	   The	   importance	   of	   this	  modification	   is	   emphasized	   by	   the	   observation	   that	   humans	  
with	   a	   FA2H	   deficiency	   develop	   a	   spastic	   paraplegia	   (autosomal	   recessive	   spastic	   paraplegia	   35	  
(SPG35)).	  Moreover,	  aged	  FA2H-­‐KO	  mice	  present	  with	  a	  similar	  phenotype,	   showing	  an	  axonal	  and	  
myelin	   sheath	   degeneration	   in	   spinal	   cord	   and	   later	   also	   in	   sciatic	   nerves.	  While	   the	   symptoms	  of	  
FA2H	  deficiency	  have	  been	  well	  described,	  so	   far	  almost	  nothing	   is	  known	  about	  the	  exact	  disease	  
mechanisms.	   Furthermore,	   there	   is	   no	   knowledge	   about	   the	   proteins	   biological	   regulation	   and	   its	  
protein	  microenvironment.	  	  
Thus,	   in	   the	   first	   part	   of	   the	   thesis	   FA2H-­‐KO	   mice	   of	   different	   ages	   (6,	   13	   &	   17	   months)	   were	  
examined	  for	  changes	  in	  their	  CNS-­‐	  and	  PNS-­‐myelin	  protein	  composition,	  which	  might	  help	  to	  better	  
understand	  the	  observed	  pathology.	  This	  was	  achieved	  using	  a	  TMT	  6-­‐plex	  gel-­‐free	  quantitative	  mass	  
spectrometry	   approach.	   In	   the	   CNS	   this	   led	   to	   the	   identification	   of	   various	   protein	   alterations,	   of	  
which	  some	  were	  already	  present	  in	  6-­‐month-­‐old	  mice.	  The	  most	  prominent	  ones,	  which	  were	  also	  
verified	   by	   Western	   blot,	   were	   upregulations	   of	   C1qb,	   C4b,	   ApoE,	   GFAP,	   tau	   protein,	   hinting	   at	  
previously	  unknown	  roles	  of	  inflammation,	  astrogliosis	  and	  tau	  aggregation	  in	  the	  pathology	  of	  FA2H	  
deficiency.	   In	   addition,	   a	   strong	   upregulation	   of	   one	   structural	   myelin	   membrane	   protein,	  
Opalin/TMEM10,	  was	  observed	  as	  well.	  Because	  not	  much	  is	  known	  about	  this	  protein’s	  function	  so	  
far,	  its	  possible	  role	  in	  the	  pathology	  of	  FA2H	  deficiency	  should	  be	  elucidated	  by	  further	  experiments.	  
The	  PNS-­‐myelin	  analysis	  also	  allowed	   for	   the	   identification	  of	  various	  protein	  changes.	  Those	  were	  
mainly	   restricted	   to	   13-­‐	   and	   17-­‐month-­‐old	   animals,	   which	   is	   in	   line	   with	   the	   late	   onset	   of	   PNS-­‐
demyelination.	  Unfortunately,	  because	  many	  of	  the	  measured	  changes	  were	  not	  consistent	  and	  thus	  
less	  confident,	  further	  experiments	  are	  still	  needed	  for	  verification.	  	  
The	  second	  part	  of	  this	  thesis	  concentrated	  on	  the	  discovery	  of	  protein	  interaction	  partners	  of	  FA2H.	  
This	  was	  done,	  because	  the	  pathology	  may	  not	  be	  caused	  by	  the	  absence	  of	  2-­‐OH	  sphingolipids,	  but	  
rather	   the	   loss	   of	   certain	   protein	   interactions	   of	   FA2H.	   For	   the	   identification,	   two	   complementary	  
affinity	  purification-­‐based	  screening	   strategies	  were	  applied	   in	   combination	  with	  quantitative	  mass	  




successfully	   verified	   by	   Western	   blotting	   and	   bimolecular	   fluorescence	   complementation	   (BiFC).	  
Finally,	   this	   for	   the	   first	   time	   allowed	   a	   description	   of	   FA2H	   interaction	   partners	   in	   mammals.	  
Interestingly,	   many	   are	   involved	   in	   metabolism,	   transport	   and	   regulation	   of	   synthesis	   of	  
sphingolipids,	   indicating	  a	   tight	   coupling	  of	  enzymes	  participating	   in	   these	  processes.	  Furthermore,	  







Sphingolipids	  are	  one	  of	  the	  major	  lipid	  constituents	  of	  cellular	  membranes	  besides	  glycerolipids	  and	  
sterols	  with	  an	  exceptional	  high	  abundance	  in	  myelin.	  Sphingolipids	  are	  characterized	  by	  containing	  a	  
sphingoid	  base	  backbone,	  which	  in	  mammals	  usually	  is	  sphingosine	  (2-­‐amino-­‐4-­‐octadecene-­‐1,3-­‐diol)	  
(Figure	  2-­‐1B).	  Based	  on	  sphingosine,	  other	  sphingolipids	  are	  derived	  by	  adding	  a	  fatty	  acid	  chain	  via	  
an	  N-­‐amide	   linkage	   at	   the	   C2-­‐position	   and/or	   other	  molecules	   via	   the	  OH-­‐group	   at	   the	   C1-­‐position	  
(Figure	  2-­‐1A).	  
One	  of	  the	  simplest	  sphingolipids	  is	  ceramide,	  consisting	  only	  of	  sphingosine	  and	  a	  N-­‐linked	  fatty	  acid	  
chain.	   Ceramide	   itself	   is	   the	   basis	   for	   the	   generation	   of	   more	   complex	   sphingolipid	   classes,	   like	  
sphingomyelins	   (SM)	   and	   glycosphingolipids	   (GSL).	   This	   is	   achieved	   by	   the	   addition	   of	   various	   O-­‐
linked	   headgroups	   by	   specific	   enzymes	   (see	   below).	   For	   sphingomyelins	   this	   headgroup	   is	   a	  
phosphocholine	   or	   phosphoethanolamine,	   while	   for	   GSLs	   it	   is	   one	   or	   more	   sugar	   molecules.	   The	  
simplest	   GSLs	  with	   only	   one	   sugar	   are	   glucosylceramide	   (GlcCer)	   and	   galactosylceramide	   (GalCer).	  
Both	   can	   be	   further	   modified	   to	   generate	   other	   sphingolipids.	   From	   GalCer,	   two	   derivatives	   are	  
derived,	   sulfatide	   (3-­‐Sulfo-­‐GalCer)	   and	   the	   ganglioside	   GM4.	   In	   contrast,	   many	   more	   different	  
gangliosides	   and	   other	   complex	   GSLs	   can	   be	   produced	   from	   GlcCer.	   These	   gangliosides	   have	  
headgroups	   consisting	  of	   larger	   sugar	   chains	   (≥2)	   and	   include	  at	   least	  one	  N-­‐acetylneuraminic	   acid	  
molecule	  (Figure	  2-­‐1C).	  
Another	   layer	  of	   complexity	   is	   given	  by	   the	   length,	  desaturation	  and	  hydroxylation	  of	   the	  N-­‐linked	  
fatty	   acid	   chain.	   In	  mammals	   the	   acid	   chain	   lengths	   usually	   vary	   from	  C16	  to	   C36.	   Desaturation	   can	  
occur	   at	   various	   positions,	   while	   hydroxylation	   is	   mainly	   found	   at	   the	   C2-­‐position	   (alpha-­‐
hydroxylation)	  or	  the	  last	  C-­‐atom	  (omega-­‐hydroxylation).	  The	  one	  enzyme	  identified	  so	  far,	  which	  is	  
responsible	   for	   the	   alpha-­‐hydroxylation,	   is	   fatty	   acid	   2-­‐hydroxylase	   (FA2H)	   (see:	   2.3	   Fatty	   acid	   2-­‐
hydroxylase).	   The	   additional	   hydroxyl	   group	   is	   thought	   to	   allow	   sphingolipids	   to	   build	   up	   more	  
hydrogen	   bonds	  with	   other	   lipids,	   thus	   increasing	  membrane	   stability	   (Pascher	   1976;	   Boggs	   et	   al.	  
1988).	   The	   corresponding	   2-­‐OH	   sphingolipids	   are	   especially	   abundant	   in	   epidermal	   and	   nervous	  














Figure	  2-­‐1:	   Structures	  of	   sphingosine	  and	   some	   sphingolipids.	   	   (A)	  General	  structure	  of	  various	  sphingolipid	  
classes	   (Picture	   based	   on:	   http://commons.wikimedia.org/wiki/File%3ASphingolipid.png).	   (B)	   Molecular	  
structure	  of	  sphingosine	  the	  most	  common	  sphingoid	  base	  in	  mammals.	  (C)	  Some	  common	  sphingolipids	  found	  
in	  mammals.	  Shown	  are	  always	  the	  d18:1/d12:0-­‐isoforms	  of	  each	  lipid.	  SM	  =	  sphingomyelin,	  GM3	  =	  ganglioside	  
GM3.	  
2.1.2 Sphingolipid	  metabolism	  
2.1.2.1 Synthesis	  
The	   synthesis	   of	   sphingolipids	   (Figure	   2-­‐2A)	   begins	  with	   the	   four-­‐stage	   generation	   of	   ceramide	   by	  
specific	  enzyme	  complexes	  at	  the	  outer	  leaflet	  of	  the	  endoplasmic	  reticulum	  (ER).	  First,	  one	  molecule	  
of	   serine	   and	   palmitoyl-­‐CoA	   are	   condensated	   by	   the	   serine	   palmitoyltransferase	   complex	   (SPT-­‐
complex)	  forming	  the	  sphingoid	  base	  3-­‐keto-­‐dihydrosphingosine.	  The	  complex	  was	  initially	  described	  
as	   a	   heterodimer	   composed	   of	   SPTLC1	   together	  with	   SPTLC2	   or	   SPTLC3,	   but	  more	   recent	   findings	  
point	  at	  a	  high	  molecular	  weight	  complex	  containing	  also	  other	  proteins	  (Hanada	  2003;	  Hornemann	  
et	   al.	   2007).	   This	   product	   is	   then	   reduced	   by	   3-­‐ketodihydrosphingosine	   reductase	   to	  
dihydrosphingosine	  (Kihara	  &	  Igarashi	  2004).	  Subsequently,	  dihydrosphingosine	  is	  acylated	  by	  one	  of	  
six	   mammalian	   ceramide	   synthases	   (CerS1-­‐6),	   giving	   rise	   to	   dihydroceramide.	   These	   six	   synthases	  
mostly	  differ	  in	  tissue	  expression	  and	  the	  chain	  length	  of	  the	  preferred	  acyl-­‐CoA	  substrates	  (Mullen	  









et	  al.	  2012).	  Moreover,	  recent	  findings	  have	  shown	  that	  active	  CerS	  function	  as	  dimers	  composed	  of	  
either	   identical	   or	   different	   CerS-­‐proteins	   (Laviad	   et	   al.	   2012).	   To	   finally	   obtain	   ceramide,	  
dihydroceramide	   is	   subsequently	   reduced	   by	   a	   desaturase,	   inserting	   a	   4,5-­‐double	   bound	   into	   the	  
sphingolipid	   backbone	   (Michel	   et	   al.	   1997).	   As	   mentioned	   above,	   ceramide	   can	   then	   be	   further	  
modified	  by	  the	  addition	  of	  various	  headgroups,	  giving	  rise	  to	  all	  other	  major	  sphingolipid	  classes.	  	  
Since	  most	  ceramide	  modifications	  are	  achieved	  by	  Golgi	  apparatus-­‐localized	  enzymes,	  ceramide	  has	  
to	  be	  transported	  to	  this	  compartment.	  This	  happens	  either	  by	  anterograde	  vesicular	  transport	  or	  by	  
a	   specific	   cytosolic	   ceramide-­‐transfer	   protein	   (CERT).	   Experiments	   indicate	   that	   both	   ways	   of	  
transport	   preferentially	   lead	   to	   the	   synthesis	   of	   different	   ceramide	   derivatives.	   While	   ceramide	  
delivered	   by	   vesicular	   transport	   is	   mainly	   used	   for	   glycosphingolipid	   synthesis,	   CERT-­‐transported	  
ceramide	  seems	  to	  be	  largely	  destined	  for	  sphingomyelin	  synthesis	  (Hanada	  et	  al.	  2003).	  
Sphingomyelins	  are	  produced	  by	  sphingomyelin	  synthases	  of	  which	  two	  isoforms	  (SMS1	  and	  SMS2)	  
are	  so	  far	  known	  in	  mammals	  sphingomyelin	  (Huitema	  et	  al.	  2004;	  Tafesse	  et	  al.	  2006).	  While	  SMS1	  
seems	  to	  be	  restricted	  to	  the	  trans-­‐Golgi	  compartment,	  SMS2	  is	  also	  found	  at	  the	  plasma	  membrane	  
(PM),	  with	  the	  enzymes’	  active	  sites	  facing	  the	  Golgi-­‐lumen	  or	  the	  extracellular	  space,	  respectively.	  
The	   enzymes	   transfer	   the	   phosphocholine	   or	   phosphoethanolamine	   headgroup	   from	   the	  
corresponding	  glycerolipid	   to	  ceramide.	  Thus,	  one	  molecule	  of	  diacylglycerol	   is	  generated	   together	  
with	  each	  molecule	  of	  sphingomyelin.	  	  
The	  Golgi-­‐located	  enzyme	   responsible	   for	  GlcCer-­‐synthesis,	   ceramide	  glucosyltransferase,	  has	  been	  
known	   for	   years,	   but	   the	   exact	   mechanisms	   of	   synthesis	   are	   still	   under	   discussion.	   It	   is	   generally	  
accepted	  that	  the	  enzymes’	  active	  site	  is	  facing	  the	  cytosol,	  therefore	  restricting	  GlcCer-­‐synthesis	  to	  
the	   outer	   leaflet	   of	   the	   Golgi	   apparatus	   (Jeckel	   et	   al.	   1992).	   Furthermore,	   the	   various	  
glycosyltransferases,	  responsible	  for	  complex	  GSL-­‐synthesis,	  are	  also	   located	  to	  the	  Golgi	  apparatus	  
with	   their	   catalytic	   sites	   directed	   to	   the	   organelles’	   lumen.	   But	   there	   are	   conflicting	   experimental	  
results	   regarding	   the	   enzyme’s	   exact	   location	   within	   the	   Golgi	   system	   and	   the	   mode	   of	   GlcCer-­‐
delivery	   to	   the	   Golgi	   lumen	   for	   complex	   GSL-­‐synthesis.	   While	   one	   group	   showed	   that	   GlcCer	   is	  
produced	  at	  the	  cis-­‐Golgi,	  transported	  to	  the	  trans-­‐Golgi	  via	  the	  lipid-­‐binding	  protein	  FAPP2	  and	  then	  
flipped	  to	  the	  Golgi	   lumen	  (D’Angelo	  et	  al.	  2007),	  another	  group	  postulated	  a	  trans-­‐Golgi	  synthesis	  
followed	   by	   GlcCer-­‐redelivery	   to	   the	   ER,	   flipping	   into	   the	   ER	   and	   finally	   vesicular	   transport	   to	   the	  








Figure	   2-­‐2:	   Mammalian	   sphingolipid	   metabolism.	   (A)	   Scheme	   of	   the	   sphingolipid	   metabolism	   within	   a	  
mammalian	  cell.	  Sphingolipid	  synthesis	  starts	  in	  the	  ER	  with	  the	  condensation	  of	  serine	  and	  palmitoyl-­‐CoA	  by	  
the	   serine	   palmitoyl	   transferase	   complex	   (SPT).	   The	   product	   3-­‐keto-­‐dihydrosphingosine	   (3-­‐KdHSph)	   is	   then	  
reduced	   by	   3-­‐keto-­‐dihydrosphingosine	   reductase	   (3-­‐KR)	   to	   dihydrosphingosine	   (dHSph),	   which	   is	   rapidly	  
acylated	   to	   dihydroceramide	   (dHCer)	   by	   one	   of	   six	   ceramide	   synthases	   (CerS).	   Finally,	   dHCer	   is	   reduced	   by	  
dihydroceramide	  desaturase	  (DES)	  to	  ceramide	  (Cer).	  Ceramide	  can	  afterwards	  be	  modified	  by	  the	  addition	  of	  
various	  headgroups.	  In	  the	  ER,	  galactosylceramide	  (GalCer)	  can	  be	  produced	  by	  ceramide	  galactosyltransferase	  
(CGT).	   After	   vesicular	   transport	   to	   the	   Golgi	   apparatus,	   GalCer	   can	   then	   be	   sulfated	   by	   cerebroside	  
sulfotransferase	   (CST),	   thereby	   producing	   sulfatide	   (Sulf).	   Alternatively,	   ceramide	   is	   transported	   to	   the	  Golgi	  
apparatus	   by	   ceramide	   transfer	   protein	   (CERT),	   where	   it	   is	   converted	   either	   to	   sphingomyelin	   (SM)	   by	  
sphingomyelin	  synthases	  (SMS)	  or	  to	  glycosphingolipids	  (GSL)	  by	  a	  variety	  of	  glycosphingolipid	  synthase	  (GCS).	  
In	  addition,	   ceramide	  kinase	   (CERK)	   in	   the	  Golgi	  or	  at	   the	  plasma	  membrane	  can	  phosphorylate	  ceramide	   to	  
ceramide1-­‐phosphate	  (C1P),	  an	  important	  signaling	  molecule.	  The	  degradation	  of	  sphingolipids	  mostly	  ensues	  
at	  the	  Golgi,	  PM	  or	  within	  the	  endolysosome.	  At	  the	  plasma	  membrane,	  SM	  is	  converted	  back	  to	  ceramide	  by	  
secretory	   (sSMase)	   or	   neutral	   sphingomyelinase	   (nSMase),	   while	   in	   the	   lysosome	   this	   is	   achieved	   by	   acidic	  
SNmase	  (aSMase).	  Sulf	  and	  GalCer	  are	  degraded	  in	  the	  endolysosome.	  First	  Sulf	  is	  desulfated	  by	  arylsulfatase	  A	  
(ASA),	  followed	  by	  GalCer’s	  breakdown	  by	  galactosyl	  ceramidase	  (GALC).	  Furthermore,	  GSLs	  are	  broken	  down	  
by	   different	   endolysosomal	   glycosidases	   (GCase).	   The	   produced	   ceramide	   can	   subsequently	   be	   further	  
degraded	   to	   sphingosine	   (Sph)	   by	   ceramidases	   (CDase),	   neutral	   CDase	   at	   the	   PM	   and	   acidic	   CDase	   in	   the	  
endolysosome.	   Thereafter,	   sphingosine	   can	   be	   either	   reused	   by	   ceramide	   synthases	   or	   phosphorylated	   by	  
sphingosine	   kinases	   (SK1	   &2).	   The	   resulting	   sphingosine	   1-­‐phosphate	   (S1P),	   also	   an	   important	   signaling	  
molecule,	   can	   be	   dephosphorylated	   by	   S1P-­‐phosphatases	   (SPP)	   or	   cleaved	   into	   ethanolamine	   1-­‐phosphate	  
(EA1P)	  and	  hexadecanal	  by	  S1P	  lyase	  (SPL).	  Hexadecanal	  can	  then	  be	  recycled	  to	  palmitoyl-­‐CoA	  in	  a	  multistep	  
enzymatic	  process.	  (Picture	  modified	  from:	  (Mullen	  et	  al.	  2012)).	  (B)	  Structures	  of	  phosphorylated	  sphingolipid	  
derivatives	  ceramide	  1-­‐phosphate	  (C1P)	  and	  sphingosine	  1-­‐phosphate	  (S1P).	  	  
In	  contrast	  to	  SM,	  GlcCer	  and	  complex	  GSLs,	  GalCer	  is	  synthesized	  by	  ceramide	  galactosyltransferase	  
(CGalT)	   in	   the	   lumen	   of	   the	   ER.	   The	   enzyme	   is	   abundantly	   expressed	   in	   oligodendrocytes	   of	   the	  
central	  and	  peripheral	  nervous	  system,	  but	  can	  also	  be	  found	  in	  some	  other	  tissues.	  Correspondingly	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(Coetzee	   et	   al.	   1996).	   The	   sulfation	   of	   GalCer	   is	   achieved	   in	   the	   Golgi	   by	   the	   enzyme	   cerebroside	  
sulfotransferase	  (CST).	  	  
Besides	   being	   a	   substrate	   for	   SM-­‐	   and	   GSL-­‐synthesis,	   ceramide	   can	   also	   be	   phosphorylated	   to	  
ceramide	  1-­‐phosphate	  (C1P)	  (Figure	  2-­‐2B)	  by	  ceramide	  kinase	  (CERK)	  at	  the	  trans-­‐Golgi	  or	  the	  plasma	  
membrane.	   C1P	   is	   a	   signaling	   molecule	   which	   numerous	   functions	   e.g.	   inhibiting	   apoptosis,	  
promoting	  cell	  survival	  and	  inducing	  inflammatory	  responses.	  Its	  cellular	  levels	  are	  regulated	  trough	  
its	  synthesis	  by	  CERK	  and	  breakdown	  by	  C1P-­‐phosphatases	  and	  lipid	  phosphate	  phosphatases	  (Arana	  
et	  al.	  2010).	  
2.1.2.2 Degradation	  
The	   degradation	   of	   sphingolipids	   (Figure	   2-­‐2A)	   is	   also	   conducted	   by	   a	   variety	   of	   enzymes.	  
Sphingomyelins	   are	   degraded	   by	   sphingomyelinases	   (SMase),	   also	   called	   sphingomyelin	  
phosphodiesterases	   (SMPD),	   to	   phosphocholin	   and	   ceramide.	   Three	   major	   subgroups	   of	   these	  
enzymes	   exist:	   the	   alkaline,	   acidic	   and	   neutral	   SMases.	  While	   alkaline	   SMase	   is	   only	   expressed	   in	  
intestine	  and	  liver,	  where	  it	  mainly	  degrades	  extracellular	  SM,	  both	  ubiquitously	  expressed	  acidic	  and	  
neutral	  SMases	  target	  endogenous	  SM.	  	  Acidic	  SMase	  (SMPD1)	  is	  either	  located	  in	  the	  endolysosome	  
(aSMase)	  or	  secreted	  into	  the	  extracellular	  space	  (sSMase).	  Neutral	  SMases	  (nSMase),	  of	  which	  three	  
enzymes	  (SMPD2,	  SMPD3	  and	  SMPD4)	  are	  known,	  can	  be	  found	  at	  the	  ER,	  Golgi	  and/or	  PM.	  Defects	  
in	   SMase	   enzymes	   can	   lead	   to	   severe	   diseases.	   For	   example,	   defects	   in	   SMPD1	   lead	   to	   the	  
accumulation	  of	  SM	  in	  the	  lysosome,	  thereby	  causing	  the	  lysosomal	  storage	  disorders	  Niemann-­‐Pick	  
type	  A	  and	  B	  (National	  Library	  of	  Medicine	  2014).	  
The	  complex	  sugar-­‐structures	  of	  GSLs	  are	  usually	  degraded	  in	  a	  sequential	  manner	  by	  different	  acidic	  
glycosidases	  within	   the	  endolysosome.	   	   The	   failure	  of	  one	  of	   these	  enzymes	  normally	   leads	   to	   the	  
accumulation	   of	   the	   respective	   substrate	   within	   the	   cell,	   giving	   rise	   to	   a	   so-­‐called	   lipid	   storage	  
disease.	  An	  overview	  of	  the	  numerous	  lysosomal	  lipid	  storage	  diseases	  can	  be	  found	  in	  the	  following	  
two	  review	  articles	  by	  Ballabio	  &	  Gieselmann	  and	  Schulze	  &	  Sandhoff	  (Ballabio	  &	  Gieselmann	  2009;	  
Schulze	  &	  Sandhoff	  2011).	  	  	  
Sulfatide	  and	  GalCer	  are	  also	  degraded	  to	  ceramide	  in	  the	  lysosome.	  First,	  sulfatide	  is	  desulfated	  to	  
GalCer	  by	  arylsulfatase	  A	  (ASA),	  followed	  by	  the	  degalactosylation	  of	  GalCer	  by	  galactosylceramidase	  
(GALC).	  The	  importance	  of	  these	  enzymes	  for	  normal	  cellular	  function	  is	  emphasized	  by	  lipid	  storage	  
diseases	   caused	   by	   defective	   ASA	   or	   GALC,	   metachromatic	   leukodystrophy	   (see	   Gieselmann	   &	  
Krägeloh-­‐Mann	  2010	  and	  the	  references	  therein)	  or	  Krabbe	  disease	  (Sakai	  2009).	  	  
All	  of	  the	  sphingolipid	  degradation	  pathways	  mentioned	  above	  produce	  ceramide.	  Ceramide	  itself	  is	  




the	  outer	  leaflet	  of	  the	  PM,	  acidic	  CDase	  in	  the	  lysosome	  or	  one	  of	  three	  alkaline	  CDases	  located	  in	  
ER	   and/or	   Golgi	   (Mao	   &	   Obeid	   2008).	   Sphingosine	   is	   subsequently	   either	   reused	   for	   ceramide	  
production	  in	  the	  so-­‐called	  salvage	  pathway	  or	  phosphorylated	  by	  one	  of	  two	  ubiquitous	  sphingosine	  
kinases	   (SK1&2)	   in	  cytosol	  and	  ER.	  Afterwards,	   sphingosine	  1-­‐phosphate	   (S1P)	   (Figure	  2-­‐2B),	  a	  very	  
important	   lipid	   signaling	  molecule	   (Pyne	  &	  Pyne	  2000;	  Maceyka	  et	   al.	   2012),	   is	   irreversibly	  broken	  
down	  by	  S1P-­‐lyase	   (SPL)	  at	   the	  cytosolic	   face	  of	   the	  ER,	  yielding	  ethanolamine	  1-­‐phosphate	   (EA1P)	  
and	   hexadecenal.	   Hexadecenal	   can	   then	   be	   converted	   back	   to	   palmitoyl-­‐CoA	   by	   in	   a	   series	   of	  
enzymatic	   reactions	   and	   subsequently	   used	   again	   for	   lipid	   synthesis	   (Nakahara	   et	   al.	   2012).	  
Alternatively	   S1P	   can	   be	   reverted	   back	   to	   sphingosine	   by	   certain	   phosphatases,	   which	   are	   lipid	  
phosphate	  phosphatases	  (LPP1-­‐3)	  at	  the	  cell	  surface	  or	  S1P-­‐phosphatases	  (SSP1&2)	  at	  the	  cytosolic	  
side	  of	  the	  ER.	  
2-­‐OH	   sphingolipids	   are	   degraded	   by	   the	   same	   processes	   described	   above,	   finally	   leading	   to	   the	  
release	   of	   sphingosine	   and	   2-­‐OH	   fatty	   acids	   by	   CDases.	   Afterwards,	   the	   2-­‐OH	   fatty	   acids	   may	  
potentially	  be	  reused	  for	  sphingolipid	  synthesis	  by	  an	  unknown	  salvage	  pathway.	  Alternatively,	  they	  
are	  activated	  to	  acyl-­‐CoAs	  and	  subsequently	  transported	  to	  the	  peroxisome	  by	  an	  unknown	  process.	  
In	   the	  peroxisome	  they	  are	  cleaved	   to	   formyl-­‐CoA	  and	  n-­‐1	  aldehyde	  by	   the	  enzyme	  2-­‐hydroxyacyl-­‐
CoA	   lyase,	   in	   a	   process	   called	   peroxisomal	   α-­‐oxidation	   (Foulon	   et	   al.	   2005).	   Ultimately,	   the	   n-­‐1	  
aldehyde	  is	  further	  degraded	  via	  peroxisomal	  β-­‐oxidation	  to	  acetyl-­‐CoA,	  NADH	  and	  FADH.	  
	  
2.2 Myelin	  and	  demyelinating	  diseases	  
2.2.1 Overview	  
Myelin	  is	  the	  insulating	  material	  surrounding	  an	  axon,	  thus	  allowing	  fast	  saltatory	  signal	  transduction.	  
It	  consists	  of	  multiple	  layers	  of	  plasma	  membrane	  of	  specialized	  glial	  cells,	  which	  are	  tightly	  wrapped	  
around	   the	   axons	   in	   an	   interspaced	   fashion.	   This	   leads	   to	   the	   segmentation	   of	   axons	   in	   isolated	  
(=internodal)	   and	   non-­‐isolated	   (=nodal)	   regions.	   The	   glial	   cells	   responsible	   are	   oligodendrocytes	   in	  
the	   central	   (CNS)	   and	   Schwann	   cells	   in	   the	   peripheral	   nervous	   system	   (PNS)	   (Figure	   2-­‐3A).	   While	  
oligodendrocytes	  are	  capable	  of	  enwrapping	  multiple	  axons	  at	  a	  time,	  Schwann	  cells	  are	  restricted	  to	  
a	   single	   axon.	   The	   segmentation	   enables	   the	   very	   rapid	  movement	   of	   action	   potentials	   along	   the	  
axon	  by	  “jumping”	  from	  one	  node	  to	  the	  other.	  Therefore,	  this	  mode	  of	  signal	  propagation	  is	  called	  
saltatory	   transmission	   and	   usually	   at	   least	   10X	   faster	   than	   the	   transmission	   along	   unmyelinated	  
axons	   (Hartline	  &	  Colman	  2007).	  Myelin	   and	   saltatory	   transmission	  were	   initially	   thought	   to	  be	  an	  
exclusive	  evolutionary	  achievement	  of	  vertebrates,	  but	  later	  discoveries	  showed	  a	  parallel	  evolution	  




Besides	  nodes	  and	  internodes	  the	  myelinated	  axon	  can	  be	  further	  separated	  into	  specialized	  regions	  
(Figure	  2-­‐3b).	  Between	  both	  regions	  there	  is	  a	  transitional	  area	  consisting	  of	  the	  juxtaparanode	  and	  
the	  paranode.	   In	   addition,	   there	   are	  differences	  between	  CNS	   and	  PNS.	   In	   the	  PNS	   the	  outermost	  
myelin	  layers	  are	  covered	  by	  a	  basal	  lamina	  and	  the	  nodes	  by	  Schwann	  cell	  microvilli.	  In	  contrast,	  no	  
basal	   lamina	   is	   evident	   in	   the	   CNS	   and	   the	   nodes	   are	   covered	   by	   perinodal	   astrocytes.	   Detailed	  
informations	  regarding	  these	  specialized	  regions	  and	  differences	  between	  CNS	  and	  PNS	  can	  be	  found	  





Figure	  2-­‐3:	  Structure	  of	  myelinated	  axons	  in	  CNS	  and	  PNS.	  (A)	  Myelinating	  glia	  cells,	  oligodendrocytes	  in	  the	  
central	  nervous	  system	  (CNS)	  and	  Schwann	  cells	  in	  the	  peripheral	  nervous	  system	  (PNS),	  wrap	  their	  membrane	  
around	   the	   axon	   of	   neurons.	   This	   segments	   axons	   in	   isolated	   (internodes)	   and	   non-­‐isolated	   areas	   (nodes	   of	  
Ranvier).	   While	   in	   the	   CNS	   one	   oligodendrocyte	   can	   engulf	   multiple	   axons	   with	   its	   membrane	   extensions,	  
Schwann	  cells	  myelinate	  only	  a	  single	  axon.	  (B)	  Schematic	  of	  a	  longitudinal	  section	  through	  a	  myelinated	  axon	  
in	   CNS	   (below)	   and	   PNS	   (above).	   Visible	   are	   the	   internode,	   followed	   by	   the	   adjacent	   juxtaparanode	   (JXP),	  
paranode	   and	   the	   non-­‐isolated	   node.	   Reprinted	   by	   permission	   from	   Macmillan	   Publishers	   Ltd:	   NATURE	  
REVIEWS	   NEUROSCIENCE	   The	   local	   differentiation	   of	  myelinated	   axons	   at	   nodes	   of	   Ranvier,	   copyright	   2003	  
(Poliak	  &	  Peles	  2003).	  
Since	  myelin	  is	  mainly	  made	  up	  of	  plasma	  membrane	  tightly	  wrapped	  around	  a	  neurons	  axon,	  its	  lipid	  
and	   protein	   composition	   are	   significantly	   different	   from	   the	   whole	   brain	   (see	   Table	   2-­‐1).	   Myelin	  
exhibits	   a	   very	   high	   lipid	   content	   of	   70%	   and	   only	   30%	   protein,	   respectively.	   The	   lipids	   consist	   of	  
~28%	   cholesterol,	   ~43%	   phospholipids	   and	   a	   very	   high	   amount	   of	   ~28%	   galactolipids.	   These	   28%	  
galactolipids	   can	  be	  mainly	   subdivided	   in	  23%	  galactosylceramide,	   the	  predominant	   cerebroside	  of	  
the	  brain,	  and	  4%	  sulfatide,	  its	  sulfated	  derivative	  (see	  also:	  2.1	  Sphingolipids).	  Considering	  that	  the	  
phospholipid	   sphingomyelin	   is	   also	   a	   sphingolipid,	   about	   35%	   of	   myelin	   lipids	   are	   sphingolipids.	  
Notably	  as	  much	  as	  60%	  of	  galactolipids	  can	  be	  hydroxylated	  at	  the	  C2-­‐position	  of	  their	  N-­‐linked	  fatty	  




any	   mammalian	   tissue	   (Maldonado	   et	   al.	   2008).	   Further	   information	   regarding	   the	   role	   of	   2-­‐OH	  
sphingolipids	   and	   their	   functions	   in	   myelin	   is	   discussed	   below	   (see	   chapter	   2.3	   Fatty	   acid	   2-­‐
hydroxylase).	  	  	  
Table	  2-­‐1:	  Lipid	  and	  protein	  composition	  of	  myelin,	  grey	  matter	  and	  whole	  brain	  in	  various	  mammals.	  	  
Protein	  and	  lipid	  numbers	  are	  given	  in	  percentage	  dry	  weight,	  while	  all	  others	  are	  given	  as	  percentage	  of	  total	  
lipid	  weight.	  Table	  adapted	  from:	  (Siegel	  et	  al.	  2005).
	   Myelin	   	   	  
Substance*	   Human	   Bovine	   Rat	   Gray	  matter	  (human)	   Whole	  brain	  (rat)	  
Protein	   30	   24.7	   29.5	   55.3	   56.9	  
Lipid	   70	   75.3	   70.5	   32.7	   37	  
Cholesterol	   27.7	   28.1	   27.3	   22	   23	  
Cerebroside	   22.7	   24	   23.7	   5.4	   14.6	  
Sulfatide	   3.8	   3.6	   7.1	   1.7	   4.8	  
Total	  galactolipid	   27.5	   29.3	   31.5	   7.3	   21.3	  
Phosphatidyethanolamine	   15.6	   17.4	   16.7	   22.7	   19.8	  
Phosphatidylcholine	   11.2	   10.9	   11.3	   26.7	   22	  
Sphingomyelin	   7.9	   7.1	   3.2	   6.9	   3.8	  
Phosphatidylserine	   4.8	   6.5	   7	   8.7	   7.2	  
Phosphatidylinositol	   0.6	   0.8	   1.2	   2.7	   2.4	  
Total	  phospholipid	   43.1	   43	   44	   69.5	   57.6	  
	  
Recent	  mass	  spectrometry	  (MS)	  based	  experiments	  have	  shown	  that	  CNS-­‐	  and	  PNS-­‐myelin	  contain	  at	  
least	  1300	  and	  550	  different	  proteins,	  respectively	  (de	  Monasterio-­‐Schrader	  et	  al.	  2012;	  Patzig	  et	  al.	  
2011).	   Still,	   this	   numbers	   are	   expected	   to	   increase	   due	   to	   advances	   in	  mass	   spectrometry	   sample	  
processing	  and	  instrument	  performance.	  Accordingly,	  a	  very	  recent	  paper,	  comparing	  the	  human	  and	  
mouse	  CNS-­‐myelin	  proteome,	  documented	  again	  ~1000	  proteins	  in	  mouse,	  but	  up	  to	  ~2300	  proteins	  
in	  humans	  (Gopalakrishnan	  et	  al.	  2013).	  Intriguingly,	  of	  these	  many	  proteins	  only	  a	  few	  exhibit	  high	  
abundances,	  being	  already	  visible	  after	  Coomassie-­‐staining	  of	  SDS-­‐PAGE	  separated	  myelin	  proteins,	  
while	  the	  majority	  have	  very	  low	  abundances	  (see	  Figure	  2-­‐4	  and	  (Jahn	  et	  al.	  2009)).	  	  In	  CNS-­‐myelin	  
the	   three	  most	   abundant	   ones	   are	   PLP	   (proteolipid	   protein,	   17%),	  MBP	   (myelin	   basic	   protein,	   8%)	  
and	   CNP	   (cyclic	   nucleotide	   phosphodiesterase,	   4%),	   which	   together	   constitute	   29%	   of	   all	   myelin	  
proteins	   according	   to	   recent	   quantitative	   mass	   spectrometry	   measurements	   (Jahn	   et	   al.	   2009).	  
Interestingly,	   older	   estimations	   based	   on	   conventional	   stained	   SDS-­‐PAGE	   gels	   showed	   even	   higher	  
numbers	   for	   these	   three	  proteins:	   30	  –	   45%	  PLP,	   22	  –	   35%	  MBP	  and	  4	  –	   15%	  CNPase	   (Jahn	   et	   al.	  
2009).	   For	   PNS-­‐myelin	   the	   situation	   is	   quite	   similar.	   According	   to	   quantitative	  mass	   spectrometry	  
data,	  only	  three	  proteins	  account	  for	  45%	  of	  all	  PNS-­‐myelin	  proteins.	  These	  are	  P0	  (protein	  P0,	  21%),	  
Periaxin	  (16%)	  and	  MBP	  (8%).	  Again,	  previous	  estimations,	  based	  on	  densitometry	  measurements	  of	  
conventionally	  stained	  gels,	  differed	  significantly	  from	  these	  findings:	  45	  –	  70%	  P0,	  2	  –	  26%	  MBP	  and	  








Figure	  2-­‐4:	  Protein	  composition	  of	  CNS-­‐	  and	  PNS-­‐myelin.	  (A)	  Pie	  chart	  depicting	  the	  relative	  abundances	  (%)	  of	  
the	  major	   CNS-­‐myelin	   proteins	   according	   to	   the	   LC-­‐MSE	   data	   published	   by	   Jahn	   and	   colleagues	   (Jahn	   et	   al.	  
2009).	   (B)	  Pie	  chart	  depicting	  the	  relative	  abundances	  (%)	  of	   the	  major	  PNS-­‐myelin	  proteins	  according	  to	  the	  
LC-­‐MSE	  data	  published	  by	  Patzig	  and	  colleagues	   (Patzig	  et	  al.	  2011).	  PLP	  =	  myelin	  proteolipid	  protein;	  MBP	  =	  
myelin	   basic	   protein;	   CNP	   =	   2’,3’-­‐cyclic	   nucleotide	   3’-­‐phosphodiesterase;	   MOG	   =	   Myelin	   oligodendrocyte	  
glycoprotein;	  MAG	  =	  myelin-­‐associated	  glycoprotein;	  Sirt2	  =	  Sirtuin2;	  OSP	  =	  oligodendrocyte-­‐specific	  protein;	  
P0	  =	  myelin	  protein	  P0.;	  Fasn	  =	  fatty	  acid	  synthase;	  4.1G	  =	  band	  4.1	  G-­‐protein.	  
2.2.2 Demyelinating	  diseases	  
The	   insulation	  of	   axons	  by	  myelin	   is	   essential	   for	   effective	  neuronal	   signal	  propagation.	   Therefore,	  
various	   often	   severe	   and/or	   lethal	   diseases	   exist,	   which	   are	   caused	   by	   damaged	   or	   structurally	  
altered	  myelin.	  Demyelination	  can	  be	   inflicted	  by	   infectious	  agents,	  certain	  chemicals,	  autoimmune	  
diseases	  or	  genetically	  inherited	  causes.	  	  
Important	   examples	   for	   demyelinating	   autoimmune	   diseases	   are	   multiple	   sclerosis,	   Guillain-­‐Barré	  
syndrome,	   transverse	  myelitis	   and	   acute	   disseminated	   encephalomyelitis.	   Examples	   for	   genetically	  
caused	   diseases	   are	   Charcot-­‐Marie-­‐Tooth	   disease	   and	   the	   large	   group	   of	   leukodystrophies	  
(Kohlschütter	   et	   al.	   2010).	   Not	   surprisingly	   the	   causative	   genes	   are	   often	   coding	   for	   important	  
structural	  myelin	  components	  or	   lipid	  metabolism	  enzymes.	  For	  example,	   in	  Pelizaeus–Merzbacher	  
disease	  the	  most	  frequent	  mutations	  are	  causing	  an	  overexpression	  of	  the	  structural	  myelin	  protein	  
PLP.	   Since	   PLP	   is	   important	   for	   the	   cohesion	   of	   opposing	   myelin	   membranes,	   deregulation	   of	   it	  
cellular	   levels	   lead	  to	  myelin	   instability.	  Another	  example	   is	  metachromatic	   leukodystrophy,	  caused	  
by	   a	   defective	   arylsulfatase	   A	   (ASA)	   enzyme.	   Since	   ASA	   is	   responsible	   for	   the	   degradation	   of	   the	  
sphingolipid	   sulfatide,	   this	   leads	   to	   the	   lysosomal	   accumulation	   of	   sulfatide.	   Similarly	   in	   Krabbe	  

































accumulation.	  In	  both	  diseases	  the	  accumulation	  of	  excess	  amounts	  of	  sphingolipids	  finally	   leads	  to	  
demyelination	  by	  mechanisms	  still	  unknown.	  
	  
2.3 Fatty	  acid	  2-­‐hydroxylase	  
2.3.1 Overview	  
Fatty	   acid	   2-­‐hydroxylase	   (FA2H)	   is	   a	   43	   kDa	   monooxygenase	   residing	   in	   the	   ER-­‐membrane	   and	  
responsible	   for	   the	   synthesis	   of	   2-­‐hydroxyacylsphingolipids	   (Figure	   2-­‐5)	   (Hama	   2010).	   The	   enzyme	  
does	   not	   hydroxylate	   ceramides	   directly,	   but	   utilizes	   fatty	   acids.	   These	   are	   then	   incorporated	   into	  
sphingolipids	  by	  the	  different	  ceramide	  synthases,	  which	  show	  the	  same	  preferences	  for	  certain	  acyl-­‐
chain	  lengths	  regardless	  of	  the	  presence	  or	  absence	  of	  a	  2-­‐OH	  group	  (Mizutani	  et	  al.	  2008).	  	  
The	  human	  enzyme	  was	  first	  discovered	  in	  2004	  by	  Alderson	  and	  colleagues	  (Alderson	  et	  al.	  2004)	  by	  
searching	  for	  proteins	  homologues	  to	  the	  known	  yeast	  FA2H	  (FAH1/Scs7p).	  Using	  Northern	  blotting	  
they	  also	  determined	  its	  expression	  pattern,	  with	  the	  highest	  expression	  in	  brain	  and	  colon	  and	  lower	  
expression	   in	   testis,	   prostate,	   pancreas	   and	   kidney.	  One	   year	   later	   our	   group	   identified	   the	   highly	  
similar	  murine	  homolog	   (Eckhardt	  et	  al.	  2005)	  and	  allocated	   its	  expression	   to	  brain,	   stomach,	   skin,	  
kidney	  and	  testis.	   In	  addition,	  a	   time-­‐course	  analysis	  of	   its	  brain	  expression	   revealed	  an	  expression	  






Figure	  2-­‐5:	  Pathway	  of	  2-­‐OH	  sphingolipid	  generation.	  The	  synthesis	  of	  2-­‐OH	  sphingolipids	  is	  achieved	  by	  the	  
same	   enzymes	   responsible	   for	   non-­‐hydroxylated	   sphingolipids.	   The	   only	   difference	   is	   that	   2-­‐OH	   fatty	   acids,	  
generated	  by	   FA2H,	   are	  used	  by	   the	   ceramide	   synthases	   instead	  of	   their	   non-­‐hydroxy	   counterparts.	   Shortly,	  
free	  fatty	  acids	  are	  first	  hydroxylated	  by	  FA2H	  and	  subsequently	  activated	  by	  acyl-­‐CoA	  synthethases	  (ACS).	  The	  
activated	  2-­‐OH	  fatty	  acyl-­‐CoAs	  are	  then	  linked	  to	  dihydrosphingosine	  by	  ceramide	  synthases	  (CerS)	  forming	  2-­‐
OH	   dihydroceramide.	   This	   is	   subsequently	   desaturated	   by	   dihydroceramide	   desaturase	   (DES)	   to	   form	   2-­‐OH	  
ceramide.	  2-­‐OH	  ceramide	  can	  then	  be	  further	  modified	  by	  various	  enzymes	  to	  form	  the	  different	  sphingolipid	  
classes	  like	  sphingomyelins,	  glycosphingolipids,	  galactosylceramides	  and	  sulfatides	  (see	  Figure	  2-­‐2).	  
The	  372	  amino	  acids	  (aa)	  long	  enzyme	  is	  anchored	  in	  the	  ER	  via	  four	  transmembrane	  domains,	  with	  
both	  protein	  termini	   localized	  to	  the	  cytosolic	  side	  of	  the	  membrane	  (Figure	  2-­‐6).	   It	  also	  contains	  a	  
conserved	   cytochrome	   b5	   heme-­‐binding	   domain	   at	   its	   N-­‐terminus	   (aa	   8-­‐86),	   probably	   an	   electron	  
acceptor-­‐domain,	   which	   is	   essential	   for	   full	   enzyme	   activity.	   A	   catalytic	   sterol	   desaturase	   domain,	  
typical	  for	  membrane-­‐located	  desaturases	  and	  hydroxylases	  (Shanklin	  &	  Cahoon	  1998),	  is	  located	  at	  
the	  C-­‐terminus.	   It	  encloses	   four	  conserved	  histidine-­‐rich	  motifs	   (HX(2-­‐3)(XH)H),	  which	  are	  thought	   to	  
bind	   iron.	   This	   domain	  probably	   transfers	   electrons,	   initially	   supplied	  by	   a	   reductase	   via	   the	   cytb5-­‐
domain,	  to	  fatty	  acids.	   In	  addition,	  an	  ER-­‐retention	  signal	  can	  be	  found	  at	  the	  enzymes	  C-­‐terminus.	  
While	   the	  enzyme	   can	  hydroxylate	   free	   fatty	   acids	   in	   vitro,	   at	   the	  moment	   it	   is	   still	   unclear,	   if	   the	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Figure	  2-­‐6:	  Structure	  of	  FA2H.	  (A)	  Sequence	  alignment	  of	  FA2H	  protein	  sequences	  from	  different	  species.	  Mus	  
musculus	   (Mm;	  FVB/N	  strain;	  GenBank®	  AY660882),	  Homo	  sapiens	   (Hs;	  GenBank®	  accession	  no.	  AAH04263),	  
Drosophila	  melanogaster	  (Dm;	  GenBank®	  AAL68319),	  Caenorhabditis	  elegans	  (Ce;	  GenBank®	  accession	  no.	  NP	  
492678)	  and	  S.	  cerevisiae	  (Sc;	  GenBank®	  NP013999).	  Sequence	  similarities	  are	  highlighted	  using	  the	  BOXSHADE	  
program.	  Conserved	  domains	  (cytochrome	  b5	  =	  cytb5;	  histidine-­‐rich	  motifs	  =	  H1-­‐4)	  are	  indicated	  by	  boxes	  and	  
putative	   transmembrane	   domains	   (TM1-­‐4)	   by	   black	   bars	   on	   top	   of	   the	   protein	   sequences.	   The	   amino	   acid	  
sequence	  of	  C57BL/6J	  mice	  (GenBank®	  NP	  835187)	  differs	  at	  three	  positions	  from	  that	  of	  FVB/N	  mice.	  Letters	  
on	   top	   of	   the	   mouse	   sequence	   indicate	   three	   sequence	   differences	   between	   FVB/N	   and	   C57BL/6J	   mice	  
(GenBank®	  NP	  835187).	  Picture	  from:	  (Eckhardt	  et	  al.	  2005).	  (B)	  General	  structure	  and	  topology	  of	  FA2H.	  The	  
protein	   is	  anchored	   in	  the	  ER	  by	  four	  transmembrane	  domains	  with	   its	  N-­‐	  and	  C-­‐terminus	   facing	  the	  cytosol.	  
The	   N-­‐terminus	   contains	   a	   cytochrome	   b5	   domain,	   which	   is	   thought	   to	   be	   important	   for	   the	   transfer	   of	  
electrons	  from	  a	  reductase	  to	  the	  enzyme.	  The	  C-­‐terminal	  part	  of	  FA2H	  contains	  four	  transmembrane	  domains,	  
which	   itself	   contain	   four	   conserved	   histidine-­‐rich	   motifs	   (H).	   These	   motifs	   are	   thought	   to	   coordinate	   iron	  
thereby	  representing	  the	  catalytic	  desaturase	  domain	  of	  the	  enzyme.	  Picture	  modified	  from:	  (Hama	  2010).	  
2.3.2 FA2H-­‐associated	  diseases	  
In	  the	  last	  years	  various	  mutations	  in	  the	  human	  FA2H	  gene	  have	  been	  described,	  causing	  a	  type	  of	  
spastic	  paraplegia	   called	  autosomal	   recessive	   spastic	  paraplegia-­‐35	   (SPG35).	   Spastic	  paraplegia	   is	   a	  
collective	   term	   for	   several	   diseases,	   of	   distinct	   genetic	   causes,	  which	   all	   lead	   to	   progressive	   lower	  
extremity	  spasticity	  and	  weakness.	  	  
Patients	   with	   SPG35	   (MIM:	   612319),	   also	   more	   generally	   termed	   fatty	   acid	   hydrolase-­‐associated	  
neurodegeneration	  (FAHN),	  present	  with	  variable	  symptoms,	  which	  also	  vary	  in	  severity,	  depending	  




















dysarthria,	   varying	   degrees	   of	   cognitive	   decline,	   leukodystrophy,	   dystonia,	   optic	   atrophy	   and	  
seizures.	  In	  addition,	  a	  couple	  of	  patients	  exhibited	  neurodegeneration	  with	  brain	  iron	  accumulation	  
(NBIA).	   The	   disease	   usually	   manifests	   in	   childhood	   and	   progresses	   rapidly	   with	   many	   patients	  
becoming	  wheelchair	  bound	  until	  reaching	  adulthood.	  
The	   first	   study	   linking	   FA2H-­‐mutations	   with	   spastic	   paraplegia	   was	   published	   by	   Edvardson	   and	  
colleagues	   (Edvardson	  et	   al.	   2008).	   They	   reported	   two	  different	  mutations	   leading	   to	  differentially	  
severe	   phenotypes.	   One	   group	   of	   patients	   exhibited	   progressive	   spasticity	   combined	   with	   ataxia,	  
dystonia,	   and	   cognitive	   decline,	  while	   another	   showed	   just	  walking	   difficulties	   and	  mild	   spasticity.	  
The	   first	   group	  carried	  an	   intronic	  G-­‐A	   transition	   in	   the	  FA2H	  gene,	  which	   leads	   to	  missplicing	  and	  
therefore	  the	  production	  of	  a	  shortened	  catalytically	   inactive	  enzyme	  (Δaa	  204–346).	  The	  mutation	  
found	  in	  the	  second	  patient	  group	  led	  to	  a	  single	  amino	  acid	  substitution	  (D35Y).	  An	  in-­‐vitro	  activity	  
assay	  revealed	  that	  this	  mutation	  abolished	  the	  enzyme’s	  activity.	  Surprisingly,	  subsequent	  analysis	  
of	  fibroblast	  from	  both	  patient	  groups	  revealed	  no	  decrease	  in	  fatty	  acid	  2-­‐hydroxylase	  activity.	  This,	  
together	  with	   findings	  by	  our	  group	  (Maier	  et	  al.	  2011),	  hints	  at	   the	  existence	  of	  a	  second	  enzyme	  
with	  fatty	  acid	  2-­‐hydroxylase	  activity.	  
The	  next	  mutations,	  found	  in	  two	  unrelated	  families,	  were	  reported	  by	  Dick	  and	  colleagues	  (Dick	  et	  
al.	   2008;	   Dick	   et	   al.	   2010).	   These	   patients	   presented	   classical	   progressing	   spastic	   paraplegia	  
symptoms.	  In	  addition,	  in	  some	  patients	  MRI	  scans	  revealed	  a	  leukodystrophy.	  The	  first	  family	  carried	  
a	   mutation	   that	   led	   to	   amino	   acid	   exchange	   (R235C).	   Interestingly,	   an	   in-­‐vitro	   functional	   activity	  
assay	   showed	   that	   this	   mutant	   enzyme	   still	   synthesized	   60	   -­‐	   80%	   of	   the	   2-­‐OH	   ceramide	   levels	  
compared	  to	  the	  wildtype	  enzyme.	  The	  second	  family	  carried	  an	  18bp-­‐deletion	  in	  exon	  1,	  leading	  to	  
the	   deletion	   of	   6	   amino	   acids	   (Δaa	   53-­‐58)	   within	   the	   cytochrome	   b5	   domain.	   The	   in-­‐vitro	   assay	  
showed	  that	  this	  deletion	  totally	  abolished	  the	  enzyme’s	  activity.	  	  
Until	  now,	  more	   than	  30	  FAHN-­‐cases	  have	  been	  described,	  with	  patients	  carrying	  additional	  FA2H-­‐
mutations	   (Kruer	   et	   al.	   2010;	  Garone	  et	   al.	   2011;	   Tonelli	   et	   al.	   2012;	   Cao	   et	   al.	   2013;	   Rupps	   et	   al.	  
2013;	  Donkervoort	  et	  al.	  2014).	  
2.3.3 FA2H-­‐KO	  mouse	  models	  
To	   further	   elucidate	   the	   functions	   of	   FA2H,	   our	   group	   generated	   KO-­‐mouse	   (FA2H-­‐/-­‐)	   deficient	   for	  
FA2H	  in	  all	  tissues	  (Zöller	  et	  al.	  2008).	  While	  the	  animals	  totally	  lacked	  2-­‐OH	  sphingolipids	  in	  central	  
and	   peripheral	   nervous	   system,	   oligodendrocyte	   differentiation,	   myelin	   structure	   and	   peripheral	  
nerve	  conduction	  velocities	  were	  unaffected	  in	  up	  to	  five-­‐month-­‐old	  animals.	  Only	  very	  old	  animals	  
(~18	  months)	  showed	  signs	  of	  axonal	  and	  myelin	  sheath	  degeneration	  in	  the	  spinal	  cord	  and	  sciatic	  




Therefore,	  it	  was	  concluded	  that	  2-­‐OH	  sphingolipids	  are	  not	  necessary	  for	  initial	  myelin	  development,	  
but	  essential	  for	   its	   long-­‐term	  stability	  and	  maintenance.	  Furthermore,	  the	  animals	  exhibited	  a	  skin	  
phenotype,	   which	   included	   hyperproliferation	   of	   sebocytes	   with	   enlarged	   sebaceous	   glands,	   an	  
altered	  sebum	  composition	  and	  a	  cycling	  alopecia	  (Maier	  et	  al.	  2011).	  Interestingly,	  despite	  the	  total	  
loss	  of	  FA2H,	  2-­‐OH	  sphingolipids	  were	  still	  present	  in	  the	  animals’	  epidermis,	  strongly	  suggesting	  that	  
at	  least	  one	  additional	  fatty	  acid	  2-­‐hydroxylase	  exist.	  	  
Additional	   information,	   focusing	  on	   the	  CNS-­‐function	  of	  FA2H,	  comes	   from	  a	  second	  mouse	  model	  
deficient	  for	  FA2H	  only	  in	  myelinating	  cells	  (FA2Hflox/flox	  Cnp1-­‐Cre)	  published	  by	  Potter	  and	  colleagues	  
(Potter	   et	   al.	   2011).	   Using	   the	   Cre-­‐lox	   system	   the	   group	   generated	   total	   (FA2H-­‐/-­‐),	   as	   well	   as	  
oligodendrocyte	  &	  Schwann	  cell	  specific	  FA2H-­‐KO	  mice.	  12-­‐month-­‐old	  mice	  from	  both	  types	  of	  KO-­‐
animals	   exhibited	   demyelination	   and	   axonal	   degeneration	   in	   the	   CNS.	   Furthermore,	   only	   minor	  
alterations	   were	   observable	   in	   the	   PNS.	   Together	   with	   the	   results	   published	   by	   our	   group	   this	  
indicates	   that	   the	   CNS-­‐pathology	   manifest	   earlier	   than	   the	   PNS-­‐pathology.	   In	   addition,	   in	   both	  
models	   they	   also	   observed	   a	   previously	   unreported	   cerebrellar	   dysfunction	   manifesting	   with	  
significant	  motor	  deficits.	   Interestingly,	  when	  assessing	   spatial	   learning	   and	  memory	  by	  behavioral	  
testing,	  only	  FA2H-­‐/-­‐	  animals	  showed	  impairments,	  while	  FA2Hflox/flox	  Cnp1-­‐Cre	  animals	  performed	  as	  
WT	   ones.	   This	   finding	   suggests,	   that	   the	   existence	   of	   2-­‐OH	   sphingolipids	   in	   other	   cells	   than	  
oligodendrocytes	  is	  essential	  for	  memory	  and	  learning.	  
2.3.4 Cell	  signaling	  by	  2-­‐OH	  sphingolipids	  
While	   the	   signaling	   functions	   of	   ceramide	   and	   ceramide	   derivatives,	   for	   example	   ceramide	   1-­‐
phosphate	  (reviewed	  in	  Arana	  et	  al.	  2010)	  and	  sphingosine	  1-­‐phosphate	  (reviewed	  in	  Maceyka	  et	  al.	  
2012),	  have	  been	  studied	  for	  several	  years,	  little	  is	  known	  about	  a	  specific	  role	  of	  2-­‐OH	  sphingolipids	  
in	  signal	  transduction.	  But	   in	  the	   last	  5	  -­‐	  6	  years	   increasing	  evidence	  emerged,	  pointing	  at	  a	  role	   in	  
cell	  differentiation	  and	  apoptosis.	  
First	  evidence	  linking	  cell	  differentiation	  and	  2-­‐OH	  sphingolipids	  came	  from	  a	  study	  on	  keratinocyte	  
differentiation	  (Uchida	  et	  al.	  2007).	  It	  was	  shown	  that	  FA2H	  and	  2-­‐OH	  sphingolipids,	  mainly	  ceramide	  
and	  GlcCer,	   increased	   during	   differentiation	   of	   cultured	   human	   keratinocytes.	   Furthermore,	   FA2H-­‐
knock	   down	   (FA2H-­‐KD)	   by	   siRNA	   interfered	   with	   this	   process	   by	   impairing	   the	   generation	   of	  
epidermal	  lamellar	  membranes.	  Further	  evidence	  was	  provided	  by	  the	  group	  of	  Hiroko	  Hama	  when	  
studying	  differentiation	  after	  dibutyryl	   cAMP-­‐administration	   (dcAMP)	   in	   rat	   Schwann	  and	   in	  D6P2T	  
Schwannoma	  cells	  (Maldonado	  et	  al.	  2008;	  Alderson	  &	  Hama	  2009).	  dcAMP,	  a	  known	  inductor	  of	  cell	  
cycle	  exit	  and	  Schwann	  cell	  differentiation,	   led	   to	   the	  upregulation	  of	  FA2H	   in	  both	  cell	   types.	  This	  
cell	  cycle	  exit	  could	  be	  inhibited	  by	  siRNA-­‐mediated	  KD	  of	  FA2H.	  Interestingly,	  two	  cyclin	  dependent	  




The	   latest	   evidence	   for	   a	   role	   of	   2-­‐OH	   sphingolipids	   in	   cell	   differentiation	   came	   from	   a	   report	  
investigating	   differentiation	   and	   lipogenesis	   in	   3T3-­‐L1	   adipocytes	   (Guo	   et	   al.	   2010).	   Again,	   a	  
significant	   increase	   in	   FA2H	   expression	   accompanied	   cell	   differentiation	   and	   this	   process	   could	   be	  
blocked	   by	   siRNA-­‐mediated	   FA2H-­‐KD.	   In	   addition,	   in	  mature	   adipocytes	   FA2H-­‐KD	   decreased	   basal	  
and	   insulin-­‐mediated	  glucose	  uptake	  and	   lipogenesis.	  While	  some	  results	  could	  be	  explained	  by	  an	  
accelerated	  GLUT4	  transporter	  endocytosis	  caused	  by	  increased	  mobility	  of	  raft	  lipids,	  a	  contribution	  
by	  direct	  signaling	  via	  2-­‐OH	  sphingolipids	  seemed	  also	  plausible.	  
Regarding	   apoptosis,	   first	   evidence	   was	   given	   by	   Kyogashima	   and	   colleagues	   (Kyogashima	   et	   al.	  
2008),	  proving	   that	   fractions	  of	   kidney	  extract	   containing	  2-­‐OH	  ceramides	   induced	  apoptosis	  more	  
strongly	  in	  three	  tested	  human	  tumor	  cell	   lines,	  than	  2-­‐OH	  ceramide	  free	  fractions.	  Two	  years	  later	  
another	  group	  evaluated	  the	  influence	  of	  different	  C6	  ceramides	  on	  cell	  growth	  in	  breast	  carcinoma	  
MCF7	  cells	  (Szulc	  et	  al.	  2010).	  They	  tested	  both	  stereoisomers	  of	  2-­‐OH-­‐C6	  ceramide/dihydroceramide	  
as	  well	   as	  non-­‐hydroxy-­‐C6	   ceramide/dihydroceramide.	  Again,	   2-­‐OH	  ceramides	  exhibited	  a	   stronger	  
growth	   inhibitory	  effect	   than	   their	  non-­‐hydroxy	   counterparts,	  with	   the	   strongest	   generated	  by	   the	  
natural	  occurring	  R-­‐stereoisomeric	  forms.	  In	  a	  follow-­‐up	  study	  by	  Kota	  et	  al.,	  R-­‐	  and	  S-­‐sterioisomers	  
of	  C16	  ceramides,	  which	  are	  more	  similar	  to	  natural	  occurring	  ceramides,	  were	  tested	  on	  C6	  glioma	  
cells	   (Kota	   et	   al.	   2013).	   Classical	   apoptosis	   assays	   and	   comparative	  mass	   spectrometric	   proteomic	  
analysis	  revealed	  that	  treatment	  with	  (2’R)-­‐2-­‐OH-­‐C16	  ceramide	  lead	  to	  a	  strong	  apoptotic	  response,	  
which	  was	   not	   observable	  when	  using	   the	   S-­‐stereoisomer	   or	   non-­‐hydroxy-­‐C16	   ceramide.	   In	   detail,	  
analysis	   of	   the	   proteomic	   data	   and	   verifications	   by	   Western	   blot	   (WB)	   further	   revealed	   an	  
involvement	  of	  Akt	  and	  MAP	  kinase	  pathways	  in	  the	  tumor	  cells’	  response	  to	  (2’R)-­‐2-­‐OH	  ceramide.	  	  
	  
2.4 Aim	  of	  this	  study	  
The	  goal	  of	  this	  thesis	  was	  to	  get	  detailed	  insights	   into	  the	  mechanisms	  governing	  the	  pathology	  of	  
FA2H	  deficiency,	  with	  the	  help	  of	  two	  mass	  spectrometry-­‐based	  proteomic	  approaches.	  
FA2H	  deficiency	   leads	  to	   long-­‐term	  myelin	   instability.	  This	  might	  be	  explained	  by	  the	  fact	  that	  non-­‐
hydroxylated	  sphingolipids	  can	  form	   less	  hydrogen	  bonds	  with	  other	   lipids	   (Pascher	  1976;	  Boggs	  et	  
al.	  1988).	  Thus,	  FA2H	  deficiency	  results	  in	  less	  stable	  lipid-­‐lipid	  interactions.	  However,	  myelin	  stability	  
is	  also	  dependent	  on	  various	  proteins.	  For	  example,	  the	  presence	  of	  structural	  myelin	  proteins,	   like	  
MBP	  or	  PLP,	  is	  usually	  indispensible	  for	  forming	  and	  maintaining	  a	  stable	  myelin	  sheath,	  as	  becomes	  
evident	  by	  animals	  carrying	  defects	  in	  such	  proteins	  (Readhead	  &	  Hood	  1990;	  Klugmann	  et	  al.	  1997).	  
In	   addition,	   the	   targeting	   of	   some	  myelin	   proteins,	   like	  MOG,	  MAG,	   CNPase,	   neurofascin	   155	   and	  




found	   in	   specialized	   cholesterol	   and	   sphingolipid-­‐rich	   membrane	   microdomains	   called	   lipid-­‐rafts	  
(Simons	  &	  Trotter	  2007;	  Dupree	  &	  Pomicter	  2010).	   Intriguingly,	  FA2H	  has	  been	  shown	  to	  modulate	  
lipid	  raft	  fluidity	  in	  adipocytes	  (Guo	  et	  al.	  2010).	  Therefore,	  one	  could	  assume	  that	  the	  changed	  lipid	  
composition,	  caused	  by	  FA2H	  deficiency,	   leads	   to	  a	  wrong	   localization	  of	  myelin	  proteins,	  which	   in	  
turn	   elicits	   the	   long-­‐term	  myelin	   stability.	   Although	   if	   such	   changes	   exist,	   they	   either	   seem	   to	   be	  
more	  subtle	  or	  occur	  at	  later	  stages	  of	  life,	  because	  initial	  analysis	  of	  young	  (three-­‐month-­‐old)	  FA2H-­‐
KO	  mice	  have	  shown	  no	  differences	  in	  the	  amount	  of	  the	  major	  myelin	  proteins	  MBP,	  CNP,	  L-­‐MAG,	  
NCAM	   and	  MAL	   (Zöller	   et	   al.	   2008).	   Thus,	   to	   clarify	   the	   role	   of	   myelin	   protein	   alterations	   in	   the	  
pathology	  of	  FA2H	  deficiency,	  a	  large-­‐scale	  quantitative	  mass	  spectrometry	  screening	  approach	  was	  
employed.	  Moreover,	  since	  it	  was	  unclear	  when	  changes	  might	  occur,	  relatively	  young	  (6	  months)	  as	  
well	  as	  old	  (13	  months)	  and	  very	  old	  mice	  (17	  months)	  were	  analyzed	  in	  parallel.	  
Alternatively,	   it	   may	   be	   the	   case	   that	   the	   pathology	   is	   not	   caused	   by	   the	   absence	   of	   2-­‐OH	  
sphingolipids,	  but	  instead	  the	  FA2H-­‐protein	  itself.	  FA2H	  may	  interact	  with	  other	  proteins	  in	  or	  at	  the	  
ER,	   as	   has	   been	   described	   for	   its	   plant	   homolog,	   which	   functionaly	   associates	  with	   the	   cell	   death	  
suppressor	  protein	  Bax	  inhibitor-­‐1	  (Nagano	  et	  al.	  2009).	  Therefore,	  the	  potential	  loss	  of	  one	  or	  more	  
interactions	   might	   cause	   the	   pathology,	   for	   example	   by	   leading	   to	   a	   wrong	   localization	   of	   the	  
interactor.	   Intriguingly,	   this	   could	   also	   potentially	   explain	   SPG35	   patient	  mutations,	  which	   showed	  
strong	  residual	  (Dick	  et	  al.	  2010)	  or	  even	  full	  enzymatic	  activity	  (Kruer	  et	  al.	  2010).	  Moreover,	  there	  is	  
almost	  no	  information	  available	  regarding	  mammalian	  FA2H	  interaction	  partners	  so	  far.	  The	  protein-­‐
protein	   interactions	   (PPI),	   found	   in	   public	   interaction	   partner	   databases,	   are	   mostly	   generated	  
automatically	  and	  not	  verified	   individually.	  Thus,	   in	   the	  second	  approach	  mammalian	  FA2H	  protein	  
interaction	  partners	  should	  be	  identified	  by	  different	  co-­‐immunoprecipitation	  (Co-­‐IP)	  experiments	  in	  
combination	  with	  quantitative	  mass	  spectrometry.	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3 Material	  &	  Methods	  
An	  overview	  of	   the	   instruments,	  equipment,	   chemicals,	   solutions,	  buffers,	   antibodies	  and	  cell	   lines	  
used	  in	  this	  thesis	  is	  given	  in	  the	  following	  sub-­‐sections.	  
3.1 Material	  
3.1.1 Instruments	  
The	  following	  table	  gives	  an	  overview	  of	  the	  instruments	  used	  in	  this	  thesis'	  research.	  
Table	  3-­‐1:	  Alphabetical	  instrument	  list.	  
Application	   Name/Type	   Manufacturer	  
Centrifuges	   	   	  
	   Allegra	  X-­‐15R	   BeckmanCoulter	  
	   Centrifuge	  5415D	  with	  F45-­‐24-­‐11	  rotor	   Eppendorf	  
	   Centrifuge	  5810R	  with	  rotors	  
• F34-­‐6-­‐38	  
• A-­‐4-­‐62	  (swing)	  
Eppendorf	  
	   L7-­‐65	  Ultracentrifuge	  with	  SW-­‐41	  rotor	   BeckmanCoulter	  
	   Optima-­‐TLX	  Benchtop	  Ultracentrifuge	  with	  TLS-­‐55	  rotor	   BeckmanCoulter	  
	   Centrifuge	  5417R	   Eppendorf	  
	   Heraeus	  Pico17	   ThermoScientific	  
Cell	  culture	   	   	  
	   37	  °C	  incubator	   New	  Brunswick	  Scientific	  
	   Laminar	  flow	  workbench	   Clean	  Air	  
	   Axio	  microscope	   Zeiss	  
	   Water	  bath	   GFL	  
Chromatographic	  
instruments	  
	   	  
	   Easy-­‐nLC	  1000	   ThermoScientific	  
	   	   	  
General	  equipment	   	   	  
	   Vortex	  Genie	  2	   Scientific	  Industries	  
	   Analytic	  scale	  CP	  124S-­‐OCE	   Sartorius	  
	   Digital	  pH-­‐Meter	  761	  Calimatic	   Knick	  
	   Dry	  block	  heater	   STAR	  LAB	  
	   Freezer	  -­‐20	  °C	   AEG	  
	   Freezer	  -­‐80	  °C	  Ultra	  Low	   Sanyo	  
	   GENios	  Microplate	  reader	   TECAN	  
	   Hot	  water	  bath	  1083	   GFL	  
	   Ice	  machine	   Ziegra	  
	   Infinite	  200	  Pro	   TECAN	  
	   Magnetic	  stirrer	   IKA	  
	   Mini	  incubator	  INCU-­‐line	   VWR	  
	   Mithras	  LB	  940	  Multimode	  Microplate	  Reader	   Berthold	  Technologies	  
	   Motor	  pump	   	  
	   PC	  4400	  scale	   Mettler	  
	   Refrigerator	   AEG	  
	   RS-­‐TR05	  roller	  mixer	  	   Phoenix	  Instruments	  
	   Rotamax	  120	  orbital	  shaker	   Heidolph	  
	   Scan	  Speed	  40	  vacuum	  concentrator	   SCANVAC	  
	   Thermomixer	  Comfort	  1.5	  ml	   Eppendorf	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   Ultrasonic	  bath	   Branson	  
	   Ultra-­‐Turrax	  homogenizer	   IKA	  
Nucleid	  acid	  handling	  	   	   	  
	   Agarose	  gel	  casting	  system	   Peqlab	  
	   Electrophoresis	  gel	  system	   Peqlab	  
	   NanoDrop	  2000	  spectrophotometer	   ThermoScientific	  
	   Thermocycler	   Biometra	  
	   UV-­‐imaging	  system	   Biometra	  
Protein/peptide	  
electrophoresis	   &	   Western	  
blotting	  
	   	  
	   Curix	  60	  image	  processor	   AGFA	  
	   FUSION-­‐Solo	  chemiluminescence	  detection	  system	   Peqlab/Vilber	  Lourmat	  
	   PerfectBlue™	  'Semi-­‐Dry'-­‐Electroblotter	  (SEDEC	  M)	   Peqlab	  
	   Mini	  PROTEAN	  3	  electrophoresis	  system	   BioRad	  
	   Power	  Pac	  200	  power	  supply	   BioRad	  
	   Mini-­‐PROTEAN®	  Tetra	  Cell	  electrophoresis	  system	   BioRad	  
	   G3100A	  OFFGEL	  Fractionator	   Agilent	  Technologies	  
	   Odyssey	  Infrared	  Imaging	  System	   Licor	  
Mass	  spectrometers	   	   	  
	   Autoflex	  III	  smartbeam	  MALDI	  TOF/TOF	   Bruker	  Daltonics	  
	   LTQ	  Orbitrap	  Velos	   ThermoScientific	  
	   	   	  
3.1.2 Equipment	  
An	  overview	  of	  the	  equipment	  used	  in	  the	  presented	  work	  is	  given	  below:	  
Table	  3-­‐2:	  Alphabetical	  equipment	  list.	  
Application	   Type	   Manufacturer	  
Chromatography	   	   	  
	   Capillary	   column	   (length	   15-­‐20cm,	   ID	   100	   µm,	   self	   packed)	   containing	  
Bruker-­‐Michrom	  Magic	  C18	  5	  µm	  particles	  
	  
General	   	   	  
	   Filter	  paper	   Whatman	  
	   Dounce	  glas	  homogenisator	   	  
	   Glass	  flasks	  50,	  100,	  200,	  500	  and	  1000	  ml	   Schott	  
	   Nitrocellulose	  blotting	  membrane	   Whatman	  
	   Pasteur	  pipettes	  15	  and	  20	  cm	   Brand	  
	   Plastic	  tubes	  15	  &	  50	  ml	   Sarstedt	  
	   PVDF	  blotting	  membrane	   Merck	  Millipore	  
	   Reaction	  micro	  tubes	  	   Sarstedt	  
	   Sterile	  filter	   Sarstedt	  
	   	   	  
	  
	  





Table	  3-­‐3:	  Alphabetical	  software	  list	  
Application	   	   	   Name	   Producer	   URL	  
Mass	   spectrometry	  
data	  analysis	  
	   	   	   	   	  








	   	   	   GOrilla	  (Gene	  Ontology	  
enRIchment	  anaLysis	  
and	  visuaLizAtion	  tool)	  
Weizmann	  Institute	  of	  
Science	  (Tel-­‐Aviv,	  Israel)	  
http://cbl-­‐gorilla.cs.technion.ac.il	  
	   	   	   PANTHER	  9.0	   University	  of	  Southern	  
California,	  laboratory	  
Prof.	  Thomas	  (Los	  
Angeles,	  USA)	  
http://www.pantherdb.org	  








	   	   Odyssey	  3.0	   Licor	  (USA)	   	  
	   	   	   FUSION-­‐Capt	  Advance	  
Solo	  4	  software	  
Vilber	  Lourmat	   	  
	   	   	   	   	   	  
3.1.4 Chemicals,	  Solutions	  and	  Buffers	  
The	  following	  table	  names	  the	  chemicals,	  solutions	  and	  buffers	  used	  in	  this	  thesis	  research.	  
Table	  3-­‐4:	  Alphabetical	  chemical,	  solution	  and	  buffer	  list.	  
Application	   Name/Type	   Supplier	   Contents	  
Agarose	  gel	  
electrophoresis	  
	   	   	  
	   10X	  TAE	   	   400	  mM	  Tris	  base	  
200	  mM	  acetic	  acid	  
12.7	  mM	  EDTA	  
	   Agarose	  UltraPure	   LifeTechnologies	   	  
	   Ethidium	  bromide	  solution	   	   5	  mg/ml	  
BlueNative-­‐PAGE	   	   	   	  
	   3X	  Gel	  buffer	   	   200	  mM	  6-­‐aminohexanoic	  acid	  
150	  mM	  Bis-­‐Tris	  




	   10X	  Anode	  buffer	   	   500	  mM	  Bis-­‐Tris	  
pH	  7.0	  
	   10X	  BlueNative	  loading	  dye	   	   5%	  w/v	  Coomassie	  brilliant	  blue	  G	  
500	  mM	  6-­‐aminohexanoic	  acid	  
100	  mM	  Bis-­‐Tris	  
pH	  7.0	  	  
	   10X	  Cathode	  buffer	   	   150	  mM	  Bis-­‐Tris	  
500	  mM	  Tricine	  
pH	  7.0	  
	   Acrylamide-­‐bisacrylamide	   mix	  
(49.5%	  T,	  3%	  C)	  
	   96	  g	  acrylamide	  
3	  g	  bisacrylamide	  
In	  200	  ml	  ddH2O	  
	   Coomassie	  solution	   	   0.2%	  (w/v)	  Coomassie	  brilliant	  blue	  G	  
in	  ddH2O	  





Cell	  lysis	   	   	   	  
	   BioID-­‐lysis	  buffer	   	   2%	  (v/v)	  Triton	  X-­‐100	  
0.4%	  (w/v)	  SDS	  
500	  mM	  NaCl	  
5	  mM	  EDTA	  
1	  mM	  DTT	  
50	  mM	  Tris	  pH	  7.4	  





	   RIPA	  buffer	   	   0.1%	  (w/v)	  SDS	  
0.5%	  (w/v)	  sodium	  deoxycholate	  
1%	  (v/v)	  Nonidet-­‐P40	  
150	  mM	  NaCl	  
50	  mM	  Tris	  pH	  8.0	  
	   StrepTag	  lysis	  buffer	   	   1%	  (v/v)	  Triton	  X-­‐100	  
150	  mM	  NaCl	  
7.5%	  (v/v)	  glycerol	  
2	  mM	  CaCl2	  
2	  mM	  MgCl2	  
50	  mM	  Tris	  pH7.4	  
Chromatography	   	   	   	  
	   Acetonitrile	  MS-­‐grade	   Biosolve	  BV	   	  
	   Formic	  acid	  MS-­‐grade	   Sigma	  Aldrich	   	  
	   Trifluoro	  acetic	  acid	  MS	  grade	   Sigma	  Aldrich	   	  
	   Water	  MS-­‐grade	   Biosolve	  BV	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Cloning	   	   	   	  
	   Phusion	  High	  Fidelity	  DNA	  
Polymerase	  Kit	  
NEB	   	  
	   QIAprep	  Midiprep	  Kit	   Qiagen	   	  
	   QIAprep	  Miniprep	  Kit	   Qiagen	   	  
	   QIAquick	  Gel	  Extraction	  Kit	   Qiagen	   	  
	   QIAquick	  PCR	  Purification	  Kit	   Qiagen	   	  
	   REDTaq	  Ready	  Mix	   Sigma	  Aldrich	   	  
	   Restriction	  enzymes	  incl.	  buffers	   Thermo	  
Scientific	  
	  
	   StarGate®	   Twin-­‐Strep®	   Cloning	  
Kit,	  mammalian	  
IBA	  lifesciences	   	  





	   	   	  
	   1000X	  4’,6-­‐diamidino-­‐2-­‐
phenylindole	  (DAPI)	  solution	  	  
	   1	  mg/ml	  in	  ddH2O	  
	   4%	  PFA	  solution	   	   4%	  (w/v)	  PFA	  in	  1X	  PBS	  
	   Ammoniumchloride	  solution	   	   50	  mM	  NH4Cl	  in	  1X	  PBS	  
	   Blocking	  solution	   	   1%	  (w/v)	  BSA	  in	  1X	  TBS	  
	   Permeablization	  solution	   	   0.3%	  (v/v)	  Triton	  X-­‐100	  in	  1X	  TBS	  





	   	   	  
	   RapiGest	  surfactant	   Waters	   	  
	   Trypsin	   from	   porcine	   pancreas	  
(Proteomics	  grade)	  
Sigma	  Aldrich	   	  
Miscellaneous	   	   	   	  
	   1X	  PBS	  	   	   137	  mM	  NaCl	  
2.7	  mM	  KCl	  
10	  mM	  Na2HPO4	  
2	  mM	  KH2PO4	  
pH	  7.4	  	  
	   1X	  TBS	  pH	  8.0	   	   100	  mM	  Tris	  	  
150	  mM	  NaCl	  
pH	  8.0	  
	   StrepTag	  washing	  buffer	   	   0.1%	  (v/v)	  Triton	  X-­‐100	  
150	  mM	  NaCl	  
7.5%	  (v/v)	  glycerol	  
2	  mM	  CaCl2	  
2	  mM	  MgCl2	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50	  mM	  Tris	  pH8.0	  
Mouse	  genotyping	   	   	   	  
	   Genotyping	  lysis	  buffer	   	   150	  mM	  NaCl	  
2	  mM	  EDTA	  
1%	  (w/v)	  SDS	  
20	  mM	  Tris	  pH	  8.0	  
	   Proteinase	  K	   	   10	  mg/ml	  in	  ddH20	  
	   saturated	  NaCl	   	   ~6	  M	  NaCl	  in	  ddH20	  
Myelin	  preparation	   	   	   	  
	   10.5%	  sucrose	  solution	   	   10.5	  g	  sucrose	  
1	  mM	  EDTA	  	  
add	  100	  ml	  H2O	  
	   30%	  sucrose	  solution	  
	  
	   30	  g	  sucrose	  
1	  mM	  EDTA	  
add	  100	  ml	  H2O	  
	   EDTA	  
(ethylenediaminetetraacetic	  
acid)	  solution	  
	   1	  mM	  EDTA	  
in	  ddH20	  
	   cOmplete™	  protease	  inhibitor	  
cocktail	  tablets	  	  
Roche	   	  
Protein	  content	  
estimation	  
	   	   	  
	   BioRad	  DC	  Protein	  Assay	   Biorad	   	  
Protein	  precipitation	   	   	   	  
	   Acetone	   Carl	  Roth	   	  
	   Chloroform/Methanol	  
(CHCl3/MeOH)	  mix	  
	   2	  volumes	  chloroform	  (CarlRoth)	  
1	  volumes	  methanol	  (CarlRoth)	  
	   Methanol	   CarlRoth	   	  
SDS-­‐PAGE	   &	   Western	  
blotting	  
	   	   	  
	   10X	  SDS	  running	  buffer	   	   0.25	  M	  Tris-­‐Base	  
14.5%	  (v/v)	  glycerol	  
1%	  (w/v)	  SDS	  
	   4X	   sample	   buffer	   (Laemmli	  
buffer)	  
	   8%	  SDS	  
40%	  (v/v)	  glycerol	  
240	  mM	  Tris-­‐HCl	  pH	  6.8	  
4%	  (w/v)	  bromphenolblue	  
4%	  (v/v)	  ß-­‐mercaptoethanol	  
	   Blotting	  buffer	   	   48	  mM	  Tris-­‐Base	  
39	  mM	  glycine	  
0.037%	  (w/v)	  SDS	  
20%	  (v/v)	  methanol	  
pH	  8.3	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   PageBlue	   Protein	   Staining	  
Solution	   (Coomassie-­‐staining	  
solution)	  
ThermoScientific	   	  





	   PonceauS	  staining	  solution	   	   0.2%	  (w/v)	  Ponceau	  S	  
3%	  (w/v)	  trichloroacetic	  acid	  (TCA)	  
	   Strep-­‐Tactin®-­‐HRP	  conjugate	   IBA	  lifesciences	   	  
	   Stripping	  buffer	  (Acidic)	   	   200	  mM	  glycine	  
0.1%	  (w/v)	  SDS	  
1%	  (v/v)	  Tween	  20	  
pH	  2.2	  
	   TBS-­‐T	   	   1	  X	  TBS	  
0.05%	  (v/v)	  Tween	  20	  
Whole	  brain	  lysate	   	   	   	  
	   High-­‐SDS	  buffer	   	   8%	  (w/v)	  SDS	  
300	  mM	  NaCl	  
100	  mM	  Tris	  
pH	  8.0	  
	   	   	   	  
3.1.5 Antibodies	  
The	  following	  table	  states	  the	  antibodies	  and	  their	  dilutions	  for	  Western	  blotting	  used	  in	  this	  study.	  
Table	  3-­‐5:	  Antibody	  list.	  




Manufacturer	   Product	  
number	  
Misc.	  
Primary	   	   	   	   	   	   	  
	   ACSL3	   rabbit	   1:1000	   ThermoScientific	   PA5-­‐29507	   	  
	   ALDH3A2	   rabbit	   1:1000	   Abcam	   ab113111	   	  
	   ApoE	   goat	   1:500	   Santa	  Cruz	  
Biotechnology	  
sc-­‐6384	   	  
	   Biotin	  	   	   1:15,000	   ThermoScientific	   	   no	  antibody	  but	  
Streptavidin-­‐HRP	  
conjugate	  
	   C1q	  	   mouse	   1:500	   Hycult	  
biotechnology	  b.v.	  
HM1096	   clone	  JL-­‐1	  
	   FA2H	  	   rabbit	   1:800	   Pineda	  (Berlin)	   -­‐	   serum	  #2,	  affinity	  
purified	  
	   GFAP	   mouse	   1:1000	   MP	  Biomedicals	  
Immuno	  
691102	   	  
	   GFP	   rabbit	   1:5000	   –	  
10,000	  
Abcam	   ab290	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   MAPT	  (Tau)	  	   mouse	   1:1000	   Dianova	   DLN-­‐08565	   Ab2,	  clone	  TAU-­‐5	  
	   MBP	   rabbit	   1:10,000	   Millipore	   AB980	   	  
	   NF-­‐H	  (NF200)	   rabbit	   1:1000	   SigmaAldrich	   N4142	   	  
	   Opalin	  	   mouse	   1:500	   Santa	  Cruz	  
Biotechnology	  
sc-­‐374490	   H12	  
	   Periaxin	  (N-­‐term.)	   rabbit	   1:20,000	   Kindly	  provided	  by	  
Prof.	  Brophy	  
(Edinburgh)	  
	   Detects	   both	  
periaxin	  isoforms	  
	   PGRMC1	   rabbit	   1:1000	   Abcam	   ab80941	   	  
	   SACM1L	   rabbit	   1:500	   ThermoScientific	   PA5-­‐26565	   	  
	   SPTLC1	   rabbit	   1:2000	   Kindly	  provided	  by	  
Prof.	  Hornemann	  
(Zurich)	  
	   	  
	   StrepTag	  	   -­‐	   1:5000	   IBA	  lifesciences	   2-­‐1502-­‐001	   no	  antibody	  but	  
StrepTactin-­‐HRP	  
conjugate	  
Secondary	   	   	   	   	   	   	  
	   α-­‐goat-­‐DyLight800	   donkey	   1:10,000	   ThermoScientific	   SA5-­‐10092	   	  
	   α-­‐goat-­‐HRP	   chicken	   1:5000	   Dianova	   	   	  
	   α-­‐mouse-­‐
DyLight649	  
goat	   1:10,000	   ThermoScientific	   	   	  
	   α-­‐mouse-­‐
DyLight800	  
goat	   1:10,000	   ThermoScientific	   	   	  
	   α-­‐mouse-­‐HRP	   goat	   1:5000	   Dianova	   	   	  
	   α-­‐rabbit-­‐DyLight649	   goat	   1:10,000	   ThermoScientific	   	   	  
	   α-­‐rabbit-­‐DyLight800	   goat	   1:10,000	   ThermoScientific	   	   	  
	   α-­‐rabbit-­‐HRP	   goat	   1:5000	   Dianova	   	   	  
	   	   	   	   	   	   	  
3.1.6 Bacterial	  strains	  
The	  table	  bellow	  lists	  the	  bacterial	  strains	  used.	  
Table	  3-­‐6:	  Bacterial	  strains	  used	  in	  this	  thesis	  work.	  
Name	   Description	  
XL1	  blue	   E.coli	  XL1	  blue	  strain	  
dam-­‐	  K12	   dam	  negative	  E.coli	  strain	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3.1.7 Eukaryotic	  cell	  lines	  
The	  following	  cell	  lines	  were	  used	  and	  cultured	  in	  the	  indicated	  media.	  
Table	  3-­‐7:	  Cell	  lines	  used	  in	  alphabetical	  order.	  
Name	   Description	   Culture	  conditions	  
BHK	   Baby	  hamster	  kidney	  cells	   DMEM-­‐GlutaMAX™	   containing	   100	   U/ml	  
Penicillin,	  100	  μg/ml	  Streptomycin	  and	  5%	  
FCS	  (heat	  inactivated)	  
HEK293	   Human	  embryonic	  kidney	  cells	  293	   DMEM-­‐GlutaMAX™	   containing	   100	   U/ml	  
Penicillin,	   100	   μg/ml	   Streptomycin	   and	  
10%	  FCS	  (heat	  inactivated)	  
HEK293+Twin-­‐Strep-­‐mFA2H	  stable	  
clone	  A3	  
Human	  embryonic	  kidney	  cells	  293	  
stably	   transfected	   with	   Twin-­‐
Strep-­‐mFA2H	  
DMEM-­‐GlutaMAX™	   containing	   100	   U/ml	  
Penicillin,	   100	   μg/ml	   Streptomycin	   and	  
10%	   FCS	   (heat	   inactivated),	   500	   µg/ml	  
G418	  
HEK293-­‐T	   Derivative	   of	   HEK293	   cells	   stably	  
transfected	   with	   SV40	   Large	   T-­‐
antigen	  
DMEM-­‐GlutaMAX™	   containing	   100	   U/ml	  
Penicillin,	   100	   μg/ml	   Streptomycin	   and	  
10%	  FCS	  (heat	  inactivated)	  
HeLa	   Immortalized	   cell	   line	   isolated	  
from	   cervical	   cancer	   Henrietta	  
Lacks	  
DMEM-­‐GlutaMAX™	   containing	   100	   U/ml	  
Penicillin,	   100	   μg/ml	   Streptomycin	   and	  
10%	  FCS	  (heat	  inactivated)	  
	   	   	  
3.1.8 Mice	  strains	  
All	  animals	  were	  obtained	  from	  our	  in-­‐house	  animal	  facility.	  The	  wildtype	  and	  FA2H-­‐KO	  animals	  used	  
in	   all	   experiments	   had	   either	   a	  mixed	   129Ola/C57BL/6	   or	   a	   C57BL/6	   genetic	   background.	   All	  mice	  
were	   raised	   in	   accordance	   with	   the	   instructions	   of	   local	   and	   state	   authorities	   regarding	   animal	  
welfare.	  
3.1.9 Oligonucleotides	  
All	  used	  oligonucleotides	  were	  ordered	  at	  Eurofins	  MWG	  Operon.	  
Table	  3-­‐8:	  Oligonucleotides	  used	  for	  cloning	  and	  PCR.	  
Name	   Sequence	  (5à3)	  
BiFC	  mFA2H_C	  (ClaI)	  RV	   TC-­‐ATCGAT-­‐CTGCATCTTCGGGTGGGC	  
BiFC	  mFA2H_C	  (EcoRI)	  FW	   AT-­‐GAATTC-­‐ATGGCCCCCGCTCCGC	  
BiFC	  mCerS2_C	  (ClaI)	  RV	   TC-­‐ATCGAT-­‐GTCATTCTTAGGATGATTGTTAT	  
BiFC	  mCerS2_C	  (EcoRI)	  FW	   AT-­‐GAATTC-­‐ATGCTCCAGACCTTGTATG	  	  
BiFC-­‐hACSL3_C	  (ClaI)	  RV	   TC-­‐ATCGAT-­‐TTTTCTTCCATACATTCGCTCAA	  
BiFC-­‐hACSL3_C	  (EcoRI)	  FW	   AT-­‐GAATTC-­‐ATGAATAACCACGTGTCTTCAAA	  
BiFC-­‐hPGRMC1_C	  (ClaI)	  RV	   TC-­‐ATCGAT-­‐ATCATTTTTCCGGGCACTCTCATC	  
BiFC-­‐hPGRMC1_C	  (EcoRI)	  FW	   AT-­‐GAATTC-­‐ATGGCTGCCGAGGATGTGGT	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BiFC-­‐hSPTLC1_C	  (EcoRI)	  FW	   CT-­‐GAATTC-­‐ATG	  GCG	  ACC	  GCC	  ACG	  GAG	  
BiFC-­‐hSPTLC1_C	  (ClaI)	  RV	   TT-­‐ATCGAT-­‐	  GAGCAGGACGGCCTGGG	  
BioID-­‐mFA2H	  (EcoRI)	  FW	   AT-­‐GAATTC-­‐ATGGCCCCCGCTCCGC	  
BioID-­‐mFA2H	  (KpnI)	  RV	   TG-­‐GGTACC-­‐TCACTGCATCTTCGGGTG	  
FA2Hanti	  (genotyping	  primer)	   GCTCTTCTTCAAGAGCCATCC	  
FA2Hneo	  (genotyping	  primer)	   ATTCGCAGCGCATCGCCTTCTATC	  
FA2Hwtsense	  (genotyping	  primer)	   GTGCTGTACCTCAGCTGGTC	  
Twin-­‐Strep-­‐mFA2H	  1-­‐163	  RV	   AGCGGCTCTTCTCCC-­‐GGCCTCGATGAGGTCTGAG	  	  
Twin-­‐Strep-­‐mFA2H	  FW	   AGCGGCTCTTCAATG-­‐GCCCCCGCTCCGCCC	  
Twin-­‐Strep-­‐mFA2H	  RV	   AGCGGCTCTTCTCCC-­‐CTGCATCTTCGGGTGGGC	  
	   	  
3.1.10 Plasmids	  
The	  table	  bellow	  list	  the	  plasmids	  utilized	  in	  this	  thesis.	  
Table	  3-­‐9:	  Plasmids	  cloned	  and/or	  used	  in	  this	  thesis.	  
Name	   Insert/protein	  product	   Source	   Remarks	  
pcDNA3	   -­‐	   Invitrogen	   	  
pcDNA3-­‐hACSL3-­‐cYFP1	   Human	  ACSL3	  with	  C-­‐
terminal	  citrine	  YFP1-­‐tag	  for	  
BiFC	  
-­‐	   PCR	  copied	  from	  pEGFP-­‐
hACSL3-­‐HA.	  Inserted	  via	  
EcoRI	  and	  ClaI.	  
pcDNA3-­‐hACSL3-­‐YFP2	   Human	  ACSL3	  with	  C-­‐
terminal	  citrine	  YFP2-­‐tag	  for	  
BiFC	  
-­‐	   PCR	  copied	  from	  pEGFP-­‐
hACSL3-­‐HA.	  Inserted	  via	  
EcoRI	  and	  ClaI.	  
pcDNA3-­‐hPGRMC1-­‐cYFP1	   Human	  PGRMC1	  with	  C-­‐
terminal	  citrine	  YFP1-­‐tag	  for	  
BiFC	  
-­‐	   PCR	  copied	  from	  pCMV-­‐
SPORT6-­‐hPGRMC1.	  Inserted	  
via	  EcoRI	  and	  ClaI.	  
pcDNA3-­‐hPGRMC1-­‐YFP2	   Human	  PGRMC1	  with	  C-­‐
terminal	  citrine	  YFP2-­‐tag	  for	  
BiFC	  
-­‐	   PCR	  copied	  from	  pCMV-­‐
SPORT6-­‐hPGRMC1.	  Inserted	  
via	  EcoRI	  and	  ClaI.	  
pcDNA3-­‐mCerS2-­‐cYFP1	   Murine	  CerS2	  (Lass2)	  with	  C-­‐
terminal	  citrine	  YFP1-­‐tag	  for	  
BiFC	  
-­‐	   PCR	  copied	  from	  pCMV-­‐
SPORT6-­‐mCerS2.	  Inserted	  
via	  EcoRI	  and	  ClaI.	  
pcDNA3-­‐mCerS2-­‐YFP2	   Murine	  CerS2	  (Lass2)	  with	  C-­‐
terminal	  citrine	  YFP2-­‐tag	  for	  
BiFC	  
-­‐	   PCR	  copied	  from	  pCMV-­‐
SPORT6-­‐mCerS2.	  Inserted	  
via	  EcoRI	  and	  ClaI.	  
pcDNA3-­‐[ClaI…EcoRI]-­‐cYFP1	  
(linearized	  vector)	  
C-­‐terminal	  citrine	  YFP1-­‐tag	  
for	  BiFC	  
Kindly	   provided	   by	   Dr.	  
Reiterer/Prof.	  Hauri	  (Nyfeler	  
et	  al.	  2005)	  




C-­‐terminal	  citrine	  YFP2-­‐tag	  
for	  BiFC	  
Kindly	   provided	   by	   Dr.	  
Reiterer/Prof.	  Hauri	  (Nyfeler	  
et	  al.	  2005)	  
ClaI	  +	  EcoRi	  cut	  pcDNA3-­‐
MCFD2-­‐YFP2	  
pcDNA3-­‐mFA2H-­‐cYFP1	   Murine	  FA2H	  with	  C-­‐ -­‐	   PCR	  copied	  from	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terminal	  citrine	  YFP1-­‐tag	  for	  
BiFC	  
pcDNA3.1/zeo/mFA2H.	  	  
Inserted	  via	  EcoRI	  and	  ClaI.	  
pcDNA3-­‐mFA2H-­‐YFP2	   Murine	  FA2H	  with	  C-­‐
terminal	  citrine	  YFP2-­‐tag	  for	  
BiFC	  
-­‐	   PCR	  copied	  from	  
pcDNA3.1/zeo/mFA2H.	  
Inserted	  via	  EcoRI	  and	  ClaI.	  
pcDNA3-­‐sscYFP1-­‐ERGIC53	   Human	  ERGIC53	  with	  N-­‐
terminal	  ER-­‐targeting	  
sequence	  (ss)	  followed	  by	  
citrine	  YFP1	  
Kindly	   provided	   by	   Dr.	  
Reiterer/Prof.	  Hauri	  (Nyfeler	  
et	  al.	  2005)	  
	  
pcDNA3-­‐hSPTLC1-­‐cYFP1	   Human	  SPTLC1	  with	  C-­‐
terminal	  citrine	  YFP1-­‐tag	  for	  
BiFC	  
-­‐	   PCR	  copied	  from	  pcDNA3.1-­‐
SPTLC1-­‐his.	  Inserted	  via	  
EcoRI	  and	  ClaI.	  
pcDNA3-­‐hSPTLC1-­‐YFP2	   Human	  SPTLC1	  with	  C-­‐
terminal	  citrine	  YFP2-­‐tag	  for	  
BiFC	  
-­‐	   PCR	  copied	  from	  
pcDNA3.1his-­‐SPTLC1.	  
Inserted	  via	  EcoRI	  and	  ClaI.	  
pcDNA3-­‐ssYFP2-­‐ERGIC53	   Human	  ERGIC53	  with	  N-­‐
terminal	  ER-­‐targeting	  
sequence	  (ss)	  followed	  by	  
citrine	  YFP2	  
Kindly	   provided	   by	   Dr.	  
Reiterer/Prof.	  Hauri	  (Nyfeler	  
et	  al.	  2005)	  
	  
pcDNA3.1/zeo/mFA2H	   Murine	  FA2H	  in	  mammalian	  
expression	  vector	  with	  
Zeocin-­‐resistance	  cassette	  
RZPD	   	  
pcDNA3.1-­‐mycBioID	   myc-­‐taged	  E.coli	  biotin-­‐
ligase	  
Kind	   gift	   from	   Kyle	   Roux	  
(Roux	  et	  al.	  2012)	  
	  
pcDNA3.1-­‐mycBioID-­‐mFA2H	   Fusion	  protein	  of	  myc-­‐taged	  
E.coli	  biotin-­‐ligase	  with	  
murine	  FA2H	  
-­‐	   PCR	  copied	  from	  
pcDNA3.1/zeo/mFA2H.	  
Inserted	  via	  KpnI	  and	  EcoRI.	  












pEGFP-­‐hACSL3-­‐HA	   Human	  ACSL3	  with	  N-­‐
terminal	  EGFP	  and	  C-­‐
terminal	  HA-­‐tag	  
Kind	   gift	   from	   Dr.	   J.	  
Füllekrug	  
	  
pENTRY-­‐IBA51	   	   iba	  GmbH	  (part	  of	  StarGate®	  
cloning	  kit)	  
	  
pENTRY-­‐IBA51-­‐mFA2H	   Murine	  FA2H	   -­‐	   	  
pESG-­‐IBA103-­‐mFA2H	   Murine	  FA2H	  with	  C-­‐
terminal	  Twin-­‐Strep-­‐tag®	  
Cloned	  via	  StarGate®	  cloning	  
kit	   (iba	   GmbH),	   mFA2H-­‐
insert	   copied	   from	  
pcDNA3.1-­‐mFA2H	  (PCR)	  
PCR	  copied	  from	  
pcDNA3.1/zeo/mFA2H.	  
Inserted	  via	  recombination	  
sites.	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pESG-­‐IBA103-­‐mFA2H1-­‐163	   Murine	  FA2H	  amino	  acids	  1-­‐
163	  with	  C-­‐terminal	  Twin-­‐
Strep-­‐tag®	  
Cloned	  via	  StarGate®	  cloning	  
kit	   (iba	   GmbH),	   mFA2H-­‐
insert	   copied	   from	  
pcDNA3.1-­‐mFA2H	  (PCR)	  
PCR	  copied	  from	  
pcDNA3.1/zeo/mFA2H.	  
Inserted	  via	  recombination	  
sites.	  
pESG-­‐IBA105-­‐mFA2H	   Murine	  FA2H	  with	  N-­‐
terminal	  Twin-­‐Strep-­‐tag®	  
Cloned	  via	  StarGate®	  cloning	  
kit	   (iba	   GmbH),	   mFA2H-­‐
insert	   from	   copied	  
pcDNA3.1-­‐mFA2H	  (PCR)	  
PCR	  copied	  from	  
pcDNA3.1/zeo/mFA2H.	  
Inserted	  via	  recombination	  
sites.	  
pESG-­‐IBA105-­‐mFA2H1-­‐163	   Murine	  FA2H	  amino	  acids	  1-­‐
163	  with	  N-­‐terminal	  Twin-­‐
Strep-­‐tag®	  
Cloned	  via	  StarGate®	  cloning	  
kit	   (iba	   GmbH),	   mFA2H-­‐
insert	   copied	   from	  
pcDNA3.1-­‐mFA2H	  (PCR)	  
PCR	  copied	  from	  
pcDNA3.1/zeo/mFA2H.	  
Inserted	  via	  recombination	  
sites.	  
pcDNA3.1his-­‐SPTLC1	   Human	  SPTLC1	  with	  N-­‐
terminal	  His-­‐tag	  
Kindly	   provided	   by	   Prof.	  
Hornemann	   (Zurich,	  
Switzerland)	  
	  
	   	   	   	  
	  
	   	  




3.2.1 Animal	  work	  &	  mouse	  tissue	  preparation	  	  
3.2.1.1 Genotyping	  
The	   mice	   used	   in	   this	   thesis	   research	   were	   genotyped	   via	   polymerase	   chain	   reaction	   (PCR)	   using	  
genomic	  DNA	  derived	  from	  a	  very	  small	  tissue	  biopsy	  (tail	  tip	  or	  piece	  of	  earlobe).	  	  
The	  tissue	  was	  first	  digested	  overnight	  at	  55	  °C	  in	  750	  µl	  genotyping	  lysis	  buffer	  containing	  Proteinase	  
K	  (20	  µg/ml).	  Next	  morning,	  250	  µl	  saturated	  NaCl	  solution	  (~6	  M)	  was	  added	  followed	  by	  another	  5	  
min	  incubation	  to	  precipitate	  proteins.	  Afterwards,	  the	  samples	  were	  centrifuged	  10	  min	  at	  18,000	  g	  
and	  4	  °C	  to	  remove	  insoluble	  material.	  Subsequently,	  750	  µl	  of	  the	  supernatant	  was	  transferred	  to	  a	  
new	  microtube	  and	  the	  DNA	  precipitated	  by	   the	  addition	  of	  500	  µl	   isopropanol.	  The	  genomic	  DNA	  
was	  then	  pelleted	  for	  20	  min	  at	  4	  °C	  and	  10,000	  g,	  washed	  once	  in	  500	  µl	  70%	  (v/v)	  ethanol	  and	  air-­‐
dried	  for	  5-­‐10	  min.	  For	  solvation	  the	  pellet	  was	  resupended	  in	  200	  -­‐	  500	  µl	  ddH2O	  and	  incubated	  for	  
2-­‐4	  h	  at	   room	  temperature.	  1	  µl	  of	   the	  genomic	  DNA	  was	   thereafter	  used	   in	   the	  PCR.	  The	  primers	  
used	  for	  FA2H-­‐KO	  project	  animals	  are	  defined	  in	  Table	  3-­‐8	  (p.27)	  and	  the	  PCR-­‐program	  is	  depicted	  in	  
the	  table	  below:	  
Table	  3-­‐10:	  PCR-­‐program	  for	  FA2H-­‐KO	  genotyping	  PCR.	  
Step	   Temperature	   Time	  	   Repeat	  
1	   94	  °C	   5	  min	   	  
2	   95	  °C	   30	  s	   	  
3	   59°C	   45	  s	   	  
4	   72	  °C	   1.5	  min	   Go	  to	  step	  2,	  Repeat	  29x	  
5	   72	  °C	   10	  min	   	  
6	   4	  °C	   hold	   	  
	   	   	   	  
3.2.1.2 Myelin	  preparation	  
3.2.1.2.1 Central	  nervous	  system	  (CNS)	  myelin	  preparation	  (brain)	  
Myelin	   from	   the	   central	   nervous	   system	   i.e.	   brain	  was	   isolated	  by	   a	  protocol,	  which	   is	   based	  on	  a	  
publication	  by	  Caroni	  and	  Schwab	  (Caroni	  &	  Schwab	  1988).	  	  
It	   is	   important	   to	  note	   that	  all	  purification	   steps	  were	  carried	  out	  at	  4	   °C.	   In	  addition,	  all	   solutions	  
used	  until	  the	  first	  water	  wash	  contained	  complete	  protease	  inhibitor	  cocktail	  (Roche).	  First,	  mouse	  
brains	  were	  homogenized	  in	  10.5%	  isotonic	  sucrose	  solution	  using	  an	  Ultra-­‐Turrax	  homogenizer	  (3X	  
intervals:	  20	  s	  homogenization,	  1	  min	  pause	  on	  ice).	  This	  led	  to	  the	  detachment	  of	  the	  myelin	  sheath	  
from	  the	  axon	  and	  the	  generation	  of	  myelin	  vesicles.	  Then,	  to	  obtain	  a	  crude	  density	  separation,	  the	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homogenates	  were	  centrifuged	  at	  18,000	  g	  for	  45	  min.	  Material	  with	  a	  density	  equal	  or	  higher	  than	  
the	  10.5%	  sucrose	  solution	  pelleted,	  whereas	  less	  dense	  constituents	  remained	  in	  the	  supernatants.	  
Subsequently,	   the	   supernatants	   were	   aspirated	   and	   the	   pellets	   dissolved	   in	   10	   ml	   30%	   sucrose	  
solution.	   Afterwards,	   the	   suspensions	   were	   transferred	   to	   a	   12	   ml	   ultracentrifugation	   tube	   and	  
overlaid	   carefully	   with	   2	  ml	   of	   10.5%	   sucrose.	   This	   was	   followed	   by	   50	  min	   ultracentrifugation	   at	  
68,000	   g	   using	   a	   SW-­‐41	   rotor.	  During	   this	   the	  myelin	  membrane	   vesicles	   accumulated	   as	   a	   clearly	  
visible	   interphase	   between	   the	   10.5	   and	   30	   %	   sucrose	   solution.	   Thereafter,	   the	   interphase	   was	  
transferred	   to	  a	  new	  ultracentifugation	   tube	  and	  washed	   two	   times	  with	  ddH2O	   (containing	  1	  mM	  
EDTA)	   at	   68,000	   g	   for	   30	   min	   (SW-­‐41	   rotor).	   This	   way,	   excess	   axolemmal	   contaminants	   were	  
removed.	  To	  gain	  higher	  myelin	  purity	  with	  less	  contaminants,	  the	  washed	  myelin	  pellets	  were	  again	  
subjected	   to	   the	   same	  sucrose	  density	  gradient	  and	   the	   two	  ddH2O-­‐washing	   steps.	   In	   the	  end,	   the	  
purified	  myelin	  samples	  were	  resuspended	  in	  100	  µl	  ddH2O	  (containing	  1	  mM	  EDTA)	  and	  stored	  at	  -­‐
80	  °C	  until	  analysis.	  
3.2.1.2.2 Peripheral	  nervous	  system	  (PNS)	  myelin	  preparation	  (sciatic	  nerves)	  
The	  preparation	  of	  PNS-­‐myelin	  was	  done	  in	  a	  similar	  way	  as	  the	  CNS-­‐myelin	  preparation	  with	  some	  
important	   alterations,	   because	   the	   raw	   tissue	   material	   was	   significantly	   less	   (one	   pair	   of	   sciatic	  
nerves).	   First,	   the	   sciatic	   nerves	   were	   homogenized	   using	   a	   Dounce	   homogenizer	   instead	   of	   an	  
UltraTurrax.	   Second,	   the	   whole	   procedure	   was	   scaled	   down	   i.e.	   microtubes	   (normal	   and	  
ultracentrifugal)	  and	  a	  benchtop	  ultracentrifuge	  (TLS-­‐55	  rotor)	  were	  used.	  Accordingly,	  smaller	  buffer	  
volumes	  were	  used.	  Third,	  myelin	  was	  not	  subjected	  to	  a	  second	  density	  gradient	   followed	  by	   two	  
ddH2O-­‐washing	  steps.	  While	  this	  would	  lead	  to	  purer	  PNS-­‐myelin,	  it	  would	  also	  cause	  a	  very	  high	  and	  
thus	   not	   desirable	   myelin	   loss.	   In	   addition,	   the	   sucrose	   contents	   of	   both	   gradient	   solutions	   were	  
slightly	   altered	   to	   9.2% and 28.4%, because	   PNS-­‐myelin	   exhibits	   a	   lower	   density	   than	   its	   CNS	  
counterpart	  (Larocca	  &	  Norton	  2007).	  
3.2.1.3 Whole	  brain	  lysate	  preparation	  
For	  preparation	  of	  whole	  brain	  lysates,	  750	  µl	  of	  the	  brain	  homogenates	  produced	  during	  CNS-­‐myelin	  
purification	  were	   transferred	   to	   a	  microtube	   and	  mixed	  with	   750	  µl	  High-­‐SDS	  buffer	   (8%	  SDS,	   300	  
mM	  NaCl,	   100	  mM	   Tris,	   pH	   8.0).	   The	   samples	   were	   heated	   to	   99	   °C	   for	   5	  min,	   followed	   by	   DNA	  
shearing	  via	  ultrasonification	  (3X	  10	  s)	  and	  another	  5	  min	  heating	  at	  99	  °C.	  Subsequently,	  the	  protein	  
amount	  was	  determined	  and	  the	  samples	  stored	  at	   -­‐80	  °C.	  Furthermore,	  150	  µl	  of	  each	   lysate	  was	  
mixed	  with	  50	  µl	  4X	  Laemmli-­‐buffer,	  denatured	  5	  min	  at	  95	  °C	  and	  also	  stored	  at	  -­‐80	  °C.	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3.2.2 Bacterial	  culture	  techniques	  
3.2.2.1 Cell	  maintenance	  
For	   liquid	   culture,	   bacteria	   were	   usually	   grown	   overnight	   in	   a	   shaking	   incubator	   in	   LB-­‐medium	  
containing	   an	   appropriate	   antibiotic	   at	   37	   °C	   and	   200	   rpm.	   To	   obtain	   single	   colonies,	   e.g.	   after	  
transformation,	   cells	  were	   spread	   onto	   LB-­‐agarose	   plates	   containing	   an	   appropriate	   antibiotic	   and	  
grown	  at	  37	  °C	  overnight.	  
3.2.2.2 Transformation	  of	  chemical	  competent	  bacteria	  
The	  delivery	  of	   plasmids	   into	   a	  bacterial	   cell	   is	   called	   transformation.	   It	   is	   generally	   used	   to	  either	  
achieve	   plasmid	   amplification	   or	   recombinant	   protein	   expression.	   One	   method	   uses	   a	   chemical	  
treatment	  in	  combination	  with	  heat-­‐shocking.	  While	  the	  first	  prevents	  the	  electrostatic	  repulsion	  of	  
the	   foreign	  DNA	  by	  the	  cell	  membrane,	  using	  high	  concentrations	  of	  calcium,	  the	  second	  opens	  up	  
pores	  in	  it,	  thereby	  allowing	  plasmid	  entry.	  
For	   this	   thesis	   ready-­‐made	   chemical	   competent	   bacteria	   were	   used.	   For	   transformation	   ~1	   ng	   of	  
plasmid-­‐DNA	  was	  mixed	  with	  100	  µl	  of	  chemically	  competent	  cells	  pre-­‐thawed	  on	  ice	  and	  incubated	  
for	   30	  min.	   To	   achieve	  plasmid	  uptake,	   they	  were	  heat	   shocked	   afterwards	   for	   1	  min	   at	   42°C	   and	  
subsequently	  put	  back	  on	  ice	  for	  2	  min.	  In	  the	  case	  of	  a	  kanamycin-­‐resistance	  containing	  plasmid,	  this	  
was	  follow	  by	  the	  addition	  of	  900	  µl	  pre-­‐warmed	  LB-­‐medium	  and	  incubation	  at	  37	  °C	  and	  600	  rpm	  for	  
1	  h.	   For	  ampicillin-­‐resistance	  plasmids	   this	   step	  was	  omitted.	   In	   the	  end,	   the	   transformed	  bacteria	  
were	  spread	  onto	  LB-­‐plates	  containing	  the	  appropriate	  antibiotic	  and	  grown	  overnight	  at	  37	  °C.	  
3.2.3 Eukaryotic	  cell	  culture	  techniques	  
3.2.3.1 Cell	  maintenance	  
Cells	  were	  handled	  under	  sterile	  conditions	  using	  laminar	  airflow	  workbenches	  and	  heat-­‐sterilized	  or	  
autoclaved	  materials.	   Cells	  were	  grown	   in	   an	   incubator	   in	   standard	   cell	   culture	   vessels	   in	   a	  water-­‐
saturated	  atmosphere	  at	  37	  °C	  and	  5%	  CO2.	  	  
3.2.3.2 Cell	  passaging	  
For	  cell	  passaging	  the	  cell	  medium	  was	  drawn	  out	  of	  the	  vessel	  and	  replaced	  with	  37	  °C	  warm	  1X	  PBS	  
to	  wash	  the	  cells.	  Afterwards,	  PBS	  was	  removed	  and	  an	  appropriate	  amount	  of	  0.05%	  (w/v)	  trypsin	  
solution	  added	  to	  cover	  the	  whole	  vessel.	  The	  cells	  were	  then	  placed	  back	  into	  a	  37	  °C	  incubator	  for	  2	  
-­‐	  5	  min	  to	  allow	  enzymatic	  cell	  detachment.	  Subsequently,	  the	  cells	  were	  resuspended	  in	  cell	  culture	  
medium	  containing	  5	  -­‐	  10%	  FCS	  to	  stop	  the	  enzymatic	  reaction.	  For	  simple	  cell	  maintenance,	  1/5	  –	  
1/10	  of	   the	   cell	   suspension	  was	   seeded	  onto	  a	  new	  culture	   vessel	   and	   filled	  up	  with	  medium.	   If	   a	  
3	  Material	  &	  Methods	  
	  
34	  
precise	  amount	  of	  cells	  was	  needed	  the	  cell	  number	  was	  determined	  before	  using	  a	  Neubauer	  cell	  
counting	  chamber.	  Thereafter,	  cells	  were	  placed	  back	  into	  the	  37	  °C	  incubator.	  
3.2.3.3 Cryo	  preservation	  
First,	  cold	  preservation	  medium	  had	  to	  be	  prepared	  by	  mixing	  9	  volumes	  of	  the	  cell	  culture	  medium	  
the	  cells	  normally	  grow	  in	  with	  1	  volume	  of	  DMSO.	  Then	  the	  cells	  were	  detached	  as	  described	  before	  
(3.2.3.2	   Cell	   passaging),	   pelleted	   by	   centrifugation	   and	   resuspended	   in	   cold	   preservation	  medium.	  
Finally,	   they	  were	   transferred	   into	   cryotubes,	   immediately	  put	  on	   ice	   to	  minimize	  DMSO-­‐mediated	  
cytotoxicity	   and	   slowly	   pre-­‐frozen	   in	   a	   Styrofoam	   block	   overnight	   to	   -­‐80	   °C.	   At	   the	   next	   day	   the	  
cryotubes	  were	  relocated	  into	  a	  liquid	  nitrogen	  tank	  for	  long-­‐term	  storage.	  
3.2.3.4 Cell	  revival	  from	  cryo	  preservation	  
Cryotubes	  were	  thawed	  until	  a	  small	  ice	  core	  remained,	  their	  content	  transferred	  to	  a	  sterile	  conical	  
tube	  containing	  ice-­‐cold	  cell	  culture	  medium	  and	  everything	  mixed	  by	  inversion.	  Next,	  the	  cells	  were	  
pelleted	  by	  centrifugation	  and	  the	  supernatant	  aspirated	  to	  remove	  toxic	  DMSO-­‐remains.	  In	  the	  end	  
they	  were	   resuspended	   in	  warm	   culture	  medium,	   transferred	   to	   a	   new	   cell	   culture	   vessel	   and	  put	  
into	  the	  37	  °C	  incubator.	  
3.2.3.5 Stable	  isotope	  labeling	  by	  amino	  acids	  in	  cell	  culture	  (SILAC)	  
In	   “stable	   isotope	   labeling	   by	   amino	   acids	   in	   cell	   culture”	   (SILAC),	   all	   proteins	   of	   a	   cell	   are	  
metabolically	  labeled	  by	  growing	  them	  for	  at	  least	  6	  cell	  divisions	  in	  media	  containing	  either	  light	  or	  
heavy	   isotopes	  of	   amino	  acids	   (usually	   arginine	  and	   lysine).	   This	   later	   allows	  a	   very	   robust	   relative	  
protein	   quantitation	   by	  mass	   spectrometry	   between	   differently	   labeled	   samples	   (Ong	   et	   al.	   2002)	  
(Figure	  3-­‐1).	  	  




Figure	   3-­‐1:	   Principle	   of	   SILAC.	   Cellular	   proteins	   are	   labeled	   by	   growing	   cells	   for	   some	   passages	   in	   culture	  
medium	  containing	  light	  or	  heavy	  isotopes	  of	  certain	  amino	  acids	  (usually	  arginine	  and/or	  lysine).	  After	  at	  least	  
six	   passages	   most	   of	   the	   proteins	   are	   labeled.	   Subsequent	   mass	   spectrometric	   processing	   allows	   the	  
comparison	   of	   protein	   abundances	   between	   differentially	   labeled	   and	   treated	   samples.	   Picture	   from:	  
https://commons.wikimedia.org/wiki/File:Silac.gif	  
In	  this	  study	  cells	  were	  labeled	  for	  at	  least	  6	  passages	  (=98.4%	  incorporation	  rate)	  with	  either	  a	  light	  
(natural	   lysine	   and	   arginine)	   or	   a	   heavy	   amino	   acid	   mix	   (15N213C6-­‐lysine	   and	   15N413C6-­‐arginine)	   in	  
DMEM.	  In	  this	  process	  the	  cells	  were	  split	  each	  day	  1:1	  into	  fresh	  medium.	  In	  the	  end	  the	  success	  of	  
label	   incorporation	   was	   assessed	   by	   MALDI-­‐TOF/TOF	   protein	   analysis	   after	   cell	   lysis	   and	   in-­‐gel	  
digestion.	  
3.2.3.6 Transfection	  
In	  this	  thesis	  the	  following	  two	  methods	  were	  used	  for	  delivering	  plasmid	  into	  eukaryotic	  cells.	  
3.2.3.6.1 Calcium	  phosphate	  method	  (CaPO4-­‐method)	  
This	   method	   for	   the	   delivery	   of	   plasmid	   DNA	   into	   eukaryotic	   cells	   is	   especially	   effective	   for	  
HEK293/HEK293-­‐T	  cells.	  Usually	  transfection	  efficiencies	  of	  ≥90%	  are	  achieved.	  The	  principle	  of	  this	  
method	  is	  that	  the	  plasmid	  DNA	  is	  precipitated	  together	  with	  calcium	  and	  phosphate,	  thereby	  giving	  
rise	   to	   DNA-­‐calcium	   phosphate	   precipitates.	   These	   precipitates	   are	   then	   spread	   on	   the	   cells	   and	  
probably	  taken	  up	  by	  endocytosis.	  After	  one	  round	  of	  mitosis,	  during	  which	  the	  nuclear	  membrane	  is	  
broken	   down,	   the	   plasmid	   DNA	   can	   finally	   reach	   the	   cell	   nucleus.	   A	   detailed	   description	   of	   the	  
method	  is	  given	  below.	  Table	  3-­‐11	  gives	  the	  seeding	  densities	  and	  transfection	  reagent	  volumes	  used	  
for	  different	  culture	  plate	  formats.	  
Table	  3-­‐11:	  Cell	  densities	  and	  transfection	  reagent	  volumes	  for	  different	  culture	  plate	  formats.	  








6	  well	   5x	  105	   13	   2	   100	   100	  
6	  cm	  plate	   3-­‐4x	  106	   26	   4	   200	   200	  
10	  cm	  plate	   3x	  106	   65	   10	   500	   500	  
15	  cm	  plate	   8x	  106	   130	   20	   1000	   1000	  




First,	  the	  cells	  were	  seeded	  one	  day	  prior	  to	  transfection	  at	  the	  appropriate	  cell	  density.	  At	  the	  next	  
step	  the	  transfection	  mixture	  was	  prepared	  by	  first	  diluting	  the	  plasmid	  together	  with	  CaCl2	  in	  sterile	  
ddH2O.	  Then	  this	  mixture	  was	  added	  drop-­‐by-­‐drop	  under	  constant	  shaking	  to	  the	  indicated	  amount	  
of	   sterile	   2X	   HBS	   (50	   mM	   HEPES,	   280	   mM	   NaCl,	   1.5	   mM	   Na2HPO4,	   pH	   7.0).	   To	   allow	   efficient	  
precipitate	   formation	   the	   mixture	   was	   kept	   at	   room	   temperature	   for	   30	   min.	   Afterwards,	   it	   was	  
mixed	   once	   by	   pipetting	   up	   and	   down	   and	   evenly	   spread	   onto	   the	   cells	   in	   a	   drop	  wise	  matter.	   In	  
addition,	   the	   culture	   plate	   was	   carefully	   tilted	   to	   achieve	   uniform	   complex	   distribution.	   The	   cells	  
were	   then	   incubated	   at	   37	   °C	   and	   5%	   CO2	   for	   24	   or	   48	   h	   depending	   on	   the	   intended	   construct	  
expression	  strength.	  	  
3.2.3.6.2 TurboFect™	  
BHK	   and	   HeLa	   cells	   were	   transfected	   using	   the	   commercial	   available	   cationic	   polymeric	   reagent	  
TurboFect™	   according	   to	   the	  manufacturers	   protocol.	   Shortly,	   cells	   were	   seeded	   one	   day	   prior	   to	  
transfection	   so	   that	   they	   showed	  about	  90%	  confluence	   the	  next	  day	   (6	  well	  =~2.5x105	   cells/well).	  
For	  transfection	  the	  plasmid	  DNA	  (6	  well	  =	  4	  µg/well)	  was	  first	  diluted	  in	  an	  appropriate	  amount	  of	  
fresh	   serum-­‐	   and	   antibiotic-­‐free	   growth	   medium	   (6	   well	   =	   400	   µl/well).	   Afterwards,	   TurboFect™-­‐
reagent	  was	  added	  (6	  well	  =	  5	  µl/well)	  and	  everything	  mixed	  thoroughly.	  After	  15	  -­‐	  20	  min	  incubation	  
at	  room	  temperature	  the	  transfection	  mixture	  was	  pipetted	  onto	  the	  cells	  and	  evenly	  distributed	  by	  
mild	  shaking.	  Cells	  were	  then	  put	  back	  into	  a	  37	  °C	  incubator	  and	  incubated	  for	  24	  or	  48	  h.	  Usually	  for	  
48	   h-­‐expressions	   the	   cell	   culture	   medium	   was	   replaced	   with	   fresh	   one	   after	   24	   h	   to	   reduce	  
cytotoxicity	  evoked	  by	  prolonged	  TurboFect™	  exposure.	  
3.2.3.7 Stable	  cell	  line	  generation	  
To	  obtain	  cell	  lines,	  which	  stably	  express	  the	  transgene	  of	  choice,	  cells	  were	  first	  transfected	  with	  an	  
appropriate	  plasmid	  containing	  both	  the	  transgene	  and	  a	  selectable	  marker	  gene,	  i.e.	  puromycin	  or	  
neomycin	   resistance	   gene.	   Therefore,	   at	   a	   first	   step	   the	   limiting	   concentration	   of	   the	   antibiotic	  
inducing	  cell	  death	  had	  to	  be	  determined	  for	  each	  cell	  line	  individually.	  Afterwards,	  the	  cells	  of	  choice	  
were	   seeded	  onto	   a	   10	   cm	   culture	   plate	   and	   transfected.	   Approximately	   24	   h	   later	   the	   respective	  
antibiotic	   was	   added	   to	   the	   cells	   at	   a	   concentration	   slightly	   over	   the	   limiting	   concentration	  
determined	  before.	  The	   cells	  were	  now	  grown	   for	  ~14	  days	  under	   constant	   selective	  pressure	  and	  
the	  medium	   replaced	   every	   2nd	   –	   3rd	   day.	   Subsequently,	   single	   colonies,	   derived	   from	   cells	   that	  
integrated	  the	  plasmid	  or	  parts	  of	  it	  stably	  into	  their	  genome,	  were	  picked	  under	  a	  microscope	  using	  
pipette	  tips.	  The	  clones	  were	  transferred	  to	   individual	  wells	  of	  a	  24	  well	  plate	  and	  cultivated	  under	  
constant	  selective	  pressure	  until	  reaching	  confluency.	  This	  was	  followed	  by	  further	  passages	  to	  well	  
plates	   of	   increasing	   sizes.	   At	   the	   6	   well	   stage	   all	   clones	   still	   viable	   were	   tested	   for	   transgene	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expression	  by	  WB.	  Then	  positive	  clones	  were	  further	  propagated	  on	  10	  cm	  dishes	  and	  finally	  stored	  
by	  cryo	  preservation	  until	  further	  usage.	  
3.2.4 Protein	  techniques	  
3.2.4.1 Proximity-­‐dependent	  protein	  biotinylation	  &	  identification	  (BioID)	  
An	  recently	  published	  method	  (Roux	  et	  al.	  2012)	  to	  identify	  interaction	  partners	  of	  a	  protein	  uses	  the	  
fusion	  of	  a	  constitutively	  active	  E.coli	  biotin	  ligase	  (BirA	  mutant	  R118G	  =	  BirA*)	  to	  it.	  When	  expressed	  
in	   cells,	   neighboring	   proteins	   are	   biotinylated	   at	   their	   N-­‐terminus	   and	   lysine	   residues,	   thereby	  
allowing	  their	  identification	  by	  mass	  spectrometry	  after	  affinity	  purification	  (Figure	  3-­‐2).	  	  
	  
Figure	   3-­‐2:	   Schematic	  model	   of	   BioID-­‐method.	   The	  protein	  of	   interest	   is	   expressed	   fused	   to	   a	   promiscuous	  
biotin	   ligase	   (BirA*),	   leading	   to	   biotinylation	   of	   proximal	   proteins.	   After	   stringent	   cell	   lysis,	   biotin-­‐marked	  
proteins	   are	   selectively	   enriched,	   digested	   to	   peptides	   and	   finally	   identified	   by	   mass	   spectrometry.	   Picture	  
adapted	  from:	  (Roux	  et	  al.	  2012).	  
For	  this	  assay,	  cells	  grown	  in	  a	  culture	  medium	  without	  biotin	  were	  first	  transfected	  with	  a	  plasmid	  
containing	   the	   fusion	   protein.	   About	   24	   h	   later,	   50	   µM	  biotin	  was	   added	   to	   the	   cells,	   followed	  by	  
another	  24	  h	  of	   incubation.	  Afterwards,	  cells	  were	  harvested	  and	  either	   lysed	  directly	  or	  stored	  at	  	  	  	  	  	  	  
-­‐20	  °C.	  	  
3.2.4.2 Paraformaldehyde	  (PFA)-­‐crosslinking	  
Another	   method	   for	   the	   identification	   of	   protein	   interaction	   partners	   is	   paraformaldehyde-­‐
crosslinking	   (PFA-­‐crosslinking).	   While	   strong	   interactions	   can	   be	   elucidated	   using	   complex	   affinity	  
purification	   and	   subsequent	   mass	   spectrometry	   analysis,	   weak	   or	   transient	   interactions	   can	   be	  
interrupted	  during	  sample	  lysis	  or	  purification.	  To	  overcome	  this,	  the	  cells	  expressing	  the	  proteins	  of	  
interest	  are	  treated	  with	  PFA	  before	  cell	  lysis,	  which	  leads	  to	  the	  covalent	  but	  reversible	  crosslinking	  
of	  proteins	  with	  their	  interacting	  and	  neighboring	  proteins	  (indirect	  interactors).	  Transient	  and	  weak	  
interactions	   are	   therefore	   preserved	   throughout	   lysis	   and	   affinity	   purification.	   During	   mass	  
spectrometric	   sample	   preparation	   the	   covalent	   bounds	   are	   again	   removed	   by	   sample	   boiling	   in	   a	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First,	   the	   cells	   expressing	   the	   protein	   of	   interest	  were	   pelleted	   and	  washed	   thrice	  with	   1X	   PBS	   to	  
remove	  all	  cell	  culture	  media	  remains.	  Then	  the	  cells	  were	  resuspended	  in	  1	  ml	  of	  37	  °C	  warm	  PFA	  
solution	   (0.25	   -­‐	   1%	   in	   1X	  PBS)	   per	   1x107	   cells	   and	   incubated	   at	   room	   temperature	  under	   constant	  
agitation	   for	   15	   min.	   Subsequently,	   they	   were	   pelleted	   at	   2000	   g	   for	   5	   min	   and	   the	   crosslinking	  
stopped	  by	  resuspension	  in	  1	  ml	  of	  ice-­‐cold	  stopping	  solution	  (1.25	  M	  glycine	  in	  PBS)	  per	  1x107	  cells.	  
Pelletizing	   and	   washing	   the	   cells	   once	   again	   with	   stopping	   solution	   finished	   the	   procedure.	  
Afterwards,	  the	  cell	  pellets	  were	  either	  lysed	  directly	  or	  stored	  at	  -­‐20	  °C.	  	  
3.2.4.3 Cell	  lysis	  
The	  cells	  were	  mixed	  with	  the	  appropriate	  amount	  (see	  Table	  3-­‐12)	  of	  the	  desired	  ice	  cold	  lysis	  buffer	  
(see	   3.1.4	   Chemicals,	   Solutions	   and	   Buffers)	   containing	   1X	   Protease	   Inhibitor	   Cocktail	  
(ThermoScientific)	  and	  resuspended	  by	  pipetting	  up	  and	  down.	  Afterwards,	  they	  were	  incubated	  for	  
30	  min	  on	  an	  overhead	  tumbling	  incubator	  at	  4	  °C,	  followed	  by	  30	  min	  centrifugation	  at	  18,000	  g	  and	  
4	  °C.	  The	  lysate	  was	  then	  transferred	  to	  a	  precooled	  microtube.	  
Table	  3-­‐12:	  Lysis	  buffer	  volumes	  used	  for	  cell	  pellets	  derived	  from	  different	  culture	  vessel	  sizes.	  
Cell	  culture	  vessel	  size	   Volume	  of	  lysis	  buffer	  
6	  well	  plate	   ~50	  -­‐	  100µl	  
10	  cm	  plate	   ~150	  -­‐	  250	  µl	  
15	  cm	  plate	   ~250	  -­‐	  500	  µl	  
	   	  
3.2.4.4 Protein	  precipitation	  
To	   remove	   excess	   amounts	   of	   lipids	   and	   to	   concentrate	   protein	   samples,	   both	   of	   the	   following	  
protein	  precipitations	  were	  employed.	  	  
3.2.4.4.1 Ice	  cold	  acetone	  
The	   protein	   samples	  were	  mixed	  with	   ice	   cold	   acetone	   at	   a	   ratio	   of	   1:4	   (vol/vol)	   and	   then	   placed	  
overnight	   at	   -­‐20	   °C	   to	   allow	   complete	   protein	   precipitation.	   At	   the	   next	   day,	   the	   samples	   were	  
centrifuged	  at	  20,000	  g	  and	  4	  °C	  for	  30	  min.	  Subsequently,	  the	  supernatants	  were	  aspirated	  carefully	  
and	  the	  pellet	  air-­‐dried	  for	  ~5	  min.	  
3.2.4.4.2 Chloroform-­‐Methanol	  
For	   CHCl3/MeOH-­‐precipitation	   the	   samples	   were	   mixed	   with	   ice-­‐cold	   chloroform/methanol	   2/1	  
(vol/vol)	   solution	   at	   a	   5:1	   ratio	   and	   vortexed	   thoroughly.	   This	   was	   followed	   by	   a	   20,000	   g	  
centrifugation	   at	   4	   °C	   for	   30	  min,	   which	   led	   to	   a	   phase	   separation	  with	   the	   precipitated	   proteins	  
contained	   in	   the	   interphase.	  Afterwards,	   the	   lower	  and	  upper	  phase	  were	  both	  carefully	  extracted	  
with	  a	  Hammilton	  syringe	  and	  the	  pellets	  washed	  with	  ice-­‐cold	  methanol.	  Therefore,	  1	  ml	  methanol	  
was	  added	  to	  each	  pellet,	  followed	  by	  15	  min	  centrifugation	  and	  drying	  in	  a	  vacuum	  centrifuge.	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3.2.4.5 Protein	  concentration	  determination	  
Protein	   concentrations	   were	   determined	   using	   the	   commercially	   available	   two-­‐step	   colorimetric	  
BioRad-­‐DC	  Protein	  Assay,	  which	  works	  similarly	  as	  the	  established	  Lowry	  assay	  (Lowry	  et	  al.	  1951).	  In	  
the	  assay	  proteins	  react	  first	  with	  an	  alkaline	  copper	  tartrate	  solution	  and	  then	  with	  the	  later	  added	  
Folin’s	  reagent,	  giving	  rise	  to	  a	  blue	  colored	  complex.	  The	  addition	  of	  the	  copper	  containing	  alkaline	  
medium	   leads	   to	   an	   interaction	   of	   copper	   and	   certain	   amino	   acid	   side	   chains	   (tyrosine	   and	  
tryptophane,	  cystine,	   cysteine,	  and	  histidine).	  Afterwards,	   these	  copper-­‐bound	  proteins	   reduce	   the	  
added	  Folin’s	  reagent	   leading	  to	  the	  blue-­‐colored	  compound,	  which	  has	  a	  maximum	  absorbance	  at	  
750	   nm.	   Because	   the	   absorbance	   intensity	   is	   proportional	   to	   the	   protein	   content	   of	   the	   solution,	  
measuring	  and	  comparing	  it	  to	  known	  values	  of	  a	  calibration	  solution	  allows	  the	  determination	  of	  it’s	  
protein	  concentration.	  
In	  this	  thesis	  experiments,	  BSA	  calibration	  dilutions	  of	  six	  concentrations	  (2,	  1,	  0.5,	  0.25,	  0.125	  and	  
0.0625	  µg/µl),	  always	  dissolved	  in	  the	  same	  buffer	  as	  the	  samples,	  were	  used.	  5	  µl	  of	  each	  standard	  
or	  sample	  were	  pipetted	  in	  triplicates	  or	  quadruplicates	  into	  wells	  of	  a	  96-­‐well	  microplate.	  This	  was	  
followed	  by	  addition	  of	  25	  µl	  alkaline	  copper	  tartrate	  solution	  (solution	  A',	  produced	  by	  mixing	  1	  ml	  
solution	  A	  with	  20	  µl	  solution	  S)	  and	  finally	  200	  µl	  Folin	  reagent	  (solution	  B).	  After	  15	  min	  incubation	  
at	  room	  temperature	  the	  absorbance	  was	  measured	  with	  a	  GENios	  microplate	  reader.	  In	  the	  end	  the	  
samples	  protein	  content	  was	  calculated	  using	  the	  linear	  equation	  of	  the	  standards	  regression	  line.	  
3.2.4.6 Protein	  electrophoresis	  
3.2.4.6.1 SDS-­‐PAGE	  
In	  sodium	  dodecyl	  sulfate	  polyacryalamide	  gel	  electrophoresis	  (SDS-­‐PAGE)	  proteins	  are	  separated	  by	  
size,	   while	   wandering	   through	   a	   SDS-­‐rich	   polyacrylamide	   gel	   matrix	   towards	   the	   anode.	   The	  
separation	   capability	   depends	   on	   the	   gels	   pore	   size,	   which	   is	   determined	   by	   the	   acrylamide	  
concentration.	   SDS	   used	   in	   this	   system	   binds	   to	   proteins,	   thereby	   disrupting	   non-­‐covalent	   bonds	  
within	  and	  unfolding	  them.	  This	  gives	  each	  protein	  a	  net	  negative	  charge,	  which	  is	  proportional	  to	  its	  
size.	   Further	   endogenous	   protein	   charges	   are	   masked	   allowing	   a	   true	   separation	   by	   molecular	  
weight.	  In	  addition,	  protein	  samples	  are	  denatured	  in	  reducing	  sample	  buffer	  under	  heating	  to	  fully	  
unfold	  proteins	  before	  electrophoretic	  separation.	  
Table	  3-­‐13:	  Composition	  of	  SDS-­‐Polyacrylamide	  gels.	  








Total	  volume	   1	  ml	   5	  ml	   5	  ml	   5	  ml	   5	  ml	  
H2O	   0.604	  ml	   2.707	  ml	   2.395	  ml	   2.082	  ml	   1.770	  ml	  
40	  %	  Acrylamide	   0.125	  ml	   0.938	  ml	   1.25	  ml	   1.563	  ml	   1.875	  ml	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Tris	  HCl	  	   0.250	  ml	  (pH	  6.8)	   1.250	  ml	  (pH	  8.8)	   1.250	  ml	  (pH	  8.8)	   1.250	  ml	  (pH	  8.8)	   1.250	  ml	  (pH	  8.8)	  
10%	  SDS	   10	  µl	   50	  µl	   50	  µl	   50	  µl	   50	  µl	  
APS	   10	  µl	   50	  µl	   50	  µl	   50	  µl	   50	  µl	  
TEMED	   1	  µl	   5	  µl	   5	  µl	   5	  µl	   5	  µl	  
	   	   	   	   	   	  
In	  this	  thesis	  0.75	  and	  1	  mm	  mini	  gels	  were	  used	  casted	  with	  the	  Mini-­‐PROTEAN®	  system	  (BioRad).	  
The	  different	  gel	   compositions	  used	  are	  given	   in	  Table	  3-­‐13.	  Before	   loading,	  protein	   samples	  were	  
mixed	  with	   4X	   Laemmli	   buffer,	   containing	   SDS	   and	   the	   strong	   reducing	   agent	   β-­‐mercaptoethanol,	  
and	  denatured	  at	  95	  °C	  for	  5	  min.	  For	  some	  heat	  sensitive	  proteins	  this	  heating	  was	  replaced	  by	  a	  20	  
min	  incubation	  at	  room	  temperature.	  After	  cool	  down,	  the	  samples	  were	  loaded	  into	  the	  gel	  pockets	  
together	  with	   a	   protein	  molecular	  weight	  marker	   (PageRuler	   Prestained	   Protein	  Marker).	   The	   gels	  
were	  run	  at	  a	  constant	  voltage	  of	  200	  V	  to	  achieve	  protein	  separation.	  	  
3.2.4.6.2 BlueNative-­‐PAGE	  
In	   blue	   native	   polyacrylamide	   gel	   electrophoresis	   (BlueNative-­‐PAGE)	  whole	   protein-­‐complexes	   and	  
not	  just	  single	  proteins	  are	  separated	  by	  size	  within	  a	  polyacrylamide	  gel	  matrix.	  This	  is	  achieved	  by	  
lysing	  the	  cells	  with	  a	  non-­‐denaturing	  buffer	  and	  replacing	  SDS	  in	  all	  buffers	  with	  Coomassie	  brilliant	  
blue.	  Like	  SDS,	  it	  binds	  to	  proteins	  giving	  them	  a	  net	  negative	  charge	  proportional	  to	  their	  size.	  	  
Table	  3-­‐14:	  Composition	  of	  8%	  BlueNative-­‐gel.	  
Name	   Volume	  
3X	  Gel	  buffer	   666.6	  µl	  
Acrylamide-­‐bisacrylamide	  
mix	  (49.5%	  T,	  3%	  C)	  
324.4	  µl	  
10%	  APS	   6.7	  µl	  
TEMED	   0.67	  µl	  
ddH2O	   1001.6	  µl	  
total	   2	  ml	  
	   	  
The	  BlueNative-­‐gels	  were	  also	  prepared	  with	  the	  Mini-­‐PROTEAN®	  system	  (BioRad).	  Before	  usage,	  all	  
equipment	  was	   thoroughly	  washed	   in	  water,	   to	   remove	   any	   traces	   of	   SDS.	   In	   addition,	   all	   buffers	  
were	  pre-­‐cooled	   to	   4	   °C.	   In	   this	   thesis	   8%	  gels	  were	  used	   for	  native	  protein	   separation	   (see	   Table	  
3-­‐14).	   Before	   loading,	   the	   protein	   samples	   as	  well	   as	   the	  molecular	  weight	  marker	   (NativeMARK™	  
Unstained	   Protein	   Standard)	   they	   were	   mixed	   with	   10X	   BlueNative	   loading	   dye.	   Furthermore,	   all	  
empty	   gel	   pockets	  were	   filled	  with	   1X	   loading	   dye	   diluted	   in	   lysis	   buffer	  without	   detergent.	   After	  
loading,	   all	   samples	  were	   overlaid	  with	   0.2%	  Coomassie	   solution	   and	   the	   gel	   run	   at	   100	  V	   for	   1	   h	  
followed	   by	   200	   V	   until	   complete	   separation.	   If	   a	   WB	   was	   done	   afterwards,	   the	   gel	   had	   to	   be	  
incubated	  in	  1X	  SDS	  running	  buffer	  for	  5	  min	  to	  allow	  protein	  transfer.	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3.2.4.7 Silver	  staining	  of	  SDS-­‐Gels	  
Sensitive	   silver	   staining	   was	   performed	   according	   to	   the	   protocol	   published	   by	   Heukeshoven	   and	  
Dernick	  (Heukeshoven	  &	  Dernick	  1986).	  
After	  SDS-­‐PAGE,	  gels	  were	   fixed	   for	  at	   least	  30	  min	  or	  overnight	   in	   fixing	   solution	   (30%	  EtOH,	  10%	  
acetic	  acid).	  Afterwards,	  gels	  were	  incubated	  in	  fresh	  sensitizer	  solution	  (30%	  EtOH,	  500	  mM	  sodium	  
acetat,	  0.5%	  (w/v)	  glutaraldehyde,	  0.2%	  (w/v)	  sodium	  thiosulfate)	  for	  30	  min	  –	  2h,	  followed	  by	  three	  
20-­‐30	  min	  washes	  in	  ddH2O.	  Then	  silver	  solution	  (0.1%	  (w/v)	  AgNO3,	  0.01%	  (v/v)	  formaldehyde)	  was	  
added	  and	   left	  on	  the	  gels	   for	  30	  min.	  Excess	  silver	   ions	  were	  removed	  by	  short	   (1-­‐2	  min)	  washing	  
with	  ddH2O	  and	  lastly	  developer	  (2.5%	  (w/v)	  NaCO3,	  0.01%	  formaldehyde)	  was	  added.	  The	  solution	  
was	  replaced	  once	  with	  fresh	  developer	  to	  remove	  silver	  precipitates.	  When	  sufficient	  staining	  was	  
achieved,	  incubating	  the	  gels	  in	  50	  mM	  glycine	  solution	  for	  5	  –	  10	  min	  stopped	  the	  staining.	  Finally,	  
gels	  were	  washed	  in	  ddH2O	  and	  digitalized	  with	  an	  image	  scanner.	  
3.2.4.8 Western	  blot	  
Western	  blotting	  (WB)	  is	  the	  transfer	  of	  all	  proteins	  separated	  by	  gel	  electrophoresis	  onto	  a	  protein	  
binding	   polymeric	  membrane	   (usually	   nitrocellulose	   or	   PVDF)	   followed	   by	   protein	   detection	   using	  
protein-­‐specific	   antibodies.	   The	   transfer	   could	   be	   achieved	   by	   capillary	   forces	   but	   is	   usually	  
accelerated	  by	  applying	  an	  electric	  current.	  	  
In	   this	   thesis,	   WB	   was	   done	   with	   a	   semi-­‐dry	   blotter	   and	   the	   following	   setup.	   First,	   three	   thin	  
Whatman	   papers	   were	   soaked	   in	   blotting	   buffer	   and	   placed	   onto	   the	   blotters	   anode.	   On	   these	  
papers	   the	   blotting	   membrane	   presoaked	   in	   buffer	   was	   placed	   followed	   by	   the	   gel	   from	   the	  
electrophoresis.	  The	  gel	  was	  covered	  with	   three	  additional	  presoaked	  papers	  and	   finally	   the	  whole	  
assembly	  covered	  with	  the	  blotters	  cathode	  lid.	  Blotting	  was	  then	  carried	  out	  for	  70	  –	  90	  min	  at	  75	  
mA	   per	   gel.	   Subsequently,	   the	   immunogenic	   detection	   was	   accomplished	   as	   follows:	   First	   the	  
membrane	  was	  placed	  in	  a	  vessel	  together	  with	  blocking	  solution	  (5%	  filtered	  skim	  milk	  in	  TBS-­‐T)	  for	  
30	  –	  60	  min	  at	  room	  temperature	  to	  saturate	  all	  parts	  of	  the	  membrane	  without	  bound	  protein.	  Then	  
the	  primary	  antibody,	  specific	  to	  the	  protein	  of	  interest,	  was	  added	  diluted	  in	  blocking	  solution.	  This	  
was	  followed	  either	  by	  incubation	  for	  2	  h	  at	  room	  temperature	  or	  overnight	  at	  4	  °C.	  Afterwards,	  the	  
membrane	  was	  washed	   thrice	   for	   5	  min	   in	   TBS-­‐T	   and	   the	   incubated	  with	   the	   secondary	   antibody	  
diluted	   in	   blocking	   solution.	   Depending	   on	   the	   detection	   system	   used,	   fluorescence	   or	  
chemiluminescence,	  the	  incubation	  lasted	  45	  or	  60	  min,	  respectively.	  In	  the	  end,	  the	  membrane	  was	  
washed	  again	  thrice	  in	  TBS-­‐T	  for	  5	  min	  and	  one	  time	  in	  1X	  TBS	  before	  signal	  detection.	  In	  the	  case	  of	  
fluorescent	   secondary	   antibodies,	   an	   Odyssey	   near-­‐infrared	   scanner	   (Licor)	   was	   employed.	   For	  
chemiluminescent	  WBs	   the	  membrane	  was	   covered	  with	   ECL	   substrate	   (ThermoScientific)	   and	   the	  
signals	  visualized	  by	  either	  a	  photographic	  film	  or	  a	  CCD-­‐camera	  system	  (Peqlab).	  Quantification	  was	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done	  with	  the	  standard	  software	  package	  of	  the	  respective	  detection	  system	  (fluorescence	  =	  Odyssey	  
V1.2,	  chemiluminescence	  =	  ).	  
3.2.4.9 Western	  blot	  stripping	  
For	   the	   removal	   of	   antibodies	   from	   a	  WB	   for	   detection	  with	   other	   antibodies	   two	   protocols	  were	  
employed,	  a	  mild	  and	  a	  harsh	  treatment,	  depending	  on	  the	  antibodies	  binding	  strength.	  	  
For	  the	  mild	  treatment,	  an	  acidic	  (pH	  2.2)	  stripping	  buffer	  containing	  200	  mM	  glycine,	  0.1%	  (w/v)	  SDS	  
and	  10%	  (v/v)	  Tween	  20	  was	  used.	  The	  blot	  was	  washed	  twice	  for	  5	  –	  10	  min	  with	  this	  buffer,	  then	  
twice	  with	  1X	  PBS	  for	  5	  -­‐	  10	  min	  and	  finally	  twice	  with	  TBS-­‐T	  for	  5	  min.	  Subsequently,	  the	  blot	  had	  to	  
be	  blocked	  again	  with	  blocking	  solution	  before	  detection	  with	  a	  new	  antibody.	  
The	  harsh	   treatment	   required	  a	  buffer	  consisting	  of	  2%	   (w/v)	  SDS,	  0.75%	   (v/v)	  β-­‐mercaptoethanol,	  
and	  62.5	  mM	  (Tris	  pH	  7.0).	  Before	  stripping,	  the	  buffer	  was	  heated	  to	  50	  °C.	  Next,	  it	  was	  added	  to	  the	  
membrane	  and	  incubated	  under	  constant	  agitation	  for	  30	  min.	  Afterwards,	  the	  stripping	  solution	  was	  
decanted,	  the	  blot	  rinsed	  2	  -­‐	  3	  times	  with	  ddH2O	  followed	  by	  two	  5	  min	  TBS-­‐T	  washes.	  Finally,	  it	  had	  
to	  be	  blocked	  again	  with	  blocking	  solution.	  
3.2.4.10 Twin-­‐Strep-­‐tag®	  affinity	  purification	  
The	  Twin-­‐Strep-­‐tag®–StrepTactin®	  affinity	  purification	  system	  (Schmidt	  et	  al.	  2013)	  was	  employed	  to	  
purify	  FA2H	  and	  its	  interacting	  proteins,	  thereby	  allowing	  their	  identification	  by	  mass	  spectrometry.	  
The	   Twin-­‐Strep-­‐tag®	   is	   an	   improved	   version	   of	   the	   StrepTag	   and	   mainly	   consists	   of	   two	   tags	  
connected	   by	   a	   short	   glycine-­‐rich	   amino	   acid	   linker	   sequence.	   The	   Twin-­‐Strep-­‐tag	   shows	   a	   higher	  
specificity	   and	   stronger	   affinity	   to	   StrepTactin®,	   being	   suitable	   for	   the	   rapid	   purification	   of	   intact	  
protein	  complexes	  under	  mild	  buffer	  conditions.	  	  
Twin-­‐Strep-­‐FA2H	  was	   purified	   directly	   from	   cell	   lysates	   using	   StrepTactin®	   coupled	   to	  MacroPrep®	  
(polymethacrylate)	   beads.	   All	   purification	   steps	   were	   carried	   out	   at	   4	   °C	   to	   minimize	   protein	  
degradation.	  For	  the	  purification	  the	  beads,	  supplied	  as	  a	  50%	  slurry,	  were	  directly	  added	  to	  the	  cell	  
lysate	  and	  incubated	  overnight	  on	  a	  tumbling	  incubator.	  25	  µl	  bead	  slurry	  were	  used	  per	  cell	   lysate	  
derived	   from	  one	   confluent	   15	   cm	   cell	   culture	  plate.	  After	   incubation,	   the	  beads	  were	   spun	  down	  
shortly	  at	  3000	  g	  and	  the	  supernatant,	  containing	  the	  unbound	  proteins,	  removed.	  Then	  the	  beads	  
were	  washed	  thrice	  with	  1	  ml	  of	  StrepTag	  washing	  buffer.	  Finally,	  the	  bound	  Twin-­‐Strep-­‐FA2H	  and	  its	  
interacting	  partners	  were	  eluted	  3-­‐4	  times	  with	  50	  µl	  washing	  buffer	  containing	  2.5	  mM	  biotin.	  For	  
this,	  the	  beads	  were	  shaken	  with	  the	  buffer	  at	  1100	  rpm	  for	  5	  min,	  followed	  by	  2	  min	  centrifugation	  
at	  10,000	  g	  and	  transfer	  of	  the	  supernatant	  (=eluate)	  to	  a	  new	  microtube.	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3.2.4.11 NeutrAvidin	  affinity	  purification	  
NeutrAvidin	   is	  produced	  from	  avidin	  via	  deglycosylation.	   It	  retains	  the	  same	  high	  binding	  affinity	  to	  
biotin	   that	   avidin	   exhibits,	   but	   has	   a	   reduced	   unspecific	   binding	   activity,	   allowing	   a	   cleaner	  
purification	  of	  biotinylated	  molecules.	  In	  this	  thesis,	  NeutrAvidin	  affinity	  purification	  was	  used	  for	  the	  
purification	  of	  proteins	  biotinylated	  in	  BioID-­‐assays.	  
Biotinylated	   proteins	  were	   directly	   purified	   from	   cell	   lysates	   by	   adding	  NeutrAvidin-­‐agarose	   beads	  
(supplied	  as	  50%	  slurry).	  200	  µl	  bead	  slurry,	  pre-­‐conditioned	  by	  washing	  three	  times	  with	  one	  bead	  
volume	  of	  lysis	  buffer,	  were	  used	  per	  cell	  lysate	  derived	  from	  one	  confluent	  15	  cm	  cell	  culture	  plate.	  
The	  whole	  purification	  process	  was	  done	  at	  4	  °C	  and	  all	  centrifugations	  to	  pellet	  the	  beads	  at	  500	  g.	  
After	  the	  addition	  of	  beads,	  the	  samples	  were	  incubated	  on	  a	  tumbling	  incubator	  overnight,	  thereby	  
guaranteeing	   complete	   protein	   binding.	   At	   the	   next	   day,	   the	   beads	  were	  washed	   thoroughly	  with	  
four	  different	  buffers	  to	  reduce	  unspecific	  binding.	  The	  washing	  was	  always	  carried	  out	  by	  incubating	  
for	   5	  min	  with	   1	  ml	  washing	   solution	   under	  mild	   agitation	   and	   subsequent	   solution	   removal	   by	   a	  
short	  centrifugation	  (500	  g).	  First,	  the	  beads	  were	  washed	  2X	  with	  2%	  SDS,	  then	  1X	  with	  0.1%	  sodium	  
deoxycholat,	  1%	  TX-­‐100,	  500	  mM	  NaCl,	  1	  mM	  EDTA,	  50	  mM	  Hepes,	  pH	  7.5,	  afterwards	  1X	  with	  250	  
mM	  LiCl,	  0.5%	  NP-­‐40,	  0.5%	  sodium	  deoxycholat,	  1	  mM	  EDTA,	  10mM	  Tris-­‐HCl,	  pH	  8.1	  and	  finally	  2X	  in	  
50	  mM	  Tris,	   50	  mM	  NaCl,	   pH	   7.4.	   Since	   the	  NeutrAvidin-­‐biotin-­‐bond	   is	   to	   strong	   for	   efficient	   and	  
complete	   protein	   elution,	   peptides	   for	   mass	   spectrometry	   analysis	   were	   generated	   by	   the	   direct	  
addition	  of	  trypsin	  to	  the	  beads	  (see:	  3.2.4.12.1.2	  On-­‐bead	  digest).	  
3.2.4.12 Mass	  spectrometry	  sample	  preparation	  
3.2.4.12.1 Generation	  of	  peptides	  
3.2.4.12.1.1 In-­‐gel	  digest	  
First,	  each	  protein	  band	  or	  gel	   region	  of	   interest	   from	  a	  Coomassie-­‐stained	  gel	  was	  excised	  using	  a	  
clean	  scalpel,	  cut	  into	  small	  pieces	  (1x1	  mm)	  and	  transferred	  into	  a	  1.5	  ml	  microtube.	  Afterwards,	  the	  
gel	  was	  destained	  by	  adding	  500	  µl	  of	  30%	  ACN	  in	  100	  mM	  NH4HCO3,	  incubating	  on	  a	  thermomixer	  at	  
25°C	  and	  1000	  rpm	  for	  30	  min	  and	  subsequently	  removing	  the	  solution.	  If	  there	  was	  still	  staining	  left,	  
the	  destaining	  procedure	  was	  repeated.	  	  
Destaining	   was	   succeeded	   by	   gel-­‐shrinking.	   For	   this,	   500	   µl	   100%	   ACN	   were	   pipetted	   to	   the	   gel	  
pieces,	   followed	  by	  a	  15	  min	   incubation	  at	  1000	  rpm	  25°C,	  removal	  of	  the	  ACN-­‐solution	  and	  finally	  
vacuum	  centrifugation	  at	  60°C	  to	  complete	  dryness.	  
Thereafter,	   10	   µl	   of	   trypsin	   solution	   (50	   ng/µl	   in	   50	  mM	  NH4HCO3)	  were	   added	   to	   each	   dried	   gel	  
sample	   and	   let	   become	   soaked	   up	   for	   ~1	   min.	   Then	   50	   µl	   100	   mM	   NH4HCO3	   were	   added	   and	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incubated	   for	   10	   min	   to	   allow	   gel	   swelling.	   If	   samples	   were	   not	   completely	   covered	   afterwards,	  
additional	   100	  mM	  NH4HCO3	  was	   transferred	   into	  each	   tube.	   The	   tubes	  were	   subsequently	  placed	  
overnight	  into	  a	  37	  °C-­‐incubator	  to	  achieve	  protein	  digestion.	  	  
At	   the	   next	   day,	   the	   peptide	   solution	   was	   transferred	   to	   a	   fresh	   microtube.	   Subsequently,	   the	  
peptides	  remaining	  in	  the	  gel	  matrix	  were	  extracted	  in	  three	  steps.	  First,	  50	  µl	  extraction	  solution	  1	  
(0.1%	  TFA	  50%	  ACN	  in	  H2O)	  were	  added	  to	  each	  tube,	   incubated	  at	  1000	  rpm	  25	  °C	  for	  15	  min	  and	  
then	  transferred	  to	  the	  peptide	  solution	  of	  the	  overnight	  digest.	  Second,	  5	  µl	  of	  extraction	  solution	  2	  
(100	  mM	  NH4HCO3)	  were	  put	  onto	  each	   sample	  and	   incubated	  as	  before.	  Third,	  without	   removing	  
solution	  2,	  100	  µl	  solution	  3	  (100%	  ACN)	  were	  added	  followed	  by	  another	  15	  min	  incubation.	  Finally,	  
this	  extract	  was	   combined	  with	   the	  one	   from	  before	  and	  dried	   in	  a	   vacuum	  centrifuge	  at	  60	   °C	   to	  
complete	   dryness.	   Usually,	   the	   dried	   peptides	   were	   then	   resuspended	   and	   cleaned	   up	   using	  
StageTips	  before	  mass	  spectrometry	  analysis	  (see	  3.2.4.12.6	  Peptide	  cleanup	  by	  StageTips).	  
3.2.4.12.1.2 On-­‐bead	  digest	  
Proteins	   bound	   to	   an	   affinity	   matrix	   can	   also	   be	   digested	   with	   trypsin	   directly	   instead	   of	   eluting,	  
running	  on	  a	  SDS-­‐PAGE	  and	  digesting	  in	  gel.	  This	  can	  be	  especially	  beneficial,	  if	  a	  complete	  elution	  is	  
hindered	   by	   very	   strong	   protein	   binding	   (see:	   3.2.4.11	   NeutrAvidin	   affinity	   purification).	   The	  
procedure	  applied	  in	  this	  thesis	  is	  described	  below:	  
The	  beads	  with	   the	  bound	  proteins,	  already	  washed	   in	  a	  buffer	  suitable	   for	   the	  subsequent	   tryptic	  
digestion,	  were	  first	  treated	  with	  10	  mM	  DTT	  in	  100	  mM	  NH4HCO3	  and	  heated	  to	  56	  °C	  for	  30	  min	  to	  
accomplish	   protein	   reduction.	   Afterwards,	   the	   reduced	   disulfide	   bridges	  were	   alkylated	   by	   adding	  
acrylamide	  to	  a	  final	  concentration	  of	  ~56	  mM	  and	  incubating	  at	  room	  temperature	  for	  30	  min	  under	  
constant	  agitation.	  Thereafter,	  the	  whole	  supernatant	  was	  removed	  by	  centrifugation	  (800	  g,	  1	  min)	  
and	   residual	   reduction	   and	   alkylation	   reagents	   eliminated	   by	   washing	   thrice	   with	   1	   ml	   100	   mM	  
NH4HCO3.	  At	  last	  1	  µg	  trypsin,	  diluted	  in	  300	  µl	  100	  mM	  NH4HCO3,	  were	  added	  to	  each	  sample	  and	  
digested	  overnight	  at	  37	  °C.	  At	  the	  next	  morning	  the	  solution	  containing	  the	  peptides	  was	  transferred	  
to	  a	  clean	  microtube.	  Then,	  remaining	  peptides	  still	  bound	  to	  the	  beads	  were	  extracted	  by	  incubating	  
twice	  with	  300	  µl	  of	  5%	  ACN	  0.1%	  FA	   (15	  min,	  800	   rpm).	  The	  digests	  and	  extracts	  were	  combined	  
afterwards	   and	   ready	   to	   be	   processed	   further	   (see:	   3.2.4.12.4	   Peptide	   cleanup	   by	   solid	   phase	  
extraction	  (SPE).	  
3.2.4.12.1.3 RapiGest-­‐assisted	  digest	  
RapiGest	   is	   a	   commercially	   available	   acid-­‐cleavable	   detergent.	   It	   is	   used	   to	   solubilize	   and	   thereby	  
improve	  the	  tryptic	  digestion	  of	  hydrophobic	  proteins	  (e.g.	  membrane	  proteins),	  which	  are	  normally	  
less	  accessible	  by	  proteases.	  After	  the	  digestion,	  RapiGest	  can	  be	  easily	  cleaved	  and	  precipitated	  by	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acidification,	  thereby	  allowing	  its	  complete	  removal	  before	  LC/MS-­‐analysis,	  where	  it	  would	  interfere.	  
RapiGest	  was	  used	  in	  this	  thesis	  as	  follows:	  
50	  µl	   of	   0.1%	  RapiGest	   (diluted	   in	   100	  mM	  TEAB)	  were	   added	   to	   each	  protein	   pellet,	   obtained	  by	  
protein	   precipitation	   (see	   3.2.4.4	   Protein	   precipitation).	   The	   samples	   were	   mixed	   thoroughly	   and	  
then	   boiled	   at	   100	   °C	   for	   5	   min	   to	   improve	   pellet	   resolubilisation.	   After	   sample	   cool	   down,	   DTT	  
(diluted	  in	  100	  mM	  TEAB)	  was	  added	  to	  a	  final	  concentration	  of	  5	  mM	  and	  incubated	  45	  min	  at	  60	  °C	  
for	   protein	   reduction.	   Subsequently,	   the	   samples	   were	   cooled	   down	   to	   room	   temperature	   and	  
acrylamide	  added	  for	  cystein	  alkylation	  (final	  concentration	  50	  mM)	  followed	  by	  20	  min	  incubation.	  
In	  the	  end,	  trypsin	  was	  added	  at	  a	  1:100	  trypsin:protein	  ratio,	  the	  sample	  filled	  up	  to	  100	  µl	  with	  100	  
mM	  TEAB	  and	  everything	  digested	  overnight	  at	  37	  °C.	  
3.2.4.12.2 Tandem	  mass	  tags	  (TMT)-­‐labeling	  of	  peptides	  
TMT-­‐labeling	   allows	   the	   relative	   protein	   quantification	   between	   up	   to	   six	   samples	   in	   a	   single	  
experiment	   (Figure	  3-­‐3A).	  Thus,	  peptides	   from	  different	  samples,	   for	  example	  cells	  or	   tissue	   lysate,	  
are	   covalently	   linked	   to	   isobaric	   mass	   tags	   via	   their	   amine	   groups.	   This	   is	   achieved	   by	   an	   amine-­‐
reactive	  NHS-­‐ester	  group	  contained	  in	  the	  tags.	  Afterwards,	  the	  samples	  can	  be	  mixed	  and	  processed	  
together	   for	   downstream	   mass	   spectrometry	   analysis.	   The	   isobaric	   mass	   tags	   have	   an	   identical	  
structure	  and	  mass,	  differing	  only	  in	  their	  isotopic	  composition	  (Figure	  3-­‐3B),	  therefore	  peptides	  from	  
each	  sample	  co-­‐elute	  during	  liquid	  chromatography.	  During	  fragmentation	  in	  the	  mass	  spectrometer	  
each	  tag	  gives	  rise	  to	  a	  specific	  reporter	  ion	  of	  a	  defined	  mass.	  This	  subsequently	  allows	  to	  relatively	  
quantify	  the	  amount	  of	  the	  fragmented	  peptide	  contributed	  by	  each	  sample	  (Figure	  3-­‐3C).	  	  
First,	  the	  TMT	  label	  reagents	  were	  removed	  from	  the	  freezer	  and	  equilibrated	  to	  room	  temperature.	  
Afterwards,	  123	  μl	  of	  100%	  acetonitrile	  were	  added	  to	  each	  tube	  and	  allowed	  to	  dissolve	  the	  reagent	  
for	  5	  minutes	  assisted	  by	  intermittent	  mixing.	  Then	  it	  was	  split	  into	  three	  40	  µl	  fractions,	  allowing	  the	  
parallel	   labeling	  of	  3	  samples.	  For	  this,	  the	  40	  µl	  were	  transferred	  to	  the	  sample	  vial	  containing	  the	  
peptides	  destined	  to	  be	  labeled.	  The	  vial	  was	  mixed	  for	  5	  minutes	  at	  600	  rpm	  on	  thermomixer	  and	  
then	  incubated	  for	  1.5	  h	  at	  room	  temperature	  to	  enable	  complete	  peptide	  labeling.	  This	  was	  stopped	  
by	  adding	  8	  µl	  quenching	  reagent	  (5%	  hydroxylamine	  in	  100	  mM	  TEAB),	  which	  contains	  an	  excess	  of	  
amine	  groups,	  mixing	  and	  incubating	  for	  15	  min	  at	  room	  temperature.	  
	   	  











Figure	   3-­‐3:	   Principle	   of	   TMT-­‐labeling.	   (A)	   Simplified	   experimental	   workflow	   of	   TMTsixplex™-­‐labeling	  
experiment.	  (B)	  Chemical	  structures	  of	  TMTzero	  (left)	  and	  TMTsixplex	  reagents	  (right).	  The	  TMTzero	  molecule	  
is	   marked	   with	   the	   important	   structural	   components	   contained	   in	   all	   isobaric-­‐labeling	  molecules.	   The	  mass	  
reporter	  region	   is	  the	  part	  of	  the	  tag	  that	  breaks	  apart	  during	  HCD	  (higher-­‐energy	  collisional	  dissociation)-­‐	  or	  
ETD	  (electron-­‐transfer	  dissociation)-­‐fragmentation	  in	  the	  mass	  spectrometer,	  thereby	  giving	  rise	  to	  a	  reporter	  
ion.	   By	   varying	   the	   presence	   of	   heavy	   isotopes	   (red	   asteriskes)	   within	   this	   region,	   each	   tag	   produces	   a	  
differentially	   sized	   reporter	   ion	   (HCD:	   126,	   127,	   128,	   129,	   130	   or	   131	   Da).	   This	   is	   counterbalanced	   by	   the	  
isotope	  composition	  within	  the	  mass	  normalizer	  region,	  because	  all	  TMT-­‐tags	  exhibit	  the	  same	  molecule	  mass.	  
In	   addition,	   there	   is	   an	   amino-­‐reactive	   NHS-­‐group,	   needed	   for	   the	   covalent	   attachment	   to	   peptides.	   (C)	  
Representative	  MS1-­‐spectrum	  with	  labeled	  precursor	  peptide	  (left)	  and	  exemplary	  fragment	  spectrum	  of	  TMT	  
reporter	   ions	   (right).	   Pictures	   from	   ThermoScientific:	   http://www.piercenet.com/product/amine-­‐reactive-­‐6-­‐
plex-­‐tandem-­‐mass-­‐tag-­‐reagents.	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3.2.4.12.3 RapiGest	  removal	  by	  precipitation	  
RapiGest	  was	  removed	  by	  acidic	  cleavage	  and	  subsequent	  centrifugation.	  Accordingly,	  each	  sample	  
was	   first	   acidified	  with	  TFA	   to	  a	   final	   concentration	  of	  5%	   (v/v)	   and	   incubated	   for	  45	  min	  at	  37	   °C	  
under	  constant	  agitation	  (800	  rpm).	  Afterwards,	  the	  samples	  were	  centrifuged	  for	  30	  min	  at	  20,000	  g	  
and	  the	  cleared	  supernatant	  transferred	  to	  a	  new	  microtube.	  
3.2.4.12.4 Peptide	  cleanup	  by	  solid	  phase	  extraction	  (SPE)	  
High	   peptide	   amounts,	   usually	   products	   of	   an	   in-­‐solution	   digest,	   were	   desalted	   via	   solid	   phase	  
extraction	  (SPE)	  using	  Oasis	  HLB	  cartridges	  (Waters).	  First,	  before	  sample	   loading	  the	  cartridge	  was	  
activated	  3x	  with	  1	  ml	  70%	  ACN	  in	  0.1%	  formic	  acid	  (FA)	  and	  subsequently	  equilibrated	  by	  flushing	  it	  
4x	   with	   1	  ml	   0.1%	   FA.	   In	   addition,	   the	   peptide	   samples	   had	   to	   be	   conditioned	   to	   allow	   cartridge	  
binding.	   For	   this,	   they	   were	   reduced	   to	   ~200	   µl	   in	   a	   vacuum	   centrifugator	   to	   evaporate	   excess	  
amounts	  of	  organic	  solvent,	  which	  would	  prevent	  column	  binding.	  Afterwards,	  they	  were	  filled	  up	  to	  
1	  ml	  with	  0.1%	  FA	  and	  acidified	  with	  10	  µl	  100%	  FA.	  
Then	  they	  were	  loaded	  onto	  the	  HLB	  cartridges	  by	  pushing	  the	  solutions	  3X	  trough.	  This	  was	  followed	  
by	  10	  column	  washes	  with	  1	  ml	  0.1%	  FA	  each.	  Finally,	  desalted	  peptides	  were	  eluted	   in	   two	  steps.	  
First	  with	  500	  µl	  30%	  ACN,	  followed	  by	  300	  µl	  70%	  ACN.	  Both	  eluates	  were	  combined	  and	  dried	  at	  
60°	  C	  in	  a	  vacuum	  centrifuge	  afterwards.	  
3.2.4.12.5 Isoelectric	  fractionation	  of	  peptides	  (OFFGEL)	  
To	   obtain	   higher	   peptide	   and	   therefore	   protein	   identifications	   of	   complex	   samples	   via	   mass	  
spectrometry,	   it	   can	  be	  useful	   to	   fractionate	   these	   samples	  before	  analysis	  by	  various	  methods.	   In	  
isoelectric	   focusing,	   peptides	   are	   fractionated	   according	   to	   their	   isoelectric	   point	   within	   a	   pH	  
gradient.	  
To	   accomplish	   this,	   an	   Agilent	   OFFGEL	   fractionation	   system	   with	   ready-­‐made	   immobilized	   pH	  
gradient	  (IPG)	  gel	  strips	  was	  used.	  In	  the	  first	  step,	  the	  IPG	  strip	  (12-­‐well	  gel	  pH	  3	  -­‐	  10)	  was	  assembled	  
into	   the	   sample	   tray	   according	   to	   the	  manufacturers	   instructions	  and	   rehydrated	  with	   rehydration	  
buffer	  (0.2	  %	  ampholyte	  solution	  pH	  3-­‐10	  in	  H2O).	  Afterwards,	  the	  vacuum	  dried	  peptide	  sample	  was	  
resuspended	   in	   rehydration	   buffer	   and	   equally	   loaded	   onto	   the	   sample	   tray.	   The	   sample	  was	   the	  
separated	   into	   12	   fractions	   by	   applying	   a	   high	   voltage	   overnight.	   Detailed	   instrument	   settings	   are	  
given	   in	  Table	  3-­‐15.	  At	  the	  next	  morning	  the	  fractions	  were	  transferred	  to	  microtubes.	  150	  µl	  0.1%	  
TFA	  were	  added	  to	  each	  well	  and	  incubated	  for	  15	  min	  for	  extraction	  of	  remaining	  peptides.	  Then	  the	  
extracts	  were	  combined	  with	  their	  respective	  fractions	  and	  cleaned	  up	  using	  StageTips.	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Table	  3-­‐15:	  OFFGEL	  instrument	  settings	  for	  12-­‐well	  peptide	  separation.	  









Focussing	   20	   4500	   50	   200	   100	  
Hold	   -­‐	   500	   20	   50	   -­‐	  
	   	   	   	   	   	  
3.2.4.12.6 Peptide	  cleanup	  by	  StageTips	  
Small	  peptide	  amounts,	  usually	  peptides	  of	  a	  single	  gel	  band	  or	  OFFGEL-­‐fraction,	  had	  to	  be	  desalted	  
and	   concentrated	   before	   mass	   spectrometric	   measurement.	   For	   this	   purpose,	   so	   called	   StageTips	  
(stop-­‐and-­‐go-­‐extraction	  tips)	  were	  self	  prepared	  from	  standard	  20	  µl	  laboratory	  pipette	  tips,	  stuffed	  
with	  a	  small	  amount	  of	  Empore	  C18	  mesh	  material	  (Rappsilber	  et	  al.	  2007).	  The	  tips	  were	  put	  in	  self-­‐
made	  adaptors,	  which	   themselves	   fitted	   into	  standard	  1.5	  ml	  microtubes.	  Thereby,	   solutions	  could	  
be	  passed	  trough	  the	  tips	  by	  short	  centrifugations	  at	  low	  g-­‐forces.	  
The	   cleanup	   procedure	   was	   as	   follows.	   First,	   the	   tips	   were	   activated	   by	   passing	   trough	   20	   µl	  
methanol,	   followed	   by	   20	   µl	   0.5%	   acetic	   acid	   in	   80%	   acetonitrile.	   This	   was	   followed	   by	   an	  
equilibration	  step	  with	  20	  µl	  0.5%	  acetic	  acid.	  Thereafter,	  peptide	  samples	  could	  be	  directly	   loaded	  
onto	  the	  tips,	  if	  they	  contained	  less	  than	  5%	  ACN.	  Otherwise	  they	  had	  to	  be	  diluted	  first	  with	  water.	  
Afterwards,	  the	  StageTips	  were	  washed	  once	  with	  20	  µl	  0.5%	  acetic	  acid.	  Subsequently,	  the	  washed	  
and	  desalted	  peptides	  were	  eluated	   in	  two	  steps	  of	  10	  µl	  0.5%	  acetic	  acid	   in	  80%	  acetonitrile	  each	  
into	  a	  fresh	  microtube.	  In	  addition,	  the	  excess	  of	  organic	  solvent,	  which	  would	  prevent	  binding	  to	  the	  
analytical	   column	   during	   MS-­‐analysis,	   had	   to	   be	   removed	   by	   vacuum	   centrifugation.	   The	   dried	  
peptides	  were	  stored	  at	  -­‐80	  °C	  before	  MS-­‐analysis.	  
3.2.4.13 Mass	  spectometric	  measurements	  
Peptides	   were	   analyzed	   by	   a	   LC-­‐MS/MS	   setup	   consisting	   of	   an	   Easy-­‐nLC	   1000	   nano	   liquid	  
chromatography	   device	   (ThermoScientific)	   coupled	   to	   an	   Orbitrap	   Velos	   mass	   spectrometer	  
(ThermoScientific).	  	  
The	  solvents	  for	  LC-­‐analysis	  were:	  solvent	  A:	  0.1%	  FA	  in	  ddH2O,	  solvent	  B:	  0.1%	  FA	  in	  ACN.	  Separation	  
of	  peptides	  was	  achieved	  on	  self-­‐prepared	  C18-­‐reversed	  phase	  capillary	  columns	  (Magic	  C18,	  5	  µm,	  
100	   µm	   X	   150-­‐200	   mm,	   Bruker-­‐Michrom)	   via	   linear	   30	   or	   60	   min	   gradients	   at	   a	   flowrate	   of	   400	  
nl/min.	  The	  linear	  gradients	  were	  always	  followed	  by	  two	  short	  column	  washes	  at	  95%	  solvent	  B	  and	  
a	  column	  equilibration	  of	  10	  min	  (Table	  3-­‐16).	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Table	  3-­‐16:	  Profile	  of	  gradients	  used	  for	  LC-­‐MS/MS	  separation	  of	  peptides.	  
Gradient	  type	   Time	  (min)	   Percentage	  of	  solvent	  B	  (%)	  
30	  min	   0	   1	  
	   30	   35	  
	   31	   95	  
	   34	   1	  
	   37	   95	  
	   40	   1	  
	   50	   1	  
	  
60	  min	   0	   1	  
	   60	   35	  
	   61	   95	  
	   64	   1	  
	   67	   95	  
	   70	   1	  
	   80	   1	  
	   	   	  
The	  mass	  spectrometer	  was	  set	  to	  acquire	  Orbitrap	  survey	  spectra	  in	  a	  mass	  range	  of	  400	  –	  1200	  m/z	  
with	  a	  resolution	  of	  30,000.	  For	  MS/MS	  peptides,	  fragmented	  by	  CID,	  were	  analyzed	  in	  the	  LTQ	  ion	  
trap	   (minimal	   ion	   population:	   5000,	   isolation	   width:	   2	   m/z,	   normalized	   collision	   energy:	   35%)	  
whereas	  HCD-­‐fragmented	  peptides	  were	  measured	   in	   the	  Orbitrap	   (minimal	   ion	   population:	   5000,	  
isolation	  width:	  2	  m/z,	  normalized	  collision	  energy:	  42%).	  In	  both	  cases,	  the	  ten	  most	  intense	  peaks	  
from	   each	   survey	   scan	   were	   chosen	   for	   fragmentation.	   To	   reduce	   repeated	   fragmentation	   of	   the	  
same	  peptides,	  dynamic	  exclusion	  was	  enabled	  (repeat	  count:	  1,	  repeat	  duration:	  30	  s,	  excl.	  list	  size:	  
500,	   excl.	   duration:	   30	   s,	   excl.	  mass	  width	   relative	   to	  mass,	   excl.	  mass	  width	   relative	   to	   low/high:	  
10.00	  ppm,	  expiration	  count:	  1,	  expiration	  S/N	  threshold:	  3.0).	  
3.2.4.14 Mass	  spectrometry	  data	  analysis	  
3.2.4.14.1 MaxQuant	  protein	  identification	  	  
Raw	  MS-­‐data	  from	  the	  SILAC-­‐IP	  interaction	  partner	  experiments	  was	  processed	  and	  searched	  against	  
a	   modified	   human	   UniProtKB	   database	   (HUMAN.fasta	   from	   06/2013)	   with	   added	   murine	   FA2H-­‐
sequence	   (Q5MPP0))	   using	   the	  MaxQuant	   1.4.1.2	   software	   package	   (http://MaxQuant.org,	   (Cox	  &	  
Mann	   2008;	   Cox	   et	   al.	   2011)).	  Note	   that	   all	   raw	   files	   of	   one	   experiment	  were	   included	   in	   a	   single	  
search.	  The	  following	  search	  settings	  were	  used:	  Precursor	  tol.	  =	  4.5	  ppm,	  MS/MS	  tol.	   (FTMS)	  =	  20	  
ppm,	  Top	  MS/MS	  peaks	  per	  100	  Da.	  (FTMS)	  =	  12,	  MS/MS	  tol.	  (ITMS)	  =	  0.5	  Da,	  Top	  MS/MS	  peaks	  per	  
100	  Da.	   (ITMS)	  =	  8,	  PSM	  FDR	  =	  0.01,	  Protein	  FDR	  =	  0.01,	  Site	  FDR	  =	  0.01,	  Min.	  peptide	  Length	  =	  7,	  
Min.	  score	  for	  unmodified	  peptides	  =	  0,	  Min.	  score	  for	  modified	  peptides	  =	  40,	  Min.	  delta	  score	  for	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unmodified	  peptides	  =	  0,	  Min.	  delta	  score	  for	  modified	  peptides	  =	  17,	  Min.	  unique	  peptides	  =	  0,	  Min.	  
razor	   peptides	   =	   1,	  Min.	   peptides	   =	   1,	   Variable	  modifications	   =	   Acetyl	   (Protein	  N-­‐term);	   Oxidation	  
(M),	  Fixed	  modifications	  =	  Propionamide	  (C);	  Match	  between	  runs	  =	  enabled,	  Matching	  time	  window	  
[min]	  =	  2,	  Alignment	  time	  window	  [min]	  =	  20.	  For	  SILAC-­‐quantification	  the	  standard	  method	  with	  of	  2	  
labeling	  states	  was	  selected.	  For	  the	  light	  channel	  no	  isotope	  labels	  were	  selected	  and	  for	  the	  heavy	  
state	   Arg+10	   and	   Lys+8.	   The	   quantification	   parameters	   were:	   Use	   only	   unmodified	   peptides	   =	  
enabled,	  Modifications	   included	   in	  protein	  quantification	  =	  Acetyl	   (Protein	  N-­‐term);	  Oxidation	   (M),	  
Peptides	  used	  for	  protein	  quantification	  =	  Razor,	  Discard	  unmodified	  counterpart	  peptides	  =	  Enabled,	  
Min.	   ratio	   count	   =	   2,	   Site	   quantification	   =	   Use	   least	  modified	   peptide.	   The	   BioID-­‐experiment	   data	  
were	  searched	  with	  the	  same	  settings	  with	  the	  addition	  of	  Biotin	  (+226.077598	  Da,	  N-­‐terminus,	  K)	  as	  
variable	  modification.	  
Data	   from	   TMT-­‐experiments	   was	   analyzed	   with	   MaxQuant	   1.4.1.2	   against	   a	   murine	   UniProtKB	  
database	   (MOUSE.fasta	   from	   11/2013).	   The	   search	   settings	   were	   the	   same	   as	   for	   the	   interaction	  
partner	   experiments	   (see	   above)	  with	   the	   exception	  of	   the	   selected	  quantification	  method,	  where	  
the	  preset	   reporter	   ion	  quantification	  method	  TMT	  6-­‐plex	  was	  selected	  with	  default	   settings.	  Note	  
that	  all	  raw	  files	  of	  one	  experiment	  were	  always	  combined	  in	  a	  single	  search.	  
3.2.4.14.2 Statistical	  analysis	  
3.2.4.14.2.1 Perseus	  
The	   protein	   result	   lists	   of	   all	   experiments	   were	   further	   analyzed	   and	   statistically	   evaluated	   with	  
Perseus	  1.4.0.12	  (http://www.perseus-­‐framework.org,	  (Cox	  &	  Mann	  2012))	  as	  follows:	  	  
For	  the	  SILAC-­‐IP	  experiments,	  protein	  groups	   identified	  by	  MaxQuant	  as	  contaminants,	  reverse	  hits	  
or	  identified	  by	  site	  hits	  were	  first	  filtered	  out.	  Subsequently,	  the	  normalized	  H/L-­‐expression	  ratios	  of	  
each	  protein	  group	  were	  linearized	  by	  log2-­‐transformation,	  followed	  by	  an	  one	  sample	  t-­‐test.	  It	  was	  
tested,	   if	   the	   log2-­‐expression	   ratios	   (log2	   fold	   change)	   differed	   significantly	   from	  0	   (=	   log2(1)	   =	   no	  
change).	  Afterwards,	  a	  volcano	  plot	  was	  produced,	  by	  plotting	  the	  average	  log2	  fold	  change	  of	  each	  
protein	   group	   against	   its	   –log-­‐transformed	   p-­‐value	   (-­‐log10	   p-­‐value).	   This	   plot	   is	   a	   frequently	   used	  
method	  to	  visualize	  the	  results	  of	  an	  interaction	  partner	  search.	  Protein	  groups	  enriched	  in	  the	  bait-­‐
containing	  sample	  should	  have	  a	  high	  log2	  fold	  change	  (=enrichment)	  in	  combination	  with	  a	  large	  –
log	   p-­‐value	   (=significance),	   therefore	   appearing	   in	   the	   upper	   right	   part	   of	   the	   plot.	   In	   contrast,	  
background	   proteins	   contributed	   by	   control	   and	   bait	   sample,	   should	   cluster	   around	   a	   log2	   fold	  
change	  of	  0.	  Finally	  protein	  groups	  were	  deemed	  significantly	  enriched,	  if	  they	  exhibited	  a	  log2	  fold	  
change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  and	  a	  –log	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  0.05).	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For	   the	  TMT	  experiments,	  protein	  groups	   identified	  by	  MaxQuant	  as	   contaminants,	   reverse	  hits	  or	  
identified	  by	  site	  hits	  were	  first	  filtered	  out.	  Next,	  the	  expression	  values	  of	  each	  TMT-­‐channel	  were	  
normalized	   by	   dividing	   them	   through	   the	   respective	   summed	   TMT-­‐channel	   intensity.	   Thereafter,	  
FA2H-­‐KO/WT	   expression	   ratios	  were	   calculated	   for	   each	   timepoint	   and	   subsequently	   linearized	   by	  
log2-­‐transformation.	   This	   was	   followed	   by	   filtering	   out	   every	   protein	   group	   with	   less	   then	   two	  
expression	  values	  for	  at	  least	  one	  timepoint.	  Afterwards	  a	  one	  sample	  t-­‐test	  was	  performed,	  testing	  
if	   the	   log2-­‐expression	   ratios	   differed	   significantly	   from	   0.	   Finally,	   protein	   groups	   were	   deemed	  
significantly	  upregulated,	  if	  they	  exhibited	  a	  log2	  fold	  change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  and	  a	  –log	  p-­‐
value	  >	  1.301	  (p-­‐value	  <	  0.05).	  Conversely,	  the	  criteria	  for	  a	  significant	  downregulation	  were	  a	   log2	  
fold	  change	  ≤	  -­‐0.585	  (fold	  change	  ≤	  0.667)	  and	  a	  –log	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  0.05).	  
3.2.4.14.2.2 GOrilla	  
Large	   scale	   gene	   function	   analysis	   was	   carried	   out	   with	   GOrilla	   (http://cbl-­‐gorilla.cs.technion.ac.il,	  
(Eden	  et	  al.	  2009)),	  using	  its	  internal	  GO-­‐term	  database	  (release	  May	  17,	  2014).	  GOrilla	  compares	  the	  
GO-­‐terms	   associated	   with	   entries	   of	   target	   list	   with	   the	   ones	   of	   a	   background	   list.	   By	   using	  
hypergeometric	   testing,	   it	   calculates	   a	   p-­‐value	   for	   each	   GO-­‐terms,	   which	   indicates	   its	   degree	   of	  
enrichment	  in	  the	  target	  list	  (Figure	  3-­‐4A).	  Accordingly,	  in	  the	  SILAC-­‐IP	  experiments,	  the	  significantly	  
enriched	  protein	  groups	  (target	  list)	  were	  searched	  against	  the	  whole	  list	  of	  identified	  protein	  groups	  
(background	   list),	   using	   each	   groups	   first	   corresponding	   gene	   name.	   A	   significance	   threshold	   was	  
applied	   filtering	   out	   all	   entries	   with	   p-­‐values	   >	   0.001.	   Furthermore,	   GOrilla	   calculates	   an	   error-­‐
corrected	   p-­‐value	   (FDR	   q-­‐value)	   by	   multiple	   testing	   using	   the	   Benjamini	   and	   Hochberg	   method	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Figure	  3-­‐4:	  Formulas	  used	  by	  GOrilla	  to	  calculate	  p-­‐values	  and	  enrichment	  factors.	  
(A)	   Formula	   using	   hypergeometric	   testing	   for	   p-­‐value	   calculation.	   (B)	   Equation	   for	   calculation	  of	   enrichment	  
factor.	  N	  =	  number	  of	  protein	  groups	  in	  ID	  list;	  B	  =	  number	  of	  protein	  groups	  associated	  with	  a	  specific	  GO	  term	  
in	  ID	  list;	  n	  =	  number	  of	  protein	  groups	  in	  target	  list;	  b	  =	  number	  of	  protein	  groups	  associated	  with	  a	  specific	  GO	  
term	  in	  target	  list.	  
3.2.4.14.2.3 Other	  statistical	  software	  
Alternatively,	   large	  scale	  annotation	  analysis	  was	  done	  using	  the	  PANTHER	  classification	  system	  9.0	  
(http://www.pantherdb.org,	   (Mi	   et	   al.	   2013))	   and	   the	  GOSlimmer	   tool	   in	   the	   AmiGO	   1.8	   database	  
(http://amigo1.geneontology.org/cgi-­‐bin/amigo/slimmer,	   annotations	   from:	   Tue	   Jun	   3	   16:12:02	  
2014),	  without	  applying	  any	  statistical	  enrichment	  analysis.	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3.2.4.15 Immunofluorescence	  staining	  and	  microscopy	  of	  cells	  
For	   immunofluorescent	   stainings,	   cells	   grown	   on	   glass	   coverslips	   were	   first	   fixed	   with	   37	   °C-­‐
prewarmed	  4%	  PFA	  in	  PBS	  for	  10	  min	  at	  room	  temperature.	  Subsequently,	  they	  were	  once	  washed	  in	  
PBS,	   incubated	   20	   min	   in	   50	   mM	   NH4Cl	   in	   PBS,	   and	   washed	   twice	   with	   TBS.	   Next,	   cells	   were	  
permeabilized	   via	   10	  min	   incubation	   in	   0.3%	   Triton	   X-­‐100	   in	   TBS,	   succeeded	   by	   two	   TBS	   washes.	  
These	   steps	   were	   omitted	   if	   only	   cell	   surface	   staining	   was	   desired.	   Afterwards,	   blocking	   of	   non-­‐
specific	  sites	  was	  performed	  with	  1%	  BSA	  in	  TBS	  for	  30	  min	  at	  room	  temperature.	  This	  was	  followed	  
by	  incubation	  with	  the	  primary	  antibodies	  in	  blocking	  solution	  for	  60	  –	  120	  min	  in	  a	  humid	  chamber.	  
Thereafter,	   excess	   antibodies	   were	   removed	   by	   washing	   three	   times	   for	   5	  min	   in	   TBS	   before	   the	  
secondary	  antibodies	   solutions	  were	  applied.	   In	  addition,	  4',6-­‐diamidino-­‐2-­‐phenylindole	   (DAPI)	  was	  
added	   (dilution	   1:1000)	   to	   these	   solutions	   to	   achieve	   nuclear	   staining.	   The	   incubations	   were	  
performed	   60	   –	   120	   min	   in	   a	   dark	   humid	   chamber	   to	   avoid	   photobleaching	   of	   the	   fluorescent	  
secondary	   antibodies.	   Afterwards	   the	   coverslips	   were	   washed	   twice	   for	   5	   min	   with	   TBS,	   shortly	  
rinsed	   in	   ddH2O	   followed	   by	   ethanol,	   and	   finally	   air	   dried	   for	   10	   min.	   The	   dried	   coverslips	   were	  
mounted	  on	  glass	  coverslides	  in	  ProLong®	  Gold	  mounting	  medium	  and	  incubated	  overnight	  at	  room	  
temperature.	  Hence,	   they	  were	  ready	   for	   fluorescent	  microscopy	  or	  stored	  at	  4	   °C.	  For	   fluorescent	  
microscopy	  an	  AxioVert	  100	  M	  (Zeiss)	  equipped	  with	  a	  CCD	  camera	  (AxioCamHR)	  was	  used.	  Pictures	  
were	  acquired	  and	  evaluated	  with	  the	  AxioVert	  4.8	  software.	  
3.2.4.16 Bimolecular	  fluorescence	  complementation	  (BiFC)	  
Bimolecular	   fluorescence	   complementation	   (BiFC)	   is	   a	   technique	   to	   verify	   protein-­‐protein	  
interactions	   previously	   identified	   in	   screening	   approaches	   in	   living	   cells	   (Kerppola	   2008).	  
Complementary	  fragments	  of	  a	  fluorescent	  protein,	  which	  are	  not	  fluorescent	  themself,	  are	  fused	  to	  
potentially	   interacting	   proteins	   and	   transiently	   expressed	   in	   cells.	   If	   the	   proteins	   do	   interact,	   their	  
attached	  protein	   fragments	  can	  reconstitute	  a	   functional	   fluorescent	  protein.	  This	  can	  be	  excitated	  
by	  its	  respective	  wavelength,	  thereby	  allowing	  an	  immediate	  visualization	  and	  quantitative	  read-­‐out	  
of	  the	  interaction.	  A	  variety	  of	  different	  fluorescent	  proteins	  can	  be	  used	  for	  BiFC,	  which	  are	  mostly	  
ECFP-­‐	  and	  EYFP-­‐variants.	  





Figure	  3-­‐5:	  Schematic	  illustration	  of	  BiFC-­‐principle.	  
Complementary	   fragments	   of	   a	   fluorescent	   protein	   (YFP-­‐N-­‐term.	   =	   YN;	   YFP-­‐C-­‐term.	   =	   YC),	   which	   are	   not	  
fluorescent	  themself,	  are	  fused	  to	  putative	  protein	  interaction	  partners	  (Protein	  A	  &	  B)	  and	  expressed	  in	  cells.	  If	  
the	   proteins	   actually	   interact	   they	   come	   in	   close	   contact,	   leading	   to	   the	   reconstitution	   of	   a	   functional	  
fluorescent	   protein	   out	   of	   the	   two	   fragments.	   This	   can	   be	   visualized	   and	   quantitatively	   measured	   by	  
fluorescent	   microscopy	   and	   related	  methods.	   In	   contrast,	   if	   they	   do	   not	   interact,	   no	   functional	   fluorescent	  
protein	  is	  reconstituted	  and	  thus	  no	  fluorescent	  signal	  measurable.	  Picture	  adapted	  from:	  (Kerppola	  2006).	  
In	   this	   thesis	   work,	   fluorescent	   fragments	   of	   the	   YFP	   Q69M-­‐variant	   called	   citrine	   were	   used.	   The	  
fragments	  were	  cYFP1	  (amino	  acids	  1-­‐158)	  and	  YFP2	  (amino	  acids	  159-­‐239),	  which	  were	  attached	  N-­‐	  
or	  C-­‐terminally	  via	  a	  short	  linker	  sequence	  (GGGGS)2.	  In	  addition,	  to	  the	  YFP-­‐fragment	  sequences	  the	  
N-­‐terminal	   tagging	   plasmids	   also	   contained	   the	   signal	   sequence	   of	   calreticulin	   (SScal)	   to	   maintain	  
protein	  ER-­‐translocation	  (Nyfeler	  et	  al.	  2005).	  The	  plasmids	  were	  kindly	  provided	  by	  Dr.	  V.	  Reiterer	  
(Biotechnologie	  Institut	  Thurgau	  -­‐	  Switzerland).	  
BiFC	   was	   performed	   as	   follows:	   First	   cells	   were	   seeded	   in	   appropriate	   culture	   vessels.	   For	  
immunofluorescence	   microscopy	   these	   were	   coverslips	   within	   12-­‐well	   plates,	   whereas	   for	  
quantitative	   measurements	   6-­‐well	   plates	   were	   used.	   After	   overnight	   attachment,	   the	   cells	   were	  
transfected	   with	   the	   respective	   plasmid	   combinations	   and	   grown	   for	   48	   h.	   Subsequently,	   either	  
immunofluorescence	   microscopy	   was	   performed	   (see	   3.2.4.15	   Immunofluorescence	   staining	   and	  
microscopy	  of	   cells)	   or	   the	   cells	   fluorescence	   (BiFC-­‐signal)	  was	  measured	  with	   a	  plate	   reader	   after	  
transfer	  to	  a	  96-­‐well	  plate.	  For	  this,	   the	  cells	  were	  detached	  using	  trypsin,	  washed	  two	  times	   in	  1X	  
PBS,	   resuspended	   in	   200	   µl	   1X	   PBS,	   and	   transferred	   to	   a	   black	   96	   well	   plate.	   Afterwards,	   the	  
measurement	  was	   performed	   using	   one	   of	   the	   following	   devices:	   (A)	  Mithras	   LB	   940	   plate	   reader	  
(Berthold	  Technologies)	  equipped	  with	  an	  excitation	  filter	  of	  510/10	  and	  an	  emission	  filter	  of	  535	  nm.	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emission	  of	  540/20.	  The	  raw	  data	  obtained	  was	  evaluated	  with	  Microsoft	  Excel.	  Note	  that	  a	  positive	  
control	   was	   included	   for	   the	   quantitative	   measurements.	   For	   this,	   cells	   were	   co-­‐transfected	   with	  
cYFP1-­‐	  and	  YFP2-­‐taged	  ER-­‐Golgi	   intermediate	  compartment	  53	  kDa	  protein	   (ERGIC53),	  a	   lectin	   that	  
oligomerizes	   in	   the	   ER	   and	   produces	   a	   strong	   BiFC-­‐signal.	   Each	   other	   interaction’s	   BiFC-­‐signal	  was	  
subsequently	   normalized	   to	   the	   positive	   control	   to	   compensate	   for	   variations	   in	   transfection	  
efficiency.	  	  
3.2.5 Lipid	  analytic	  techniques	  
3.2.5.1 Bligh-­‐Dyer	  lipid	  extraction	  
Lipids	  were	  extracted	   from	  cells	   by	  a	  protocol	  based	  on	   the	   rapid	  extraction	  method	  published	  by	  
Bligh	   &	   Dyer	   (Bligh	   &	   Dyer	   1959).	   Shortly,	   cells	   from	   one	   confluent	   well	   of	   a	   6	   well	   plate	   were	  
harvested	  and	  washed	  once	  in	  1X	  PBS.	  Afterwards,	  they	  were	  resuspended	  in	  200	  µl	  1X	  PBS	  followed	  
by	   successive	   addition	   and	  mixing	   with	   750	   µl	   chloroform-­‐methanol	   (1:2,	   v/v),	   250	   µl	   chloroform	  
(CHCl3)	  and	  250	  µl	  ddH2O.	  Finally,	  a	  phase	  separation	  was	  achieved	  by	  centrifuging	  for	  2	  min	  at	  3000	  
g.	  The	  extracted	  lipids,	  contained	  in	  the	  lower	  chloroform-­‐rich	  phase,	  were	  subsequently	  transferred	  
to	  a	  microtube	  and	  dried	   in	  a	   vacuum	  centrifuge	  at	  60°C.	   If	   the	   lipids	  were	  not	   further	  processed,	  
they	  were	  stored	  at	  -­‐20	  °C.	   If	   larger	  or	  smaller	  amounts	  of	  cells	  were	  processed,	  the	  volumes	  of	  all	  
buffers	   were	   adjusted	   accordingly,	   thereby	   maintaining	   the	   same	   proportions	   of	   chloroform,	  
methanol	  and	  water	  during	  the	  extraction	  process.	  
3.2.5.2 Alkaline	  methanolysis	  of	  glycerolipids	  
Alkaline	  methanolysis	  of	  glycerolipids	  was	  done	  according	  to	  the	  method	  published	  by	  Bodennec	  and	  
colleagues	  (Bodennec	  et	  al.	  2000).	  First,	  the	  already	  extracted	  and	  dried	  lipids,	  derived	  from	  one	  well	  
of	  a	  6	  well	  plate,	  were	  dissolved	  in	  a	  400	  µl	  1:1-­‐solution	  (v/v)	  of	  chloroform/0.6	  M	  NaOH	  in	  methanol	  
and	   incubated	   at	   RT	   for	   2	   h.	   Subsequently	   160	   µl	   of	   ddH2O	   were	   added	   and	   the	   sample	   mixed	  
vigorously.	  Then	  the	  mixture	  was	  centrifuged	  at	  3000	  g	  for	  1	  min	  to	  achieve	  phase	  separation.	  The	  
upper	   phase	   was	   aspirated	   and	   the	   lower	   phase	   washed	  with	   a	   theoretical	   upper	   phase	   of	   98	   µl	  
chloroform-­‐methanol-­‐ddH2O	  (3:48:47,	  v/v/v).	  After	  another	  short	  centrifugation,	  the	  lower	  lipophilic	  
phase	  was	  removed	  to	  a	  microtube,	  dried	  in	  a	  vacuum	  centrifuge	  at	  60°C	  and	  stored	  at	  -­‐20	  °C.	  
3.2.5.3 Thin-­‐layer	  chromatography	  (TLC)	  
In	  thin	  layer	  chromatography	  substances	  are	  separated	  while	  migrating	  trough	  a	  solid	  matrix	  made	  of	  
an	  adsorbent	  material	  called	  the	  stationary	  phase.	  Usually,	  the	  matrix	  material	  is	  spread	  onto	  a	  solid	  
support	  glass	  plate	   (TLC	  plate).	  To	  achieve	  analyte	  separation,	   it	   is	  applied	  to	  the	  stationary	  phase.	  
Afterwards,	  the	  plate	  is	  put	  into	  a	  solvent	  mixture,	  the	  mobile	  phase.	  The	  mobile	  phase	  is	  drawn	  up	  
3	  Material	  &	  Methods	  
	  
55	  
by	  capillary	  forces	  taking	  the	  analyte	  with	  it,	  thereby	  achieving	  separation	  due	  to	  different	  migration	  
rates.	  
In	   this	   thesis	  work,	  HPTLC	  silica	  plates	   (Merck)	  were	  used	  for	   lipid	  analytics.	  Before	  sample	   loading	  
the	   plates	   were	   activated	   at	   180	   °C	   for	   10	   min.	   As	   the	   standard	   mobile	   phase	   for	   sphingo-­‐	   and	  
phospholipid	   separation	   a	  mixture	   of	   chloroform-­‐methanol-­‐water	   (70:30:4,	   v/v/v)	   was	   used.	   After	  
chromatographic	   separation	   the	   plates	   were	   dried	   completely.	   Finally,	   for	   lipid	   visualization,	   the	  
plates	  were	  sprayed	  with	  cupric	  sulfate	  solution,	  dried	  completely,	  and	  charred	  for	  5	  min	  at	  180	  °C.	  In	  
the	  end,	  the	  TLC	  plates	  were	  digitalized	  with	  an	  image	  scanner.	  
3.2.6 Nucleic	  acid	  and	  cloning	  techniques	  
3.2.6.1 Polymerase	  chain	  reaction	  
Polymerase	   chain	   reaction	   (PCR)	   is	   a	   method	   to	   specifically	   amplify	   regions	   of	   DNA	   using	   short	  
sequence-­‐complementary	   oligonucleotides	   (primers)	   and	   a	   heat-­‐resistant	   DNA-­‐dependent	   DNA-­‐
polymerase.	  The	  PCR	  reaction	  consists	  of	  three	  phases.	  First,	  the	  DNA	  is	  denatured	  at	  95-­‐98	  °C	  for	  20	  
–	  30	  s	   to	  separate	  all	  double	  stranded	  DNA.	  Then	  the	  temperature	   is	   lowered	  for	  ~30	  s	   to	  a	  value,	  
which	   allows	   binding	   of	   the	   primers	   to	   their	   complementary	   target	   sequence.	   This	   step	   is	   called	  
annealing	  and	  its	  temperature	  is	  dependent	  on	  the	  primers	  sequence	  (~50	  –	  68	  °C).	  Afterwards,	  the	  
temperature	  is	  risen	  to	  72	  °C	  at	  which	  the	  polymerase	  starts	  amplifying	  the	  DNA	  from	  the	  3’	  end	  of	  
the	   primer.	   The	   time	   of	   the	   amplification	   step	   depends	   on	   the	   length	   of	   DNA	   to	   be	   amplified.	   To	  
obtain	  high	  amounts	  of	  amplified	  DNA,	  the	  three	  steps	  are	  generally	  repeated	  in	  20	  -­‐35	  cycles.	  	  
In	   this	   thesis	   two	   different	   DNA-­‐polymerases	   were	   used:	   For	   genotyping	   of	   mice	   REDTaq®	   DNA	  
Polymerase	   (SigmaAldrich)	   and	   for	   all	   cloning	   purposes	   Phusion®	   High-­‐Fidelity	   DNA	   Polymerase	  
(NEB).	  While	  REDTaq®	  DNA	  Polymerase	  was	  provided	  in	  a	  ready-­‐to-­‐use	  mix	  already	  containing	  buffer	  
and	  dNTPs,	   for	   Phusion®	  PCRs	   all	   constituents	   had	   to	   be	  mixed	  before.	   The	  pipetting	   schemes	   for	  
both	   PCR	   reactions	   are	   given	   below	   (Table	   3-­‐18	   and	   Table	   3-­‐18).	   The	   PCRs	   were	   conducted	   on	   a	  
Biometra	  Thermocycler	  2000	  with	  a	  heated	  lid.	  After	  PCR,	  the	  samples	  were	  cleaned	  for	  subsequent	  
reactions	  using	  a	  QIAquick	  PCR	  Purification	  Kit®	   (Qiagen)	  according	   to	   the	  manufacturers	  protocol.	  
Alternatively,	  the	  samples	  were	  first	  separated	  by	  agarose	  gel	  electrophoresis	  followed	  by	  gel-­‐cutting	  
and	  nucleotide-­‐extraction	  using	  a	  QIAquick	  Gel	  Extraction	  Kit®	  (Qiagen).	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Table	  3-­‐17:	  Pipetting	  scheme	  for	  REDTaq®	  PCR	  reactions.	  
	   20	  µl	  reaction	   50	  µl	  reaction	  
Name	   Volume/amount	   Volume/amount	  
REDTaq®	  Ready	  Mix	   10	  µl	   25	  µl	  
100	  µM	  Forward	  primer	   0.1	  µl	   0.25	  µl	  
100	  µM	  Reverse	  primer	   0.1	  µl	   0.25	  µl	  
Template	  DNA	   1-­‐10	  ng	   1-­‐10	  ng	  
Nuclease	  free	  H2O	   Fill	  up	  to	  20	  µl	   Fill	  up	  to	  50	  µl	  
	   	   	  
Table	  3-­‐18:	  Pipetting	  scheme	  for	  Phusion®	  PCR	  reactions.	  
	   20	  µl	  reaction	   50	  µl	  reaction	  
Name	   Volume/amount	   Volume/amount	  
5X	  HF	  or	  GC	  buffer	   4	  µl	   10	  µl	  
100	  µM	  Forward	  primer	   0.1	  µl	   0.25	  µl	  
100	  µM	  Reverse	  primer	   0.1	  µl	   0.25	  µl	  
Template	  DNA	   1-­‐10	  ng	   1-­‐10	  ng	  
2mM	  dNTPs	   2	  µl	   5	  µl	  
Phusion	  DNA	  Polymerase	   0.2	  µl	   0.5	  µl	  
Nuclease	  free	  H2O	   Fill	  up	  to	  20	  µl	   Fill	  up	  to	  50	  µl	  
	   	   	  
3.2.6.2 Isolation	  of	  plasmid	  DNA	  
Plasmid	   DNA	   was	   isolated	   from	   transformed	   bacteria	   using	   Qiagen	   MiniPrep	   or	   Midiprep	   Kits®	  
depending	  on	  the	  size	  of	  the	  bacterial	  starting	  material.	  For	  mini	  scale	  preparations	  a	  single	  colony	  
was	  picked	  from	  a-­‐plate,	  inoculated	  into	  5	  ml	  liquid	  LB-­‐medium	  (including	  appropriate	  antibiotic)	  and	  
incubated	  over	  night	  at	  250	  rpm	  37	  °C.	  In	  the	  case	  of	  a	  midi	  preparation	  50	  ml	  medium	  were	  used.	  At	  
the	   next	   day,	   the	   cells	   were	   pelleted	   and	   resuspended	   with	   the	   provided	   resuspension	   buffer	  
containing	   RNAse	   in	   a	   volume	   according	   to	   the	   manufacturers	   manual.	   Afterwards,	   alkaline	   lysis	  
buffer	   containing	   SDS	   was	   added	   to	   break	   up	   the	   cells.	   The	   lysis	   was	   stopped	   and	   proteins	  
precipitated	   by	   adding	   acidic	   neutralization	   buffer.	   Then	   the	   samples	  were	   centrifuged	   to	   remove	  
any	   precipitated	   material	   and	   the	   clear	   supernatant	   loaded	   onto	   positively	   charged	   nucleic	   acid	  
binding	  columns.	  The	  columns	  were	  spun	  and	  afterwards	  washed	  with	  the	  provided	  washing	  buffers.	  
In	  the	  end,	  the	  bound	  plasmids	  were	  eluted	  with	  either	  ddH2O	  (mini	  kit)	  or	  elution	  buffer	  (midi	  kit).	  
When	  a	  midi	  kit	  was	  used,	  three	  additional	  steps	  followed.	  First,	  the	  plasmid-­‐DNA	  was	  precipitated	  
from	  the	  eluate	  with	   isopropanol.	  Second,	   the	  pellet	  was	  washed	  once	   in	  70%	  ethanol.	   In	   the	  end,	  
the	   DNA	   was	   resuspended	   in	   ddH2O.	   The	   plasmid	   obtained	   by	   both	   kits	   were	   finally	   evaluated	  
regarding	  DNA-­‐content	   and	   purity	  with	   a	  NanoDrop	   spectrophotometer	   and	   stored	   at	   -­‐20	   °C	   until	  
further	  usage.	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3.2.6.3 Restriction	  digest	  
DNA	  was	  digested	  with	  restriction	  endonucleases,	  which	  cleave	  the	  phosphodiester	  bound	  of	  DNA	  at	  
specific	  recognition	  sites.	  This	  technique	  was	  on	  the	  one	  hand	  used	  for	  subcloning	  of	  DNA-­‐fragments	  
and	  on	  the	  other	  hand	  for	  the	  verification	  of	  plasmid	  identities.	  The	  digestion	  was	  usually	  done	  for	  1-­‐
2	  h	  at	  37	  °C	  in	  20	  µl	  reactions	  according	  to	  the	  following	  table:	  
Table	  3-­‐19:	  Reaction	  volumes	  for	  restriction	  digest.	  
Name	   Volume/amount	  
10X	  restriction	  buffer	   2	  µl	  
DNA	   1-­‐2	  µg	  
Restriction	  enzyme	  (10	  units/µl)	   0.5	  -­‐	  1	  µl	  
ddH2O	   Fill	  up	  to	  20	  µl	  
	   	  
3.2.6.4 Agarose	  gel	  electrophoresis	  
Agarose	   gel	   electrophoresis	   is	   used	   to	   separate	   nucleotides	   by	   size,	   thereby	   allowing	   the	  
determination	  of	  their	  molecular	  weight	  when	  run	  in	  parallel	  with	  a	  DNA-­‐concentration	  standard.	  In	  
addition,	   it	   can	   also	   be	   applied	   in	   a	   preparative	   manner	   to	   purify	   certain	   nucleotides	   out	   of	   a	  
nucleotide	  mixture	   e.g.	   after	   restriction	   digest	   or	   PCR.	   The	   separation	   is	   achieved	   by	   applying	   an	  
electric	   field	   to	  a	  polymeric	  agarose	  matrix	  with	  the	  nucleotide	  samples	   loaded	  onto	   it.	  Because	  of	  
their	  negatively	  charges	  they	  move	  towards	  the	  anode.	  While	  small	  molecules	  can	  pass	  the	  gel	  matrix	  
more	   easily	   larger	   molecules	   are	   slowed	   down	   by	   it,	   leading	   to	   a	   separation	   by	   size.	   The	   matrix	  
separation	   capabilities	   are	   directly	   given	   by	   its	   composition,	   so	   depending	   of	   the	  molecules	   to	   be	  
separated	  agarose	  gels	  of	  different	  percentages	  have	  to	  be	  used.	  	  
In	   this	   thesis	   0.5	   –	   2%	   agarose	   mini-­‐gels	   in	   1X	   TAE	   buffer	   supplemented	   with	   ethidium	   bromide	  
(1:200	  from	  stock	  solution)	  were	  used.	  Samples	  were	  premixed	  with	  6X	  loading	  dye	  and	  run	  at	  120	  –	  
140	  V	   for	  30	   -­‐	  45	  min	  depending	  on	   the	  gels	  agarose	  composition.	  Usually,	   a	  GeneRuler	  1	  kb	  DNA	  
ladder	   (ThermoScientific)	  was	  used.	  The	  visualization	  of	  nucleotides	  was	  achieved	  by	  UV-­‐excitation	  
and	  gel	  images	  were	  acquired	  with	  a	  CCD-­‐based	  camera	  system.	  	  
3.2.6.5 Nucleotide-­‐extraction	  from	  agarose	  gels	  
Nucleotides	  were	  extracted	  after	  gel	  electrophoresis	  by	  using	  a	  QIAquick	  Gel	  Extraction	  Kit®	  (Qiagen)	  
according	   to	   the	  manufacturers	   protocol.	   Shortly,	   the	   bands	   of	   interest	  were	   cut	   out	  with	   a	   clean	  
scalpel,	   weighted,	   and	   melted	   for	   10	   -­‐	   15	   min	   at	   50	   °C	   after	   mixing	   with	   3	   gel	   volumes	   of	   gel	  
solubilization	  buffer.	  Thereafter,	  1	  gel	  volume	  of	  isopropanol	  was	  added	  and	  the	  mixture	  loaded	  onto	  
positively	   charged	   spin	   columns	   for	   nucleotide	   retrieval.	   The	   columns	   were	   centrifuged	   1	   min	   at	  
16,000	  g,	  the	  flow	  through	  discarded,	  and	  the	  columns	  washed	  once	  with	  500	  µl	  ethanol-­‐containing	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washing	  buffer.	  In	  the	  end,	  residual	  ethanol	  was	  removed	  by	  another	  centrifugation	  and	  the	  cleaned	  
nucleotides	   eluted	  with	   30-­‐50µl	   ddH2O	   to	   fresh	  microtubes.	   If	   not	   used	   directly	   the	   eluates	   were	  
stored	  at	  -­‐20	  °C.	  
3.2.6.6 DNA-­‐concentration	  determination	  
3.2.6.6.1 Exact	  determination	  via	  spectrophotometry	  
DNA	  shows	  a	  high	  absorbance	  of	  UV-­‐light	  at	  260	  nm,	  which	   is	  proportional	  to	   its	  amount	  (50	  ng/µl	  
dsDNA	   &	   1cm	   light	   path	   =	   1	   absorbance	   unit).	   Therefore,	   a	   sample’s	   DNA-­‐concentration	   can	   be	  
estimated	  by	  measuring	  its	  absorbance	  at	  260	  nm	  via	  a	  spectrophotometer.	  In	  this	  work,	  a	  NanoDrop	  
spectrophotometer	   was	   used	   which	   only	   needs	   0.5	   -­‐1	   µl	   of	   a	   sample	   to	   determine	   its	   DNA-­‐
concentration.	  
3.2.6.6.2 Determination	  via	  agarose	  gel	  
The	   DNA-­‐concentration	   of	   a	   sample	   can	   also	   be	   determined	   by	   separating	   it	   on	   an	   agarose	   gel	  
together	  with	  a	   size	   standard	  of	   known	  concentration.	   The	   comparison	  of	   the	   sample’s	  nucleotide	  
band	  intensity	  with	  the	  ones	  of	  the	  standard	  finally	  allows	  a	  determination	  of	  its	  DNA-­‐concentration.	  
3.2.6.7 DNA-­‐Ligation	  
DNA-­‐ligation	   is	   the	  enzymatic	   joining	  of	  DNA	  ends	  by	  phosphodiester	  bonds.	   In	   this	   thesis	  work	  T4	  
DNA	  ligase	  (ThermoScientific)	  was	  used.	  Depending	  if	  DNA	  fragments	  with	  blunt	  or	  sticky	  ends	  were	  
present,	  one	  of	  the	  following	  procedures	  was	  applied.	  
For	  sticky	  end	  ligations	  a	  20	  µl	  ligation	  reaction	  was	  mixed	  according	  to	  Table	  3-­‐20	  and	  incubated	  for	  
1	  h	  at	  room	  temperature.	  	  
Table	  3-­‐20:	  Reaction	  mixture	  for	  sticky	  end	  ligation.	  
Name	   Volume/amount	  
10X	  T4	  DNA	  ligase	  buffer	   2	  µl	  
T4	  DNA	  ligase	  (1	  unit/µl)	   1	  µl	  
Linear	  vector	  DNA	   20	  ng	  
Insert	  DNA	   3:1	  molar	  ratio	  over	  vector	  
ddH2O	   Fill	  up	  to	  20	  µl	  
	   	  
Blunt	   end	   ligation	   reactions	   were	   pipetted	   as	   described	   in	   Table	   3-­‐21	   and	   incubated	   for	   2	   h	   -­‐	  
overnight	  at	  room	  temperature.	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Table	  3-­‐21:	  Reaction	  mixture	  for	  blunt	  end	  ligation.	  
Name	   Volume/amount	  
10X	  T4	  DNA	  ligase	  buffer	   2	  µl	  
T4	  DNA	  ligase	  (1	  unit/µl)	   5	  µl	  
Linear	  vector	  DNA	   20	  ng	  
Insert	  DNA	   3:1	  molar	  ratio	  over	  vector	  
ddH2O	   Fill	  up	  to	  20	  µl	  
	   	  
After	   ligation,	   5	   µl	   of	   the	   mixture	   were	   transformed	   into	   competent	   bacteria	   (see	   3.2.2.2	  
Transformation	  of	  chemical	  competent	  bacteria).	  
3.2.6.8 StarGate®	  cloning	  
Directional	  cloning	  of	  Twin-­‐Strep	  constructs	  into	  mammalian	  expression	  vectors	  was	  achieved	  by	  the	  
StarGate®	  combinatorial	  cloning	  system	  (IBA	  lifesciences).	  This	  system	  utilizes	  two	  types	  of	  vectors,	  a	  
universal	   donor	   and	   various	   acceptor	   vectors.	   Initially,	   the	   gene	   of	   interest	   is	   amplified	   via	   PCR	  
thereby	   adding	   recombinase	   recognition	   sites,	   which	   allow	   directional	   subcloning	   into	   the	   donor	  
vector.	  From	  this,	  donor	  vector	  the	  gene	  of	   interest	  can	  than	  be	  subcloned	  in	  a	  variety	  of	  different	  
acceptor	   vectors	   by	   another	   recombinase-­‐mediated	   reaction.	   For	   a	   detailed	   description	   of	   the	  
cloning	   procedure	   consult	   the	   manufactures	   manual.	   The	   primers	   used	   for	   donor	   generation	   are	  
detailed	  in	  Table	  3-­‐8.	  




4.1 Comparative	  quantitative	  myelin	  proteome	  analysis	  of	  FA2H-­‐KO	  mice	  	  
Changes	  in	  the	  myelin	  protein	  composition	  of	  FA2H-­‐KO	  compared	  to	  WT	  mice	  were	  measured	  using	  a	  
reporter	   ion-­‐based	   quantification	   approach	   (see	   3.2.4.12.2	   Tandem	   mass	   tags	   (TMT)-­‐labeling	   of	  
peptides).	  The	  assay	  was	  done	  separately	  for	  myelin	  originating	  from	  two	  different	  tissues	  e.g.	  brain	  
(=CNS	  myelin)	   and	   sciatic	   nerves	   (=PNS	  myelin)	   and	   from	   animals	   at	   6,	   13	   and	   17	  months	   of	   age.	  
Furthermore,	   each	   assay	   was	   conducted	   in	   three	   biological	   replicates.	   Note	   that	   no	   technical	  
replicates	  were	  conducted	  due	  to	  the	  high	  cost	  of	  labeling	  reagents	  and	  the	  limited	  amount	  of	  PNS-­‐
myelin	  available	  per	  animal.	  A	  schematic	  depicting	  the	  analysis	  workflow	  is	  given	  in	  Figure	  4-­‐1.	  	  
Myelin	  was	  purified	   from	  the	  different	  animals	  and	  tissues	  by	  density	  gradient	  purification.	  After	  a	  
quality	   assessment	   by	   SDS-­‐PAGE	   and	   silver	   staining,	   myelin	   from	   both	   tissues	   was	   processed	   as	  
follows.	   First,	   equal	   protein	   amounts	  of	  myelin	  were	   tryptically	   digested.	  Afterwards,	   the	   resulting	  
peptides	   of	   each	   genotype	   and	   animal	   age	   were	   individually	   labeled	   with	   a	   distinct	   isobaric	   label	  
(TMT	  6-­‐plex).	  Following	  labeling,	  the	  six	  samples	  were	  combined	  and	  the	  sample	  complexity	  reduced	  
by	   12-­‐well	   OFFGEL	   fractionation.	   Thereafter,	   each	   fraction	   was	   analyzed	   by	   LC-­‐MS/MS	   in	   a	   high	  
resolution	  Orbitrap	  Velos	  hybrid	  mass	  spectrometer.	  During	  fragmentation	  in	  the	  mass	  spectrometer	  
each	   isobaric	   tag	   leads	   to	   the	   generation	   of	   a	   specific	   fragment	   (reporter	   ion),	   allowing	   the	  
determination	   of	   each	   peptide’s	   relative	   abundance	   in	   comparison	   to	   the	   five	   others.	   For	   each	  
protein	  the	  relative	  protein	  amount	  can	  thus	  be	  easily	  calculated	  from	  the	  sum	  of	  its	  peptide	  values.	  	  




Figure	  4-­‐1:	  Scheme	  of	  quantitative	  myelin	  proteome	  analysis	  by	  TMT-­‐labeling	  approach.	  
Myelin	  containing	  neural	  tissues,	  i.e.	  brain	  and	  sciatic	  nerves	  of	  WT	  and	  FA2H-­‐KO	  mice,	  of	  three	  stages	  of	  age	  
(6,	  13	  and	  17	  months)	  were	  obtained	  and	  myelin	  was	  individually	  purified	  from	  each	  tissue	  by	  density	  gradient	  
centrifugation.	  Equal	  protein	  amounts	  of	  myelin	  from	  one	  tissue	  type	  were	  tryptically	  digested,	  assisted	  by	  the	  
acid-­‐labile	  and	  mass	  spectrometry	  compatible	  detergent	  RapiGest.	  Subsequently,	  the	  resulting	  peptides	  of	  each	  
sample	   were	   differentially	   labeled	   with	   one	   of	   six	   TMT	   6-­‐plex	   tags	   followed	   by	   sample	   combination.	   The	  
combined	   peptides	   were	   then	   desalted,	   the	   sample	   complexity	   reduced	   by	   isoelectric	   peptide	   focusing	  
(OFFGEL)	   and	   all	   fractions	   finally	   analyzed	   by	   LC-­‐MS/MS.	   The	   acquired	   spectra	   were	   finally	   processed	   by	  
MaxQuant,	   allowing	   the	   identification	   and	   relative	   quantification	   of	   myelin	   proteins	   based	   on	   reporter	   ion	  
intensities.	  The	  experiment	  was	  repeated	  three	  times	  using	  animals	  of	  the	  same	  age	  and	  genotype	  (3	  biological	  
replicates).	  	  
4.1.1 Myelin	  purification	  &	  quality	  assessment	  
Myelin	  from	  WT	  and	  FA2H-­‐KO	  animals	  was	  prepared	  by	  the	  well-­‐established	  sucrose	  density	  gradient	  
centrifugation	  method	   (see	   3.2.1.2	  Myelin	   preparation).	   Because	   of	   its	   relatively	   unique	   density,	   a	  
reasonably	   pure	  myelin	   enriched-­‐fraction	   can	   be	   obtained	   by	   this	  method.	   After	   preparation,	   the	  
myelin	   quality	   was	   examined	   by	   separating	   small	   amounts	   via	   SDS-­‐PAGE	   and	   performing	   a	  
subsequent	  silver	  staining.	  



























































Figure	  4-­‐2:	  Isolation	  of	  myelin	  from	  brains	  and	  sciatic	  nerves.	  
(A)	   Scheme	   depicting	   myelin	   purification	   procedure	   by	   sucrose	   density	   gradient.	   (B)	   Example	   picture	   for	  
myelin-­‐enriched	   fraction	   (from	   brain)	   obtained	   by	   sucrose	   density	   gradient	   centrifugation.	   Myelin	   is	   clearly	  
visible	  as	  a	  distinct	  white	  layer	  between	  the	  two	  differentially	  concentrated	  sucrose	  solutions	  (10.5	  and	  30%).	  
Note	  that	  for	  sciatic	  nerve	  myelin,	  sucrose	  solutions	  of	  slightly	  altered	  concentrations	  (9.2%	  and	  28.4%,)	  were	  
used.	  (C)	  and	  (D)	  1	  µg	  of	  brain/sciatic	  nerve	  myelin	  from	  one	  animal	  of	  each	  genotype	  (WT	  and	  FA2H-­‐KO)	  and	  
age	   (6,	  13	  and	  17	  months)	  was	   separated	  by	  12.5%	  SDS-­‐PAGE	  and	  proteins	   subsequently	  visualized	  by	   silver	  
staining.	  Myelin	  from	  the	  same	  animals	  was	  used	  for	  all	  gels.	  Strongly	  stained	  protein	  bands	  representing	  some	  
known	   myelin	   proteins	   are	   marked	   with	   arrows.	   CNP	   =	   2',3'-­‐cyclic-­‐nucleotide	   3'-­‐phosphodiesterase;	   PLP	   =	  
proteolipid	  protein;	  MBP	  =	  myelin	  basic	  protein;	  PRX	  =	  periaxin;	  P0	  =	  myelin	  protein	  zero.	  
The	  silver	  stained	  gels	  (Figure	  4-­‐2C	  and	  D)	  indicated	  that	  myelin	  was	  successfully	  purified	  from	  brains	  
and	   sciatic	   nerves	  of	   6,	   13	   and	  17	  months	  old	  WT	  and	   FA2H-­‐KO	  animals.	   The	  protein	  pattern	  was	  
similar	  to	  the	  one	  described	   in	  the	   literature	  (Larocca	  &	  Norton	  2007).	  Typical	  major	  protein	  bands	  
usually	  found	  in	  CNS-­‐	  (MBP,	  CNP)	  and	  PNS-­‐myelin	  (MBP,	  P0,	  PRX)	  were	  visible.	  Surprisingly,	  the	  PLP-­‐
signal	  (~35	  kDa)	  was	  absent	  in	  the	  brain	  samples	  for	  unknown	  reasons.	  However,	  the	  following	  mass	  
spectrometry	  analyzes	  clearly	   showed	   its	  presence	   in	   the	  myelin	  preparations	   (Figure	  4-­‐4).	  Overall,	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purification	  procedure.	  Furthermore,	  there	  were	  no	  apparent	  differences	  between	  WT	  and	  FA2H-­‐KO	  
animals	  at	  any	  given	  time	  point,	  indicating	  that	  the	  high	  abundant	  myelin	  proteins	  are	  unchanged.	  
4.1.2 Identification	  of	  myelin	  proteome	  alterations	  in	  FA2H-­‐KO	  mice	  
For	   the	   quantitative	   analysis	   of	   myelin	   proteome	   changes	   in	   FA2H-­‐KO	   mice	   the	   samples	   were	  
processed	  as	   follows.	  For	  each	  tissue	   (brain	  or	  sciatic	  nerves)	  40	  µg	  of	  myelin	   from	  6-­‐,	  13-­‐	  and	  17-­‐
month-­‐old	  WT	   and	   FA2H-­‐KO	  mice	  were	   first	   delipidated	   by	   aceton	   precipitation.	   Afterwards,	   each	  
sample	  was	   resolubilized	   in	  0.1%	  RapiGest	   containing	  buffer,	   reduced	  and	  alkylated,	  digested	  with	  
trypsin	   and	   the	   peptides	   TMT-­‐6plex	   labeled.	   The	   labeled	   peptides	   were	   then	   combined,	   RapiGest	  
removed	   by	   acidic-­‐cleavage	   and	   precipitation,	   and	   the	   combined	   samples	   desalted	   by	   solid-­‐phase	  
extraction	   (SPE).	   Subsequently,	   the	   complexity	   of	   the	   sample	   was	   reduced	   by	   isoelectric	   peptide	  
fractionation	  (OFFGEL).	  Thereafter,	  the	  resulting	  12	  fractions	  were	  desalted	  using	  C18-­‐StageTips	  and	  
analyzed	   by	   LC-­‐MS/MS.	   Finally,	   the	   36	   raw	   data	   files	   (12	   fractions	   X	   3	   biological	   replicates)	   were	  
combined	   and	   protein	   groups	   identified	   by	   searching	   against	   a	   murine	   Uniprot	   database	   using	  
MaxQuant.	  The	  identifications	  are	  given	  as	  protein	  groups	  and	  not	  single	  proteins.	  A	  protein	  group	  is	  
an	  identifier,	  which	  includes	  all	  proteins,	  protein	  isoforms	  and	  protein	  sequence	  variants	  that	  can	  be	  
explained	  by	  the	  same	  detected	  peptides.	  A	  protein	  group	  can	  also	  contain	  one	  single	  protein,	  but	  
only	  if	  peptides	  unique	  for	  it	  were	  found.	  Additionally,	  MaxQuant	  calculated	  reporter	  ion	  intensities	  
for	  each	  protein.	  Afterwards,	  the	  resulting	  protein	  group	  lists	  were	  further	  processed	  using	  Perseus.	  
Shortly,	   the	   data	   were	   normalized,	   FA2H-­‐KO/WT	   expression	   ratios	   calculated,	   entries	   with	  
insufficient	  quantitative	  values	  removed,	  and	  significantly	  changed	  protein	  groups	  identified	  by	  one-­‐
sample	   t-­‐tests.	   	   Moreover,	   annotation	   analyses	   of	   significantly	   changed	   protein	   groups	   were	  
conducted	  using	  AmiGO	  and	  PANTHER.	  The	  results	   for	  each	   tissue	  are	  given	   in	   the	  sections	  below.	  
The	   details	   of	   the	   data	   analysis	   are	   described	   in	   the	  method	   section	   (3.2.4.14	  Mass	   spectrometry	  
data	  analysis).	  
4.1.2.1 Brain	  myelin	  analysis	  
4.1.2.1.1 Mass	  spectrometric	  analysis	  using	  TMT-­‐labeling	  
The	  comparative	  brain	  myelin	  proteome	  analysis	  was	  carried	  out	  as	  described	  above.	  A	  first	  overview	  
of	  its	  results	  and	  a	  comparison	  to	  previously	  published	  CNS-­‐myelin	  data	  is	  given	  in	  Figure	  4-­‐3.	  Note	  
that	   the	   original	  MaxQuant	   result	   files	   and	   the	   processed	   protein	   group	   list	   can	   be	   found	   on	   the	  
supplemental	  DVD.	  











Figure	  4-­‐3:	  Quantitative	  brain	  myelin	  (CNS)	  proteome	  analysis.	  
(A)	   Diagram	   depicting	   the	   workflow	   of	   protein	   group	   results	   processing.	  MaxQuant	   identified	   1682	   protein	  
groups	  after	  combined	  analysis	  of	  all	  raw	  files	  (matched	  against	  murine	  Uniprot	  database).	  The	  data	  were	  then	  
normalized	   (each	   reporter	   intensity	   divided	   by	   summed	   reporter	   channel	   intensity)	   and	   log2	   FA2H-­‐KO/WT	  
expression	   ratios	   (log2	   fold	   change)	   calculated	   for	   each	   timepoint.	   Subsequently,	   the	   data	  were	   filtered	   for	  
protein	  groups	  with	  at	  least	  two	  expression	  ratios	  at	  one	  timepoint	  leaving	  1205.	  To	  assess	  proteins,	  which	  had	  
a	  significantly	  changed	  expression	  in	  FA2H-­‐KO	  mice,	  the	  log2	  transformed	  expression	  values	  were	  evaluated	  by	  
a	  one-­‐sample	  t-­‐test	  against	  0	  (log2(1)	  =	  0	  =	  no	  change)	  for	  each	  timepoint.	  This	  resulted	  in	  the	  identification	  of	  
145	  significantly	  changed	  protein	  groups.	  (B)	  Proportional	  Venn	  diagram	  comparing	  the	  proteins	  identified	  with	  
TMT	   6-­‐plex	   brain	   myelin	   proteome	   analysis	   in	   this	   thesis	   with	   the	   published	   CNS	   myelin	   reference	   list	   (de	  
Monasterio-­‐Schrader	   et	   al.	   2012).	   The	   first	   gene	   name	   of	   each	   protein	   group	  was	   used	   as	   identifier.	   A	   list,	  
containing	  all	  gene	  names	  related	  to	  the	  overlapping	  areas,	  can	  be	  found	  on	  the	  supplemental	  DVD.	  
1682	  protein	  groups	  were	  identified	  by	  MaxQuant	  (razor	  or	  unique	  peptides	  ≥	  1;	  false	  discovery	  rate	  
(FDR)	  =	  0.01)	  in	  the	  brain	  myelin	  dataset	  (Figure	  4-­‐3A),	  thereby	  significantly	  exceeding	  the	  number	  of	  
~1300	   currently	   known	   CNS-­‐myelin	   proteins	   (de	   Monasterio-­‐Schrader	   et	   al.	   2012).	   Still,	   when	  
comparing	   the	   brain	  myelin	   dataset	   with	   the	   reference	   list,	   there	   was	   a	   large	   congruency	   of	   829	  
protein	   groups	   identified	   in	   both,	   as	   becomes	   obvious	   from	   the	   Venn	   diagram	   (Figure	   4-­‐3B).	   This	  
further	  proved	  the	  successful	  myelin	  preparation	  by	  the	  sucrose	  density	  gradient	  protocol.	  	  
To	   identify	   protein	   abundance	   differences	   between	  WT	   and	   FA2H-­‐KO	  mice,	   the	   data	  were	   further	  
processed	   (Figure	   4-­‐3A).	   Therefore,	   after	   normalization,	   expression	   ratios	   FA2H-­‐KO/WT	   were	  
calculated	   for	   each	   timepoint	   (6,	   13	   and	   17	  months),	  which	  were	   afterwards	   linearized	   by	   a	   log2-­‐
transformation	  (log2	  fold	  change).	  Because	  quantitative	  information	  was	  not	  available	  for	  all	  protein	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at	  at	   least	  one	  timepoint,	  were	  filtered	  out.	  This	  reduced	  the	  list	  to	  1205	  entries.	  To	  assess	  protein	  
groups,	   which	   had	   a	   significantly	   changed	   expression	   in	   FA2H-­‐KO	   mice,	   a	   one-­‐sample	   t-­‐test	   was	  
performed	  for	  each	  timepoint.	  On	  the	  basis	  of	   the	  generated	  –log10-­‐transformed	  p-­‐values	  and	  the	  
magnitude	   of	   the	   log2	   fold	   change,	   the	   protein	   groups	   were	   filtered	   for	   being	   significantly	  
upregulated	   and	   downregulated.	   Protein	   groups	   were	   deemed	   significantly	   upregulated,	   if	   they	  
exhibited	  a	  relevant,	  i.e.	  sufficiently	  large	  enough,	  log2	  fold	  change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  and	  a	  
–log10	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  0.05).	  Conversely,	  the	  criteria	  for	  a	  significant	  downregulation	  were	  
a	  log2	  fold	  change	  ≤	  -­‐0.585	  (fold	  change	  ≤	  0.667)	  and	  a	  –log10	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  0.05).	  This	  
led	   to	   145	   protein	   groups,	   which	   were	   significantly	   changed	   at	   at	   least	   one	   timepoint.	   Note	   that	  
some	  of	  these	  were	  changed	  at	  more	  than	  one	  timepoint.	  
Before	  analyzing	   this	   relatively	   large	  number	  of	   changed	  protein	  groups	   in	  more	  detail,	   it	  was	   first	  
evaluated	  if	  major	  CNS-­‐myelin	  proteins,	  e.g.	  MBP,	  CNP,	  MOG	  etc.,	  were	  not	  changed	  between	  FA2H-­‐
KO	  and	  WT	  at	  all	  three	  timepoints.	  As	  mentioned	  before	  (see:	  2.4	  Aim	  of	  this	  study),	  initial	  analyses	  
of	  young	  FA2H-­‐KO	  CNS-­‐myelin	  had	  shown	  no	  differences	  in	  such	  proteins,	  therefore	  arguing	  for	  more	  
subtle	   changes	   causing	   the	   FA2H	  deficiency	   phenotype.	   In	   the	   figure	   below	   (Figure	   4-­‐4)	   the	  mean	  
log2	   fold	  changes	   for	   some	  major	  CNS-­‐myelin	  proteins	  are	  plotted	  against	   the	  animal	  ages.	  Within	  
these	  plot	  dashed	  black	  lines	  mark	  the	  borders	  for	  a	  log2	  fold	  change	  to	  be	  deemed	  relevant.	  Further	  
note	   that	   MaxQuant	   had	   possible	   MBP-­‐isoforms	   and	   sequence	   variants	   subdivided	   into	   three	  
separate	  protein	  groups.	  	  
The	   plot	   revealed	   that	   the	   examined	   major	   CNS-­‐myelin	   proteins	   were	   not	   substantially	   changed	  
between	   FA2H-­‐KO	   and	  WT	   at	   all	   three	   timepoints.	   Only	   for	  MBP,	   two	   of	   its	   three	   protein	   groups	  
showed	  a	  log2	  fold	  change	  close	  to	  the	  lower	  border.	  Accordingly,	  a	  slight	  downregulation	  of	  some	  
MBP-­‐isoforms	  could	  not	  be	  excluded	  completely.	  




Figure	   4-­‐4:	   Expression	   differences	   of	  major	   CNS-­‐myelin	   proteins	   between	   FA2H-­‐KO	   and	  WT	  mice	   in	   brain	  
myelin.	  Each	  protein	  group’s	  mean	   log2	  transformed	  KO/WT	  expression	  ratios	   (log2	  fold	  change)	  are	  plotted	  
against	  the	  mice	  age	  in	  month.	  For	  each	  line	  the	  standard	  deviation	  at	  each	  time	  point	  is	  given	  by	  error	  bars,	  if	  
it	   was	   calculable	   (n	   =	   2-­‐3).	   Horizontal	   doted	   black	   lines	  mark	   the	   borders	   for	   relevant,	   i.e.	   sufficiently	   large	  
enough,	  log2	  fold	  changes	  (log2	  fold	  change	  ≥	  0.585	  &	  ≤	  -­‐0.585).	  Note	  that	  MaxQuant	  assigned	  different	  MBP-­‐
isoforms	  and	   sequence	  variants	   to	   three	   separate	  protein	   group	  entries,	  with	   all	   had	   slightly	  different	  mean	  
log2	  fold	  changes.	  	  CNP	  =	  cyclic	  nucleotide	  phosphodiesterase;	  MAG	  =	  myelin-­‐associated	  glycoprotein;	  MBP	  =	  
myelin	  basic	  protein;	  MOBP	  =	  myelin-­‐associated	  oligodendrocyte	  basic	  protein;	  MOG	  =	  myelin-­‐oligodendrocyte	  
glycoprotein;	  PLP	  =	  proteolipid	  protein.	  
After	   showing	   no	   relevant	   change	   in	   major	   CNS-­‐myelin	   proteins,	   the	   145	   significantly	   changed	  
protein	  groups	  were	  evaluated	  in	  more	  detail.	  At	  each	  single	  timepoint	  between	  50	  and	  71	  protein	  
groups	   were	   significantly	   up-­‐	   or	   downregulated	   (Figure	   4-­‐5A).	   Moreover,	   a	   trend	   was	   observable	  
showing	   that	   the	   number	   of	   significantly	   upregulated	   proteins	   increased,	   while	   the	   number	   of	  
significantly	  downregulated	  protein	  groups	  decreased	  over	  time.	  While	  the	  increase	  in	  upregulations	  
can	   be	   likely	   attributed	   to	   the	   aggravating	   pathology	   of	   the	   FA2H-­‐KO	   deficiency,	   the	   decrease	   in	  
downregulations	  cannot	  be	  explained	  conclusively.	  Potentially,	  it	  may	  reflect	  compensatory	  reactions	  
within	  the	  organisms	  of	  the	  KO-­‐mice,	  which	  tried	  to	  restore	  the	  amounts	  of	  the	  affected	  proteins	  to	  
WT-­‐levels.	  	  
Next,	   for	  assessing	  the	  persistence	  of	  an	  expression	  change,	   the	  protein	  group	   identifications	  were	  
compared	   to	   each	   other	   between	   the	   three	   timepoints.	   This	  was	   done	   separately	   for	   the	   up-­‐	   and	  
downregulated	   protein	   groups	   and	   depicted	   in	   proportional	   Venn	   diagrams	   (Figure	   4-­‐5B).	   The	  
respective	   Venn	   diagrams	   showed	   that	   the	   majority	   of	   protein	   groups	   significantly	   up-­‐	   or	  
downregulated	  were	  unique	  for	  one	  timepoint,	  thereby	  further	  supporting	  the	  possible	  influence	  of	  
compensatory	  effects	  mentioned	  above.	  Still,	  for	  the	  upregulated	  ones	  there	  were	  also	  three	  protein	  
groups	  displaying	  a	  constant	  significant	  change	  from	  the	  first	  to	  the	  last	  timepoint.	  In	  contrast,	  others	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13	  and	  17M	  (up	  =	  11).	  Moreover,	  no	  protein	  groups	  were	  significantly	  downregulated	  between	  the	  
last	   two	   timepoints.	   For	   the	   upregulations	   the	   greatest	   congruency	   was	   observable	   for	   the	   later	  
timepoints	   (13	   &	   17M),	   thus	   emphasizing	   that	   at	   least	   some	   upregulations	   were	   persistent.	   The	  
opposite	  was	  true	  for	  the	  downregulations,	  with	  the	  biggest	  congruency	  between	  timepoints	  6	  and	  
13M.	  Accordingly,	   the	  majority	  of	  downregulations	  were	  only	   temporary	   and	   reverted	  back	   to	   the	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Figure	  4-­‐5:	  The	  145	  protein	  groups	  significantly	  up-­‐	  and	  downregulated	  in	  FA2H-­‐KO	  brain	  myelin.	  
(A)	   Number	   of	   significantly	   up-­‐	   and	   downregulated	   protein	   groups	   at	   each	   time	   point.	   Note	   that	   the	   same	  
proteins	  can	  be	  changed	  at	  more	  than	  one	  timepoint.	  (B)	  Comparison	  of	  the	  significantly	  upregulated	  (left)	  or	  
downregulated	   (right)	   protein	   group	   identifications	   at	   the	   three	   timepoints	   by	   area-­‐proportional	   Venn	  
diagrams.	  The	  first	  gene	  name	  of	  each	  protein	  group	  was	  used	  as	  identifier.	  The	  identities	  of	  the	  protein	  groups	  
behind	  each	  number	  are	  given	  in	  Table	  4-­‐1	  and	  Table	  4-­‐2.	  
To	  get	  an	  overview	  about	  the	  identity	  of	  the	  relatively	  large	  number	  of	  significantly	  changed	  protein	  
groups,	  tables	  were	  generated	  for	  the	  upregulated	  (Table	  4-­‐1)	  and	  downregulated	  (Table	  4-­‐2)	  protein	  
groups.	   In	  each	  table	   the	  protein	  groups	   (indicated	  by	   their	   respective	  gene	  names)	  are	  given	  with	  
their	  log2	  fold	  change	  for	  each	  timepoint.	  Log2	  fold	  changes,	  which	  were	  significant	  (-­‐log10	  p-­‐value	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Table	  4-­‐1:	  Protein	  groups	  significantly	  upregulated	  in	  brain	  myelin	  at	  at	  least	  one	  timepoint.	  
The	  table	  contains	  the	  proteins	  groups,	   indicated	  by	  their	  respective	  gene	  games,	  which	  showed	  a	  significant	  
upregulation	  at	  one	  timepoint	  or	  more.	  Besides	  each	  gene	  name	  the	  log2	  fold	  change	  (log2	  ratio	  FA2H-­‐KO/WT)	  






















Acta2	   -­‐0.0720	   0.2839	   0.6950	  
	  
Map4	   0.2376	   0.5922	   0.6228	  
Actr1a	   -­‐0.1490	   0.1302	   0.7189	   Mapt	   0.6290	   0.9679	   0.8513	  
Amph	   0.0955	   0.3769	   0.6115	   Mark1	   0.2406	   0.1035	   0.8548	  
Ank3	   0.5887	   0.2829	   0.2405	   Mcam	   0.7237	   0.7853	   0.4283	  
Apoe	   0.7043	   0.9555	   0.8848	   Mink1	   0.6205	   0.6720	   0.2816	  
Asap1	   0.3882	   0.7889	   0.9565	   Msn	   0.3920	   0.6559	   0.7229	  
Aspa	   -­‐0.5010	   0.3926	   0.6325	   Mvp	   0.2602	   0.4356	   0.7386	  
Atpif1	   0.5085	   0.7005	   0.4411	   Myo18a	   0.5086	   0.5106	   0.7845	  
Bcr;Abr	   -­‐0.4705	   0.2027	   0.5948	   Myo6	   0.2016	   0.2955	   0.5923	  
C1qb	   0.8778	   1.3776	   1.8911	   Nefh	   -­‐0.1186	   -­‐0.1319	   0.8063	  
C4b	   0.8363	   2.2834	   2.2925	   Nefl	   -­‐0.2225	   -­‐0.0120	   0.8806	  
Cadm4	   0.4227	   0.5109	   0.5865	   Nefm	   -­‐0.1590	   0.0074	   0.9354	  
Ccdc124	   0.4023	   0.9786	   1.0150	   Opalin	   0.9294	   0.7626	   1.0055	  
Ckap5	   0.3293	   0.8913	   0.6070	   Pacsin2	   -­‐0.0391	   0.7413	   0.8693	  
Clasp2	   0.3196	   0.7513	   0.8451	   Pcbp1;Pcbp3;Pcbp2	   -­‐0.3535	   0.0142	   0.6486	  
Crocc	   -­‐0.2277	   0.4888	   0.8973	   Pclo	   0.5574	   0.5999	   0.5811	  
Ctsd	   -­‐0.1608	   -­‐0.3405	   0.7346	   Phgdh	   -­‐0.4710	   0.2983	   0.6935	  
Dctn2	   -­‐0.1720	   0.1688	   0.8316	   Plcb3	   0.3215	   0.6531	   0.7000	  
Ddc	   -­‐0.3853	   -­‐0.1371	   1.2003	   Ppib	   0.6318	   0.6871	   0.3067	  
Dhrs1	   0.5075	   0.6540	   0.3471	   Ppp2r2d;Ppp2r2a	   -­‐0.3603	   0.1090	   0.7866	  
Dnm1	   0.0991	   0.6994	   0.7395	   Prkag2	   0.0326	   -­‐0.1270	   0.6919	  
Dnm1;Dnm2	   0.3480	   0.8480	   0.8157	   Prkcb	   0.1015	   0.1065	   0.8838	  
Dnm3	   0.1777	   0.6094	   0.6263	   Ptn	   0.9249	   0.9370	   1.1389	  
Dock5	   0.5089	   0.2775	   0.6296	   Qdpr	   -­‐0.1557	   0.3143	   0.8409	  
Dstn	   -­‐0.4120	   0.0149	   0.7185	   Rras2	   0.6441	   0.2492	   0.3820	  
Edil3	   0.5759	   0.7566	   0.5890	   Scamp4	   0.5675	   0.6194	   0.6117	  
Erbb2ip	   0.5556	   0.8849	   1.0746	   Scrn1	   -­‐0.4814	   -­‐0.3127	   0.6217	  
Fabp5	   -­‐0.0659	   0.3053	   0.9348	   Sirpa	   0.6224	   0.2730	   0.4804	  
Fasn	   -­‐0.1297	   0.2606	   0.7930	   Slk	   0.5733	   0.7763	   0.4949	  
Fnbp1	   -­‐0.0046	   0.6370	   0.9081	   Stk39	   -­‐0.3923	   0.0483	   0.6105	  
Gfap	   0.7495	   1.2719	   1.3426	   Synj1	   0.5233	   0.2845	   0.6140	  
Glul	   -­‐0.2428	   -­‐0.0898	   0.6266	   Sypl;Sypl1	   0.6302	   0.0889	   -­‐0.0907	  
Gpd1	   -­‐0.3174	   0.3608	   0.7428	   Taok1	   0.6467	   0.5343	   0.1024	  
Gprc5b	   1.1533	   0.5885	   0.0125	   Taok2	   0.6946	   0.7244	   0.3054	  
Grn	   -­‐0.1810	   0.8560	   1.2189	   Tbc1d10b	   0.6993	   0.5429	   0.1998	  
Hip1r	   -­‐0.0294	   0.6531	   0.8620	   Tjp2	   0.1258	   0.2978	   0.7369	  
Hmgn1	   0.7984	   1.6866	   1.7496	   Tollip	   -­‐0.0211	   0.5463	   0.7647	  
Hmgn2	   0.8473	   0.8366	   1.2773	   Tom1l2	   -­‐0.2676	   0.1462	   0.6152	  
Hspa2	   -­‐0.0844	   0.6976	   0.4684	   Trim2	   0.2501	   0.6443	   0.6697	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Htra1	   0.6387	   0.7627	   0.8122	   Tubb4a	   -­‐0.3010	   -­‐0.0226	   0.7120	  
Ina	   -­‐0.1040	   0.0648	   0.7080	  
Ubc;Ubb;Uba52;Rps27a;Kxd
1;Gm7866;Gm7808;Gm5239	   0.1421	   0.4133	   0.5903	  
Kif5b	   0.0281	   0.4120	   0.8226	   Unc5b;Unc5c	   0.3316	   0.6333	   0.4732	  
Lap3	   -­‐0.2801	   0.2666	   0.9373	   Wasl	   0.4393	   0.9207	   1.1548	  
Lyz2	   0.7505	   2.7104	   2.5483	   Wdr37	   0.0063	   0.1217	   0.7047	  
Map2	   0.6758	   1.0630	   0.8366	  
	   	   	   	  Map4	   0.2265	   0.4813	   0.8030	   	   	   	   	  
	  
From	   the	   table,	   it	   is	   possible	   to	   immediately	   identify	   the	   3	   constantly	   significantly	   upregulated	  
protein	   groups	   as	   C1q	   (complement	   C1q	   subcomponent	   subunit	   B),	   Gfap	   (glial	   fibrillary	   acidic	  
protein)	   and	   Htra1	   (high-­‐temperature	   requirement	   A	   serine	   peptidase	   1).	   The	   information	   in	   the	  
table	  furthermore	  suggests	  that	  other	  protein	  groups,	  like	  Apoe	  (apolipoprotein	  E),	  C4b	  (complement	  
C4-­‐B),	   Map2	   (microtubule-­‐associated	   protein	   2)	   and	   Ptn	   (pleiotrophin),	   presumably	   exhibited	   a	  
relevant	   (log2	   fold	   changes	   ≥	   0.585)	   constant	   upregulation	   as	   well,	   but	   the	   measured	   log2	   fold	  
change	  was	  not	  significant	  at	  one	  of	  the	  timepoints.	  The	  same	  seemed	  to	  be	  the	  case	  for	  the	  protein	  
groups,	   Hmgn1	   and	   Hmgn2	   (high	   mobility	   group	   nucleosome	   binding	   domain	   1	   and	   2),	   Lyz2	  
(lysozyme	   2),	  Mapt	   (microtubule-­‐associated	   protein	   tau)	   and	   Opalin,	   whose	   log2	   fold	   change	  was	  
significant	  at	  just	  one	  timepoint.	  
	  
Table	  4-­‐2:	  Protein	  groups	  significantly	  downregulated	  in	  brain	  myelin	  at	  at	  least	  one	  timepoint.	  
The	  table	  contains	  the	  proteins	  groups,	   indicated	  by	  their	  respective	  gene	  games,	  which	  showed	  a	  significant	  
upregulation	  at	  one	  timepoint	  or	  more.	  Besides	  each	  gene	  name	  the	  log2	  fold	  change	  (log2	  ratio	  FA2H-­‐KO/WT)	  






















Abhd4	   -­‐0.5925	   -­‐0.6092	   0.4023	  
	  
Kiaa1045	   -­‐0.7019	   -­‐0.7071	   -­‐0.5826	  
Acot7	   -­‐1.2128	   -­‐0.5868	   0.2210	   Ldhb	   -­‐1.0794	   -­‐0.6953	   -­‐0.0277	  
Ak1	   -­‐0.6498	   -­‐0.2080	   0.0317	   Mgll	   -­‐0.8237	   -­‐0.3642	   -­‐0.6474	  
Alb	   -­‐0.4564	   -­‐0.7814	   -­‐1.0302	   Mif	   -­‐0.8627	   -­‐0.9866	   -­‐0.6688	  
Anln	   -­‐1.4509	   -­‐0.7394	   -­‐0.1650	   Mtm1	   -­‐0.5302	   -­‐0.0827	   -­‐0.6154	  
Arf1	   -­‐0.6650	   -­‐0.5018	   -­‐0.0926	   Ndrg1	   -­‐0.4332	   -­‐0.7046	   -­‐0.4743	  
Ass1	   -­‐0.9718	   -­‐1.0498	   -­‐1.0878	   Nme2	   -­‐0.6253	   -­‐0.3788	   -­‐0.0773	  
Atp6v1a	   -­‐0.7774	   -­‐0.8999	   -­‐0.4470	   Osbpl1a	   -­‐0.4199	   -­‐1.0502	   -­‐0.3687	  
Atp6v1b2	   -­‐0.7630	   -­‐0.8421	   -­‐0.4614	   Otub1	   -­‐0.5923	   -­‐0.4805	   0.4450	  
Calb2	   -­‐0.9340	   -­‐0.5588	   -­‐0.1104	   Pea15	   -­‐0.6085	   0.0680	   0.5501	  
Cd59a	   -­‐0.2263	   0.0700	   -­‐1.5964	   Pebp1	   -­‐0.8469	   -­‐0.3353	   0.0185	  
Eci1	   -­‐0.9595	   -­‐1.0367	   -­‐0.7363	   Pfn2	   -­‐0.8564	   -­‐0.5189	   0.1678	  
Eno2	   -­‐0.9176	   -­‐0.7428	   0.2245	   Pkm	   -­‐0.8415	   -­‐0.5933	   -­‐0.0293	  
Esyt2	   0.2264	   0.2598	   -­‐4.0012	   Rheb	   -­‐0.7894	   -­‐0.4185	   -­‐0.2079	  
Etfa	   -­‐0.5757	   -­‐0.9288	   -­‐0.4890	   Sept4	   -­‐1.1114	   -­‐0.7994	   -­‐0.1521	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Fam177a1	   -­‐0.1735	   -­‐0.9156	   0.5258	   Sept7	   -­‐0.6701	   -­‐0.3843	   -­‐0.0654	  
Fam65a	   -­‐1.0919	   -­‐0.8042	   -­‐0.9517	   Sept8	   -­‐0.6604	   -­‐0.2637	   0.0320	  
Fyco1	   -­‐0.9593	   -­‐0.6965	   -­‐0.8515	   Sh3bgrl3	   -­‐0.7466	   -­‐0.2425	   0.3845	  
Gdi2	   -­‐1.0315	   -­‐0.5867	   -­‐0.2466	   Slc38a3	   0.0915	   0.1123	   -­‐1.5563	  
Gng11	   -­‐0.8004	   -­‐0.3230	   0.1118	   Sod2	   -­‐0.3777	   -­‐0.6764	   -­‐0.0969	  
Got1	   -­‐0.8329	   -­‐0.8483	   -­‐0.2828	   Tbc1d24	   0.3491	   -­‐0.5494	   -­‐0.7648	  
Got2	   -­‐0.8063	   -­‐0.6099	   -­‐0.8573	   Tpi1	   -­‐0.7629	   -­‐0.5181	   0.1142	  
Gstm5	   -­‐0.5899	   -­‐0.2790	   -­‐0.0843	   Tubb3	   -­‐0.6201	   -­‐0.1562	   0.0822	  
Hadha	   0.3959	   0.1597	   -­‐0.6310	   Txn	   -­‐0.5970	   -­‐0.4495	   0.0646	  
Hba-­‐a1	   -­‐0.7853	   -­‐1.2451	   -­‐1.3723	   Ube2n	   -­‐0.5733	   -­‐0.7180	   -­‐0.3655	  
Hsd17b11	   -­‐1.0919	   -­‐0.4842	   -­‐0.2682	   Vat1	   -­‐1.0215	   -­‐0.4316	   -­‐0.1652	  
Igsf8	   -­‐0.2213	   -­‐0.4264	   -­‐0.5899	   Vsnl1	   -­‐0.6109	   -­‐0.4655	   -­‐0.2883	  
Ist1	   -­‐0.7412	   -­‐0.4349	   -­‐0.0049	  
	   	   	   	  	  
The	   table	   further	   emphasized	   that	   no	   single	   protein	   group	   was	   constantly	   significantly	  
downregulated	  in	  FA2H-­‐KO	  mice.	  Still,	  when	  considering	  also	  the	  non	  significant	  but	  sufficient	  log	  2	  
fold	   changes	   (log2	   fold	   change	   ≤	   -­‐0.585),	   it	   seemed	   that	   at	   least	   some	   protein	   groups	   were	  
potentially	  downregulated	  at	  all	   three	   timepoints.	  These	  were	  Ass1	   (argininosuccinate	   synthase	  1),	  
Eci1	  (enoyl-­‐CoA	  delta	  isomerase	  1),	  Fam65a	  (enoyl-­‐CoA	  delta	  isomerase	  1),	  Fyco1	  (FYVE	  and	  coiled-­‐
coil	   domain	   containing	   1),	   Got2	   (glutamic-­‐oxaloacetic	   transaminase	   2),	   Hba-­‐a1	   (hemoglobin	   alpha,	  
adult	  chain	  1)	  and	  Mif	   (macrophage	  migration	   inhibitory	   factor).	   In	  addition,	  as	  described	   in	  Figure	  
4-­‐5,	  many	  protein	  groups	  were	  downregulated	  only	  in	  younger	  mice	  (6	  and	  13	  months),	  but	  reverted	  
back	  to	  WT-­‐levels	  in	  the	  older	  animals	  (17	  months).	  	  
	  
To	   also	   get	   a	   general	   functional	   idea	   about	   the	   protein	   groups	   up-­‐	   or	   downregulated	   at	   each	  
timepoint,	   annotation	   analyses	   were	   conducted	   by	   AmiGO	   (http://tools.bioso.org/cgi-­‐
bin/amigo/slimmer)	   and	   PANTHER	   (pantherdb.org)	   using	   each	   group’s	   first	   gene	   name.	   The	   two	  
terms	  “Cellular	  Component”	  (GOslim	  by	  AmiGO)	  and	  “Protein	  Classification”	  (PANTHER	  classification)	  
were	   evaluated	   and	   the	   results	   depicted	   in	   the	   bar	   charts	   (Figure	   4-­‐6).	   Detailed	   tables	   with	   the	  
absolute	  numbers	  of	  the	  assigned	  annotations	  can	  be	  found	  on	  the	  supplemental	  DVD.	  In	  addition,	  
PANTHER-­‐generated	   gene	   lists,	   containing	   information	   for	   each	  of	   the	   submitted	   gene	  names,	   can	  
















Figure	  4-­‐6:	  Annotation	  analysis	  of	  protein	  groups	  up-­‐	  or	  downregulated	  in	  brain	  myelin	  of	  FA2H-­‐KO	  mice	  at	  
each	  timepoint.The	  protein	  groups	  significantly	  up-­‐	  or	  downregulated	  in	  brain	  myelin	  of	  FA2H-­‐KO	  mice	  at	  each	  
timepoint	   (6M,	   13M,	   17M	   =	   6,	   13	   and	   17	   months)	   were	   analyzed	   for	   annotation	   terms	   using	   AmiGO	   and	  
PANTHER.	   As	   an	   identifier	   the	   first	   major	   gene	   name	   for	   each	   protein	   group	   was	   used	   and	   the	   up-­‐	   and	  
downregulated	   protein	   groups	   were	   evaluated	   separately.	   The	   results	   for	   the	   two	   assessed	   categories	  
(“Cellular	   Component”,	   “Protein	   Classification”)	   are	   given	   in	   bar	   charts	   (left	   =	   downregulated;	   right	   =	  
upregulated).	   In	   the	  charts	  each	  bar	   indicates	   the	  number	  of	  protein	  groups	  at	  a	  given	   timepoint	  associated	  
with	  a	  certain	  annotation	  subcategory.	  Note	  that	  every	  protein	  group	  can	  be	  associated	  with	  more	  than	  one	  
subcategory.	   In	   the	   chart	   legends	   n	   signifies	   the	   number	   of	   significantly	   changed	   proteins	   at	   that	   specific	  
timepoint,	  which	  could	  be	  annotated	  by	  the	  annotation	  tool.	  (A)	  Cellular	  Compartment	  chart.	  Result	  of	  AmiGO	  
GOslim	  analysis.	  (B)	  Protein	  Classification	  chart.	  Result	  of	  PANTHER	  analysis.	  
In	  line	  with	  the	  observations	  made	  above,	  regarding	  the	  changes	  in	  protein	  up-­‐	  and	  downregulations	  
in	  CNS-­‐myelin	  of	  FA2H-­‐KO	  mice,	  the	  “Cellular	  Component”	  annotation	  analysis	  (Figure	  4-­‐6A)	  showed	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that	  the	  number	  of	  protein	  groups	  in	  almost	  all	  of	  the	  assessed	  subcategories	  increased	  over	  time	  for	  
the	  upregulated	  protein	  groups.	  The	  opposite	  was	  true	  for	  the	  downregulated	  protein	  groups,	  which	  
showed	   a	   decrease	   in	   all	   subcategories.	   Considering	   the	   upregulated	   protein	   groups,	   the	  majority	  
were	  linked	  to	  an	  intracellular	  cytoplasmic	  and	  known	  organelle	  localization.	  In	  regard	  to	  organelles,	  
the	  largest	  numbers	  were	  found	  for	  nuclear	  proteins.	  Nevertheless,	  at	  the	  later	  timepoints,	  13M	  and	  
17M	   (13	   and	   17	  months),	   there	  was	   also	   a	   relatively	   large	   group	  of	   protein	   groups	  with	   a	   plasma	  
membrane	   localization.	   In	   addition,	   one	   could	   also	   observe	   a	   strong	   increase	   in	   the	   number	   of	  
cytoskeletal-­‐related	  protein	  groups	  over	  time.	  Regarding	  solely	  the	  downregulated	  protein	  groups,	  it	  
became	  obvious	  that	  they	  were	  largely	  localized	  intracellulary	  in	  the	  cytoplasm	  with	  known	  organelle	  
localization.	   Regarding	   organelles,	   protein	   groups	   containing	   mitochondrial,	   nuclear	   and	   plasma	  
membrane	  proteins	  made	  up	  the	  biggest	  groups	  of	  the	  downregulated	  ones.	  	  
The	  “Protein	  Classification”	  analysis	  (Figure	  4-­‐6B)	  provided	  a	  more	  detailed	  overview	  of	  the	  protein	  
classes	   the	   changed	   protein	   groups	   belong	   to.	   For	   the	   upregulated	   protein	   groups	   the	   number	   of	  
proteins	  within	  almost	  all	  protein	  classes	  increased	  over	  time.	  The	  most	  striking	  change	  was	  seen	  for	  
cytoskeletal	  proteins.	  While	  only	  two	  were	  upregulated	  at	  timepoint	  6M,	  seven	  were	  upregulated	  at	  
timepoint	   13M	   and	   fourteen	   at	   timepoint	   17M.	   The	   second	   strongest	   increase	   was	   observed	   for	  
enzyme	  modulators.	  Furthermore,	  hydrolases,	  receptors,	  signaling	  molecules	  and	  structural	  proteins	  
also	   increased	   strongly.	   Last,	   there	   was	   a	   small	   group	   of	   upregulated	   defense/immunity	   related	  
protein	  groups.	  The	  downregulated	  protein	  groups	  belonged	  to	  many	  different	  protein	  classes	  with	  
the	  number	  of	  entries	  within	  each	  class	  changing	  quite	  drastically	  over	  time.	  At	  the	  earliest	  timepoint	  
(6M)	  the	  largest	  protein	  classes	  were	  enzyme	  modulators	  (9),	  followed	  by	  hydrolases	  (5),	  cytoskeletal	  
proteins	   (4)	   and	   oxidoreductases	   (4).	   In	   comparison,	   at	   timepoint	   13M	   the	   majority	   were	  
oxidoreductases	  (4),	  transferases	  (3)	  and	  transfer/carrier	  proteins	  (3).	  At	  timepoint	  17M,	  in	  contrast,	  
only	  a	  very	  small	  number	  of	  10	  potein	  groups	  were	  significantly	  changed,	  which	  showed	  no	  tendency	  
in	  belonging	  to	  certain	  protein	  classes.	  
In	   summary,	   a	   quite	   large	   number	   of	   up-­‐	   and	   downregulated	   protein	   groups	   existed	   in	   FA2H-­‐KO	  
mice,	   which	   had	   diverse	   localizations	   and	   functions.	   Additionally,	   the	   strongest	   and	   the	   largest	  
number	   of	   upregulations	   were	   found	   in	   very	   old	   animals	   (timepoint	   17M),	   with	   a	   noticeable	  
incidence	  of	  cytoskeletal	  and	  immune	  system	  related	  proteins	  groups.	  	  
Consequently,	   a	   selection	   of	   seven	   protein	   groups,	   strongly	   upregulated	   at	   timepoint	   17M	   and	  
mainly	   linked	  to	  these	  processes,	  was	  reviewed	  in	  more	  detail.	  Figure	  4-­‐7A	  depicts	  a	   line	  plot	  of	  all	  
the	   145	   significantly	   changed	  protein	   groups	   by	   plotting	   each	  proteins	   expression	   ratios	   (log2	   fold	  
changes)	  against	  its	  respective	  timepoint.	  The	  seven	  protein	  groups	  are	  depicted	  in	  an	  additional	  line	  
plot	  (Figure	  4-­‐7B)	  including	  standard	  deviations.	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Figure	  4-­‐7:	  Line	  plot	  of	  proteins	  groups	  significantly	  changed	  in	  FA2H-­‐KO	  mice	  at	  at	  least	  one	  timepoint.	  
(A)	   Line	   plot	   of	   the	   145	   significantly	   changed	   protein	   groups.	   Each	   protein	   group’s	  mean	   log2	   transformed	  
KO/WT	  expression	  ratios	  (log2	  fold	  change)	  are	  plotted	  against	  the	  mice	  age	  in	  month.	  Horizontal	  doted	  black	  
lines	   indicate	  the	  borders	  for	  relevant	   log2	  fold	  changes	  (log2	  fold	  change	  ≥	  0.585	  &	  ≤	  -­‐0.585).	  (B)	  Additional	  
line	  plot	  showing	  only	  a	  selection	  of	  strongly	  upregulated	  protein	  groups.	  For	  each	  line	  the	  standard	  deviation	  
at	  each	  time	  point	  is	  given	  by	  error	  bars,	  if	  it	  was	  calculable	  (n	  =	  2-­‐3).	  A	  horizontal	  doted	  black	  line	  indicates	  the	  
border	  for	  relevant	  upregulations	  (log2	  fold	  change	  ≥	  0.585).	  MAPT	  =	  Microtubule-­‐associated	  protein	  tau;	  C1qb	  
=	  Complement	  C1q	   subcomponent	   subunit	  B;	  GFAP	  =	  Glial	   fibrillary	   acidic	  protein;	  C4b	  =	  Complement	  C4-­‐B;	  
Apo-­‐E	  =	  Apolipoprotein	  E,	  NF-­‐H	  =	  Neurofilament	  heavy.	  
The	   protein	   groups	   selected	   contained	   three	   cytoskeletal	   related	   polypeptides:	   Microtubule-­‐
associated	  protein	  tau	  (MAPT),	  glial	  fibrillary	  acidic	  protein	  (GFAP)	  and	  neurofilament	  heavy	  (NF-­‐H).	  
Of	   the	   three,	   MAPT	   and	   GFAP	   were	   already	   upregulated	   at	   timepoint	   6M	   increasing	   even	   more	  
towards	  timepoint	  13M	  and/or	  17M,	  while	  NF-­‐H	  was	  only	  significantly	  increased	  in	  17M	  old	  FA2H-­‐KO	  
animals.	  Moreover,	  of	  the	  three	  protein	  groups	  GFAP	  presented	  with	  the	  strongest	  upregulation	  at	  
all	  timepoints.	  Interestingly,	  MAPT	  and	  GFAP	  are	  also	  linked	  to	  immunological	  processes.	  Regarding	  
proteins	   directly	   involved	   in	   immunological	   processes,	   Complement	   C1q	   subcomponent	   subunit	   B	  
(C1qb),	   Complement	   C4-­‐B	   (C4b)	   and	   apolipoprotein	   E	   (Apo-­‐E)	   were	   chosen.	   Both	   complement	  
proteins	  showed	  an	  about	  2-­‐fold	  (log2	  fold	  change	  =	  1)	  upregulation	  at	  6	  months,	  and	  increased	  even	  
more	  at	  the	  later	  timepoints.	  Especially	  C4b	  was	  already	  upregulated	  almost	  5-­‐fold	  (log2	  fold	  change	  
≈	  2.3)	  at	  timepoint	  13M,	  staying	  at	  that	  high	  level	  until	  timepoint	  17M.	  Moreover,	  Apo-­‐E,	  well	  known	  
for	  its	  role	  in	  cholesterol	  transport,	  was	  also	  integrated	  into	  the	  selection,	  because	  it	  also	  plays	  a	  role	  
in	  neuroinflammation	  and	  neurodegenerative	  diseases.	   Its	  upregulation	  was	  very	  similar	  to	  the	  one	  
of	  MAPT	  being	  about	  2-­‐fold	  increased	  at	  the	  later	  timepoints.	  Lastly,	  the	  structural	  myelin	  membrane	  
protein	  Opalin,	  which	   is	  not	   linked	   to	   the	  cytoskeleton	  or	   immune	  system	  processes,	  was	   included	  
into	  the	  selection.	  This	  was	  done,	  because	  Opalin	  was	  the	  only	  potential	  structural	  myelin	  membrane	  
protein	  being	  upregulated	  (~2-­‐fold	  at	  all	  timepoints)	  and	  might	  explain	  the	  myelin	  phenotype	  caused	  
by	   FA2H	   deficiency.	   Fittingly,	   Opalin’s	   corresponding	   gene	   is	   found	   in	   a	   locus	   linked	   to	   spastic	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4.1.2.1.2 Verifications	  by	  Western	  Blot	  analyses	  
To	  verify	  some	  of	  the	  upregulations	  observed	  in	  brain	  myelin	  of	  very	  old	  FA2H-­‐KO	  (17M)	  compared	  
to	  WT	  mice,	  quantitative	  WB-­‐analyses	  were	  conducted.	  For	  this,	  myelin	  and	  whole	  brain	  lysates	  were	  
prepared	   from	  another	   independent	  group	  of	   four	  WT	  and	   four	  FA2H-­‐KO	  animals	  of	  advanced	  age	  
(21	   -­‐	  23	  months).	  These	  were	  probed	  with	  antibodies	  against	  MBP,	  MAPT,	  GFAP,	  NF-­‐H,	  C1q,	  ApoE,	  
and	   Opalin.	  MBP	   was	   included,	   because	   its	   mass	   spectrometric	   quantitative	   analysis	   results	   were	  
inconsistent.	  MaxQuant	  had	  different	  MBP-­‐isoforms	  and	  sequence	  variants,	  which	  are	  contained	   in	  
the	   used	  Uniprot	   database,	   subdivided	   into	   three	   separate	   protein	   groups.	   These	   differed	   in	   their	  
expression	  ratios,	  with	  two	  almost	  reaching	  the	  threshold	  for	  a	  relevant	  change	  in	  expression	  (log2	  
fold	   change	   ≤	   0.585).	   Thus,	   the	  WB	   should	   clarify	   this	   issue.	   Furthermore,	   an	   antibody	   against	   α-­‐
Tubulin	  was	  included	  as	  loading	  control	  in	  all	  lysate	  samples.	  In	  the	  myelin	  samples	  a	  loading	  control	  
was	   not	   possible,	   because	   the	   level	   of	   each	   myelin	   protein	   could	   potentially	   be	   altered.	   After	  
detection,	   the	  acquired	  WB-­‐signals	  were	  quantified	  with	  the	  respective	  software	  depending	  on	  the	  
detection	  system	  used	  (fluorescence	  =	  Odyssey	  3.0;	  chemiluminescence	  =	  FUSION-­‐Capt	  Advance	  Solo	  
4).	  	  
	   	  







Figure	   4-­‐8:	  MBP-­‐WB	   analyses	   of	   brain	  myelin	   and	  whole	   tissue	   lysate	   from	   21-­‐	   to	   23-­‐month-­‐old	  WT	   and	  
FA2H-­‐KO	  mice.	  The	  indicated	  amount	  (protein	  content)	  of	  brain	  myelin	  or	  whole	  brain	  lysate	  from	  each	  animal	  
were	   separated	   by	   SDS-­‐PAGE	   and	   blotted	   onto	   nitrocellulose.	   Afterwards,	   proteins	   were	   detected	   using	  
appropriate	  primary	  antibodies	  in	  combination	  with	  fluorescent	  secondary	  antibodies.	  Signals	  were	  visualized	  
and	   quantified	   using	   the	   near-­‐infrared	   Odyssey	   detection	   system.	   Expression	   differences	   were	   statistically	  
evaluated	  by	  Student’s	  t-­‐	  test	  and	  plotted	  in	  bar	  charts	  with	  significant	  changes	  marked	  with	  p-­‐values.	  (A)	  Brain	  
myelin	  analysis	  acquired	  by	  incubation	  with	  MBP	  antibody	  (rabbit,	  1:10000,	  ON,	  4	  °C)	  followed	  by	  anti-­‐rabbit-­‐
DyLight649	  secondary	  antibody	  incubation	  (1:5000,	  1	  h,	  RT).	  Black	  arrows	  indicate	  the	  four	  major	  MBP	  isoform	  
protein	   bands.	   The	   absolute	  MBP-­‐expression	   for	   both	   genotypes	   is	   given	   in	   a	   bar	   chart	   (below)	   as	   average	  
integrated	   intensity	   (+/-­‐	   standard	   deviation)	   of	   the	   indicated	   MBP-­‐signals.	   (B)	   Whole	   brain	   lysate	   analysis	  
obtained	  by	  concomitant	   incubation	  with	  MBP	  (rabbit,	  1:10000,	  ON,	  4°C)	  and	  α-­‐Tubulin	   (mouse,	  1:5000,	  ON,	  
4°C)	  antibodies.	  Secondary	  antibodies	  were	  anti-­‐rabbit-­‐DyLight649	  and	  anti-­‐mouse-­‐DyLight800	  (both	  1:5000,	  1	  
h,	  RT).	  Black	  arrows	   indicate	  major	  MBP-­‐isoforms.	  The	  quantification	   results	  are	  given	   in	  a	  bar	  chart	   (below)	  
depicting	  the	  mean	  relative	  MBP-­‐expression	  (ratio	  to	  α-­‐Tubulin)	  for	  both	  genotypes	  (+/-­‐	  standard	  deviation).	  	  
While	   the	   WB	   clearly	   showed	   the	   four	   major	   MBP	   protein	   bands	   (14,	   17,	   18.5	   and	   21.5	   kDa)	   in	  
purified	  myelin,	   only	   three	   of	   them	   (14,	   17,	   18.5	   kDa)	   were	   detectable	   in	   the	   whole	   brain	   lysate	  
(Figure	   4-­‐8).	   The	   quantification	   of	   these	   bands	   proved	   no	   difference	   in	   the	   brain	   myelin	   MBP-­‐
expression	  between	  21-­‐	   to	  23-­‐month-­‐old	  WT	  and	  FA2H-­‐KO	  animals.	   In	  contrast,	  a	   strong	   (about	  2-­‐
fold)	  and	  significant	  reduction	  of	  MBP	  was	  evident	  in	  FA2H-­‐KO	  mice,	  when	  looking	  at	  the	  whole	  brain	  
lysate	  WB.	   This	   implied	   that	   brains	   of	   aged	   FA2H-­‐KO	  mice	   have	   a	   reduced	  myelin	   amount.	  When	  
solely	  analyzing	  purified	  myelin	  this	  effect	  is	  overseen,	  because	  equal	  protein	  amounts	  are	  loaded.	  



















































































































































































































































Figure	   4-­‐9:	  MAPT-­‐WB	  analyses	  of	   brain	  myelin	   and	  whole	   tissue	   lysate	   from	  21-­‐	   to	   23-­‐month-­‐old	  WT	  and	  
FA2H-­‐KO	  mice.The	  indicated	  amount	  (protein	  content)	  of	  brain	  myelin	  or	  whole	  brain	  lysate	  from	  each	  animal	  
were	   separated	   by	   SDS-­‐PAGE	   and	   blotted	   onto	   nitrocellulose.	   Afterwards,	   proteins	   were	   detected	   using	  
appropriate	  primary	  antibodies	  in	  combination	  with	  fluorescent	  secondary	  antibodies.	  Signals	  were	  visualized	  
and	   quantified	   using	   the	   near-­‐infrared	   Odyssey	   detection	   system.	   Expression	   differences	   were	   statistically	  
evaluated	  by	  Student’s	  t-­‐test	  and	  plotted	  in	  bar	  charts	  with	  significant	  changes	  marked	  with	  p-­‐values.	  (A)	  Brain	  
myelin	  analysis	  obtained	  by	  incubation	  with	  MAPT	  antibody	  (mouse,	  1:1000,	  ON,	  4	  °C)	  followed	  by	  anti-­‐mouse-­‐
DyLight649	  secondary	  antibody	  incubation	  (1:5000,	  1	  h,	  RT).	  The	  black	  arrow	  indicates	  the	  MAPT	  protein	  band.	  
The	   absolute	   MAPT-­‐expression	   for	   both	   genotypes	   is	   given	   in	   a	   bar	   chart	   (below)	   as	   average	   integrated	  
intensity	   (+/-­‐	   standard	   deviation).	   (B)	  Whole	   brain	   lysate	   analysis	   obtained	   by	   simultaneous	   incubation	  with	  
MAPT	  (mouse,	  1:1000,	  ON,	  4°C)	  and	  α-­‐Tubulin	  (rabbit,	  1:5000,	  ON,	  4°C)	  antibodies.	  Secondary	  antibodies	  were	  
anti-­‐mouse-­‐DyLight649	  and	  anti-­‐rabbit-­‐DyLight800	  (both	  1:5000,	  1	  h,	  RT).	  The	  black	  arrow	  points	  at	  the	  MAPT-­‐
signal.	  The	  quantification	  results	  are	  given	  in	  a	  bar	  chart	  (below)	  depicting	  the	  mean	  relative	  MAPT-­‐expression	  
(ratio	  to	  α-­‐Tubulin)	  for	  both	  genotypes	  (+/-­‐	  standard	  deviation).	  	  
In	   the	  MAPT-­‐WBs	  of	  purified	  myelin	  and	  whole	  brain	  of	  21-­‐	   to	  23-­‐month-­‐old	  mice	   (Figure	  4-­‐9)	   the	  
protein	  became	  visible	  as	  a	  relatively	  weak	  but	  still	  quantifiable	  signal	  at	  55	  kDa.	  Considering	  myelin,	  
a	  significant	  ~3-­‐fold	  upregulation	  of	  MAPT	  was	  observed	  in	  FA2H-­‐KO	  mice,	  thus	  being	  a	  little	  higher	  
then	  value	  obtained	  for	  the	  younger	  17-­‐month-­‐old	  animals	  analyzed	  by	  mass	  spectrometry	  (~2-­‐fold).	  
In	   the	  whole	   brain	   the	   average	  MAPT-­‐expression	  was	   also	   higher	   in	   the	   KO	   compared	   to	   the	  WT	  
mice,	   but	   the	   difference	   was	   not	   significant.	   This	   difference	   between	   myelin	   and	   whole	   brain	   is	  
probably	   explained	   by	   the	   observation	   made	   above,	   that	   FA2H-­‐KO	   mice	   have	   a	   reduced	   myelin	  
amount.	  Consequently,	  upregulations	  visible	   in	  myelin	  normalized	  to	  the	  same	  protein	  amount	  will	  
















































































































































































































































Figure	  4-­‐10:	  GFAP-­‐WB	  analyses	  of	  brain	  myelin	  and	  whole	   tissue	   lysate	   from	  21-­‐	   to	  23-­‐month-­‐old	  WT	  and	  
FA2H-­‐KO	  mice.The	  indicated	  amount	  (protein	  content)	  of	  brain	  myelin	  or	  whole	  brain	  lysate	  from	  each	  animal	  
were	   separated	   by	   SDS-­‐PAGE	   and	   blotted	   onto	   nitrocellulose.	   Afterwards,	   proteins	   were	   detected	   using	  
appropriate	  primary	  antibodies	  in	  combination	  with	  fluorescent	  secondary	  antibodies.	  Signals	  were	  visualized	  
and	   quantified	   using	   the	   near-­‐infrared	   Odyssey	   detection	   system.	   Expression	   differences	   were	   statistically	  
evaluated	  by	  Student’s	  t-­‐test	  and	  plotted	  in	  bar	  charts	  with	  significant	  changes	  marked	  with	  p-­‐values.	  (A)	  Brain	  
myelin	  analysis	  obtained	  by	  incubation	  with	  GFAP	  antibody	  (mouse,	  1:1000,	  ON,	  4	  °C)	  followed	  by	  anti-­‐mouse-­‐
DyLight649	  secondary	  antibody	  incubation	  (1:5000,	  1	  h,	  RT).	  The	  black	  arrow	  indicates	  the	  GFAP	  protein	  band.	  
The	  absolute	  GFAP-­‐expression	  for	  both	  genotypes	  is	  given	  in	  a	  bar	  chart	  (below)	  as	  average	  integrated	  intensity	  
(+/-­‐	   standard	   deviation).	   (B)	   Whole	   brain	   lysate	   analysis	   obtained	   by	   concomitant	   incubation	   with	   GFAP	  
(mouse,	  1:1000,	  ON,	  4°C)	  and	  α-­‐Tubulin	  (rabbit,	  1:5000,	  ON,	  4°C)	  antibodies.	  Secondary	  antibodies	  were	  anti-­‐
mouse-­‐DyLight649	   and	   anti-­‐rabbit-­‐DyLight800	   (both	   1:5000,	   1	   h,	   RT).	   The	   black	   arrow	   points	   at	   the	   GFAP-­‐
signal.	  The	  quantification	  results	  are	  given	  in	  a	  bar	  chart	  (below)	  depicting	  the	  mean	  relative	  GFAP-­‐expression	  
(ratio	  to	  α-­‐Tubulin)	  for	  both	  genotypes	  (+/-­‐	  standard	  deviation).	  	  
The	  GFAP-­‐WBs	  of	  brain	  myelin	  and	  whole	  brain	  lysate	  from	  21-­‐	  to	  23-­‐month-­‐old	  mice	  (Figure	  4-­‐10)	  
showed	  a	  single	  protein	  band	  of	  50	  kDa,	  corresponding	  to	  the	  protein’s	  expected	  size.	  Quantification	  
of	  this	  band	  revealed	  a	  significant	  upregulation	  of	  GFAP	  in	  brain	  myelin	  and	  whole	  brain	  of	  FA2H-­‐KO	  
compared	   to	   WT	   mice.	   In	   myelin	   it	   was	   ~6-­‐fold	   and	   in	   whole	   brain	   about	   2-­‐fold.	   As	   mentioned	  
before,	  this	  difference	  can	  be	  explained	  by	  the	  generally	  reduced	  myelin	  amount	   in	  FA2H-­‐KO	  mice.	  
Furthermore,	  the	  ~6-­‐fold	  upregulation	  of	  GFAP	  in	  myelin	  of	  21-­‐	  to	  23-­‐month-­‐old	  FA2H-­‐KO	  mice	  was	  
markedly	  higher	  than	  the	  one	  measured	  by	  mass	  spectrometry	  in	  younger	  17-­‐month-­‐old	  KO-­‐animals	  
(	  ~2.5-­‐fold).	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Figure	  4-­‐11:	  NF-­‐H-­‐WB	  analyses	  of	   brain	  myelin	   and	  whole	   tissue	   lysate	   from	  21-­‐	   to	  23-­‐month-­‐old	  WT	  and	  
FA2H-­‐KO	  mice.The	  indicated	  amount	  (protein	  content)	  of	  brain	  myelin	  or	  whole	  brain	  lysate	  from	  each	  animal	  
were	   separated	   by	   SDS-­‐PAGE	   and	   blotted	   onto	   nitrocellulose.	   Afterwards,	   proteins	   were	   detected	   using	  
appropriate	  primary	  antibodies	  in	  combination	  with	  fluorescent	  secondary	  antibodies.	  Signals	  were	  visualized	  
and	   quantified	   using	   the	   near-­‐infrared	   Odyssey	   detection	   system.	   Expression	   differences	   were	   statistically	  
evaluated	  by	  Student’s	  t-­‐test	  and	  plotted	  in	  bar	  charts	  with	  significant	  changes	  marked	  with	  p-­‐values.	  (A)	  Brain	  
myelin	   analysis	  obtained	  by	   incubation	  with	  NF-­‐H	  antibody	   (rabbit,	   1:500,	  ON,	  4	   °C)	   followed	  by	  anti-­‐rabbit-­‐
DyLight649	  secondary	  antibody	   incubation	  (1:5000,	  1	  h,	  RT).	  The	  black	  arrow	  indicates	  the	  NF-­‐H-­‐protein.	  The	  
absolute	  NF-­‐H-­‐expression	  for	  both	  genotypes	  is	  given	  in	  a	  bar	  chart	  (below)	  as	  average	  integrated	  intensity	  (+/-­‐	  
standard	   deviation).	   (B)	  Whole	   brain	   lysate	   analysis	   obtained	   by	   simultaneous	   incubation	  with	  NF-­‐H	   (rabbit,	  
1:500,	  ON,	   4°C)	   and	  α-­‐Tubulin	   (mouse,	   1:5000,	  ON,	   4°C)	   antibodies.	   Secondary	   antibodies	  were	   anti-­‐mouse-­‐
DyLight649	  and	  anti-­‐rabbit-­‐DyLight800	  (both	  1:5000,	  1	  h,	  RT).	  The	  black	  arrow	  points	  at	   the	  NF-­‐H-­‐signal.	  The	  
quantification	  results	  are	  given	  in	  a	  bar	  chart	  (below)	  depicting	  the	  mean	  relative	  NF-­‐H-­‐expression	  (ratio	  to	  α-­‐
Tubulin)	  for	  both	  genotypes	  (+/-­‐	  standard	  deviation).	  	  
NF-­‐H	  became	  visible	  in	  the	  WB	  as	  a	  prominent	  band	  corresponding	  to	  the	  expected	  molecular	  weight	  
of	  ~200	  kDa.	   In	  brain	  myelin	  of	  21-­‐	  to	  23-­‐month-­‐old	  mice	  the	   intensity	  of	  this	  band	  varied	  strongly	  
between	  each	  animal	  regardless	  of	   its	  genotype.	  The	  signal	  quantification	  showed	  that	  the	  average	  
expression	  was	  lower	  in	  the	  KO-­‐animals,	  but	  the	  expression	  difference	  was	  not	  significant	  due	  to	  the	  
high	  signal	  variance.	  Thus,	  the	  mass	  spectrometric	  measured	  ~2-­‐fold	  upregulation	  of	  NF-­‐H	  in	  myelin	  
of	   old	   FA2H-­‐KO	   animals	   could	   not	   be	   verified	   by	   WB.	   In	   the	   whole	   brain	   lysate	   WB	   the	   signal	  
intensities	  were	  constant,	  but	  the	  quantification	  showed	  again	  no	  significant	  difference	  between	  WT	  



















































































40 µg protein 
NF-H 





















































































































40 µg protein 
NF-H 


































3         4  







Figure	   4-­‐12:	   C1q-­‐WB	   analyses	   of	   brain	  myelin	   and	  whole	   tissue	   lysate	   from	   21-­‐	   to	   23-­‐month-­‐old	  WT	   and	  
FA2H-­‐KO	  mice.The	  indicated	  amount	  (protein	  content)	  of	  brain	  myelin	  or	  whole	  brain	  lysate	  from	  each	  animal	  
were	   separated	   by	   SDS-­‐PAGE	   and	   blotted	   onto	   nitrocellulose.	   Afterwards,	   proteins	   were	   detected	   using	  
appropriate	  primary	  antibodies	  in	  combination	  with	  fluorescent	  or	  HRP-­‐coupled	  secondary	  antibodies.	  Signals	  
were	  visualized	  and	  quantified	  using	  the	  appropriate	  detection	  system.	  Expression	  differences	  were	  statistically	  
evaluated	  by	  Student’s	  t-­‐test	  and	  plotted	  in	  bar	  charts	  with	  significant	  changes	  marked	  with	  p-­‐values.	  (A)	  Brain	  
myelin	  analysis	  obtained	  by	   incubation	  with	  C1q	  antibody	   (mouse,	  1:500,	  ON,	  4	   °C)	   followed	  by	  anti-­‐mouse-­‐
HRP	  secondary	  antibody	  incubation	  (1:5000,	  1	  h,	  RT).	  The	  C1q-­‐protein	  band	  and	  an	  additional	  band	  of	  unknown	  
identity	   are	  marked	  with	   an	   arrow.	   The	   absolute	   C1q-­‐expression	   for	   both	   genotypes	   is	   given	   in	   a	   bar	   chart	  
(below)	  as	  average	  intensity	  (+/-­‐	  standard	  deviation).	  (B)	  Whole	  brain	  lysate	  analysis	  obtained	  by	  concomitant	  
incubation	  with	   C1q	   (mouse,	   1:500,	   ON,	   4°C)	   and	   α-­‐Tubulin	   (rabbit,	   1:5000,	   ON,	   4°C)	   antibodies.	   Secondary	  
antibodies	  were	  anti-­‐mouse-­‐DyLight649	  and	  anti-­‐rabbit-­‐DyLight800	  (both	  1:5000,	  1	  h,	  RT).	  Black	  arrows	  point	  
at	   the	   C1q-­‐signal	   and	   an	   additional	   signal	   of	   unknown	   identity.	   The	   quantification	   results	   are	   given	   in	   a	   bar	  
chart	  (below)	  depicting	  the	  mean	  relative	  C1q-­‐expression	  (ratio	  to	  α-­‐Tubulin)	  for	  both	  genotypes	  (+/-­‐	  standard	  
deviation).	  	  
The	  C1q-­‐WB	  showed	  two	  polypeptides,	  one	  at	  ~25	  and	  the	  other	  at	  ~55	  kDa	  respectively,	  of	  which	  
only	  the	  lower	  band	  agrees	  with	  the	  proteins	  known	  molecular	  weight.	  Therefore,	  the	  quantification	  
was	  solely	  based	  on	   this	   signal.	   Furthermore,	  because	  a	   strong	  unspecific	  background	  staining	  was	  
overlapping	  with	  parts	  of	  the	  α-­‐Tubulin	  signal,	  WT	  animal	  #2	  was	  left	  out	  of	  the	  quantification	  (WT	  
n=3).	  The	  quantification	  demonstrated	  that	  a	  significant	   larger	  amount	  of	  C1q	  was	  present	   in	  brain	  
myelin	   of	   21-­‐	   to	   23-­‐month-­‐old	   FA2H-­‐KO	   mice	   compared	   to	   the	   WT-­‐controls.	   Interestingly,	   this	  
increase	   was	   only	   ~2-­‐fold	   and	   thus	   less	   strong	   than	   the	   ~4-­‐fold	   increase	   determined	   by	   mass	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expression	  was	  higher	   in	  the	  KO-­‐animals	  as	  well,	  but	  this	  difference	  was	  not	  statistically	  significant.	  
Consequently,	   no	   upregulation	   could	   be	   observed	   in	   the	   whole	   brain.	   As	   mentioned	   before,	   the	  
difference	   between	   myelin	   and	   whole	   brain	   can	   be	   explained	   by	   the	   generally	   reduced	   myelin	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Figure	  4-­‐13:	  ApoE-­‐WB	  analyses	  of	  brain	  myelin	  and	  whole	   tissue	   lysate	   from	  21-­‐	   to	  23-­‐month-­‐old	  WT	  and	  
FA2H-­‐KO	  mice.The	  indicated	  amount	  (protein	  content)	  of	  brain	  myelin	  or	  whole	  brain	  lysate	  from	  each	  animal	  
were	   separated	  by	   SDS-­‐PAGE	   and	  blotted	  onto	   PVDF.	  Afterwards,	   proteins	  were	  detected	  using	   appropriate	  
primary	   antibodies	   in	   combination	   with	   fluorescent	   or	   HRP-­‐coupled	   secondary	   antibodies.	   Signals	   were	  
visualized	   and	   quantified	   using	   the	   appropriate	   detection	   system.	   Expression	   differences	   were	   statistically	  
evaluated	  by	  Student’s	  t-­‐test	  and	  plotted	  in	  bar	  charts	  with	  significant	  changes	  marked	  with	  p-­‐values.	  (A)	  Brain	  
myelin	  analysis	  obtained	  by	   incubation	  with	  ApoE	  antibody	  (goat,	  1:500,	  ON,	  4	  °C)	  followed	  by	  anti-­‐goat-­‐HRP	  
secondary	   antibody	   incubation	   (1:5000,	   1	   h,	   RT).	   The	   ApoE	   protein	   band	   is	  marked	  with	   an	   arrow.	   Because	  
ApoE	   was	   only	   detectable	   in	   one	   WT,	   but	   in	   all	   four	   FA2H-­‐KO	   samples,	   a	   quantification	   and	   statistical	  
evaluation	  was	  not	   feasible.	   (B)	  Whole	  brain	   lysate	   analysis	   obtained	  by	   simultaneous	   incubation	  with	  ApoE	  
(goat,	   1:500,	   ON,	   4°C)	   and	   α-­‐Tubulin	   (mouse,	   1:5000,	   ON,	   4°C)	   antibodies.	   Secondary	   antibodies	  were	   anti-­‐
mouse-­‐DyLight649	  and	  anti-­‐goat-­‐DyLight800	  (both	  1:5000,	  45	  min,	  RT).	  Black	  arrows	  indicate	  the	  ApoE	  and	  the	  
α-­‐Tubulin	  protein	  band.	  α-­‐Tubulin	  was	  also	   visible	   in	   the	  800	  nm	  channel,	   because	   the	  anti-­‐goat-­‐DyLight800	  
secondary	  antibody	  also	  bound	  to	  the	  secondary	  anti-­‐mouse	  antibody.	  Quantification	  results	  are	  given	  in	  a	  bar	  
chart	   (below)	   depicting	   the	   mean	   relative	   ApoE-­‐expression	   (ratio	   to	   α-­‐Tubulin)	   for	   both	   genotypes	   (+/-­‐	  
standard	  deviation).	  	  
The	   ApoE-­‐WB	   gave	   a	   signal	   of	   ~36	   kDa,	   which	   is	   in	   line	   with	   the	   protein’s	   molecular	   weight.	   In	  
addition,	  an	  unspecific	  background	  staining	  of	  the	  whole	  blotting	  area	  was	  visible	  as	  well,	  which	  was	  
especially	  intense	  in	  the	  brain	  myelin	  WB.	  In	  brain	  myelin,	  one	  WT	  sample	  exhibited	  a	  relatively	  weak	  
ApoE	  signal,	  while	  no	  ApoE	  was	  detectable	  in	  the	  three	  others.	  On	  the	  other	  hand,	  a	  stronger	  ApoE	  
signal	  was	   observable	   in	   all	   four	   FA2H-­‐KO	   samples,	   signifing	   increased	  ApoE	   amounts	   in	  myelin	   of	  
FA2H-­‐KO	   mice.	   The	   whole	   brain	   WB	   analysis	   revealed	   ApoE	   signals	   in	   all	   animals	   assessed,	   with	  
generally	   stronger	   signals	   in	   the	   FA2H-­‐KO	   mice.	   Accordingly,	   the	   quantification	   of	   the	   signals	  
revealed	  a	  significant	  ~2-­‐fold	  elevation	  of	  the	  protein	  in	  FA2H-­‐KO	  animals.	  	  
	   	  








Figure	  4-­‐14:	  Opalin-­‐WB	  analyses	  of	  brain	  myelin	  and	  whole	  tissue	  lysate	  from	  21-­‐	  to	  23-­‐month-­‐old	  WT	  and	  
FA2H-­‐KO	  mice.The	  indicated	  amount	  (protein	  content)	  of	  brain	  myelin	  or	  whole	  brain	  lysate	  from	  each	  animal	  
were	   separated	   by	   SDS-­‐PAGE	   and	   blotted	   onto	   nitrocellulose.	   Afterwards,	   proteins	   were	   detected	   using	  
appropriate	  primary	  antibodies	  in	  combination	  with	  fluorescent	  secondary	  antibodies.	  Signals	  were	  visualized	  
and	   quantified	   using	   the	   near-­‐infrared	   Odyssey	   detection	   system.	   Expression	   differences	   were	   statistically	  
evaluated	  by	  Student’s	  t-­‐test	  and	  plotted	  in	  bar	  charts	  with	  significant	  changes	  marked	  with	  p-­‐values.	  (A)	  Brain	  
myelin	  analysis	  obtained	  by	  incubation	  with	  Opalin	  antibody	  (mouse,	  1:500,	  ON,	  4	  °C)	  followed	  by	  anti-­‐mouse-­‐
DyLight649	  secondary	  antibody	  incubation	  (1:5000,	  1	  h,	  RT).	  The	  black	  arrow	  indicates	  the	  Opalin-­‐protein.	  The	  
absolute	  Opalin-­‐expression	  for	  both	  genotypes	   is	  given	   in	  a	  bar	  chart	   (below)	  as	  average	   integrated	   intensity	  
(+/-­‐	   standard	   deviation).	   (B)	   Whole	   brain	   lysate	   analysis	   obtained	   by	   concomitant	   incubation	   with	   Opalin	  
(mouse,	  1:500,	  ON,	  4°C)	  and	  α-­‐Tubulin	   (rabbit,	  1:5000,	  ON,	  4°C)	  antibodies.	  Secondary	  antibodies	  were	  anti-­‐
mouse-­‐DyLight649	   and	   anti-­‐rabbit-­‐DyLight800	   (both	   1:5000,	   1	   h,	   RT).	   The	   black	   arrow	   points	   at	   the	  Opalin-­‐
signal.	  The	  quantification	  results	  are	  given	  in	  a	  bar	  chart	  (below)	  depicting	  the	  mean	  relative	  Opalin-­‐expression	  
(ratio	  to	  α-­‐Tubulin)	  for	  both	  genotypes	  (+/-­‐	  standard	  deviation).	  	  
The	   antibody	   against	   Opalin	   gave	   a	   signal	   of	   34	   -­‐	   39	   kDa,	   corresponding	   with	   the	   glycosylated	  
protein’s	   molecular	   weight.	   In	   addition,	   some	   background	   bands	   of	   various	   sizes	   were	   visible.	  
Quantification	  of	   the	  Opalin-­‐signals	   in	  brain	  myelin	   and	  whole	  brain	   lysate	  of	   21-­‐	   to	  23-­‐month-­‐old	  
mice	  proved	  the	  protein’s	  significant	  upregulation	  in	  FA2H-­‐KO	  compared	  to	  WT.	  It	  was	  upregulated	  
~5-­‐fold	  in	  myelin	  and	  only	  ~3-­‐fold	  in	  the	  whole	  brain.	  As	  argued	  above,	  this	  was	  probably	  due	  to	  the	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FA2H-­‐KO	   myelin	   was	   significantly	   higher	   than	   the	   ~2-­‐fold	   increase	   determined	   in	   17-­‐month-­‐old	  
animals	  by	  mass	  spectrometry.	  	  
Altogether,	   the	   different	   WB-­‐verifications	   using	   very	   old	   mice	   could	   confirm	   the	   upregulation	   of	  
MAPT,	   GFAP,	   C1q,	   ApoE	   and	   Opalin	   found	   in	   the	   mass	   spectrometric	   brain	   myelin	   analysis.	  
Intriguingly,	  for	  MAPT,	  GFAP	  and	  Opalin	  the	  measured	  upregulation	  was	  even	  stronger	  than	  the	  one	  
determined	  by	  mass	  spectrometry.	  This	  can	  be	  explained	  by	  the	  age	  difference	  between	  the	  animals	  
used	  in	  the	  two	  analyses.	  Apparently,	  the	  four-­‐	  to	  six-­‐month-­‐older	  mice	  used	  in	  the	  WB	  analyses	  had	  
an	  aggravated	  phenotype	   reflected	  by	   the	   increase	   in	   the	   three	  proteins.	  Moreover,	   for	  GFAP	  and	  
Opalin	  the	  upregulation	  was	  also	  detectable	  in	  whole	  brain	  lysates,	  but	  to	  a	  lesser	  extent.	  In	  contrast,	  
no	   significant	   change	   was	   evident	   for	   MAPT	   and	   C1q	   in	   the	   whole	   brain.	   Furthermore,	   the	  
upregulation	  of	  NF-­‐H	  could	  neither	  be	  verified	   in	  myelin	  nor	   in	   the	  total	  brain	  of	  FA2H-­‐KO	  mice	  by	  
WB.	   The	   amount	   of	   NF-­‐H	   in	   myelin	   was	   very	   variable	   in	   all	   eight	   animals	   assessed.	   Finally,	   the	  
uncertain	  quantification	  status	  of	  MBP	  in	  myelin	  could	  be	  cleared.	  The	  myelin	  MBP-­‐levels	  were	  not	  
changed	   between	   the	   two	   genotypes.	   On	   the	   other	   hand,	   a	   previously	   not	   described	   significant	  
reduction	  of	  MBP	  in	  FA2H-­‐KO	  mice	  was	  observed	  in	  the	  total	  brain	  analysis.	  
	  
4.1.2.2 Sciatic	  nerve	  myelin	  analysis	  
4.1.2.2.1 Mass	  spectrometric	  analysis	  using	  TMT-­‐labeling	  
Analogous	  to	  the	  comparative	  brain	  myelin	  analysis,	  the	  sciatic	  nerve	  myelin	  of	  the	  same	  animals	  was	  
analyzed	   to	   see	   if	   similar	  proteome	  alterations	  are	  also	  present	   in	  PNS-­‐myelin.	  An	  overview	  of	   the	  
analysis	  results	  and	  a	  comparison	  to	  previously	  published	  PNS-­‐myelin	  data	  is	  depicted	  in	  Figure	  4-­‐15.	  
Note	  that	  the	  original	  MaxQuant	  result	  files	  and	  the	  processed	  protein	  group	  list	  can	  be	  found	  on	  the	  
supplemental	  DVD.	  











Figure	  4-­‐15:	  Quantitative	  sciatic	  nerve	  myelin	  (PNS)	  proteome	  analysis.	  
(A)	   Diagram	   depicting	   the	   workflow	   of	   protein	   group	   results	   processing.	  MaxQuant	   identified	   1309	   protein	  
groups	  after	  combined	  analysis	  of	  all	  raw	  files	  (matched	  against	  murine	  Uniprot	  database).	  The	  data	  were	  then	  
normalized	   (each	   reporter	   intensity	   divided	   by	   summed	   reporter	   channel	   intensity)	   and	   log2	   FA2H-­‐KO/WT	  
expression	   ratios	   (log2	   fold	   change)	   calculated	   for	   each	   timepoint.	   Subsequently,	   the	   data	  were	   filtered	   for	  
protein	  groups	  with	  at	  least	  two	  expression	  ratios	  at	  one	  timepoint	  leaving	  830.	  To	  assess	  proteins,	  which	  had	  a	  
significantly	  changed	  expression	  in	  FA2H-­‐KO	  mice,	  the	  log2	  transformed	  expression	  values	  were	  evaluated	  by	  
an	  one-­‐sample	  t-­‐test	  against	  0	  (log2(1)	  =	  0	  =	  no	  change)	  for	  each	  timepoint.	  This	  resulted	  in	  the	  identification	  of	  
96	  significantly	  changed	  protein	  groups.	  (B)	  Venn	  diagram	  comparing	  the	  protein	  groups	  identified	  with	  TMT	  6-­‐
plex	  brain	  myelin	  proteome	  analysis	   in	   this	   thesis	  with	   the	  published	  PNS	  myelin	   reference	   list	   (Patzig	   et	   al.	  
2011).	   The	   first	   gene	   name	   of	   each	   protein	   group	   was	   used	   as	   identifier.	   A	   list	   containing	   all	   gene	   names	  
related	  to	  the	  overlapping	  areas	  can	  be	  found	  on	  the	  supplemental	  DVD.	  
With	  the	  help	  of	  MaxQuant,	  1309	  protein	  groups	  were	  identified	  in	  the	  combined	  analysis	  of	  all	  three	  
sciatic	   nerve	  myelin	   triplicates	   (Figure	   4-­‐15A),	   thereby	   significantly	   expanding	   the	   currently	   known	  
PNS-­‐myelin	  proteome	  of	  about	  550	  proteins	  (Patzig	  et	  al.	  2011).	  When	  comparing	  the	  identifications	  
of	  both	  datasets,	  there	  was	  a	  large	  congruency	  (Figure	  4-­‐15B).	  The	  majority	  (387	  of	  546	  =	  ~71%)	  of	  
the	  proteins	  identified	  in	  the	  published	  dataset	  were	  also	  found	  in	  the	  present	  study.	  	  
To	  see	  possible	  changes	  in	  the	  sciatic	  nerve	  myelin	  proteome	  composition,	  the	  results	  were	  further	  
processed	   analogous	   to	   the	   brain	  myelin	   analysis	   (see:	   p.64).	   This	   reduced	   the	   protein	   list	   to	   830	  
quantified	  protein	  groups,	  which	  was	  additionally	  filtered	  for	  significantly	  changed	  protein	  groups	  at	  
each	  of	   the	   three	   assessed	   timepoints	   (6,	   13	   and	  17M).	   Finally,	   this	   led	   to	   the	   identification	  of	   96	  
protein	  groups	  significantly	  changed	  at	  at	  least	  one	  timepoint.	  	  
Similar	  to	  the	  CNS-­‐myelin	  analysis,	  the	  expression	  differences	  of	  major	  PNS-­‐myelin	  between	  FA2H-­‐KO	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were	  plotted	  against	  the	  animal	  ages	  (Figure	  4-­‐16).	  Two	  horizontal	  doted	  black	  lines	  mark	  the	  area,	  
within	  which	  log2	  fold	  changes	  are	  considered	  not	  relevant.	  Note	  that	  MaxQuant	  assigned	  different	  
sequence	   variants	   of	   periaxin,	   derived	   from	   different	   mouse	   strains,	   into	   two	   separate	   protein	  
groups:	  PRX	  (C57BL/6)	  and	  PRX	  (129Sv/Ola).	  This	  was	  likely	  the	  case,	  because	  the	  older	  mice	  still	  had	  
a	  mixed	  genetic	  background	  of	  129/Ola	  and	  C57BL/6	  (see	  3.1.8	  Mice	  strains).	  
	  
Figure	  4-­‐16:	  Expression	  differences	  of	  major	  PNS-­‐myelin	  proteins	  between	  FA2H-­‐KO	  and	  WT	  mice	  in	  sciatic	  
nerve	  myelin.	   Each	   protein	   group’s	  mean	   log2	   transformed	   KO/WT	   expression	   ratios	   (log2	   fold	   change)	   are	  
plotted	  against	  the	  mice	  age	  in	  month.	  For	  each	  line	  the	  standard	  deviation	  at	  each	  time	  point	  is	  given	  by	  error	  
bars,	   if	   it	  was	  calculable	   (n	  =	  2-­‐3).	  Horizontal	  doted	  black	   lines	  mark	  the	  borders	   for	   relevant,	   i.e.	  sufficiently	  
large	  enough,	  log2	  fold	  changes	  (log2	  fold	  change	  ≥	  0.585	  &	  ≤	  -­‐0.585).	  Note	  that	  MaxQuant	  assigned	  distinctive	  
Periaxin-­‐sequence	  variants	  derived	  from	  different	  mouse	  strains	  to	  two	  separate	  protein	  group	  entries,	  with	  all	  
had	  significantly	  different	  mean	  log2	  fold	  changes.	  CNP	  =	  cyclic	  nucleotide	  phosphodiesterase;	  MAG	  =	  myelin-­‐
associated	  glycoprotein;	  MBP	  =	  myelin	  basic	  protein;	  P0/MPZ	  =	  myelin	  protein	  zero;	  PLP	  =	  proteolipid	  protein;	  
PMP2	  =	  myelin	  P2	  protein;	  PRX	  =	  periaxin.	  
At	   the	  most	   timepoints,	  major	   PNS-­‐myelin	   proteins	  were	   not	   extensively	   changed	   in	   sciatic	   nerve	  
myelin	  between	  both	  genotypes.	  Only	  for	  the	  protein	  groups	  MAG,	  PMP2	  (myelin	  P2	  protein)	  or	  PLP,	  
some	   of	   the	   mean	   log2	   fold	   changes	   also	   laid	   outside	   the	   borders	   marking	   sufficiently	   changed	  
groups.	  But	   these	  changes	  were	  not	   significant,	  as	  became	  obvious	  when	   taking	   into	  account	   their	  
large	   standard	   deviations.	   Interestingly,	   one	   of	   the	   two	   periaxin	   protein	   groups,	   PRX	   (129Sv/Ola),	  
showed	  a	  very	  extensive	  upregulation	  (~120-­‐fold)	  at	  timepoints	  13	  and	  17M,	  while	  the	  second	  group,	  
PRX	   (C57BL/6)	  did	  not.	  Moreover,	   the	  silver-­‐stain	  gel	  analysis	  of	  PNS-­‐myelin	   (Figure	  4-­‐2D)	  also	  had	  
shown	   no	   difference	   in	   periaxin’s	   expression	   between	  WT	   and	   FA2H-­‐KO	  mice.	   Thus,	   to	   clarify	   the	  
expression	  of	  periaxin	   in	  FA2H-­‐KO	  animals,	   its	  protein	   level	  was	  analyzed	  by	  WB	  using	  whole	  nerve	  
lysates	  from	  another	  independent	  group	  of	  four	  WT	  and	  three	  FA2H-­‐KO	  animals	  of	  advanced	  age	  (21	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Figure	  4-­‐17:	  Analysis	  of	  periaxin	  protein	  levels	  in	  sciatic	  nerves	  of	  21-­‐	  to	  23-­‐month-­‐old	  WT	  and	  FA2H-­‐KO	  mice	  
by	  WB.	  The	  indicated	  amount	  (protein	  content)	  of	  sciatic	  nerve	  lysate	  from	  each	  animal	  was	  concentrated	  by	  
CHCl3/MeOH-­‐precipitation,	  resuspended	  in	  2X	  Laemmli	  buffer,	  separated	  by	  SDS-­‐PAGE	  and	  blotted	  onto	  PVDF.	  
Afterwards,	   periaxin	   (PRX)	   was	   detected	   using	   an	   anti-­‐periaxin	   primary	   antibody	   (α-­‐PRX	   N-­‐term,	   rabbit,	  
1:20,000,	  4°C,	  ON)	  in	  combination	  with	  a	  fluorescent	  secondary	  goat-­‐α-­‐rabbit-­‐DyLight800	  antibody	  (1:5000,	  45	  
min,	  RT).	  Signals	  were	  visualized	  and	  quantified	  using	  the	  near-­‐infrared	  Odyssey	  detection	  system.	  Expression	  
differences	  were	  statistically	  evaluated	  by	  Student’s	  t-­‐test.	  (A)	  WB	  image	  of	  periaxin	  in	  sciatic	  nerves	  of	  WT	  and	  
FA2H-­‐KO	  mice.	  Periaxin	  is	  indicated	  by	  a	  black	  arrow.	  (B)	  Bar	  chart	  depicting	  the	  quantification	  results	  for	  the	  
PRX	  protein	  band.	  Note	  that	  the	  protein	  was	  not	  significantly	  changed	  between	  both	  genotypes.	  
In	   the	   WB	   periaxin	   (PRX)	   became	   visible	   as	   a	   protein	   signal	   with	   a	   molecular	   weight	   >170	   kDa.	  
Quantification	   of	   the	   signal	   showed	   that	   the	   expression	   of	   PRX	   was	   not	   significantly	   different	  
between	  WT	  and	  FA2H-­‐KO	  animals,	  thereby	  clarifying	  the	  conflicting	  result	  of	  the	  mass	  spectrometric	  
analysis.	  Accordingly,	   it	   could	  be	   concluded	   that	   the	  major	  PNS-­‐myelin	  proteins	  were	  not	   changed	  
between	   both	   genotypes.	   The	   very	   extensive	   overexpression	   of	   periaxin	   measured	   by	   mass	  
spectrometry	  was	  an	  artificial	  result,	  likely	  caused	  by	  the	  fact	  that	  by	  chance	  only	  the	  old	  KO	  animals	  
expressed	   the	   129SV/Ola	   sequence	   variant	   of	   periaxin.	   In	   theory,	   a	   similar	   influence	   of	   the	   mice	  
strain	  could	  also	  have	  affected	  the	  quantification	  of	  other	  protein	  groups.	  But	  since	  the	  majority	  of	  
proteins	   should	   not	   differ	   substantially	   in	   their	   amino	   acid	   sequence	   between	   mice	   strains,	   the	  
influence	  of	  this	  effect	  is	  probably	  small.	  
Thus,	  all	  of	   the	   identified	  96	  protein	  groups	  significantly	  changed	   in	  FA2H-­‐KO	  PNS-­‐myelin	  were	  still	  
evaluated	  in	  more	  detail	  (Figure	  4-­‐18).	   It	  became	  obvious,	  that	  at	  the	  early	  timepoints	  (6	  and	  13M)	  
mainly	   significant	   upregulations,	   but	   almost	   no	   downregulations	   were	   present	   in	   PNS-­‐myelin	   of	  
FA2H-­‐KO	  mice.	  While	  only	  a	   single	  protein	  group	  was	  downregulated	  at	  both	   timepoints,	  35	  or	  11	  
were	   upregulated.	   In	   contrast,	   the	  most	   significant	   protein	   changes	  were	   observable	   at	   timepoint	  
17M	  with	  28	  down-­‐	  and	  22	  upregulations,	  respectively.	  Interestingly,	  this	  high	  number	  of	  50	  changes	  













































Figure	  4-­‐18:	  96	  protein	  groups	  significantly	  up-­‐	  and	  downregulated	  in	  FA2H-­‐KO	  sciatic	  nerve	  myelin.	  
Number	  of	  significantly	  up-­‐	  and	  downregulated	  protein	  groups	  at	  each	  time	  point.	  Note	  that	  the	  same	  proteins	  
can	  be	  changed	  at	  more	  than	  one	  timepoint.	  
In	  addition,	  for	  assessing	  the	  persistence	  of	  a	  protein	  group	  expression	  change,	  the	  identifications	  of	  
the	  upregulated	  protein	   groups	  were	   compared	   to	   each	  other	   between	   the	   three	   timepoints.	   This	  
comparison	   clearly	   showed	   almost	   no	   congruency	   between	   the	   significantly	   upregulated	   protein	  
groups.	  There	  was	  only	  a	  congruency	  of	  2	  protein	  groups	  at	  timepoint	  13	  and	  17M,	  hinting	  at	  a	  high	  
degree	  of	   biological	   variability.	   Thus,	   some	  protein	   groups	  were	  potentially	   changed	   at	  more	   then	  
one	  timepoint,	  but	  filtered	  out	  according	  to	  the	  applied	  p-­‐value	  threshold.	  Thus,	  for	  a	  more	  detailed	  
view	  of	   the	   significantly	  up-­‐	  and	  downregulated	  protein	  groups,	   they	  are	  depicted	   in	   two	  separate	  
tables	  (Table	  4-­‐3	  and	  Table	  4-­‐4).	  In	  the	  tables	  the	  significant	  log2	  fold	  changes	  are	  indicated	  by	  color	  
shading.	  These	  tables	  showed	  that	  some	  of	  the	  protein	  groups	  had	  non-­‐significant	  log2	  fold	  changes	  
at	  the	  other	  timepoints,	  which	  passed	  the	  criterium	  for	  a	  relevant	  change	  (log2	  fold	  change	  ≥	  0.585	  
or	  ≤-­‐0.585).	  Accordingly,	  these	  proteins	  might	  have	  been	  changed	  more	  constantly.	  
Table	  4-­‐3:	  Protein	  groups	  significantly	  upregulated	  in	  sciatic	  nerve	  myelin	  at	  at	  least	  one	  timepoint.	  
The	  table	  contains	  the	  proteins	  groups,	   indicated	  by	  their	  respective	  gene	  games,	  which	  showed	  a	  significant	  
upregulation	  at	  one	  timepoint	  or	  more.	  Next	  to	  each	  gene	  name	  the	  log2	  fold	  change	  (log2	  ratio	  FA2H-­‐KO/WT)	  
is	  given	  for	  each	  timepoint.	  Significant	  changes	  (log2	  fold	  change	  ≥	  0.585	  &	  -­‐log10	  p	  >	  1.301)	  are	  shaded	  in	  red.	  





















Aldh1a1;Aldh1a7	   0.7458	   0.3614	   -­‐0.3449	  
	  
Lyz1	   0.6435	   0.5410	   1.5422	  
Aoc3	   0.3152	   1.2030	   1.7538	   Map1b	   -­‐0.4230	   0.2745	   -­‐0.5373	  
Arf1;Arf3;Arf2	   0.6607	   -­‐0.1374	   -­‐0.1833	   Mif	   0.6618	   0.0509	   -­‐0.2833	  
Arf5	   1.0884	   0.0503	   -­‐0.3965	   Mpp6	   0.3816	   -­‐0.0133	   0.6416	  
Ca3	   -­‐0.8108	   2.0841	   -­‐0.3282	   Mras	   0.7056	   -­‐0.3389	   0.0228	  
Cadm4	   0.4947	   0.0010	   0.6080	   Myh9	   0.2899	   0.5331	   0.6757	  
Calb2	   0.9536	   -­‐0.4999	   -­‐0.1689	   Napg	   0.9044	   -­‐0.0753	   -­‐0.3692	  
Cat	   -­‐0.1388	   1.0159	   0.1170	   Nars	   0.6022	   -­‐0.5758	   -­‐0.3375	  
Cd36	   0.0440	   1.2747	   1.8291	   Nedd4l	   0.6082	   0.1371	   -­‐0.1547	  
Cdh1	   0.6125	   -­‐0.2669	   0.2309	   Ola1	   0.8036	   -­‐0.3030	   -­‐0.1230	  
Ces1d	   -­‐0.2911	   2.4419	   1.3073	   Pfkl	   0.2432	   0.6032	   -­‐0.1309	  
Cmtm5	   -­‐0.5606	   0.2052	   0.8544	   Pfn2	   0.8944	   -­‐0.3632	   -­‐0.1176	  
Ctnna1	   0.3467	   0.6749	   0.8268	   Phpt1	   1.4332	   -­‐0.3146	   -­‐0.9006	  
Ddost	   -­‐0.2480	   0.7186	   0.4159	   Plg	   0.7654	   -­‐0.0880	   -­‐0.4177	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Entpd2	   -­‐0.1333	   0.1342	   0.9926	   Por	   0.0089	   0.9354	   0.6637	  
Epb41l2	   0.3938	   -­‐0.0496	   0.5945	   Ppia	   0.8250	   -­‐0.1071	   -­‐0.0169	  
Etfb	   -­‐0.0271	   0.5978	   0.3332	   Prx	   0.3137	   1.9547	   6.8462	  
Fam213a	   -­‐0.2442	   0.7995	   0.3780	   Psap	   0.6151	   0.1777	   0.0293	  
Fbn1	   -­‐0.5481	   0.0922	   0.8802	   Rpl14	   0.5220	   0.6726	   -­‐0.2304	  
Fkbp1a	   0.6657	   -­‐0.1790	   -­‐0.3025	   Sfn	   0.5876	   -­‐0.2769	   0.0210	  
Gmfb	   0.7212	   -­‐0.4018	   -­‐0.2959	   Sh3bgrl3	   0.5864	   -­‐0.0581	   -­‐0.1553	  
H2-­‐K1;H2-­‐Q4;H2-­‐D1;H2-­‐Q7;H2-­‐
Q10;H2-­‐Q6;H2-­‐Q8;H2-­‐Q1;H2-­‐
L;Gm8909	   0.3478	   0.8448	   1.2740	   Slc27a1	   -­‐0.1520	   1.1278	   0.9321	  
H3f3a;Hist1h3b;Hist1h3a;H3f3c	   -­‐0.9270	   0.3071	   0.9981	  
Tuba1a;Tuba1c
;Tuba3a;Tuba8	   0.6135	   -­‐0.3046	   -­‐0.0391	  
Hagh	   0.8233	   0.2771	   -­‐0.4650	   Tuba4a	   0.6569	   -­‐0.5561	   -­‐0.2197	  
Hbb-­‐b1	   3.0594	   0.3689	   0.0117	   Tubb2a	   0.9108	   -­‐0.3937	   -­‐0.0559	  
Hbb-­‐b2	   3.0499	   0.7280	   -­‐0.1449	   Tubb3	   0.7540	   -­‐0.4070	   -­‐0.0984	  





2ba;Hist2h2be	   -­‐0.6878	   0.3831	   0.8346	  
Tubb4b;Tubb4
b-­‐ps1	   0.6675	   -­‐0.3565	   -­‐0.0543	  
Hist1h4a	   -­‐1.1001	   0.7419	   1.0788	   Tubb5	   0.8640	   -­‐0.5981	   -­‐0.1452	  
Itgb6	   -­‐0.3327	   0.0401	   1.1889	  
	  
Txn	   1.0622	   0.2652	   -­‐0.1932	  
Lgals3	   0.5747	   0.9390	   1.1667	   Uchl1	   0.6595	   -­‐0.0959	   -­‐0.3411	  
Lin7c;Lin7a	   0.3966	   -­‐0.0130	   0.6037	   Ywhaq	   0.6798	   -­‐0.0378	   -­‐0.1323	  
Lxn	   0.8072	   -­‐0.0094	   -­‐0.0731	  
	   	   	   	  	  
The	  table	  emphasized	  that	  the	  only	  two	  protein	  groups	  exhibiting	  a	  constant	  significant	  upregulation	  
at	   timepoints	   13	   and	   17M	   contained	   histone	   proteins	   (Hist1h4a;	   H2-­‐K1…).	   Considering	   also	   non-­‐
significant,	   but	   large	   enough	   log2	   fold	   changes	   (≥	   0.585),	   no	   protein	   group	   that	   was	   significantly	  
changed	   at	   timepoint	   6M	   showed	   a	   relevant	   degree	   of	   upregulation	   at	   the	   later	   timepoints.	   In	  
contrast,	  10	  protein	  groups	  exhibited	  a	  potential	  upregulation	  at	  both	  later	  timepoints	  (highlighted	  in	  
bold).	   These	   were	   amine	   oxidase	   copper	   containing	   3	   (Aoc3),	   platelet	   glycoprotein	   4	   (Cd36),	  
carboxylesterase	   1D	   (Ces1d),	   catenin	   alpha-­‐1	   (Ctnna1),	   histones	   (Hist1h1d/e),	   galectin	   3	   (Lgals3),	  
perilipin	  (Plin1),	  NADPH-­‐cytochrome	  P450	  reductase	  (Por),	  periaxin	  (Prx)	  and	  Slc27a1	  (solute	  carrier	  
family	  27	  member	  1).	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Table	  4-­‐4:	  Protein	  groups	  significantly	  downregulated	  in	  sciatic	  nerve	  myelin	  at	  at	  least	  one	  timepoint.	  
The	  table	  contains	  the	  proteins	  groups,	   indicated	  by	  their	  respective	  gene	  games,	  which	  showed	  a	  significant	  
downregulation	  at	  one	   timepoint	  or	  more.	  Next	   to	  each	  gene	  name	   the	   log2	   fold	   changes	   (log2	   ratio	   FA2H-­‐
KO/WT)	   for	   each	   timepoint	   are	   given.	   Significant	   changes	   (log2	   fold	   change	   ≤	   0.585	  &	   -­‐log10	  p	   >	   1.301)	   are	  






















Atp6v1c1	   0.3182	   -­‐0.0344	   -­‐0.8649	  
	  
Prelp	   -­‐0.6200	   0.2474	   -­‐0.1466	  
Atpif1	   0.3614	   0.2107	   -­‐0.6507	   Prnp	   -­‐0.2175	   -­‐0.8843	   -­‐0.5892	  
Cacybp	   -­‐0.1720	   0.2130	   -­‐0.6303	   Rab6b	   0.2329	   -­‐0.9942	   -­‐1.1359	  
Cfh	   0.3548	   0.9513	   -­‐0.9888	   S100b	   1.0783	   -­‐0.8920	   -­‐0.9166	  
Chmp1b2;Chmp1b1	   -­‐0.2626	   -­‐0.0121	   -­‐1.1573	   Sbds	   -­‐0.2634	   -­‐0.4987	   -­‐1.1183	  
Cst3	   -­‐0.2777	   0.0653	   -­‐0.6068	   Serf1;Serf2	   0.1914	   -­‐0.7458	   -­‐0.5933	  
Eef1a1	   -­‐0.4326	   -­‐0.2638	   -­‐0.6327	   Slc4a1	   -­‐0.1976	   1.0789	   -­‐1.3713	  
Eef1a2	   -­‐1.2212	   -­‐0.0080	   -­‐0.8551	   Stk10	   0.5149	   -­‐0.1280	   -­‐0.6872	  
Fam213b	   -­‐0.4982	   -­‐0.5936	   -­‐0.1663	   Svip	   0.0599	   -­‐1.0607	   -­‐0.8819	  
Fkbp3	   -­‐0.3242	   -­‐0.6214	   -­‐1.1188	   Tma7	   -­‐0.2545	   -­‐0.9634	   -­‐0.6264	  
Fsd1	   0.1414	   -­‐0.0395	   -­‐0.7791	   Tmod1	   -­‐0.2073	   -­‐0.3371	   -­‐0.5992	  
Ist1	   0.1953	   0.2656	   -­‐0.6884	   Tppp	   -­‐0.1606	   -­‐0.3736	   -­‐1.1166	  
Map7d2	   -­‐0.2048	   -­‐0.6719	   -­‐0.7621	   Tppp3	   -­‐0.3707	   -­‐0.7085	   -­‐1.1668	  
Mapt	   0.1929	   -­‐0.1960	   -­‐0.6002	   Vsnl1	   0.5659	   -­‐0.6144	   -­‐0.6665	  
Ppp1r1c	   0.1724	   -­‐0.3234	   -­‐1.1159	  
	   	   	  
	  	  
	  
Table	  4-­‐4	  underlined	  the	  observation	  that	  almost	  all	  protein	  downregulations	  in	  PNS-­‐myelin	  of	  FA2H-­‐
KO	  mice	  were	  exclusively	  found	  at	  timepoint	  17M.	  When	  taking	  into	  account	  also	  non-­‐significant,	  but	  
large	  enough	  log2	  fold	  changes	  (≤-­‐0.585),	  10	  of	  these	  protein	  groups	  may	  have	  been	  downregulated	  
already	  at	  timepoint	  13M	  (highlighted	  in	  bold).	  These	  were	  FK506-­‐binding	  protein	  3	  (Fkbp3),	  MAP7	  
domain-­‐containing	  protein	  2	  (Map7d2),	  prion	  protein	  (Prnp),	  Rab6b,	  S100	  calcium	  binding	  protein	  B	  
(S100b),	  small	  EDRK-­‐rich	  factors	  1	  and	  2	  (Serf1	  and	  Serf2),	  small	  VCP/p97-­‐interacting	  protein	  (Svip),	  
translation	   machinery	   associated	   7	   homolog	   (Tma7),	   tubulin	   polymerization-­‐promoting	   protein	   3	  
(Tppp3)	  and	  visinin-­‐like	  1	  (Vsnl1).	  
Taken	   together,	   the	   comparative	   PNS-­‐myelin	   analysis	   revealed	   that	   almost	   all	   major	   PNS-­‐myelin	  
proteins	   were	   largely	   unchanged.	   Of	   them,	   only	   periaxin	   was	   potentially	   elevated,	   but	   this	   was	  
disproved	   by	   a	   subsequent	   WB	   analysis.	   Moreover,	   other	   protein	   groups	   were	   also	   significantly	  
changed,	  but	  usually	  at	  a	   single	   timepoint	  only.	  Of	  all	   timepoints	   the	  majority	  were	  present	  at	   the	  
latest	   timepoint	   (17M),	  which	   is	   in	   line	  with	   the	   late	   onset	   of	   the	   PNS-­‐pathology.	   In	   addition,	   the	  
expression	  of	  many	  protein	   groups	   varied	  heavily	   between	   the	   three	   timepoints.	   Still,	   a	   few	  other	  
interesting	   protein	   groups,	   like	   CD36,	   Por,	   Prnp	   etc.,	  might	   had	   been	   altered	   already	   at	   timepoint	  
13M,	   but	   since	   not	   all	   of	   their	   log2	   fold	   changes	   were	   significant,	   this	   cannot	   be	   said	   for	   sure.	  
Accordingly,	   further	   experiments	   are	   needed	   to	   verify	   these	   putative	   PNS-­‐myelin	   protein	   changes.
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4.2 Identification	  of	  FA2H	  interaction	  partners	  
After	  the	  comparative	  proteomic	  CNS-­‐	  and	  PNS-­‐myelin	  analyses	  of	  FA2H-­‐KO	  mice,	  the	  second	  part	  of	  
this	   thesis	   focused	   on	   the	   discovery	   of	   FA2H	   interaction	   partners.	   This	   was	   done,	   because	   the	  
pathology	  found	  in	  FA2H-­‐KO	  mice	  potentially	  is	  not	  caused	  by	  the	  absence	  of	  2-­‐OH	  sphingolipids,	  but	  
rather	  the	  loss	  of	  certain	  protein	  interactions	  of	  FA2H.	  
The	  most	  widely	  used	  method	  to	  identify	  a	  protein’s	  interaction	  partners	  is	  co-­‐immunoprecipitation	  
(Co-­‐IP)	   followed	   by	   Western	   blotting	   (WB)	   and/or	   mass	   spectrometry.	   The	   proteins	   are	   usually	  
precipitated	  by	  using	  an	  antibody	  together	  with	  Protein	  G/A-­‐coupled	  beads	  or,	  alternatively,	  via	  an	  
affinity	   tag	  based	  purification	   system.	  Of	   the	  available	  affinity	   tags	   the	  Twin-­‐Strep-­‐tag	  was	  chosen,	  
because	  it	  has	  a	  very	  high	  affinity	  to	  its	  binding	  partner	  StrepTactin	  and	  thus	  allows	  a	  fast	  and	  specific	  
one-­‐step	   IP	  of	   the	  bait	   protein.	  Moreover,	   a	   tag-­‐based	   system	  has	   the	   general	   advantage	   that	   the	  
bait	  proteins	  have	  a	  good	  accessibility,	  because	  they	  are	  usually	  tagged	  at	  their	  termini.	  Antibodies	  
on	  the	  other	  hand	  may	  also	  bind	  to	  more	  central,	  less	  accessible	  regions,	  limiting	  an	  efficient	  IP.	  	  
As	  a	  second	  approach,	  the	  recently	  published	  BioID	  (biotin	  identification)	  method	  was	  used	  (Roux	  et	  
al.	  2012).	  Its	  working	  principle	  is	  the	  fusion	  of	  a	  permanently	  active	  mutant	  Biotin-­‐ligase	  from	  E.coli	  
(BirA*)	   to	   the	   bait	   protein.	   This	   ligase	   biotinylates	   the	   proteins	   in	   the	   vicinity	   of	   the	   bait	   protein,	  
thereby	  allowing	   their	   identification	  by	  mass	   spectrometry	   after	   selective	  enrichment	  using	  biotin-­‐
affinity	  purification.	  	  
In	  the	  process	  of	  this	  assay,	  the	  tagged-­‐mFA2H	  enzymes	  were	  first	  cloned,	  followed	  by	  an	  assessment	  
of	   their	   expression	   and	   functionality.	   Then	   the	   presence	   of	   FA2H-­‐containing	   protein	   complexes	   in	  
mammalian	  cells	  was	  proven	  by	  initial	  BlueNative	  PAGE	  and	  PFA-­‐crosslinking	  experiments.	  After	  this	  
initial	  positive	  result,	  potential	  FA2H-­‐interacting	  proteins	  were	  then	  identified	  in	  different	  screening	  
experiments	   using	   quantitative	   mass	   spectrometry.	   Finally,	   a	   selection	   of	   these	   newly	   identified	  
putative	   interaction	   partners	   was	   verified	   by	   WB	   and	   bimolecular	   fluorescence	   complementation	  
(BiFC).	  	  
4.2.1 Cloning,	  expression	  and	  functionality	  assessment	  of	  mFA2H-­‐bait	  constructs	  
4.2.1.1 Cloning,	  expression	  and	  purification	  of	  Twin-­‐Strep-­‐FA2H	  
FA2H	  was	   tagged	  with	   a	   Twin-­‐StrepTag,	   allowing	   its	   precipitation	  with	   StrepTactin-­‐coated	  polymer	  
beads.	  In	  addition,	  a	  shortened	  Twin-­‐Strep-­‐tagged	  mFA2H,	  consisting	  only	  of	  its	  N-­‐terminal	  cytosolic	  
part	   (mFA2H1-­‐163),	   was	   initially	   produced	   as	   well.	   The	   shortened	   protein	   was	   produced	   for	   the	  
identification	  of	  proteins,	  which	   interact	  with	  FA2H’s	  via	   its	  N-­‐terminus.	  But	   since	   the	  experiments	  
with	  the	  full-­‐length	  protein	  were	  successful,	  this	  approach	  was	  not	  further	  pursued	  in	  this	  thesis.	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First,	   full-­‐length	  and	   the	  N-­‐terminal	   cytosolic	  part	   (amino	  acids	  1-­‐163)	  of	  murine	  FA2H	  was	   cloned	  
into	   both	   mammalian	   Twin-­‐Strep	   vectors	   (pESG-­‐IBA103	   [C-­‐terminal	   tag]	   and	   pESG-­‐IBA105	   [N-­‐
terminal	  tag])	  contained	  in	  the	  StarGate®	  Twin-­‐Strep®	  mammalian	  cloning	  kit	  (IBA	  lifesciences).	  The	  
cloning	   was	   done	   according	   to	   the	  manufacturers	   instructions	   via	   a	   DNA-­‐recombinase	   dependent	  
process	   (see	   3.2.6.8	   StarGate®	   cloning).	   Afterwards,	   the	   vectors	  were	   transiently	   transfected	   into	  
HeLa	  cells	  and	  the	  constructs	  expression	  and	  their	  solubility	  evaluated	  in	  a	  mild	  detergent-­‐containing	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Figure	  4-­‐19:	  Expression	  and	  solubility	  analysis	  of	  Twin-­‐Strep	  FA2H-­‐constructs	   in	  HeLa	  cells.	  HeLa	  cells	  were	  
transfected	  with	  mock	  (pcDNA3),	  untagged	  mFA2H,	  mFA2H-­‐Twin-­‐Strep,	  mFA2H1-­‐163-­‐Twin-­‐Strep,	  Twin-­‐Strep-­‐
mFA2H	  and	  Twin-­‐Strep-­‐mFA2H1-­‐163	  using	  Turbofect.	  After	  24	  h,	  cells	  were	  harvested,	  lysed	  in	  50	  µl	  StrepTag	  
lysis	  buffer	   (cont.	  1%	  TX-­‐100),	  and	  centrifuged	   to	  obtain	  an	   insoluble	  pellet	   (P)	  and	  soluble	  supernatant	   (SN)	  
fraction.	  The	  pellet	  was	  resuspended	  in	  50	  µl	  1X	  Laemmli	  and	  20	  µl	  of	  both	  fractions	  separated	  via	  SDS-­‐PAGE.	  
Subsequently,	  both	   fractions	  were	  evaluated	  by	  WB	  with	   chemiluminescent	  detection.	  The	  expected	  protein	  
sizes	  were:	  mFA2H	  =	  38	  kDa;	  mFA2H-­‐Twin-­‐Strep/Twin-­‐Strep-­‐mFA2H	  =	  40	  kDa;	  mFA2H1-­‐163-­‐Twin-­‐Strep/Twin-­‐
Strep-­‐mFA2H1-­‐163	  =	  25	  kDa.	  (A)	  FA2H	  blot	  obtained	  by	  incubation	  with	  FA2H	  antiserum	  #2	  (dilution	  1:800,	  ON,	  
4	  °C)	  followed	  by	  goat-­‐anti-­‐rabbit-­‐HRP	  secondary	  antibody	  incubation	  (dilution	  1:5000,	  1.5	  h,	  RT).	  Twin-­‐Strep-­‐
tagged	   and	   untagged	   mFA2H	   signals	   are	   indicated	   by	   arrows.	   (B)	   StrepTag	   blot	   developed	   by	   applying	  
StrepTactin-­‐HRP	   substrate	   (dilution	  1:5000,	   1.5	  h,	   RT).	   Twin-­‐Strep	   tagged	  mFA2H	   signals	   are	   indicated	  by	   an	  
arrow.	  	  
The	   WB	   against	   FA2H	   showed	   specific	   FA2H-­‐signals,	   corresponding	   with	   the	   expected	   molecular	  
weights	  of	  the	  transfected	  constructs	  (mFA2H	  =	  38	  kDa;	  mFA2H-­‐Twin-­‐Strep/Twin-­‐Strep-­‐mFA2H	  =	  40	  
kDa;	  mFA2H1-­‐163-­‐Twin-­‐Strep/Twin-­‐Strep-­‐mFA2H1-­‐163	  =	  25	  kDa).	  In	  all	  samples	  the	  FA2H-­‐signal	  was	  
stronger	   in	   the	   supernatant	   (SN),	   than	   in	   the	   pellet	   fraction,	   showing	   an	   efficient	   protein	  
solubilization	   by	   the	   applied	   StrepTag	   lysis	   buffer.	   Moreover,	   the	   strongest	   FA2H-­‐signal	   was	  
observable	  in	  the	  SN-­‐sample	  transfected	  with	  N-­‐terminally	  tagged	  Twin-­‐Strep-­‐mFA2H.	  Furthermore,	  
there	  were	   some	  unspecific	  background	  bands	  present	   in	   all	   samples	  and	   fractions,	  with	   the	  most	  
intense	  ones	  at	  ~38,	  45	  and	  70	  kDa.	  
The	  StrepTag-­‐WB	  gave	  a	   similar	   result.	  As	  expected,	  only	   the	  Twin-­‐Strep-­‐tagged	  mFA2H-­‐constructs	  
were	   detectable	   at	   their	   predicted	   molecular	   weights	   (Twin-­‐Strep	   mFA2H	   =	   40	   kDa,	   Twin-­‐Strep	  
mFA2H1-­‐163	  =	  25	  kDa),	  while	  untagged	  mFA2H	  was	  not.	  Again,	  each	  Twin-­‐Strep-­‐mFA2H	  signal	  was	  
more	   intense	   in	  the	  supernatant,	  than	  in	  the	  pellet	  fraction	  and	  the	  strongest	  signal	  was	  visible	  for	  
full	   length	  Twin-­‐Strep-­‐mFA2H.	  Moreover,	  in	  all	  samples	  background	  bands	  were	  present	  at	  ~70	  and	  
>100	  kDa.	  	  
Taken	   together,	   all	   tagged	   mFA2H-­‐constructs	   could	   be	   detected	   after	   transient	   expression	   in	  
mammalian	  cells.	  Furthermore,	  the	  majority	  of	  each	  protein,	  including	  the	  full	  length	  ones,	  could	  be	  
efficiently	  solubilized	  in	  lysis	  buffer,	  which	  is	  a	  prerequisite	  for	  subsequent	  affinity	  purifications.	  	  
At	   the	  next	  step,	   the	   functionality	  of	   the	   tagged	  mFA2H-­‐constructs	  was	  evaluated	  by	  analyzing	   the	  
sphingolipid	  profile	  of	  transfected	  HeLa	  cells	  (Figure	  4-­‐20).	  Overexpression	  of	  active	  FA2H	  should	  lead	  
to	  an	  increase	  in	  2-­‐OH	  sphingolipids,	  which	  can	  be	  detected	  via	  thin	  layer	  chromatography	  (TLC).	  	  




Figure	   4-­‐20:	   Sphingolipid	   analysis	   of	   HeLa	   cells	   transfected	   with	   Twin-­‐Strep	  mFA2H-­‐constructs.	  HeLa	   cells	  
were	   transfected	  with	  mock	   (pcDNA3),	  untagged	  mFA2H,	  mFA2H-­‐Twin-­‐Strep,	  mFA2H1-­‐163-­‐Twin-­‐Strep,	  Twin-­‐
Strep-­‐mFA2H	   and	   Twin-­‐Strep-­‐mFA2H1-­‐163	   using	   Turbofect.	   After	   24	   h,	   cells	   were	   harvested	   and	   lipids	  
extracted	  by	  the	  modified	  Bligh-­‐Dyer-­‐method	  followed	  by	  phospholipid	  degradation	  by	  alkaline	  methanolysis.	  
The	  extracts	  and	   lipid	  standards	  (cholesterol,	  GlcCer,	  sulfatide,	  sphingomyelin)	  were	  applied	  to	  a	  HPTLC-­‐silica	  
plate	  and	  separated	  by	  a	  mobile	  phase	  of	  70/30/4	  CHCl3/CH3OH/H2O.	  Lipid	  bands	  were	  made	  visible	  by	  copper	  
sulfate	  charring.	  The	  filled	  arrow	  points	  at	  2-­‐OH	  cerebrosides,	  which	  have	  a	  slightly	  lower	  retardation	  factor	  (Rf)	  
value,	  than	  their	  non-­‐hydroxy	  counterparts.	  The	  non-­‐filled	  arrow	  indicates	  another	  band,	  which	  becomes	  more	  
intense	  in	  FA2H-­‐transfected	  cells	  and	  might	  reflect	  2-­‐OH	  lactosylceramide.	  
As	   becomes	   clear	   from	   Figure	   4-­‐20,	   only	   the	   overexpression	   of	   full-­‐length,	   but	   not	   shortened,	  
mFA2H-­‐constructs	   led	   to	   the	   appearance	   of	   an	   extra	   band	   (filled	   arrow)	   running	   slightly	   below	  
GlcCer,	   which	   was	   used	   as	   a	   lipid	   standard.	   Based	   on	   its	   retardation	   factor	   (Rf),	   this	   substance	  
probably	   represented	   hydroxylated	   GlcCer	   or	   GalCer.	   The	   intensity	   of	   this	   signal	   was	   of	   similar	  
strength	   for	   all	   FA2H-­‐constructs,	   thereby	  demonstrating	   that	   the	  presence	  of	   the	   Twin-­‐StrepTag	   is	  
not	   substantially	   affecting	   the	   proteins	   enzymatic	   activity.	   Furthermore,	   another	   band	   (non-­‐filled	  
arrow),	  probably	   representing	  2-­‐OH	   lactosylceramide,	  was	   significantly	  more	   intense	   in	  all	   samples	  
expressing	  full-­‐length	  mFA2H-­‐constructs.	  This	  further	  proved	  the	  activity	  of	  the	  full-­‐length	  proteins.	  
At	   this	   point	   it	  was	   clear	   that	   enzymatically	   active	  mFA2H,	   tagged	  N-­‐	   or	   C-­‐terminally	  with	   a	   Twin-­‐
StrepTag,	   could	   be	   expressed	   successfully	   in	   an	   immortalized	   human	   cell	   line.	   Since	   N-­‐terminally	  
tagged	  mFA2H	  was	  expressed	  at	  a	  slightly	  higher	  amount	  and	  C-­‐terminal	  tagging	  could	  possibly	  mask	  
FA2H’s	   ER-­‐retention	   signal,	   it	   was	   decided	   to	   use	   N-­‐terminally	   tagged	   Twin-­‐Strep-­‐mFA2H	   for	   all	  
following	  experiments.	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At	  the	  next	  step,	  Twin-­‐Strep-­‐mFA2Hs	  precipitation	  by	  StrepTag-­‐affinity	  purification	  was	  tested.	  Thus,	  
Twin-­‐Strep-­‐mFA2H	  was	   transiently	   transfected	   into	   HEK293-­‐T	   cells,	   the	   cells	   lysed	   and	   the	   affinity	  
purification	   performed.	   The	   precipitation	   result	   was	   thereafter	   tested	   by	   a	   StrepTag	   WB	   of	   all	  
fractions.	   This	   analysis,	   shown	   in	   Figure	   4-­‐21,	   demonstrated	   the	   successful	   and	   complete	  
precipitation	  of	  Twin-­‐Strep-­‐mFA2H	  from	  the	  cell	  lysate	  and	  its	  subsequent	  almost	  complete	  elution.	  	  
	  
Figure	  4-­‐21:	  Affinity	  purification	  of	  Twin-­‐Strep-­‐mFA2H	  transiently	  expressed	  in	  HEK293-­‐T.	  Twin-­‐Strep-­‐mFA2H	  
was	   transfected	   using	   the	   CaPO4-­‐method	   and	   expressed	   for	   48	   h.	   Subsequently,	   the	   cells	   were	   lysed	   in	  
StrepTag	   lysis	  buffer	  and	  centrifuged	   to	  obtain	  a	   cleared	   lysate	   (L).	   Then	  StrepTactin	  MacroPrep	  beads	  were	  
added	  and	  the	  sample	  incubated	  overnight	  at	  4	  °C	  under	  constant	  agitation.	  Afterwards,	  the	  lysate	  containing	  
the	  not	  binding	  proteins	  (NB)	  was	  removed,	  the	  beads	  washed	  three	  times	  with	  StrepTag	  washing	  buffer	  (W1-­‐
3)	   and	   the	   bound	   proteins	   eluted	   in	   three	   fractions	   of	   StrepTag	   elution	   buffer	   (E1-­‐3).	   In	   addition,	   to	   assess	  
elution	   efficiency,	   the	   MacroPrep	   beads	   (B)	   were	   afterwards	   boiled	   with	   1X	   Laemmli.	   All	   fractions	   were	  
subsequently	  separated	  via	  SDS-­‐PAGE	  and	  analyzed	  by	  a	  StrepTag	  WB	  using	  StrepTactin-­‐HRP	  substrate	  (dilution	  
1:5000,	  2	  h,	  RT).	  The	   following	  amounts	  of	  each	   fraction	  were	   loaded:	   lysate	   (L)	  10%,	  non-­‐bound	   lysate	   (NB)	  
10%,	  wash	   fractions	   (W1-­‐3)	  3%,	  eluates	   (E1-­‐3)	  30%	  and	  boiled	  beads	   (B)	  50%.	  A	  black	  arrow	   indicates	  Twin-­‐
Strep-­‐mFA2H	  (~40	  kDa)	  and	  a	  black	  star(*)	  unspecific	  background	  bands.	  
The	  strongest	  Twin-­‐Strep-­‐mFA2H	  signals	  (~40	  kDa)	  were	  present	  in	  the	  lysate	  (L)	  and	  the	  first	  elution	  
fraction	   (E1).	   Furthermore,	  no	  Twin-­‐Strep-­‐mFA2H	  was	  detectable	   in	   the	  non-­‐bound	   (NB)	  and	  wash	  
fractions	  (W1	  –	  W3),	  and	  only	  a	  small	  amount	  in	  the	  beads	  fraction	  (B).	  Taken	  together,	  this	  proved	  
the	   accessibility	   of	   Twin-­‐Strep-­‐mFA2H	   to	   StrepTactin-­‐affinity	   purification,	   a	   prerequisite	   for	  
subsequent	  mass	  spectrometry-­‐based	  interaction	  partner	  identifications.	  
4.2.1.2 Cloning,	  expression	  and	  functionality	  assessment	  of	  BirA*-­‐mFA2H	  
FA2H	   was	   subcloned	   into	   the	   BioID-­‐vector,	   downstream	   of	   the	   BirA*-­‐sequence,	   after	   adding	  
compatible	   restriction	   sites	   via	   PCR-­‐amplification.	   Following	   sequence	   verification	   by	   DNA-­‐
sequencing,	   the	   construct	   was	   transfected	   into	   cells	   to	   assess	   its	   expression	   and	   functionality.	  
Therefore,	   control	   (pcDNA3),	   BirA*	   (pcDNA3.1-­‐mycBioID)	   and	   BirA*-­‐mFA2H	   (pcDNA3.1-­‐mycBioID-­‐
mFA2H)	   vectors	   were	   transiently	   transfected	   into	   HEK293-­‐T	   cells	   grown	   in	   low-­‐biotin	   medium	  
(DMEM	  +	  10%	  FCS)	  in	  four	  replicates	  each.	  DMEM	  itself	  contains	  no	  biotin,	  thus	  the	  only	  endogenous	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biotin-­‐source	  is	  FCS.	  24	  h	  after	  transfection,	  biotin	  was	  added	  to	  one	  half	  of	  the	  replicates,	  while	  the	  
other	  half	  was	  left	  untreated.	  After	  another	  24	  h	  the	  cells	  were	  harvested,	  lysed	  and	  evaluated	  by	  a	  
Streptavidin-­‐HRP	  WB	  (Figure	  4-­‐22).	  
	  
Figure	   4-­‐22:	   Expression	   and	   functionality	   analysis	   of	   BirA*-­‐mFA2H.	   HEK293-­‐T	   cells	   were	   transfected	   using	  
CaPO4	  with	  either	  mock	  (pcDNA3),	  BirA*	  (pcDNA3.1-­‐mycBioID)	  or	  BirA*-­‐mFA2H	  (pcDNA3.1-­‐mycBioID-­‐mFA2H)	  
in	  four	  replicates	  each.	  24	  h	  later,	  one	  half	  of	  the	  replicates	  were	  supplemented	  with	  50	  µM	  biotin	  and	  all	  cells	  
grown	  for	  another	  24	  h.	  Subsequently,	  the	  cells	  were	  harvested,	  lysed	  in	  StrepTag	  lysis	  buffer	  and	  the	  protein	  
amounts	  determined.	  Finally,	  50	  µg	  of	  total	  protein	  from	  each	  sample	  were	  separated	  by	  SDS-­‐PAGE	  (10%	  gel)	  
and	  analyzed	  via	  a	  Streptavidin-­‐HRP	  WB	  (dilution	  1:15,000,	  1	  h,	  RT).	  Since	  milk	  contains	  biotin,	  a	  BSA-­‐solution	  
(2.5%	  BSA,	  0.4%	  TX-­‐100	  in	  PBS)	  was	  used	  for	  blocking	  and	  antibody	  incubation.	  	  
The	  WB	  showed	  the	  successful	  expression	  and	  functionality	  of	  the	  BirA*-­‐mFA2H	  fusion	  protein.	  The	  
samples	  from	  cells	  transfected	  with	  an	  empty	  vector	  (mock)	  exhibited	  only	  one	  intense	  major	  band	  
of	  ~80	  kDa	  and	  only	  a	  weak	  staining	  of	  other	  bands,	  regardless	  of	  the	  addition	  of	  biotin.	  The	  samples	  
derived	   from	   cells	   transfected	   with	   pcDNA3.1-­‐mycBioID	   (BirA*)	   or	   pcDNA3.1-­‐mycBioID-­‐mFA2H	  
(BirA*-­‐mFA2H)	   had	   a	   similar	   staining	   pattern	   when	   no	   additional	   biotin	   was	   present,	   but	   a	  
significantly	  different	  one	  in	  the	  presence	  of	  50	  µM	  biotin.	  Without	  its	  addition,	  only	  one	  additional	  
intense	   band	   of	   ~40	   kDa	   appeared	   and	   the	  whole	   lane	   staining	   increased	   slightly.	   In	   contrast,	   the	  
presence	   of	   50	   µM	   biotin	   led	   to	   an	   intense	   staining	   of	   various	   proteins	   over	   the	   whole	   lane,	  
indicating	   the	   biotinylation	   of	   various	   proteins	   by	   the	   biotin	   ligase.	   This	   staining	   was	   more	  
pronounced	   in	   the	  BirA*	   compared	   to	   the	  BirA*-­‐mFA2H	   samples.	   In	   addition,	   both	   samples,	   BirA*	  
and	  BirA*-­‐mFA2H,	  differed	  in	  their	  staining	  patterns.	  	  
In	   summary,	   the	   results	   of	   this	   assay	   led	   to	   three	   conclusions.	   First,	   regardless	   of	   the	   addition	   of	  
external	   biotin,	   the	   amount	   of	   biotinylated	   proteins	  within	  HEK293-­‐T	   cells	   not	   expressing	   a	   BirA*-­‐
enzyme	  is	   low.	  Second,	  even	   in	  the	  presence	  of	  BirA*,	  the	  normal	  amount	  of	  biotin	   in	  the	  medium	  
was	  not	  sufficient	   for	  widespread	  cellular	  biotinylation	  of	  various	  proteins	  proximal	  to	  the	  enzyme.	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Therefore,	   the	   assay	   is	   inducible	   by	   the	   addition	   of	   external	   biotin.	   Third,	   cells	   transfected	   with	  
pcDNA3.1-­‐mycBioID-­‐mFA2H	   exhibited	   a	   less	   intense	   and	   divergent	   staining	   pattern	   compared	   to	  
pcDNA3.1-­‐mycBioID-­‐transfected	   ones.	   This	   was	   expected,	   since	   both	   proteins	   have	   a	   distinct	  
localization	  and	  thus	  different	  biotinylation	  targets.	  While	  the	  BirA*-­‐protein	  alone	  is	  localized	  in	  the	  
cytosol,	  the	  fusion	  enzyme	  is	  integral	  to	  the	  ER-­‐membrane	  via	  its	  FA2H	  part,	  with	  its	  biotin-­‐ligase	  part	  
facing	  the	  cytosol.	  
4.2.2 Identification	  of	  a	  FA2H-­‐containing	  protein	  complex	  
Before	   starting	   the	   analysis	   of	   Twin-­‐Strep-­‐mFA2H	   precipitates	   for	   interaction	   partners	   by	   mass	  
spectrometry,	   the	   presence	   of	   such	   a	   complex/complexes	   should	   be	   confirmed.	   Accordingly,	   cells	  
expressing	  Twin-­‐Strep-­‐mFA2H	  were	  analysed	  by	  BlueNative	  PAGE	  and	  a	  PFA-­‐cross	  linking	  assay.	  
4.2.2.1 BlueNative	  PAGE	  
Cell	   lysate	   of	   HEK293-­‐T	   cells,	   transiently	   transfected	   with	   Twin-­‐Strep-­‐mFA2H,	   was	   separated	   via	  
BlueNative	  PAGE	  followed	  by	  StrepTag	  WB	  detection	  (Figure	  4-­‐23)	  to	  assess	  if	  FA2H	  is	  part	  of	  one	  or	  
more	  multiprotein	  complexes.	  




Figure	   4-­‐23:	  BlueNative	  PAGE	  analysis	   of	   Twin-­‐Strep-­‐mFA2H.	  HEK293-­‐T	  cells	  were	  transfected	  with	  pcDNA3	  
(mock)	  or	  Twin-­‐Strep-­‐mFA2H	  via	  the	  CaPO4-­‐method.	  After	  48	  h	  the	  cells	  were	  harvested	  and	  lysed	  in	  1%	  TX-­‐100	  
lysis	  buffer.	  Then	  40	  and	  80	  µg	  of	   total	  protein	  were	  separated	  using	  BlueNative	  PAGE,	  blotted	  onto	  a	  PVDF	  
membrane,	   and	   analyzed	   by	   a	   StrepTag	  WB	   using	   StrepTactin-­‐HRP	   substrate	   (dilution	   1:5000,	   2	   h,	   RT)	   and	  
subsequent	  chemiluminescent	  detection.	  Note	  that	  empty	  lanes	  were	  left	  between	  samples.	  Areas	  of	  the	  blot	  
corresponding	  to	   the	  original	  stacking	  and	  resolving	  gel	  are	   indicated	  on	  the	  right.	  Regions	  with	  very	   intense	  
staining,	  hinting	  at	  the	  existence	  of	  a	  protein	  complex,	  are	  marked	  with	  an	  arrow.	  	  
The	   anti-­‐StrepTag	   WB	   revealed	   the	   existence	   of	   three	   major	   Twin-­‐Strep-­‐mFA2H	   containing	  
complexes:	  a	  small	  one	  of	  ~80	  kDa,	  a	  medium	  one	  of	  ~750	  -­‐	  900	  kDa	  at	  the	  border	  of	  stacking	  and	  
resolving	   gel,	   and	   a	   large	   one	   of	   >1000	   kDa	   at	   the	   border	   between	   the	   SDS-­‐gel	   pockets	   and	   the	  
stacking	  gel.	  While	   the	  small	   signal	  was	  exclusively	  observed	   in	   the	  Twin-­‐Strep-­‐mFA2H	  sample,	   the	  
two	  larger	  ones	  were	  also	  present	  in	  the	  mock	  sample.	  It	  can	  be	  therefore	  assumed	  that	  all	  protein	  
complexes	  to	  large	  to	  pass	  one	  of	  these	  borders	  were	  arrested	  there.	  Obviously,	  the	  StrepTactin-­‐HRP	  
substrate	  had	  bound	  to	  some	  of	  these	  complexes	  unspecifically,	  leading	  to	  a	  signal	  in	  all	  samples.	  But	  
since	   their	   intensities	   were	   much	   stronger	   in	   the	   Twin-­‐Strep-­‐mFA2H	   sample,	   compared	   to	   the	  
control,	   it	   can	   be	   concluded	   that	   specific	   FA2H-­‐containing	   complexes	   were	   also	   present	   there.	   In	  
addition,	   because	  of	   its	   approximate	   size	  of	   80	   kDa,	   corresponding	   to	   about	   two	   times	   the	   size	  of	  
FA2H,	  the	  smallest	  complex	  might	  have	  represented	  FA2H-­‐homodimers.	  
4.2.2.2 PFA-­‐crosslinking	  
Another	  complementary	  method	  employed	  to	  visualize	  a	  FA2H-­‐protein	  complex	   is	  PFA-­‐crosslinking.	  
The	   advantage	   of	   this	   method	   is	   that	   it	   allows	   the	   identification	   of	   less-­‐stable	   and	   transient	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complexes,	  which	  are	  normally	  lost	  during	  cell	  lysis.	  Unfortunately,	  it	  has	  to	  be	  considered,	  that	  not	  
all	   complexes	   detected	  by	   this	  method	   are	   specific,	   because	   it	   can	   also	   lead	   to	   the	   appearance	  of	  
unspecifically	  crosslinked	  proteins.	  
The	   optimal	   amount	   of	   PFA	   necessary	   for	   efficient	   crosslinking	   varies,	   depending	   on	   the	   target	  
protein	  and	   the	   cells	  used	   for	  expression.	  Thus,	   it	  had	   to	  be	  elucidated	  by	   titration.	  Consequently,	  
HEK293-­‐T	   cells,	   transiently	   transfected	   with	   mock	   (pcDNA3)	   or	   Twin-­‐Strep-­‐mFA2H,	   were	   treated	  
(after	   24	   h)	   with	   increasing	   amounts	   of	   PFA	   (0	   –	   1%	   in	   1X	   PBS)	   for	   20	   min	   at	   37	   °C.	   After	   the	  
crosslinking	  was	   stopped	   by	   the	   addition	   of	   ice-­‐cold	   glycine	   solution,	   the	   cells	  were	   lysed	   in	   RIPA-­‐





Figure	  4-­‐24:	  Evaluation	  of	  PFA-­‐concentration	  needed	  for	  Twin-­‐Strep-­‐mFA2H	  crosslinking.	  Mock	  (pcDNA3)	  or	  
Twin-­‐Strep-­‐mFA2H	  was	   transiently	   expressed	   in	   HEK293-­‐T	   cells	   grown	   in	   6-­‐well	   plates	   for	   24	   h.	   Afterwards,	  
they	  were	  washed	  with	  PBS	  and	  treated	  for	  20	  min	  with	  0	  –	  1%	  (v/v)	  PFA	  (in	  1	  XPBS)	  at	  37	  °C.	  Crosslinking	  was	  
stopped	   by	   the	   addition	   of	   1.25	   M	   ice-­‐cold	   glycine.	   Cells	   were	   then	   harvested,	   washed	   once	   in	   PBS	   and	  
subjected	  to	  lysis	  in	  RIPA	  buffer.	  Of	  each	  lysate	  15	  µg	  of	  total	  protein	  were	  mixed	  with	  Laemmli	  buffer	  (without	  
boiling),	  separated	  via	  SDS-­‐PAGE	  and	  analyzed	  by	  anti-­‐StrepTag	  WB	  (dilution	  1:5000,	  2	  h,	  RT).	  Potential	  FA2H-­‐
containing	  protein	  complexes	  are	  marked	  with	  “complex?”	  and	  unspecific	  background	  bands	  with	  a	  black	  star	  
(*).	   (A)	   No	   StrepTag-­‐mFA2H	   signal	   could	   be	   detected	   in	   samples	   originating	   from	   cells	   transfected	   with	   an	  
empty	  vector.	  (B)	  Samples	  derived	  from	  cells	  expressing	  Twin-­‐Strep-­‐mFA2H	  exhibited	  intense	  staining	  in	  anti-­‐
StrepTag	  WB.	   First	   a	   strong	   Twin-­‐Strep-­‐mFA2H	   signal	   (~40	   kDa)	   can	   be	   observed	   in	   all	   samples.	  Moreover,	  
samples	   treated	   with	   PFA	   showed	   several	   additional	   signals	   at	   higher	   molecular	   weights	   marked	   with	  
“complex?”.	  Note	  that	  an	  airbubble	  was	  accidentialy	  introduced	  during	  blotting	  in	  the	  1%	  PFA	  sample.	  Thus,	  no	  
signals	  were	  visible	  at	  ~130	  kDa.	  
The	  treatment	  of	  Twin-­‐Strep-­‐mFA2H	  expressing	  HEK293-­‐T	  cells	  with	  increasing	  concentrations	  of	  PFA	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(~40	  kDa).	  This	  effect	  was	  not	  found	  in	  the	  mock-­‐transfected	  cells,	  which	  exhibited	  just	  very	  weakly	  
the	  70	  kDa	  background	  signal	  (*)	  present	  in	  all	  anti-­‐StrepTag	  WBs	  (see:	  Figure	  4-­‐19	  or	  Figure	  4-­‐21).	  In	  
contrast,	  three	  very	  prominent	  background	  signals	  of	  50,	  70	  and	  130	  kDa	  (*)	  were	  observable	  in	  the	  
Twin-­‐Step-­‐mFA2H	   sample,	   even	   without	   PFA-­‐crosslinking.	   Furthermore,	   four	   additional	   signals	  
became	  visible,	  ~60	  kDa,	  ~80	  kDa	  and	  two	  larger	  ones	  of	  >170	  kDa,	  which	  probably	  reflected	  FA2H-­‐
containing	  protein	  complexes.	  With	  approximately	  two	  times	  the	  molecular	  weigth	  of	  FA2H	  the	  ~80	  
kDa	   complex	   might	   have	   reflected	   FA2H	   homodimers.	   Furthermore,	   there	   was	   a	   generally	   more	  
intense	  staining	  over	  the	  whole	  lane,	  possibly	  derived	  from	  various	  less	  abundant	  proteins	  proximal	  
to	  Twin-­‐Strep-­‐mFA2H.	  All	  of	  these	  signals	  appeared	  even	  at	  the	  lowest	  concentration	  of	  PFA	  and	  did	  
not	   increase	   in	   intensity,	   when	   using	   more	   than	   0.25%	   PFA.	   Moreover,	   some	   signals,	   especially	  
background	   ones,	   became	   even	   weaker	   at	   higher	   PFA-­‐concentrations,	   probably	   due	   to	   protein	  
insolubility	   caused	   by	   excessive	   crosslinking.	   Thus,	   the	   end	   it	   was	   decided	   to	   use	   0.5%	   PFA	   in	   all	  
further	   PFA-­‐crosslinking	   experiments,	   because	   at	   this	   concentration	   the	   potential	   complexes	  were	  
still	  visible,	  while	  the	  background	  ones	  were	  significantly	  reduced	  in	  intensity.	  
As	   the	   next	   step,	   the	   accessibility	   of	   the	   crosslinked	   complexes	   by	   StrepTactin-­‐affinity	   purification	  
was	  assessed.	  Twin-­‐Strep-­‐mFA2H	  was	  again	  expressed	  transiently	   in	  HEK293-­‐T	  cells.	  After	  48	  h,	  the	  
cells	  were	  treated	  with	  0.5%	  PFA	  for	  20	  min,	  the	  crosslinking	  stopped	  with	  ice-­‐cold	  glycine	  solution	  
and	   the	   cells	   lysed	   in	   RIPA-­‐buffer.	   Afterwards,	   the	   lysates	   were	   subjected	   to	   StrepTactin-­‐affinity	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Figure	   4-­‐25:	   Purification	   of	   Twin-­‐Strep-­‐mFA2H	   after	   PFA-­‐crosslinking.	   Either	  mock	   (pcDNA3)	  or	   Twin-­‐Strep-­‐
mFA2H	  was	  expressed	  for	  48	  h	  in	  one	  10	  cm	  plate	  of	  HEK293-­‐T	  cells.	  Afterwards,	  cells	  were	  washed	  two	  times	  
in	   PBS,	   fixed	   for	   20	   min	   with	   0.5%	   PFA,	   and	   finally	   washed	   twice	   with	   ice-­‐cold	   glycine	   stopping	   solution.	  
Subsequently,	   the	   cells	   were	   lysed	   in	   150	   µl	   RIPA	   buffer	   (incl.	   proteinase	   inhib.)	   for	   30	   min	   at	   4	   °C	   and	  
centrifuged	  30	  min	  at	  20,000	  g.	  While	  the	  pellet	  (P)	  was	  resuspended	  in	  40	  µl	  1X	  Laemmlli,	  the	  cleared	  lysate	  
(L)	  was	  incubated	  with	  50	  µl	  StrepTactin-­‐MacroPrep	  beads	  under	  constant	  agitation	  at	  4	  °C	  overnight.	  Then	  the	  
beads	  were	  washed	  thrice	  with	  500	  µl	  RIPA	  buffer	  (W1-­‐3)	  and	  bound	  proteins	  eluted	  three	  times	  with	  50	  µl	  2.5	  
mM	  biotin	   in	   RIPA	   buffer	   (E1-­‐3).	   In	   addition,	   the	   beads	   (B)	  were	   boiled	   in	   20	   µl	   1X	   Laemmli.	   Thereafter,	   all	  
fractions	  were	  separated	  by	  SDS-­‐PAGE	  and	  evaluated	  by	  anti-­‐StrepTag	  WB	  (dilution	  1:5000,	  2	  h,	  RT).	  Of	  each	  
fraction	  the	  following	  amounts	  were	  loaded:	  pellet	  (P)	  50%,	  lysate	  (L)	  10%,	  non-­‐bound	  lysate	  (NB)	  10%,	  wash	  
fractions	  (W1-­‐3)	  3%,	  eluates	  (E1-­‐3)	  30%	  and	  boiled	  beads	  (B)	  100%.	  (A)	  StrepTag	  WB	  of	  mock	  transfected	  cells.	  
The	  purification	  fractions	  showed	  only	  a	  background	  signals	  at	  70	  and	  130	  kDa,	  marked	  with	  black	  stars	  (*),	  but	  
no	  Twin-­‐Strep-­‐mFA2H	  signal.	  While	  the	  70	  kDa	  signal	  could	  be	  observed	   in	  all	  except	  the	  wash	  fractions,	   the	  
130	   kDa	   signal	   was	   only	   visible	   in	   the	   pellet	   and	   lysate	   fraction.	   (B)	   StrepTag	   WB	   of	   Twin-­‐Strep-­‐mFA2H	  
transfected	  cells.	  All	  except	  the	  wash	  fractions	  displayed	  differentially	  intense	  protein	  bands	  in	  the	  WB.	  Besides	  
the	  40	  kDa	  FA2H-­‐signal,	  there	  were	  three	  prominent	  protein	  bands	  at	  higher	  molecular	  weights	  marked	  with	  
black	  arrows.	  
While	   the	   fractions,	   obtained	   from	   mock-­‐transfected	   cells,	   showed	   mainly	   the	   70	   and	   130	   kDa	  
background	   signals	   (*)	   previously	   seen	   in	   StrepTag	  WBs	   (see:	   Figure	   4-­‐19),	   the	   Twin-­‐Strep-­‐mFA2H	  
expressing	  cells	  showed	  similar	  signals	  as	  before	  (see:	  Figure	  4-­‐24).	  Besides	  the	  strong	  40	  kDa	  FA2H-­‐
signal,	   in	   all	   but	   the	  washing	   fractions,	   there	  were	   putative	   complexes	   at	   ~60,	   ~80	   and	   >170	   kDa	  
(black	  arrows).	  Furthermore,	   the	  general	  background	  staining,	  derived	  from	  less	  abundant	  proteins	  
crosslinked	  to	  FA2H,	  was	  also	  present.	  When	  looking	  closely	  at	  the	  fractions,	  it	  became	  evident	  that	  
besides	  FA2H	  only	  the	  ~60	  and	  ~80	  kDa	  complexes,	  as	  well	  as	  the	  less	  abundant	  crosslinked	  proteins,	  
were	  purified.	  In	  contrast,	  the	  >170	  kDa	  complex	  did	  not.	  This	  could	  be	  partly	  explained	  by	  the	  fact	  
that	   a	   part	   of	   it	   did	   not	   bind	   to	   the	   affinity	   matrix	   (see	   signal	   in	   non-­‐bound	   fraction).	   Still,	   the	  
remaining	  amounts	  of	  this	  complex	  were	  not	  present	  in	  the	  elution	  fractions	  (E1	  –	  E3),	  which	  might	  
reflect	   a	   strong	   unspecific	   binding	   to	   the	   StrepTactin-­‐beads.	   Interestingly,	   the	   ~60	   kDa	   complex	  
seemed	  to	  have	  been	  enriched	  by	  the	  purification	  process,	  which	  became	  apparent	  as	  a	  strong	  signal	  
in	  the	  first	  elution	  fraction.	  This	  complex	  could	  almost	  not	  be	  discerned	  from	  the	  background	  signals,	  
when	   looking	   at	   the	   lysate	   fraction.	   Taken	   together,	   Twin-­‐Strep-­‐mFA2H	   and	   some	   of	   crosslinked	  
proteins	  could	  be	  purified	  by	  StrepTactin-­‐affinity	  purification.	  
4.2.3 Determination	  of	  FA2H-­‐protein	  complex	  constituents	  
With	  the	  existence	  of	  a	  FA2H-­‐containing	  protein	  complex	  proven,	  the	  next	  step	  was	  to	  elucidate	  its	  
composition.	   Therefore,	   two	  mass	   spectrometry	   based	   screening	   approaches	   were	   applied,	   Twin-­‐
StrepTag	   pulldown	   and	   BioID	   (in-­‐vivo	   protein	   biotinylation).	   In	   both	   approaches,	   FA2H	   and	  
interacting	  proteins	  were	  first	  enriched	  by	  an	  affinity	  purification	  step.	  The	  identity	  of	  putative	  FA2H-­‐
interacting	  proteins	  was	  then	  revealed	  by	  mass	  spectrometry	  using	  a	  high	  resolution	  Orbitrap	  Velos	  
mass	  spectrometer.	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4.2.3.1 SILAC	  Twin-­‐StrepTag	  pulldown	  &	  MS-­‐analysis	  	  
For	  the	  first	  approach,	  StrepTactin-­‐affinity	  purification	  was	  used	  in	  combination	  with	  stable	   isotope	  
labeling	  of	  cells	   (SILAC).	   In	  SILAC,	  all	  proteins	  of	  a	  cell	  are	  metabolically	   labeled	  with	   light	  or	  heavy	  
amino	   acids	   containing	   light	   or	   heavy	   isotopes.	   This	   permits	   robust	   relative	   protein	   quantification	  
between	   the	   differentially	   labeled	   cells	   by	   mass	   spectrometry.	   The	   combination	   of	   SILAC	   with	  
immunoprecipitation	  or	  affinity	  purification,	  also	  called	  SILAC	  IP	  (see	  review	  by	  Ong	  &	  Mann	  (Ong	  &	  
Mann	  2005)),	  then	  helps	  to	   identify	  real	   interacting	  proteins	  and	  distinguishing	  them	  from	  proteins	  
binding	  unspecifically	  to	  the	  affinity	  matrix	  (Figure	  4-­‐26A).	  Hence,	  an	  empty	  control	  plasmid	  and	  one	  
coding	   for	   the	   bait	   protein	   (for	   example:	   Twin-­‐Strep-­‐mFA2H)	   are	   transfected	   in	   differently	  
isotopically	   labeled	  cells.	  After	  1	  –	  2	  days	  of	   transgene	  expression,	  both	  cell	   types	  are	  subjected	  to	  
lysis	  and	  protein	  determination.	  Then	  both	  lysates	  are	  mixed	  at	  a	  1:1	  protein	  ratio	  and	  StrepTactin-­‐
affinity	  purification	  is	  performed.	  Afterwards,	  the	  proteins	  in	  the	  eluate	  are	  enzymatically	  digested	  to	  
peptides,	   allowing	   their	   identification	   and	   quantification	   by	   mass	   spectrometry.	   The	   quantitative	  
information	   now	   directly	   allows	   separating	   proteins	   binding	   unspecifically	   to	   the	   affinity	   matrix	  
(background)	   from	   interacting	   proteins.	  While	   background	   proteins,	   contributed	   by	   both	   samples,	  
will	  exhibit	  heavy	  and	  light	  peptide	  signals	  of	  equal	  intensity,	  selectively	  enriched	  interacting	  proteins	  
will	  have	  significantly	  larger	  heavy	  peptide	  signals.	  
	  







Figure	   4-­‐26:	   SILAC-­‐IP.	   (A)	   General	   overview	   of	   SILAC-­‐IP	   procedure.	   Control	   and	   bait-­‐coding	   plasmids	   are	  
transfected	  into	  cells	  labeled	  with	  light	  or	  heavy	  SILAC-­‐medium.	  After	  protein	  expression,	  cells	  are	  lysed,	  their	  
protein	  amount	  determined	  and	  the	   lysates	  mixed	  at	  a	  1:1	   ratio.	  Subsequently,	   immunoprecipitation/affinity	  
purification	   of	   the	   bait	   protein	   is	   performed	   followed	   by	   protein	   digestion	   and	   LC-­‐MS/MS	   analysis.	   While	  
peptides	  derived	  from	  unspecific	  binding	  proteins	  exhibit	  equal	  light	  and	  heavy	  intensities,	  specific	  interaction	  
partners	   are	   identifiable	   by	   higher	   intensities	   for	   the	   heavy	   peptides.	   (B)	   Schematic	   workflow	   of	   PFA-­‐
crosslinking	   assisted	   IP.	   Cells	   expressing	   the	   bait	   protein	   of	   interest	   are	   treated	   with	   formaldehyde/PFA	  
chemically	  crosslinking	  proteins	  in	  close	  vicinity	  of	  each	  other.	  Afterwards,	  the	  cells	  are	  lysed	  and	  subjected	  to	  
immunoprecipitation	  or	  affinity	  purification	  of	  the	  bait	  protein.	  During	  subsequent	  washing	  steps	  not	  binding	  
proteins	   are	   washed	   away.	   Then	   the	   protein	   with	   its	   crosslinked	   partners	   is	   eluted.	   After	   removing	   the	  
crosslinks	  by	  heating	  and	  protein	  digestion,	  the	  complex	  constituents	  can	  be	  identified	  by	  mass	  spectrometry.	  
In	  a	  variation	  of	  this	  method	  an	  additional	  PFA-­‐crosslinking	  step	  (Vasilescu	  et	  al.	  2004;	  Klockenbusch	  
&	  Kast	  2010)	  is	  added	  before	  cell	   lysis	  (Figure	  4-­‐26B).	  Hence,	  proteins,	  which	  are	  in	  close	  vicinity	  of	  
each	  other,	  are	  covalently	   linked.	  On	  the	  one	  hand	  this	  facilitates	  the	  identification	  of	  medium	  and	  
weak	  interactors,	  which	  are	  normally	  lost	  during	  the	  washing	  steps	  of	  the	  affinity	  purification.	  On	  the	  
other	  hand	  this	  also	  inevitably	  increases	  the	  number	  of	  false	  positive	  identifications,	  due	  to	  proteins	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indirect	   interactions,	   i.e.	  ones	  facilitated	  by	  one	  ore	  more	  additional	  proteins,	  will	  also	  be	  captured	  
by	   this	  method.	  But	   these	  disadvantages	  of	  PFA-­‐crosslinking	  have	  to	  be	  accepted,	   if	  also	  weak	  and	  
transient	  interactors	  should	  be	  identified.	  Moreover,	  since	  most	  random	  interactions	  should	  happen	  
at	  low	  rates,	  a	  high	  H/L-­‐ratio	  should	  help	  to	  distinguish	  them	  from	  true	  interactors	  at	  least	  partially.	  	  
4.2.3.1.1 Twin-­‐Strep	  pulldown	  of	  transiently-­‐overexpressed	  mFA2H	  
For	   the	   first	   SILAC	  Twin-­‐StrepTag	  pulldown	  experiment	   (Figure	  4-­‐27A),	  HEK293-­‐T	   cells	   labeled	  with	  
light	  or	  heavy	  SILAC-­‐medium,	  were	  transiently	  transfected	  with	  an	  empty	  control	  vector	  (pcDNA3)	  or	  
with	  Twin-­‐Strep-­‐mFA2H	  (pESG-­‐IBA105-­‐mFA2H)	  and	  grown	  for	  48	  h.	  Afterwards,	  the	  cells	  were	  lysed,	  
StrepTactin-­‐affinity	   purification	   performed	   and	   the	   samples	   processed	   for	   the	   subsequent	   mass	  
spectrometric	   analysis.	   Finally,	   the	   mass	   spectrometric	   data	   were	   analyzed	   by	   MaxQuant	   and	  
Perseus.	  While	  MaxQuant	  was	  used	   for	  protein	   identification	  and	  quantification,	  Perseus	  was	  used	  
for	   the	   following	   statistical	   analysis	   including	   a	   one-­‐sample	   t-­‐test	   (different	   from	   0)	   and	   the	  
generation	  of	  a	  Volcano	  plot.	  The	  results	  are	  depicted	  in	  Figure	  4-­‐27B	  and	  Table	  4-­‐5.	  Moreover,	  the	  
MS	  raw	  data	  and	  the	  unprocessed	  as	  well	  as	   the	  processed	  MaxQuant	  result	   files	  can	  be	   found	  on	  
the	  DVD	  accompanying	  this	  thesis.	  Note	  again	  that	  MaxQuant	  did	  not	  present	  the	  identifications	  as	  





Light (L) Heavy (H) 
+ctrl +Twin-Strep- 
mFA2H 
Cell lysis & protein determination 
Mix L & H      lysates 1:1 
StrepTag-affinity purification  
1D SDS-PAGE separation 
LC-MS/MS  
Gel lane fractionation & tryptic digestion 






















-2 0 2 4
log2 fold change
4	  Results	  -­‐	  Identification	  of	  FA2H	  interaction	  partners	  
	  
104	  
Figure	  4-­‐27:	  Twin-­‐Strep-­‐mFA2H	  interaction	  partner	  analysis	  after	  overexpression	  in	  HEK293-­‐T	  cells.	  	  
(A)	  Workflow	  diagram	  illustrating	  the	  assay	  procedure.	  Twelve	  15	  cm	  dishes	  of	  HEK293-­‐T	  cells	  (6x	  light	  and	  6x	  
heavy	   SILAC-­‐labeled)	  were	   transiently	   transfected	  with	   either	   empty	   control	   (pcDNA3)	  or	   Twin-­‐Strep-­‐mFA2H	  
vector	  (pESG-­‐IBA105-­‐mFA2H).	  After	  48	  h,	  cells	  were	  harvested,	  thereby	  pooling	  two	  dishes	  of	  equally	   labeled	  
and	  transfected	  cells.	  The	  cells	  were	  lysed	  in	  StrepTag-­‐lysis	  buffer	  followed	  by	  protein	  amount	  determination.	  
Subsequently	  each	  empty	  vector-­‐lysate	  was	  mixed	  with	  a	  differentially	   labeled	  Twin-­‐Strep-­‐mFA2H	   lysate	  at	  a	  
protein	  ratio	  of	  1:1.	  The	  resulting	  three	  replicates	  were	  then	  subjected	  to	  StrepTactin-­‐affinity	  purification.	  The	  
resulting	  eluates	  of	   each	  purification	  were	  pooled,	   concentrated	  by	  CHCl3/MeOH-­‐precipitation,	   separated	  by	  
SDS-­‐PAGE	   and	   Coomassie-­‐stained.	   Thereafter,	   the	   complete	   protein	   lane	   of	   each	   replicate	   was	   cut	   into	  
fractions	  of	  equal	  protein	  amount	  and	  processed	  by	  tryptic	  in-­‐gel	  digestion.	  Finally,	  the	  resulting	  peptides	  were	  
cleaned	   using	   StageTips	   and	   analyzed	   by	   LC-­‐MS/MS.	   This	   was	   followed	   by	   protein	   identification	   (human	  
Uniprot	   database	   +mFA2H),	   quantification	   and	   ratio-­‐normalization	   by	   MaxQuant	   and	   statistical	   evaluation	  
using	  Perseus.	  (B)	  Volcano	  plot	  of	  all	  protein	  groups	  identified	  and	  quantified	  in	  at	  least	  two	  replicates.	  After	  
a	  one-­‐sample	  t-­‐test	  against	  0,	  the	  resulting	  –log10-­‐transformed	  p-­‐values	  (-­‐log10	  p-­‐value)	  of	  each	  protein	  group	  
were	  plotted	  against	  their	  log2-­‐transformed	  average	  H/L-­‐ratio	  (log2	  fold	  change).	  Significantly	  enriched	  protein	  
groups	  having	  a	   log2	  fold	  change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  and	  –log10	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  0.05)	  are	  
highlighted	  in	  red.	  	  
Overall,	   716	   protein	   groups	   were	   identified	   and	   quantified	   in	   at	   least	   two	   replicates	   (Complete	  
protein	  list	  can	  be	  found	  on	  the	  accompanying	  DVD).	  After	  performing	  a	  one-­‐sample	  t-­‐test	  they	  can	  
be	  depicted	  in	  a	  volcano	  plot	  (Figure	  4-­‐27B),	  comparing	  the	  log2-­‐transformed	  average	  H/L-­‐ratio	  (log2	  
fold	  change)	  of	  each	   identified	  and	  quantified	  protein	  group	  with	   its	  –log10-­‐transformed	  p-­‐value	   (-­‐
log10	  p-­‐value).	  This	  plot	  is	  a	  frequently	  used	  method	  to	  visualize	  the	  results	  of	  an	  interaction	  partner	  
search.	  Protein	  groups	  enriched	   in	   the	  bait-­‐containing	   sample	   should	  have	  a	  high	   log2	   fold	   change	  
(=enrichment)	  in	  combination	  with	  a	  large	  –log10	  p-­‐value	  (=significance),	  therefore	  appearing	  in	  the	  
upper	  right	  part	  of	  the	  plot.	  In	  contrast,	  background	  proteins	  contributed	  by	  both	  samples	  (control	  &	  
bait)	   should	   cluster	   around	   a	   log2	   fold	   change	   of	   0.	   In	   all	   SILAC-­‐IP	   experiments	   presented	   in	   this	  
thesis	   the	   thresholds	   for	   a	   protein	   group	   to	   be	   considered	   significantly	   enriched	   were:	   log2	   fold	  
change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  and	  –log10	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  0.05)	  	  
As	  becomes	  evident	  for	  this	  pulldown	  analysis,	  only	  three	  protein	  groups,	  containing	  FA2H	  and	  two	  
proteasomal	  proteins,	  26S	  proteasome	  non-­‐ATPase	  regulatory	  subunit	  2	  (PSMD2)	  and	  26S	  protease	  
regulatory	  subunit	  10B	   (PSMC6),	  passed	   the	  criteria	   for	   significant	  enrichment.	  The	  majority	  of	   the	  
proteins	  clustered	  around	  the	  y-­‐axis,	  having	  only	  a	  low	  level	  of	  enrichment.	  Also	  when	  looking	  at	  all	  
protein	   groups	   with	   a	   log2	   fold	   change	   ≥	   0.585	   (see	   Table	   4-­‐5),	   the	   number	   of	   potential	   FA2H	  
interaction	  partners	  did	  not	  increase	  drastically.	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Table	   4-­‐5:	   Protein	   groups	   significantly	   enriched	   in	   Twin-­‐Strep-­‐mFA2H-­‐containing	   samples	   after	   pulldown	  
from	  transiently	  transfected	  HEK293-­‐T	  cells.	  Shown	  are	  all	  protein	  groups	  identified	  with	  a	  log2	  fold	  change	  ≥	  
0.585.	   The	   protein	   groups	   are	   given	   by	   their	   corresponding	   gene	   name	   and	   sorted	   by	   their	   –log10	   p-­‐value.	  
Groups	  associated	  with	  protein	  quality	  control	  processes	  are	  highlighted	  in	  red.	  	  








1	   Fa2h	   4.4894	   2.0110	   8	   SMARCA4;SMARCA2	   0.7752	   0.3034	  
2	   PSMD2	   0.6296	   1.9286	   9	   TOP2A	   1.1422	   0.0000	  
3	   PSMC6	   0.6266	   1.3054	   10	   AIFM1	   1.1391	   0.0000	  
4	   HAX1	   0.8132	   1.0709	   11	   BAG2	   0.8654	   0.0000	  
5	   UBB;RPS27A;UBC;UBA52;UBBP4	   1.3620	   1.0696	   12	   SEC24A	   0.7250	   0.0000	  
6	   ESYT1	   0.7239	   0.9522	   13	   CACYBP	   0.6805	   0.0000	  
7	   TFRC	   1.5195	   0.5825	   	   	   	   	  
	   	   	   	   	   	   	   	   	  
Considering	  protein	   groups	  with	   lower	  p-­‐values	  only	   slightly	   extended	   the	   list.	   The	   largest	   amount	  
(6/13	   ≈	   46%)	   of	   protein	   groups,	   like	   ubiquitin	   or	   the	   above	  mentioned	   proteasomal	   subunits,	   are	  
involved	   in	   protein	   quality	   control	   processes.	   In	   general,	   finding	   such	   proteins	   is	   not	   unexpected,	  
since	  most	   cellular	   proteins	   have	   a	   limited	   lifetime	   and	   are	   subjected	   to	   normal	   cellular	   turnover	  
mechanims.	   Still,	   the	   large	   amount	   of	   these	   proteins	   may	   argue	   for	   an	   artificial	   effect	   caused	   by	  
FA2H’s	  overexpression.	  According	  to	  this,	  the	  majority	  of	  the	  overexpressed	  Twin-­‐Strep-­‐mFA2H	  was	  
ubiquitinated,	  exported	  from	  the	  ER	  and	  afterwards	  degraded	  by	  the	  proteasome.	  This	  in	  turn	  then	  
might	  have	  impeded	  the	  identification	  of	  other	  proteins	  associated	  with	  FA2H.	  	  
4.2.3.1.2 PFA-­‐assisted	  Twin-­‐Strep	  pulldown	  of	  transiently-­‐overexpressed	  mFA2H	  
As	   mentioned	   above,	   PFA-­‐crosslinking	   can	   help	   to	   identify	   weak	   and	   transient	   interactions.	  
Therefore,	  the	  assay	  was	  also	  done	  with	  the	  inclusion	  of	  an	  additional	  PFA-­‐crosslinking	  step	  between	  
cell	  harvesting	  and	  lysis.	  In	  addition,	  since	  the	  crosslinking	  should	  preserve	  and	  strengthen	  even	  weak	  
protein-­‐protein	  interactions,	  a	  more	  stringent	  washing	  and	  elution	  buffer	  (RIPA)	  was	  used.	  Finally,	  a	  
decrosslinking-­‐step	   had	   to	   be	   included	   after	   elution	   to	   remove	   the	   PFA-­‐derived	   covalent	   protein-­‐
protein	   bridges.	   The	   results	   obtained	   after	   subsequent	   processing	   with	   MaxQuant,	   Perseus	   and	  
GOrilla	  are	  depicted	  in	  Figure	  4-­‐28B,	  Table	  4-­‐6,	  Table	  4-­‐7	  and	  Table	  4-­‐8.	  
	   	  







Figure	  4-­‐28:	  PFA-­‐assisted	  Twin-­‐Strep-­‐mFA2H	  interaction	  partner	  analysis	  after	  overexpression.	  	  
(A)	  Workflow	  of	  the	  performed	  analysis.	  Twelve	  15	  cm	  dishes	  of	  HEK293-­‐T	  cells	  (6x	  light	  and	  6x	  heavy	  SILAC-­‐
labeled)	  were	  transiently	  transfected	  with	  either	  empty	  control	  (pcDNA3)	  or	  Twin-­‐Strep-­‐mFA2H	  vector	  (pESG-­‐
IBA105-­‐mFA2H).	  After	  48	  h,	  the	  cells	  were	  harvested	  thereby	  always	  pooling	  two	  dishes	  of	  equally	  labeled	  and	  
transfected	   cells.	   Then	   all	   six	   cell	   pellets	   were	   fixed	   for	   20	   min	   with	   0.5%	   PFA	   at	   room	   temperature.	   The	  
fixations	  were	  stopped	  by	  the	  addition	  of	  ice-­‐cold	  1.25	  M	  glycine	  solution.	  Subsequently,	  each	  pellet	  was	  lysed	  
in	  RIPA	  buffer	  followed	  by	  protein	  amount	  determination.	  Thereafter,	  each	  light-­‐labeled	  lysate	  was	  mixed	  with	  
one	  heavy-­‐labeled	  lysate	  at	  a	  protein	  ratio	  of	  1:1.	  The	  resulting	  three	  replicates	  were	  subsequently	  subjected	  to	  
StrepTactin-­‐affinity	   purification	   using	   RIPA-­‐buffer.	   The	   eluate	   fractions	   of	   each	   purification	   were	   pooled,	  
concentrated	  by	  CHCl3/MeOH-­‐precipitation,	   resuspended	  and	   reduced	   in	   2X	   Laemmli	   buffer	   (95	   °C,	   10	  min),	  
separated	  by	  SDS-­‐PAGE	  and	  Coomassie-­‐stained.	  Then	  the	  complete	  protein	  lane	  of	  each	  replicate	  was	  cut	  into	  
fractions	  of	  equal	  protein	  amount	  and	  processed	  by	  tryptic	  in-­‐gel	  digestion.	  In	  the	  end,	  the	  resulting	  peptides	  
were	  cleaned	  using	  StageTips	  and	  analyzed	  by	  LC-­‐MS/MS,	   followed	  by	  protein	   identification	   (human	  Uniprot	  
database	  +mFA2H),	  quantification	  and	  ratio-­‐normalization	  by	  MaxQuant.	  Finally,	   the	  resulting	  protein	  groups	  
were	   statistically	   evaluated	  with	   Perseus	   and	  GOrilla.	   (B)	  Volcano	   plot	   of	   all	   protein	   groups	   identified	   and	  
quantified	  in	  at	  least	  two	  replicates.	  After	  performing	  a	  one-­‐sided	  t-­‐test	  against	  0,	  the	  resulting	  –log	  p-­‐values	  
of	   each	   protein	   group	   were	   plotted	   against	   their	   log2-­‐transformed	   average	   H/L-­‐ratio	   (log2	   fold	   change).	  
Significantly	  enriched	  protein	  groups	  having	  a	  log2	  fold	  change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  and	  –log10	  p-­‐value	  >	  
1.301	  (p-­‐value	  <	  0.05)	  are	  highlighted	  in	  red.	  
In	   this	   analysis	  840	  protein	  groups	   could	  be	   identified	  and	  quantified	   in	  at	   least	   two	   replicates.	  Of	  
these	  125	  exhibited	  a	   log2	  fold	  change	  ≥	  0.585	  together	  with	  a	  good	  level	  of	  confidence	  (–log10	  p-­‐
value	  >	  1.301).	  These	  protein	  groups	  sorted	  by	  their	  log2	  fold	  change	  are	  given	  in	  Table	  4-­‐6.	  For	  the	  
complete	  protein	  group	  list	  consult	  the	  supplemental	  DVD.	  	  	  
Light (L) Heavy (H) 
+ctrl +Twin-Strep- 
mFA2H 
Cell lysis & protein determination 
Mix L & H      lysates 1:1 
StrepTag-affinity purification  
1D SDS-PAGE (de-crosslinking by heating) 
LC-MS/MS  
Gel lane fractionation & tryptic digestion 
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Table	   4-­‐6:	   Protein	   groups	   significantly	   enriched	   in	   Twin-­‐Strep-­‐mFA2H-­‐containing	   samples	   after	   pulldown	  
from	  transiently	  transfected	  and	  PFA-­‐crosslinked	  HEK293-­‐T	  cells.	  Shown	  are	  all	  protein	  groups	  identified	  in	  at	  
least	  two	  replicates	  with	  a	  log2	  fold	  change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  and	  –log10	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  
0.05).	   Protein	   groups	   are	   given	   by	   their	   respective	   gene	   names	   and	   sorted	   by	   their	   log2	   fold	   change	   in	  
descending	  order.	  Proteins	  groups	  associated	  with	  protein	  quality	  control	  processes	  are	  highlighted	  in	  red	  and	  
with	  (sphingo-­‐)lipid	  metabolism	  in	  bold.	  	  








1	   Fa2h	   5.4958	   5.4827	   64	   TMPO	   1.6111	   2.3139	  
2	   UBB;RPS27A;UBC;UBA
52;UBBP4	  
3.3651	   2.8557	   65	   TOR1AIP1	   1.5902	   2.2823	  
3	   LRRC59	   3.1670	   2.7849	   66	   RPN2	   1.5854	   2.5481	  
4	   ERLIN2	   3.1417	   3.2035	   67	   RAB8A;RAB8B;RAB13	   1.5479	   2.4963	  
5	   GOLGA2	   3.0727	   3.0404	   68	   COPA	   1.5385	   1.8321	  
6	   EMC2	   3.0275	   2.6455	   69	   CAPZA1	   1.5359	   1.5248	  
7	   OSBPL8	   2.9854	   1.6175	   70	   RAB1A	   1.5202	   3.0729	  
8	   SRPRB	   2.9262	   2.9514	   71	   RAB14	   1.4368	   2.1397	  
9	   ESYT1	   2.8924	   2.7621	   72	   RAB2A	   1.4226	   1.6727	  
10	   CKAP4	   2.8293	   3.8363	   73	   CYB5R3	   1.4125	   2.0875	  
11	   STIM1	   2.8183	   2.1622	   74	   TMEM109	   1.3949	   1.8409	  
12	   SEC22B	   2.7978	   2.4560	   75	   RAB1B;RAB1C	   1.3735	   2.7733	  
13	   SPTLC1	   2.7454	   3.0873	   76	   DNAJA1	   1.3480	   2.8504	  
14	   SPTLC2	   2.7327	   2.7170	   77	   NCLN	   1.3230	   2.4832	  
15	   STX18	   2.7006	   1.3384	   78	   HSD17B12	   1.2913	   2.4890	  
16	   KTN1	   2.6016	   1.4226	   79	   TMED1	   1.2727	   1.8053	  
17	   ERLIN1	   2.6010	   2.8339	   80	   DPM1	   1.2242	   3.0326	  
18	   POR	   2.5668	   2.6340	   81	   HSPA8	   1.2225	   1.9162	  
19	   HMOX2	   2.4849	   1.7230	   82	   HSPA6;HSPA7	   1.2177	   2.6754	  
20	   RPN1	   2.4811	   3.7498	   83	   RAB11B;RAB11A	   1.2144	   2.1319	  
21	   CCDC47	   2.4724	   2.8743	   84	   RAB5C	   1.1743	   2.1232	  
22	   MIA3	   2.4404	   2.9753	   85	   SND1	   1.1323	   2.6438	  
23	   BCAP31	   2.4400	   2.1806	   86	   PDIA3	   1.1079	   2.0923	  
24	   ATP2A2	   2.3959	   3.2260	   87	   HSPA5	   1.0890	   2.1675	  
25	   VAPA	   2.3748	   2.9680	   88	   PCYOX1	   1.0887	   1.3520	  
26	   SLC27A4	   2.3607	   2.8470	   89	   PPIB	   1.0821	   1.6068	  
27	   VAPB	   2.3508	   2.5712	   90	   SURF4	   1.0770	   2.3657	  
28	   SACM1L	   2.3110	   2.1876	   91	   TOLLIP	   1.0373	   1.4804	  
29	   PTPN1	   2.2487	   1.3647	   92	   PDIA3	   1.0306	   1.9473	  
30	   TMED9	   2.2460	   2.3799	   93	   PSMC4	   0.9820	   1.6857	  
31	   ACSL3	   2.2416	   2.0170	   94	   HSD17B7	   0.9531	   2.1170	  
32	   PTRH2	   2.2392	   1.3850	   95	   LBR	   0.9433	   1.6940	  
33	   SPCS2	   2.2144	   1.9552	   96	   PSMD6	   0.9011	   1.7816	  
34	   RDH11	   2.1961	   2.4627	   97	   RPL14	   0.8837	   1.9330	  
35	   TFRC	   2.1897	   2.4552	   98	   PSMD11	   0.8750	   1.5857	  
36	   EPHX1	   2.1857	   2.5343	   99	   PSMD2	   0.8716	   1.4179	  
37	   TMX1	   2.1012	   2.1208	   100	   GNB2;GNB4	   0.8207	   2.4884	  
38	   SDCBP	   2.1001	   2.0992	   101	   ATP1A1;ATP1A3	   0.7979	   2.4411	  
39	   SSR4	   2.0929	   2.5328	   102	   RHOT2	   0.7935	   2.3484	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40	   RAB6A	   2.0774	   2.8583	   103	   DNAJC7	   0.7696	   1.9204	  
41	   NOMO2;NOMO3;NO
MO1	  
2.0330	   1.5703	   104	   RPL7	   0.7626	   2.3759	  
42	   NSDHL	   2.0248	   3.6691	   105	   RPL10A	   0.7216	   2.4374	  
43	   ZW10	   1.9876	   2.3597	   106	   RPL13	   0.6907	   1.4209	  
44	   LMAN1	   1.9858	   1.6262	   107	   AMOT	   0.6845	   1.9892	  
45	   SCFD1	   1.9845	   2.3757	   108	   ATP6V0D1	   0.6785	   1.3905	  
46	   ALDH3A2	   1.9656	   2.8884	   109	   YIPF5	   0.6755	   1.8147	  
47	   NSF	   1.9427	   2.0021	   110	   PDIA4	   0.6744	   1.7131	  
48	   DHCR7	   1.9388	   2.5147	   111	   RPL8	   0.6672	   1.5207	  
49	   PLD3	   1.9272	   1.8886	   112	   HYOU1	   0.6619	   1.6970	  
50	   CANX	   1.9132	   2.3357	   113	   SEC23A	   0.6596	   2.5929	  
51	   DDOST	   1.9121	   3.4491	   114	   PSMC3	   0.6517	   1.3750	  
52	   AAAS	   1.8152	   1.4704	   115	   RPL27	   0.6461	   1.7736	  
53	   PTPLAD1	   1.8122	   2.2742	   116	   NCL	   0.6412	   1.4936	  
54	   VCP	   1.7863	   1.7622	   117	   PSMC5	   0.6398	   1.5693	  
55	   FAF2	   1.7843	   2.4030	   118	   RPLP0;RPLP0P6	   0.6394	   1.6239	  
56	   STT3A	   1.7683	   2.0973	   119	   FLOT1	   0.6289	   1.3431	  
57	   PGRMC1	   1.7594	   2.3419	   120	   PDIA6	   0.6135	   2.0210	  
58	   RAB7A	   1.7463	   2.4234	   121	   ERP29	   0.6106	   1.5141	  
59	   EMD	   1.7331	   2.5587	   122	   DNAJB1	   0.6091	   1.6038	  
60	   NAPA	   1.6985	   2.1838	   123	   P4HB	   0.6009	   2.2157	  
61	   HSPA1A	   1.6758	   2.0928	   124	   PSMC6	   0.5944	   1.6244	  
62	   PGRMC2	   1.6514	   2.7803	   125	   RPL23A	   0.5877	   2.9015	  
63	   APMAP	   1.6203	   2.5128	   	   	   	   	  
	   	   	   	   	   	   	   	   	  
The	   results	   cleary	   showed	   that,	   by	   applying	   PFA-­‐crosslinking,	   the	   number	   of	   significantly	   enriched	  
protein	   groups	   increased	  dramatically	   compared	   to	   the	  pulldown	  without	  PFA.	  125	  protein	   groups	  
presented	  with	  sufficient	  degree	  of	  enrichment	  (log2	  fold	  change	  ≥	  0.585)	  together	  with	  a	  good	  level	  
of	   confidence	   (–log10	   p-­‐value	   >	   1.301).	   Similar	   to	   the	   experiment	   before	   (4.2.3.1.1	   Twin-­‐Strep	  
pulldown	  of	  transiently-­‐overexpressed	  mFA2H),	  a	  significant	  number	  of	  protein	  groups	  were	  general	  
(e.g.	  proteasomal	  subunits,	  chaperones)	  as	  well	  as	  ER-­‐specific	  (e.g.	  ER-­‐associated	  protein	  degradation	  
proteins)	  components	  of	  the	  protein	  quality	  control	  machinery.	   In	  this	  experiment	  they	  constituted	  
about	  22%	  (28	  of	  125)	  of	  all	  putative	  FA2H	  interaction	  partners.	  Since	  the	  expression	  conditions	  were	  
not	   changed,	   this	   was	   expected.	   Nevertheless,	   there	   was	   also	   a	   large	   number	   of	   other	   proteins	  
present	   of	   which	   many	   were	   associated	   with	   lipid	   metabolism	   (highlighted	   in	   bold).	   While	   some	  
protein	   groups	   are	   directly	   involved	   in	   sphingolipid	   metabolism	   (SPTLC1	   and	   SPTLC2	   =	   serine	  
palmitoyl	  transferase	  long	  chain	  1	  and	  2),	  others	  are	  linked	  to	  cholesterol	  metabolism	  (12HSD17B12	  
=	   hydroxysteroid	   17-­‐beta	   dehydrogenase,	   HSD17B7	   =	   hydroxysteroid	   17-­‐beta	   dehydrogenase	   7,	  
DHCR7	  =	   7-­‐dehydrocholesterol	   reductase,	  NSDHL	   =	  NAD(P)	   dependent	   steroid	   dehydrogenase-­‐like,	  
LBR	  =	  lamin	  B	  receptor).	  In	  addition,	  protein	  groups	  were	  present	  linked	  to	  lipid	  transport	  (VAPA/B	  =	  
vesicle-­‐associated	   membrane	   protein-­‐associated	   protein	   A	   and	   B,	   OSBPL8	   =	   oxysterol	   binding	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protein-­‐like	  8,	  SLC27A4	  =	  solute	  carrier	   family	  27	  A4),	  as	  well	  as	   fatty	  acid	  metabolism	   (PTPLAD1	  =	  
protein	  tyrosine	  phosphatase-­‐like	  A	  domain	  containing	  1,	  ALDH3A2	  =	  aldehyde	  dehydrogenase	  3A2,	  
ACSL3	   =	   acyl-­‐CoA	   synthetase	   long-­‐chain	   3).	   Last	   but	   not	   least,	   some	   of	   the	   identified	   proteins	   are	  
regulators	  of	  lipid	  metabolism	  (SACM1L	  =	  SAC1	  suppressor	  of	  actin	  mutations	  1-­‐like)	  or	  phospholipid	  
metabolism	   (PLD3	   =	   phospholipase	   D3).	   There	   were	   also	   two	   reductases	   enriched	   known	   to	   be	  
involved	   in	   lipid	  metabolism	   (POR	  =	  NADPH-­‐cytochrome	  P450	   reductase,	  CYB5R3	  =	   cytochrome	  b5	  
reductase	  3)	  and	  the	  cytb5-­‐containing	  proteins	  progesterone	  receptor	  membrane	  component	  1	  and	  2	  
(PGRMC1	   and	   PGRMC2),	   which	   are	   implicated	   in	   regulating	   the	   activities	   of	   various	   metabolic	  
enzymes.	   In	  addition,	  a	  substantial	  number	  of	  ribosomal	  protein	  groups	  were	  significantly	  enriched	  
as	   well,	   like	   ribosomal	   protein	   L	   (RPL7,	   RPL13,	   and	   RPL14),	   nucleolin	   (NCL)	   and	   signal	   recognition	  
particle	   receptor	  B	   (SRPRB).	  Moreover,	  vesicular	   transport-­‐related	  protein	  groups	  e.g.	  Rab-­‐proteins	  
(RAB7A,	   RAB5C,…),	   Sec-­‐proteins	   SEC22B	   and	   SEC23A,	   coatomer	   protein	   alpha	   (COPA)	   and	   N-­‐
ethylmaleimide-­‐sensitive	  factor	  (NSF)	  also	  showed	  a	  significant	  enrichment.	  
To	   further	   evaluate	   the	   dataset,	   the	   125	   significantly	   enriched	   protein	   groups	   were	   analyzed	   for	  
enrichment	   of	   GO-­‐terms	   (GeneOntology)	   with	   GOrilla	   (Gene	   Ontology	   enRIchment	   anaLysis	   and	  
visuaLizAtion	  tool).	  For	  this	   the	  125	  protein	  groups	   (target	   list)	  were	  compared	  to	  the	  whole	  set	  of	  
840	   identified	  protein	  groups	   (ID	   list).	  The	  “Biological	  Process”	   (BP)	  and	  “Cellular	  Component”	   (CC)	  
categories	   of	   GO-­‐terms	   were	   assessed	   separately.	   As	   identifiers	   for	   the	   GOrilla	   analysis	   the	   first	  
major	  gene	  name	  of	  each	  protein	  group	  was	  used.	  The	  output	  of	  both	  enrichment	  analyses	  is	  given	  in	  
tables	   (Table	   4-­‐7,	   Table	   4-­‐8),	   containing	   the	   enriched	   GO-­‐terms	   sorted	   by	   their	   significance	   of	  
enrichment	   (p-­‐value),	   which	   were	   calculated	   by	   hypergeometric	   testing	   (see	   3.2.4.14.2.2	   GOrilla).	  
Note	   that	   entries	  with	   p-­‐values	   >	   0.001	  were	   filtered	   out.	   Tables	   comprising	   the	   complete	  GOrilla	  
results,	   including	   false-­‐discovery	   rate-­‐corrected	   p-­‐values	   (FDR	   q),	   enrichments	   factors	   and	   the	  
protein	   groups	   contributing	   to	   each	   GO-­‐term,	   can	   be	   found	   on	   the	   accompanying	   DVD.	   Table	   4-­‐7	  
gives	  the	  results	  for	  the	  “Biological	  Process”	  GO-­‐category.	  
Table	  4-­‐7:	  “Biological	  Process”	  GO-­‐enrichment	  analysis	  results	  for	  protein	  groups	  significantly	  enriched	  after	  
Twin-­‐Strep-­‐mFA2H	  pulldown	   from	  PFA-­‐treated	  HEK293-­‐T	   cells.	  The	  set	  of	  125	  significantly	  enriched	  protein	  
groups	  (target	  list)	  was	  analyzed	  for	  GO-­‐term	  enrichment	  by	  comparing	  it	  with	  the	  whole	  set	  of	  identified	  840	  
protein	   groups	   (ID	   list)	   using	   GOrilla.	   As	   identifier	   the	   first	   major	   gene	   name	   for	   each	   protein	   group	   was	  
imputed	   into	   GOrilla.	   GOrilla	   could	   assign	   terms	   to	   123	   (of	   125)	   and	   833	   (of	   840)	   gene	   names.	   Each	   terms	  
degree	  of	  enrichment	  is	  given	  by	  an	  uncorrected	  p-­‐value	  calculated	  by	  hypergeometric	  testing.	  The	  list	  is	  sorted	  
by	  p-­‐values	  in	  ascending	  order.	  Entries	  with	  p-­‐values	  >	  0.001	  were	  filtered	  out.	  
GO	  Term	   Description	   P-­‐value	  
GO:0015031	   protein	  transport	   3.07E-­‐08	  
GO:0045184	   establishment	  of	  protein	  localization	   1.07E-­‐07	  
GO:0016192	   vesicle-­‐mediated	  transport	   1.66E-­‐07	  
GO:0007165	   signal	  transduction	   1.02E-­‐06	  
GO:0071702	   organic	  substance	  transport	   2.07E-­‐06	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GO:0018196	   peptidyl-­‐asparagine	  modification	   2.10E-­‐06	  
GO:0018279	   protein	  N-­‐linked	  glycosylation	  via	  asparagine	   2.10E-­‐06	  
GO:0006487	   protein	  N-­‐linked	  glycosylation	   2.10E-­‐06	  
GO:0034976	   response	  to	  endoplasmic	  reticulum	  stress	   5.21E-­‐06	  
GO:0050789	   regulation	  of	  biological	  process	   5.41E-­‐06	  
GO:0035556	   intracellular	  signal	  transduction	   6.05E-­‐06	  
GO:0050794	   regulation	  of	  cellular	  process	   6.81E-­‐06	  
GO:0048193	   Golgi	  vesicle	  transport	   7.55E-­‐06	  
GO:0044765	   single-­‐organism	  transport	   7.82E-­‐06	  
GO:0051649	   establishment	  of	  localization	  in	  cell	   8.92E-­‐06	  
GO:0006810	   transport	   1.04E-­‐05	  
GO:0050896	   response	  to	  stimulus	   1.26E-­‐05	  
GO:0065007	   biological	  regulation	   1.27E-­‐05	  
GO:0006486	   protein	  glycosylation	   1.29E-­‐05	  
GO:0043413	   macromolecule	  glycosylation	   1.29E-­‐05	  
GO:0070085	   glycosylation	   1.29E-­‐05	  
GO:0051234	   establishment	  of	  localization	   1.88E-­‐05	  
GO:0006888	   ER	  to	  Golgi	  vesicle-­‐mediated	  transport	   2.06E-­‐05	  
GO:0043687	   post-­‐translational	  protein	  modification	   2.66E-­‐05	  
GO:0007264	   small	  GTPase	  mediated	  signal	  transduction	   2.80E-­‐05	  
GO:0006984	   ER-­‐nucleus	  signaling	  pathway	   5.38E-­‐05	  
GO:0046907	   intracellular	  transport	   5.46E-­‐05	  
GO:0008610	   lipid	  biosynthetic	  process	   5.57E-­‐05	  
GO:0051716	   cellular	  response	  to	  stimulus	   5.70E-­‐05	  
GO:0006986	   response	  to	  unfolded	  protein	   7.26E-­‐05	  
GO:0035966	   response	  to	  topologically	  incorrect	  protein	   7.26E-­‐05	  
GO:1902582	   single-­‐organism	  intracellular	  transport	   9.44E-­‐05	  
GO:0046165	   alcohol	  biosynthetic	  process	   1.07E-­‐04	  
GO:0030163	   protein	  catabolic	  process	   1.12E-­‐04	  
GO:0018193	   peptidyl-­‐amino	  acid	  modification	   1.18E-­‐04	  
GO:0016482	   cytoplasmic	  transport	   1.22E-­‐04	  
GO:0002474	   antigen	  processing	  and	  presentation	  of	  peptide	  
antigen	  via	  MHC	  class	  I	  
1.57E-­‐04	  
GO:0019941	   modification-­‐dependent	  protein	  catabolic	  process	   1.69E-­‐04	  
GO:0006066	   alcohol	  metabolic	  process	   1.74E-­‐04	  
GO:0010498	   proteasomal	  protein	  catabolic	  process	   2.40E-­‐04	  
GO:0043161	   proteasome-­‐mediated	  ubiquitin-­‐dependent	  protein	  
catabolic	  process	  
2.40E-­‐04	  
GO:0019882	   antigen	  processing	  and	  presentation	   2.45E-­‐04	  
GO:0043632	   modification-­‐dependent	  macromolecule	  catabolic	  
process	  
2.49E-­‐04	  
GO:0006695	   cholesterol	  biosynthetic	  process	   3.46E-­‐04	  
GO:0046467	   membrane	  lipid	  biosynthetic	  process	   3.46E-­‐04	  
GO:0006511	   ubiquitin-­‐dependent	  protein	  catabolic	  process	   3.59E-­‐04	  
GO:0048002	   antigen	  processing	  and	  presentation	  of	  peptide	  
antigen	  
3.59E-­‐04	  
GO:0051603	   proteolysis	  involved	  in	  cellular	  protein	  catabolic	  
process	  
3.59E-­‐04	  
GO:0031401	   positive	  regulation	  of	  protein	  modification	  process	   6.86E-­‐04	  
GO:0019725	   cellular	  homeostasis	   7.08E-­‐04	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GO:0002478	   antigen	  processing	  and	  presentation	  of	  exogenous	  
peptide	  antigen	  
7.46E-­‐04	  
GO:0019884	   antigen	  processing	  and	  presentation	  of	  exogenous	  
antigen	  
7.46E-­‐04	  
GO:0034620	   cellular	  response	  to	  unfolded	  protein	   8.30E-­‐04	  
GO:0030968	   endoplasmic	  reticulum	  unfolded	  protein	  response	   8.30E-­‐04	  
GO:0035967	   cellular	  response	  to	  topologically	  incorrect	  protein	   8.30E-­‐04	  
GO:0048518	   positive	  regulation	  of	  biological	  process	   9.00E-­‐04	  
	  
Gorilla	  could	  assign	  GO-­‐terms	  for	  833	  of	  the	  840	  imputed	  gene	  names	  on	  the	  ID-­‐list	  and	  for	  123	  of	  
the	  125	  on	  the	  target	  list.	  The	  following	  enrichment-­‐analysis	  revealed	  a	  couple	  of	  things.	  Regarding	  
the	  “Biological	  Process”–terms,	  it	  became	  obvious	  that	  many	  of	  the	  enriched	  proteins	  are	  associated	  
with	   cellular	   transport	   (GO:0006810	   transport,	   GO:0015031	   protein	   transport,	   GO:0045184	  
establishment	  of	  protein	  localization,	  GO:0016192	  vesicle-­‐mediated	  transport,	  …).	  In	  addition,	  there	  
were	   enriched	   BP-­‐terms	   related	   to	   protein	   quality	   control	   (GO:0006487	   protein	   N-­‐linked	  
glycosylation,	   GO:0034976	   response	   to	   ER	   stress,	   GO:0030968	   ER-­‐unfolded	   protein	   response,	  
GO:0043161	   proteasome-­‐mediated	   ubiquitin-­‐dependent	   protein	   catabolic	   process,	   …).	   This	   was	  
similar	   to	   the	   results	   obtained	   before	   (see	   4.2.3.1.1	   Twin-­‐Strep	   pulldown	   of	   transiently-­‐
overexpressed	  mFA2H).	  FA2H-­‐overexpression	  may	  have	  led	  to	  aggregation	  of	  the	  enzyme	  causing	  an	  
ER	  stress	  response.	  However,	  an	  enrichment	  of	  terms	   linked	  to	   lipid	  metabolism	  (GO:0008610	   lipid	  
biosynthetic	   process,	   GO:0006695	   cholesterol	   biosynthetic	   process,	   GO:0046467	   membrane	   lipid	  
biosynthetic	   process)	   was	   also	   observable,	   showing	   that	   a	   significant	   number	   of	   protein	   groups	  
identified	  in	  this	  experiment	  are	  associated	  with	  lipid	  metabolism.	  	  	  
The	  results	  for	  the	  “Cellular	  Component”	  category	  are	  shown	  in	  Table	  4-­‐8.	  
Table	   4-­‐8:	   “Cellular	   Component”	   GO-­‐enrichment	   analysis	   results	   for	   protein	   groups	   significantly	   enriched	  
after	   Twin-­‐Strep-­‐mFA2H	   pulldown	   from	   PFA-­‐treated	   HEK293-­‐T	   cells.	   The	   set	   of	   125	   significantly	   enriched	  
protein	   groups	   (target	   list)	   was	   analyzed	   for	   GO-­‐term	   enrichment	   by	   comparing	   it	   with	   the	   whole	   set	   of	  
identified	  840	  protein	   groups	   (ID	   list)	   using	  GOrilla.	  As	   identifier	   the	   first	  major	   gene	  name	   for	   each	  protein	  
group	  was	  imputed	  into	  GOrilla.	  GOrilla	  could	  assign	  terms	  to	  123	  (of	  125)	  and	  833	  (of	  840)	  gene	  names.	  Each	  
terms	  degree	  of	  enrichment	  is	  given	  by	  an	  uncorrected	  p-­‐value	  calculated	  by	  hypergeometric	  testing.	  The	  list	  is	  
sorted	  by	  p-­‐values	  in	  ascending	  order.	  Entries	  with	  p-­‐values	  >	  0.001	  were	  filtered	  out.	  
GO	  Term	   Description	   P-­‐value	  
GO:0044432	   endoplasmic	  reticulum	  part	   1.42E-­‐39	  
GO:0005789	   endoplasmic	  reticulum	  membrane	   1.03E-­‐37	  
GO:0098588	   bounding	  membrane	  of	  organelle	   1.61E-­‐36	  
GO:0098589	   membrane	  region	   2.06E-­‐35	  
GO:0016021	   integral	  component	  of	  membrane	   2.95E-­‐23	  
GO:0044425	   membrane	  part	   1.87E-­‐19	  
GO:0031090	   organelle	  membrane	   1.19E-­‐15	  
GO:0005783	   endoplasmic	  reticulum	   3.57E-­‐14	  
GO:0016020	   membrane	   1.05E-­‐13	  
GO:0031410	   cytoplasmic	  vesicle	   1.88E-­‐08	  
GO:0000139	   Golgi	  membrane	   6.40E-­‐08	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GO:0016023	   cytoplasmic	  membrane-­‐bounded	  vesicle	   2.86E-­‐07	  
GO:0044446	   intracellular	  organelle	  part	   3.13E-­‐07	  
GO:0044422	   organelle	  part	   4.22E-­‐07	  
GO:0042470	   melanosome	   1.14E-­‐06	  
GO:0048770	   pigment	  granule	   1.14E-­‐06	  
GO:0044431	   Golgi	  apparatus	  part	   4.34E-­‐06	  
GO:0033116	   endoplasmic	  reticulum-­‐Golgi	  intermediate	  
compartment	  membrane	  
9.26E-­‐06	  
GO:0005811	   lipid	  particle	   2.06E-­‐05	  
GO:0005774	   vacuolar	  membrane	   2.66E-­‐05	  
GO:0005793	   endoplasmic	  reticulum-­‐Golgi	  intermediate	  
compartment	  
1.23E-­‐04	  
GO:0005765	   lysosomal	  membrane	   1.23E-­‐04	  
GO:0008250	   oligosaccharyltransferase	  complex	   4.56E-­‐04	  
GO:0044437	   vacuolar	  part	   6.33E-­‐04	  
GO:0022625	   cytosolic	  large	  ribosomal	  subunit	   8.30E-­‐04	  
	   	   	  
Considering	  the	  “Cellular	  Component”-­‐category,	  a	  very	  strong	  enrichment	  of	  terms	  related	  to	  the	  ER	  
(GO:0044432	   endoplasmic	   reticulum	   part,	   GO:0005789	   endoplasmic	   reticulum	   membrane,	   …),	  
membrane	  or	  membrane-­‐associated	  proteins	  (GO:0098589	  membrane	  region,	  GO:0016021	   integral	  
component	   of	  membrane,	   GO:0044425	  membrane	   part)	   and	   to	   the	   Golgi	   apparatus	   (GO:0000139	  
Golgi	  membrane,	  GO:0044431	  Golgi	  apparatus	  part)	  was	  observable.	  This	  indicated	  that	  most	  of	  the	  
proteins	  co-­‐precipitated	  with	  FA2H	  were	  ER	  or	  Golgi	  or	  associated	  proteins,	  respectively.	  	  
Taken	   together,	   while	   many	   of	   FA2H	   potential	   interaction	   partners	   were	   again	   linked	   to	   protein	  
quality	  control	  processes,	  the	  use	  of	  PFA-­‐crosslinking	  allowed	  the	  identification	  of	  additional	  protein	  
groups.	   However,	   because	   I	   could	   not	   be	   exluded	   that	   the	   transient	   overexpression	   had	   caused	   a	  
cellular	  stress	  response,	  at	   least	   in	  some	  of	   the	  transfected	  cells,	   they	  were	  repeated	  with	  a	  stable	  
cell	  line.	  Furthermore,	  the	  interaction	  with	  quality	  control	  proteins	  might	  impede	  the	  identification	  of	  
less	  abundant	  interaction	  partners	  by	  competing	  with	  their	  binding	  to	  FA2H.	  
4.2.3.1.3 Twin-­‐Strep	  pulldown	  of	  stably	  transfected	  mFA2H	  
The	  assay	  was	  performed	  as	  before	  (see:	  4.2.3.1.1	  Twin-­‐Strep	  pulldown	  of	  transiently-­‐overexpressed	  
mFA2H)	  with	  some	  minor	  changes.	  First,	  HEK293	  stably	  transfected	  with	  Twin-­‐Strep-­‐FA2H	  were	  used,	  
because	  HEK293-­‐T	  cells	  are	  not	  compatible	  with	  stable-­‐transfection.	  Second,	  non-­‐transfected	  and	  not	  
mock-­‐transfected	   HEK293	   cells,	   labeled	   with	   light	   SILAC	   medium,	   were	   used	   as	   control	   samples.	  
Third,	   the	  mixing	  of	  each	   light	  control	  sample	  with	  one	  heavy	  Twin-­‐Strep-­‐mFA2H	  sample	  was	  done	  
one	  step	  later,	  after	  the	  affinity	  purification.	  This	  should	  ensure	  that	  high	  H/L-­‐ratios,	  indicating	  true	  
interactors,	   are	   not	   lost	   due	   to	   protein	   exchanges	   between	   complexes	   from	   differentially	   labeled	  
cells.	  The	  results	  of	  the	  analysis	  are	  depicted	  in	  Figure	  4-­‐29,	  Table	  4-­‐9,	  Table	  4-­‐10	  and	  Table	  4-­‐11.	  







Figure	   4-­‐29:	   Identification	   of	   FA2H	   interaction	   partners	   via	   Twin-­‐Strep-­‐FA2H	   pulldown	   from	   stably	  
transfected	  HEK293.	  
(A)	  Workflow	  diagram	  illustrating	  the	  assay	  procedure.	  HEK293	  cells	  (ctrl.;	  light	  SILAC-­‐labeled)	  and	  of	  HEK293	  
stably	  expressing	  pESG-­‐IBA105-­‐mFA2H	   (+Twin-­‐Strep-­‐mFA2H;	  heavy	  SILAC-­‐labeled)	  were	   seeded	  on	   six	  15	   cm	  
dishes	  each	  and	  grown	  to	  confluency.	  Afterwards,	  they	  were	  harvested,	  thereby	  pooling	  two	  dishes	  of	  equally	  
labeled	   and	   transfected	   cells.	   The	   cells	   were	   lysed	   in	   StrepTag-­‐lysis	   buffer	   followed	   by	   protein	   amount	  
determination.	  Subsequently,	  StrepTactin-­‐affinity	  purification	  was	  performed	  with	  each	  lysate	  separately	  using	  
equal	   protein	   amounts.	   Then	   the	   eluates	   from	   each	   light	   ctrl-­‐sample	  were	   combined	  with	   one	   heavy	   Twin-­‐
Strep-­‐mFA2H	   sample,	   concentrated	   by	   CHCl3/MeOH-­‐precipitation,	   separated	   by	   SDS-­‐PAGE	   and	   Coomassie-­‐
stained.	  Thereafter,	  the	  complete	  protein	  lane	  of	  each	  replicate	  was	  cut	  into	  fractions	  of	  equal	  protein	  amount	  
and	   processed	   by	   tryptic	   in-­‐gel	   digestion.	   Finally,	   the	   resulting	   peptides	   were	   cleaned	   using	   StageTips	   and	  
analyzed	   by	   LC-­‐MS/MS.	   This	   was	   followed	   by	   protein	   identification	   (human	   Uniprot	   database	   +mFA2H),	  
quantification	  and	  ratio-­‐normalization	  by	  MaxQuant	  and	  statistical	  evaluation	  using	  Perseus.	  (B)	  Volcano	  plot	  
of	  all	  protein	  groups	  identified	  and	  quantified	  in	  at	  least	  two	  replicates.	  After	  performing	  a	  one-­‐sample	  t-­‐test	  
against	   0,	   the	   resulting	   –log	   p-­‐values	   of	   each	   protein	   group	   were	   plotted	   against	   their	   log2-­‐transformed	  
average	   H/L-­‐ratio	   (log2	   fold	   change).	   Significantly	   enriched	   protein	   groups	   (log2	   fold	   change	   ≥	   0.585	   (fold	  
change	  ≥	  1.5);	  –log	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  0.05))	  are	  highlighted	  in	  red.	  
In	   this	   analysis	  992	  protein	  groups	   could	  be	   identified	  and	  quantified	   in	  at	   least	   two	   replicates.	  Of	  
these,	  27	  exhibited	  a	  log2	  fold	  change	  ≥	  0.585	  together	  with	  a	  good	  level	  of	  confidence	  (–log	  p-­‐value	  
>	  1.301).	  Note	  that	  the	  unprocessed	  and	  processed	  results	  can	  be	  found	  on	  the	  supplemental	  DVD.	  
	   	  
Light (L) Heavy (H) 
+ctrl +Twin-Strep- 
mFA2H (stable) 
Cell lysis & protein determination 
Mix L & H      eluates 
StrepTag-affinity purification  
(equal protein amounts) 
1D SDS-PAGE separation 
LC-MS/MS  
Gel lane fractionation & tryptic digestion 
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Table	   4-­‐9:	   Protein	   groups	   significantly	   enriched	   after	   pulldown	   from	  HEK293	   cells	   stably	   transfected	  with	  
Twin-­‐Strep-­‐mFA2H.	   Shown	   are	   the	   all	   protein	   groups	   identified	   in	   at	   least	   two	   replicates	   with	   a	   log2	   fold	  
change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  and	  a	  –log10	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  0.05).	  Protein	  groups	  are	  given	  by	  
their	   respective	   gene	   names	   and	   sorted	   by	   their	   log2	   fold	   change	   in	   descending	   order.	   Proteins	   groups	  
associated	  with	  protein	  quality	  control	  processes	  are	  highlighted	  in	  red	  and	  with	  (sphingo-­‐)lipid	  metabolism	  in	  
bold.	  	  










1	   Fa2h	   4.293	   2.520	   15	   ARPC3	   0.846	   1.447	  
2	   MYO1E	   2.468	   2.318	   16	   NOP58	   0.829	   2.148	  
3	   VCP	   1.495	   1.487	   17	   HSPA1A	   0.800	   1.569	  
4	   SNX33	   1.491	   2.136	   18	   AP2A2	   0.766	   1.611	  
5	   PTK7	   1.264	   2.262	   19	   SPTLC1	   0.726	   2.600	  
6	   TFRC	   1.190	   1.939	   20	   WDR67	   0.704	   1.647	  
7	   RACGAP1	   0.984	   1.369	   21	   AP2S1	   0.690	   1.332	  
8	   FXR1	   0.979	   1.423	   22	   NEDD4L	   0.670	   1.572	  
9	   ARPC2	   0.977	   1.608	   23	   CTTN	   0.660	   1.314	  
10	   SSX2IP	   0.977	   1.550	   24	   PELP1	   0.659	   1.642	  
11	   FAF2	   0.918	   1.313	   25	   PEG10	   0.620	   2.122	  
12	   HAX1	   0.886	   1.493	   26	   LAS1L	   0.614	   1.374	  
13	   ARPC1A	   0.877	   1.611	   27	   EPN1	   0.587	   1.668	  
14	   TJP2	   0.866	   1.842	   	   	   	   	  
	   	   	   	   	   	   	   	   	  
Only	   a	   small	   number	   of	   the	   identified	   protein	   groups	   exhibited	   a	   significant	   enrichment	   (log2-­‐fold	  
change	  ≥	  0.585	  and	  –log10	  p-­‐value	  >	  1.301),	  as	  was	  the	  case	  in	  the	  previous	  experiment	  without	  PFA-­‐
crosslinking	  (4.2.3.1.1	  Twin-­‐Strep	  pulldown	  of	  transiently-­‐overexpressed	  mFA2H).	  Again,	  the	  highest	  
enrichment	   was	   seen	   for	   the	   bait	   protein	   FA2H.	   Furthermore,	   there	   was	   one	   co-­‐purification	   of	   a	  
sphingolipid	  metabolism	  enzyme,	  SPTLC1,	  which	  catalyzes	  the	  first	  step	  in	  sphingolipid	  synthesis.	   In	  
addition,	  there	  were	  again	  some	  protein	  groups	  present,	  which	  are	  related	  to	  protein	  quality	  control	  
processes	  (VCP	  =	  valosin	  containing	  protein,	  FAF2	  =	  Fas	  associated	  factor	  family	  member	  2,	  HAX1	  =	  
HCLS1	  associated	  protein	  X-­‐1,	  HSPA1A	  =	  heat	   shock	  70kDa	  protein	  1A,	  NEDD4L	  =	  neural	  precursor	  
cell	   expressed	   developmentally	   down-­‐regulated	   4-­‐like).	   They	  made	   up	   about	   19%	   (5	   of	   27)	   of	   the	  
significantly	  enriched	  protein	  groups.	  
To	   further	   functionally	   assess	   the	   co-­‐purified	   27	   protein	   groups,	   a	   GO-­‐enrichment	   analysis	   was	  
performed	   with	   GOrilla,	   comparing	   them	   to	   the	   whole	   set	   of	   992	   identified	   protein	   groups.	   Each	  
protein	  group’s	  major	  gene	  name	  was	  used	  as	  identifier.	  The	  GO-­‐subcategories	  “Biological	  Process”,	  
“Cellular	   Component”	   and	   “Molecular	   Function”	   were	   analyzed.	   The	   results	   are	   depicted	   in	   Table	  
4-­‐10	   and	   Table	   4-­‐11.	   The	   complete	  GO-­‐term	   result	   tables	   can	  be	   found	  on	   the	   supplemental	   data	  
DVD.	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Table	  4-­‐10:	  “Biological	  Process”	  GO-­‐enrichment	  analysis	  results	  for	  protein	  groups	  significantly	  enriched	  after	  
Twin-­‐Strep-­‐mFA2H	  pulldown	  from	  stably	  transfected	  HEK293	  cells.	  The	  set	  of	  27	  significantly	  enriched	  protein	  
groups	  (target	  list)	  was	  analyzed	  for	  GO-­‐term	  enrichment	  by	  comparing	  it	  with	  the	  whole	  set	  of	  identified	  992	  
protein	   groups	   (ID	   list)	   using	   GOrilla.	   As	   identifier	   the	   first	   major	   gene	   name	   for	   each	   protein	   group	   was	  
imputed	  into	  GOrilla.	  GOrilla	  could	  assign	  terms	  to	  26	  (of	  27)	  and	  963	  (of	  992)	  gene	  names.	  Each	  terms	  degree	  
of	  enrichment	  is	  given	  by	  an	  uncorrected	  p-­‐value	  calculated	  by	  hypergeometric	  testing.	  The	  list	  is	  sorted	  by	  p-­‐
values	  in	  ascending	  order.	  Entries	  with	  p-­‐values	  >	  0.001	  were	  filtered	  out.	  
GO	  Term	   Description	   P-­‐value	  
GO:0006897	   endocytosis	   1.43E-­‐04	  
GO:0043254	   regulation	  of	  protein	  complex	  assembly	   7.33E-­‐04	  
	  
Table	  4-­‐11:	  Molecular	  Function	  GO-­‐enrichment	  analysis	  results	  for	  protein	  groups	  significantly	  enriched	  after	  
Twin-­‐Strep-­‐mFA2H	  pulldown	  from	  stably	  transfected	  HEK293	  cells.	  The	  set	  of	  27	  significantly	  enriched	  protein	  
groups	  (target	  list)	  was	  analyzed	  for	  GO-­‐term	  enrichment	  by	  comparing	  it	  with	  the	  whole	  set	  of	  identified	  992	  
protein	   groups	   (ID	   list)	   using	   GOrilla.	   As	   identifier	   the	   first	   major	   gene	   name	   for	   each	   protein	   group	   was	  
imputed	  into	  GOrilla.	  GOrilla	  could	  assign	  terms	  to	  26	  (of	  27)	  and	  963	  (of	  992)	  gene	  names.	  Each	  terms	  degree	  
of	  enrichment	  is	  given	  by	  an	  uncorrected	  p-­‐value	  calculated	  by	  hypergeometric	  testing.	  The	  list	  is	  sorted	  by	  p-­‐
values	  in	  ascending	  order.	  Entries	  with	  p-­‐values	  >	  0.001	  were	  filtered	  out.	  
GO	  Term	   Description	   P-­‐value	  
GO:0008289	   lipid	  binding	   5.74E-­‐04	  
	  
GOrilla	  could	  assign	  GO-­‐terms	  to	  963	  of	  the	  992	  imputed	  gene	  names	  and	  found	  only	  a	  small	  number	  
of	   enriched	   terms	   in	   the	   “Biological	   Process”-­‐	   and	   “Molecular	   Function”-­‐category,	   but	   not	   in	   the	  
“Cellular	   Component”-­‐category.	   The	   low	  number	   of	   enriched	   terms	  was	   expected	   since	   the	   target	  
list,	   containing	   the	   significantly	   enriched	   proteins,	  was	   very	   small.	   It	   seemed	   that	   the	   proteins	   co-­‐
purified	  with	  FA2H	  are	  mainly	   involved	   in	  endocytosis	   (AP2A2	  =	  adaptor-­‐related	  protein	  complex	  2	  
alpha	   2	   subunit,	   SNX33	   =	   sorting	   nexin	   33,	   TFRC	   =	   transferrin	   receptor,	   AP2S1	   =	   adaptor-­‐related	  
protein	  complex	  2	  sigma	  1	  subunit,	  EPN1	  =	  epsin	  1,	  MYO1E	  =	  myosin	  IE)	  and	  the	  regulation	  of	  protein	  
complex	  assembly	  (ARPC1A	  =	  actin	  related	  protein	  complex	  subunit	  1A,	  ARPC2	  =	  actin	  related	  protein	  
complex	   subunit	  2,	  ARPC3	  =	  actin	   related	  protein	   complex	   subunit	  3,	  VCP,	  HAX1).	  Within	   the	   later	  
group	   the	   ARPC-­‐genes	   indicate	   that	   the	   major	   complex	   for	   regulation	   of	   actin-­‐filament	  
polymerization	   was	   co-­‐purified	   along	   with	   FA2H.	   Furthermore,	   6	   proteins	   (AP2A2,	   SNX33,	   EPN1,	  
MYO1E,	   VCP,	   RACGAP1	   =	   Rac	   GTPase	   activating	   protein	   1)	   have	   a	   known	   lipid	   binding	   activity	  
(GO:0008289).	  The	  exact	  definition	  of	  this	  GO-­‐term	  is:	  Interacting	  selectively	  and	  non-­‐covalently	  with	  
a	  lipid.	  	  
Taken	  together,	  the	  pulldown	  of	  stably	  expressed	  Twin-­‐Strep-­‐mFA2H	  showed	  two	  positive	  changes	  in	  
comparison	   to	   the	   previous	   one	   utilizing	   transiently	   transfected	   cells.	   First,	   while	   protein	   quality	  
control	  protein	  groups	  were	  still	  present,	  proteins	  unrelated	  to	  this	  process	  could	  also	  be	  co-­‐purified.	  
In	   the	   experiment	   with	   transiently	   transfected	   HEK293-­‐T	   the	  majority	   of	   co-­‐purified	   proteins	   was	  
associated	  with	  protein	  quality	  control	  processes.	  In	  contrast,	  such	  proteins	  constituted	  only	  ~20%	  in	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this	   approach,	   which	   is	   significantly	   less.	   Moreover,	   since	   protein	   quality	   control	   proteins	   should	  
examine	   all	   proteins	   imported	   into	   the	   ER,	   a	   certain	   amount	   of	   these	  will	   always	   be	   identified	   in	  
interaction	  partner	  screenings.	  The	  second	  change	  was	  that	  SPTLC1,	  an	  enzyme	  working	  in	  the	  same	  
metabolic	  pathway	  as	  FA2H,	  was	  now	  identifiable	  also	  without	  the	  use	  of	  PFA-­‐crosslinking.	  	  
4.2.3.1.4 PFA-­‐assisted	  Twin-­‐Strep	  pulldown	  of	  stably	  transfected	  FA2H	  
Analogous	   to	   the	   experiment	   with	   transiently	   transfected	   cells	   (4.2.3.1.2	   PFA-­‐assisted	   Twin-­‐Strep	  
pulldown	   of	   transiently-­‐overexpressed	   mFA2H),	   PFA-­‐crosslinking	   was	   used	   together	   with	   stably	  
transfected	  cells	  to	  identify	  weak	  or	  minor	  interactors,	  which	  are	  otherwise	  lost	  during	  the	  pulldown	  
process.	   Therefore,	   a	   PFA-­‐crosslinking	   step	   was	   added	   between	   cell	   harvesting	   and	   cell	   lysis.	   In	  
addition,	   samples	   had	   to	  be	  decrosslinked	   after	   elution.	   	   Figure	   4-­‐30B,	   Table	   4-­‐12,	   Table	   4-­‐13	   and	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Figure	  4-­‐30:	  PFA-­‐assisted	  interaction	  partner	  analysis	  of	  stably	  transfected	  Twin-­‐Strep-­‐mFA2H.	  
(A)	  Workflow	  of	  the	  performed	  analysis.	  Six	  15	  cm	  dishes	  each	  of	  untransfected	  HEK293	  grown	  in	  SILAC	  light	  
(control)	  and	  stably	  expressing	  Twin-­‐Strep-­‐mFA2H	  HEK293	  grown	   in	  heavy	  SILAC	  medium	  were	  used.	  Always	  
two	  equal	  plates	  were	  pooled,	  thereby	  leading	  to	  three	  replicates	  of	  untransfected	  and	  stably	  transfected	  cells,	  
fixed	  for	  20	  min	  with	  0.5%	  PFA	  and	  stopped	  by	  icecold	  1.25	  M	  glycine	  buffer	  addition.	  Afterwards,	  all	  cells	  were	  
lysed	   in	  RIPA	  buffer	  and	  the	  protein	  amounts	  determined.	  StrepTactin-­‐affinity	  purification	  was	  performed	  on	  
equal	  protein	  amounts	  of	  each	   lysate	   individually.	  Subsequently,	  each	   light-­‐labeled	  control	  eluate	  was	  mixed	  
with	   one	   heavy-­‐labeled	   stably	   expressing	   Twin-­‐Strep-­‐mFA2H	   eluate.	   Each	   combined	   eluate	   was	   then	  
concentrated	  by	  CHCl3/MeOH-­‐precipitation,	  resuspended	  in	  2X	  Laemmli,	  reduced	  and	  decrosslinked	  by	  heating	  
to	   95	   °C	   for	   10	   min	   and	   separated	   by	   SDS-­‐PAGE.	   After	   Coomassie-­‐staining,	   each	   lane	   was	   separated	   into	  
fractions	  of	  equal	  protein	  amount	  and	  subjected	  to	  tryptic	  in-­‐gel	  digestion.	  The	  resulting	  peptides	  were	  cleaned	  
via	  C18-­‐StageTipps	  and	  finally	  analyzed	  by	  LC-­‐MS/MS.	  Protein	  identification	  (human	  Uniprot	  database	  +mFA2H)	  
and	   quantification	   was	   performed	   with	   MaxQuant	   and	   statistical	   evaluation	   with	   Perseus	   and	   GOrilla.	   (B)	  
Volcano	  plot	  of	  all	  protein	  groups	  identified	  and	  quantified	  in	  at	  least	  two	  replicates.	  After	  performing	  a	  one-­‐
sided	   t-­‐test	   against	   0,	   the	   resulting	   –log	   p-­‐values	   of	   each	   protein	   group	   were	   plotted	   against	   their	   log2-­‐
transformed	  average	  H/L-­‐ratio	  (log2	  fold	  change).	  Proteins	  with	  a	  log2	  fold	  change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  
and	  a	  –log	  p-­‐value	  >	  1.301	  (p-­‐value	  <	  0.05)	  are	  considered	  significantly	  enriched	  and	  highlighted	  in	  red.	  	  
With	  this	  approach,	  1062	  protein	  groups	  were	  identified	  and	  quantified	  in	  at	  least	  two	  replicates.	  Of	  
these	  a	  very	  high	  number,	  437,	  were	  significantly	  enriched	  exhibiting	  a	  log2	  fold	  change	  ≥	  0.585	  and	  
a	   -­‐log10	  p-­‐value	  >	  1.301.	  375	  protein	  groups	   showed	  even	  a	  very	  high	  degree	  of	  enrichment	   (log2	  
fold	   change	   ≥	   1).	   The	   50	   protein	   groups	  with	   the	   highest	   degree	   of	   enrichment	   are	   shown	   below	  
(Table	  4-­‐12).	  For	  the	  comprehensive	  protein	  group	  list	  with	  all	  437	  entries	  see	  to	  the	  supplementary	  
DVD.	  	  	  
Table	   4-­‐12:	   50	   most	   highly	   enriched	   protein	   groups	   after	   PFA-­‐assisted	   Twin-­‐Strep-­‐mFA2H	   pulldown	   from	  
stably	   transfected	   HEK293	   cells.	   Depicted	   are	   the	   50	   protein	   groups	   identified	   with	   the	   highest	   log2	   fold	  
change.	  All	  protein	  groups	  were	   found	   in	  at	   least	   two	  replicates	  and	  had	  a	   -­‐log10	  p-­‐value	  >	  1.301	   (p-­‐value	  <	  
0.05).	   Protein	   groups	   are	   given	   by	   their	   respective	   gene	   names	   and	   sorted	   by	   their	   log2	   fold	   change	   in	  
descending	  order.	  Protein	  groups	  associated	  with	  protein	  quality	  control	  processes	  are	  highlighted	  in	  red,	  and	  
with	  (sphingo-­‐)lipid	  metabolism	  in	  bold.	  	  










1	   Fa2h	   4.8168	   1.6974	   26	   SEC62	   3.3296	   1.9376	  
2	   UBB;RPS27A;UBC;UBA52;UBBP
4	  
4.2411	   3.0434	   27	   SEC22B	   3.3174	   2.0514	  
3	   LRRC59	   3.8879	   2.3980	   28	   AMFR	   3.3059	   1.7645	  
4	   PTPLAD1	   3.7153	   2.6568	   29	   SPTLC1	   3.2840	   2.5805	  
5	   LBR	   3.7036	   2.2442	   30	   APLP2	   3.2789	   1.7938	  
6	   SURF4	   3.6677	   3.0665	   31	   RAB10	   3.2461	   2.3173	  
7	   TMEM161A	   3.6552	   2.4273	   32	   ATP2A2	   3.2292	   2.8144	  
8	   TNFRSF10B	   3.6294	   3.1774	   33	   RPN1	   3.2155	   4.0398	  
9	   STT3A	   3.5966	   3.1653	   34	   KCT2	   3.2111	   2.9395	  
10	   ANTXR1	   3.5880	   1.8430	   35	   TECR	   3.2079	   2.6661	  
11	   OSBPL8	   3.5339	   2.8360	   36	   TOLLIP	   3.1759	   2.4233	  
12	   SEC63	   3.5101	   2.7854	   37	   RAB6A	   3.1691	   2.0366	  
13	   VAPA	   3.4946	   2.1985	   38	   AUP1	   3.1206	   1.6761	  
14	   DHCR7	   3.4427	   1.7817	   39	   GOLIM4	   3.1179	   2.2114	  
15	   RDH11	   3.4424	   2.5201	   40	   EMD	   3.1096	   2.7882	  
16	   ELOVL5	   3.4310	   1.7753	   41	   TMED2	   3.1023	   2.6106	  
17	   EMC10	   3.4266	   3.5028	   42	   GOSR1	   3.0956	   2.3715	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18	   SDCBP	   3.4039	   2.0016	   43	   RAB14	   3.0888	   2.6959	  
19	   SRPR	   3.3962	   2.7603	   44	   SLC20A1	   3.0866	   1.3557	  
20	   EMC1	   3.3830	   3.0258	   45	   SSR1	   3.0814	   3.2738	  
21	   MFSD10	   3.3731	   2.5739	   46	   TM9SF3	   3.0731	   3.8667	  
22	   TMEM30A	   3.3677	   1.5093	   47	   NEDD4L	   3.0703	   1.8659	  
23	   KIAA2013	   3.3653	   2.2982	   48	   UGCG	   3.0697	   1.8757	  
24	   STT3B	   3.3563	   2.5675	   49	   RAB1B	   3.0640	   3.1481	  
25	   RAB1A	   3.3448	   2.9493	   50	   SRPRB	   3.0595	   1.5005	  
	   	   	   	   	   	   	   	   	  
The	   inclusion	   of	   a	   PFA-­‐crosslinking	   step	   into	   the	   analysis	   workflow	   again	   largely	   increased	   the	  
number	  of	  significantly	  enriched	  protein	  groups	  after	  Twin-­‐Strep-­‐mFA2H	  pulldown.	  With	  437	  out	  of	  
1062	  (≈41%)	  protein	  groups	  this	  number	   is	  very	  high.	   In	  addition,	  with	  559	  out	  of	  1062	  (~47%)	  the	  
number	   of	   background	   protein	   groups	   (log2	   fold	   change	   between	   0.58	   and	   -­‐0.58)	   was	   quite	   low,	  
compared	   to	   the	   PFA-­‐crosslinking	   experiment	   with	   transiently	   transfected	   cells	   (709/840	   ≈	   85%).	  
Normally,	   the	  majority	   of	   the	   non-­‐interacting	   background	   protein	   groups	   should	   cluster	   around	   a	  
log2	   fold	   change	   of	   0,	   being	   equally	   contributed	   by	   the	   control	   and	   bait-­‐containing	   sample.	   This	  
indicates	   that	   the	   PFA-­‐fixation	   lasted	   too	   long,	   leading	   to	   more	   background	   proteins	   becoming	  
crosslinked	  to	  FA2H.	  Thus,	  the	  putative	  interaction	  candidates	  identified	  in	  this	  experiment	  probably	  
contained	  a	  larger	  amount	  of	  false	  positive	  identifications.	  
Looking	  only	  at	  the	  50	  protein	  groups	  with	  the	  highest	  enrichment	  (Table	  4-­‐12),	  as	  observed	  before,	  
about	   18%	   (9	   of	   50)	   were	   known	   to	   be	   involved	   in	   protein	   quality	   control	   (UBB	   =	   ubiquitin	   B,	  
TNFRSF10B	  =	  tumor	  necrosis	  factor	  receptor	  superfamily	  member	  10b,	  STT3A	  =	  STT3A	  subunit	  of	  the	  
oligosaccharyltransferase	   complex,	   EMC10	   =	   ER	   membrane	   protein	   complex	   subunit	   10,	   …).	   The	  
amount	  was	  similar,	  when	  considering	  all	  significantly	  enriched	  437	  protein	  groups	  (76	  of	  437	  ≈	  17%).	  
Moreover,	  within	  the	  50	  protein	  groups	  there	  were	  also	  10	  groups	  present	  linked	  to	  lipid	  metabolism	  
processes.	   For	   example,	   these	   were	   proteins	   involved	   in	   sphingolipid	   anabolism	   (SPTLC1,	   UGCG	   =	  
glucosylceramide	   synthase),	   cholesterol	   metabolism	   (DHCR7),	   lipid	   transport	   (VAPA;	   OSBPL8)	   and	  
fatty	  acid	  metabolism	  (PTPLAD1	  =	  protein	  tyrosine	  phosphatase-­‐like	  A	  domain	  containing	  1,	  ELOVL5	  =	  
ELOVL	  fatty	  acid	  elongase	  5).	   Interestingly,	  many	  of	  those	  have	  been	  also	   identified	   in	  the	  previous	  
pulldown	  experiment	  including	  a	  PFA-­‐crosslinking	  step	  (Table	  4-­‐6).	  
To	   further	   characterize	   the	   large	   amount	   of	   437	   significantly	   enriched	   protein	   groups,	   a	   GO-­‐term	  
analysis	  was	  performed	  with	  GOrilla.	  Again,	  the	  enriched	  protein	  groups	  (target	  list)	  were	  compared	  
to	   the	   whole	   number	   of	   1062	   identified	   and	   quantified	   protein	   groups	   (background	   list).	   As	  
identifiers	   the	   first	   gene	   name	   associated	  with	   a	   protein	   group	  was	   used.	   The	   results	   for	   the	  GO-­‐
categories	  “Biological	  Process”	  and	  “Cellular	  Component”	  are	  shown	  below	  in	  Table	  4-­‐13	  and	  Table	  
4-­‐14.	  Complete	  tables,	  containing	  also	  the	  gene	  names	  associated	  with	  each	  GO-­‐term,	  can	  be	  found	  
on	  the	  supplemental	  DVD.	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Table	  4-­‐13:	  “Biological	  Process”	  GO-­‐enrichment	  analysis	  results	  for	  protein	  groups	  significantly	  enriched	  after	  
Twin-­‐Strep-­‐mFA2H	  pulldown	  from	  stably	  transfected	  &	  PFA-­‐treated	  HEK293	  cells.	  The	  set	  of	  437	  significantly	  
enriched	  protein	  groups	  (target	  list)	  was	  analyzed	  for	  GO-­‐term	  enrichment	  by	  comparing	  it	  with	  the	  whole	  set	  
of	  identified	  1062	  protein	  groups	  (ID	  list)	  using	  GOrilla.	  As	  identifier	  the	  first	  major	  gene	  name	  for	  each	  protein	  
group	  was	   imputed	   into	  GOrilla.	  GOrilla	   could	  assign	   terms	   to	  432	   (of	  437)	  and	  1049	   (of	  1062)	  gene	  names.	  
Each	  terms	  degree	  of	  enrichment	  is	  given	  by	  an	  uncorrected	  p-­‐value	  calculated	  by	  hypergeometric	  testing.	  The	  
list	  is	  sorted	  by	  p-­‐values	  in	  ascending	  order.	  Entries	  with	  p-­‐values	  >	  0.001	  were	  filtered	  out.	  
GO	  Term	   Description	   P-­‐value	  
GO:0006810	   transport	   9.14E-­‐16	  
GO:0051234	   establishment	  of	  localization	   9.10E-­‐15	  
GO:0044765	   single-­‐organism	  transport	   1.24E-­‐13	  
GO:0071702	   organic	  substance	  transport	   3.63E-­‐12	  
GO:0015031	   protein	  transport	   4.00E-­‐10	  
GO:1902582	   single-­‐organism	  intracellular	  transport	   5.05E-­‐10	  
GO:0045184	   establishment	  of	  protein	  localization	   2.33E-­‐09	  
GO:0046907	   intracellular	  transport	   1.17E-­‐08	  
GO:0051649	   establishment	  of	  localization	  in	  cell	   3.44E-­‐07	  
GO:0007264	   small	  GTPase	  mediated	  signal	  transduction	   4.12E-­‐07	  
GO:0006886	   intracellular	  protein	  transport	   1.09E-­‐06	  
GO:0006605	   protein	  targeting	   1.41E-­‐06	  
GO:0006184	   GTP	  catabolic	  process	   1.49E-­‐06	  
GO:0006811	   ion	  transport	   1.88E-­‐06	  
GO:0009203	   ribonucleoside	  triphosphate	  catabolic	  process	   2.87E-­‐06	  
GO:0009207	   purine	  ribonucleoside	  triphosphate	  catabolic	  process	   2.87E-­‐06	  
GO:0009146	   purine	  nucleoside	  triphosphate	  catabolic	  process	   2.87E-­‐06	  
GO:0009143	   nucleoside	  triphosphate	  catabolic	  process	   2.87E-­‐06	  
GO:0016482	   cytoplasmic	  transport	   3.25E-­‐06	  
GO:0055085	   transmembrane	  transport	   3.85E-­‐06	  
GO:0072594	   establishment	  of	  protein	  localization	  to	  organelle	   4.03E-­‐06	  
GO:1901069	   guanosine-­‐containing	  compound	  catabolic	  process	   4.47E-­‐06	  
GO:0046039	   GTP	  metabolic	  process	   4.47E-­‐06	  
GO:0048193	   Golgi	  vesicle	  transport	   5.18E-­‐06	  
GO:0009261	   ribonucleotide	  catabolic	  process	   5.82E-­‐06	  
GO:0009154	   purine	  ribonucleotide	  catabolic	  process	   5.82E-­‐06	  
GO:0016050	   vesicle	  organization	   6.28E-­‐06	  
GO:1901136	   carbohydrate	  derivative	  catabolic	  process	   6.45E-­‐06	  
GO:0007165	   signal	  transduction	   9.88E-­‐06	  
GO:0006152	   purine	  nucleoside	  catabolic	  process	   1.14E-­‐05	  
GO:0006195	   purine	  nucleotide	  catabolic	  process	   1.14E-­‐05	  
GO:1901292	   nucleoside	  phosphate	  catabolic	  process	   1.14E-­‐05	  
GO:1901658	   glycosyl	  compound	  catabolic	  process	   1.14E-­‐05	  
GO:0072523	   purine-­‐containing	  compound	  catabolic	  process	   1.14E-­‐05	  
GO:0042454	   ribonucleoside	  catabolic	  process	   1.14E-­‐05	  
GO:0046130	   purine	  ribonucleoside	  catabolic	  process	   1.14E-­‐05	  
GO:0009166	   nucleotide	  catabolic	  process	   1.14E-­‐05	  
GO:0009164	   nucleoside	  catabolic	  process	   1.14E-­‐05	  
GO:0035556	   intracellular	  signal	  transduction	   1.20E-­‐05	  
GO:0006901	   vesicle	  coating	   1.54E-­‐05	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GO:0048205	   COPI	  coating	  of	  Golgi	  vesicle	   2.17E-­‐05	  
GO:0048200	   Golgi	  transport	  vesicle	  coating	   2.17E-­‐05	  
GO:0046434	   organophosphate	  catabolic	  process	   2.29E-­‐05	  
GO:0016192	   vesicle-­‐mediated	  transport	   2.78E-­‐05	  
GO:1901068	   guanosine-­‐containing	  compound	  metabolic	  process	   2.98E-­‐05	  
GO:0061024	   membrane	  organization	   3.41E-­‐05	  
GO:0090150	   establishment	  of	  protein	  localization	  to	  membrane	   3.42E-­‐05	  
GO:0006820	   anion	  transport	   3.71E-­‐05	  
GO:0009205	   purine	  ribonucleoside	  triphosphate	  metabolic	  process	   4.32E-­‐05	  
GO:0009144	   purine	  nucleoside	  triphosphate	  metabolic	  process	   4.32E-­‐05	  
GO:0006613	   cotranslational	  protein	  targeting	  to	  membrane	   4.38E-­‐05	  
GO:0045047	   protein	  targeting	  to	  ER	   4.38E-­‐05	  
GO:0072599	   establishment	  of	  protein	  localization	  to	  endoplasmic	  reticulum	   4.38E-­‐05	  
GO:0006612	   protein	  targeting	  to	  membrane	   6.61E-­‐05	  
GO:0006614	   SRP-­‐dependent	  cotranslational	  protein	  targeting	  to	  membrane	   8.03E-­‐05	  
GO:0009199	   ribonucleoside	  triphosphate	  metabolic	  process	   1.25E-­‐04	  
GO:0023051	   regulation	  of	  signaling	   1.57E-­‐04	  
GO:0010646	   regulation	  of	  cell	  communication	   2.15E-­‐04	  
GO:0006890	   retrograde	  vesicle-­‐mediated	  transport,	  Golgi	  to	  ER	   3.61E-­‐04	  
GO:0019439	   aromatic	  compound	  catabolic	  process	   4.84E-­‐04	  
GO:0044270	   cellular	  nitrogen	  compound	  catabolic	  process	   7.01E-­‐04	  
GO:0009141	   nucleoside	  triphosphate	  metabolic	  process	   7.88E-­‐04	  
GO:0046467	   membrane	  lipid	  biosynthetic	  process	   9.15E-­‐04	  
GO:1901361	   organic	  cyclic	  compound	  catabolic	  process	   9.34E-­‐04	  
	  
Table	   4-­‐14:	   “Cellular	   Component”	  GO-­‐enrichment	   analysis	   results	   for	   protein	   groups	   significantly	   enriched	  
after	   Twin-­‐Strep-­‐mFA2H	   pulldown	   from	   stably	   transfected	   &	   PFA-­‐treated	   HEK293	   cells.	   The	   set	   of	   437	  
significantly	  enriched	  protein	  groups	   (target	   list)	  was	  analyzed	   for	  GO-­‐term	  enrichment	  by	  comparing	   it	  with	  
the	  whole	  set	  of	  identified	  1062	  protein	  groups	  (ID	  list)	  using	  GOrilla.	  As	  identifier	  the	  first	  major	  gene	  name	  for	  
each	  protein	  group	  was	   imputed	   into	  GOrilla.	  GOrilla	   could	  assign	   terms	   to	  432	   (of	  437)	  and	  1049	   (of	  1062)	  
gene	  names.	  Each	  terms	  degree	  of	  enrichment	  is	  given	  by	  an	  uncorrected	  p-­‐value	  calculated	  by	  hypergeometric	  
testing.	  The	  list	  is	  sorted	  by	  p-­‐values	  in	  ascending	  order.	  Entries	  with	  p-­‐values	  >	  0.001	  were	  filtered	  out.	  
GO	  Term	   Description	   P-­‐value	  
GO:0016021	   integral	  component	  of	  membrane	   1.04E-­‐46	  
GO:0044425	   membrane	  part	   2.15E-­‐41	  
GO:0098588	   bounding	  membrane	  of	  organelle	   8.18E-­‐28	  
GO:0031090	   organelle	  membrane	   3.68E-­‐23	  
GO:0016020	   membrane	   2.70E-­‐22	  
GO:0044432	   endoplasmic	  reticulum	  part	   3.72E-­‐17	  
GO:0005789	   endoplasmic	  reticulum	  membrane	   2.67E-­‐16	  
GO:0098589	   membrane	  region	   2.10E-­‐15	  
GO:0044431	   Golgi	  apparatus	  part	   1.76E-­‐11	  
GO:0000139	   Golgi	  membrane	   6.54E-­‐11	  
GO:0005887	   integral	  component	  of	  plasma	  membrane	   1.24E-­‐09	  
GO:0005783	   endoplasmic	  reticulum	   3.78E-­‐09	  
GO:0044446	   intracellular	  organelle	  part	   3.69E-­‐07	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GO:0044422	   organelle	  part	   2.32E-­‐06	  
GO:0005886	   plasma	  membrane	   2.72E-­‐06	  
GO:0044459	   plasma	  membrane	  part	   3.19E-­‐06	  
GO:0030139	   endocytic	  vesicle	   1.54E-­‐05	  
GO:0005794	   Golgi	  apparatus	   2.08E-­‐04	  
GO:0030659	   cytoplasmic	  vesicle	  membrane	   2.89E-­‐04	  
GO:0031410	   cytoplasmic	  vesicle	   6.27E-­‐04	  
GO:0031965	   nuclear	  membrane	   7.21E-­‐04	  
GO:0012506	   vesicle	  membrane	   7.88E-­‐04	  
	   	   	  
GOrilla	  found	  GO-­‐terms	  for	  1049	  gene	  identifiers	  on	  the	  ID-­‐list	  and	  432	  on	  the	  target-­‐list.	  The	  results	  
for	  the	  Biological	  Process	  GO-­‐category	  showed	  a	  significant	  enrichment	  of	  various	  terms.	  The	  by	  far	  
largest	   amount	   of	   terms	   was	   again	   related	   to	   transport	   processes	   (GO:0006810	   transport,	  
GO:0051234	  establishment	  of	   localization,	  …)	  of	  various	  substrates	   (GO:0015031	  protein	   transport,	  
GO:0071702	   organic	   substance	   transport,	  GO:0006811	   ion	   transport,	  …).	   Furthermore,	   there	  were	  
also	   many	   terms	   enriched,	   which	   are	   linked	   to	   GTP-­‐metabolism	   and	   small	   GTPase	   signaling	  
(GO:0007264	   small	   GTPase	   mediated	   signal	   transduction,	   GO:0006184	   GTP	   catabolic	   process,	  
GO:0046039	  GTP	  metabolic	  process).	  	  
Nonetheless,	  there	  was	  also	  an	  enrichment	  of	  a	  GO-­‐term	  indicating	  the	  presence	  of	  lipid	  metabolism-­‐
related	  proteins	  co-­‐purifying	  with	  Twin-­‐Strep-­‐mFA2H.	  The	  gene	  names	  corresponding	  to	  the	  protein	  
groups	  within	  this	  enriched	  term	  (GO:0046467	  membrane	  lipid	  biosynthetic	  process)	  are	  given	  in	  the	  
table	  below.	  
Table	  4-­‐15:	  Genes	  associated	  with	  enriched	  GO-­‐term	  GO:0046467	  membrane	  lipid	  biosynthetic	  process.	  
P-­‐value	  =	  enrichment	  p-­‐value	  calculated	  by	  hypergeometric	  testing	  
GO:0046467	  membrane	  lipid	  biosynthetic	  process	  (P-­‐value=	  9.15E-­‐04)	  
DPM1	  	  -­‐	  	  dolichyl-­‐phosphate	  mannosyltransferase	  polypeptide	  1,	  catalytic	  subunit	  
	  SGPL1	  	  -­‐	  	  sphingosine-­‐1-­‐phosphate	  lyase	  1	  
	  SMPD4	  	  -­‐	  	  sphingomyelin	  phosphodiesterase	  4,	  	  neutral	  membrane	  (neutral	  sphingomyelinase-­‐3)	  
	  UGCG	  	  -­‐	  	  udp-­‐glucose	  ceramide	  glucosyltransferase	  
	  SPTLC1	  	  -­‐	  	  serine	  palmitoyltransferase,	  long	  chain	  base	  subunit	  1	  
	  SPTLC2	  	  -­‐	  	  serine	  palmitoyltransferase,	  long	  chain	  base	  subunit	  2	  
	  DEGS1	  	  -­‐	  	  delta(4)-­‐desaturase,	  sphingolipid	  1	  
	  VAPA	  	  -­‐	  	  vamp	  (vesicle-­‐associated	  membrane	  protein)-­‐associated	  protein	  a	  33kda	  
	  VAPB	  	  -­‐	  	  vamp	  (vesicle-­‐associated	  membrane	  protein)-­‐associated	  protein	  b	  and	  c	  
	  CERS2	  	  -­‐	  	  ceramide	  synthase	  2	  
	  
Table	   4-­‐15	   illustrated	   that	   the	   majority	   of	   the	   proteins	   are	   related	   to	   sphingolipid	   metabolism	  
(SGPL1,	   SMPD4,	   UGCG,	   SPTLC1,	   SPTLC2,	   DEGS1,	   VAPA/B,	   CERS2).	   Only	   DPM1	   (dolichyl-­‐phosphate	  
mannosyltransferase	   polypetide	   1)	   is	   involved	   in	   the	   synthesis	   of	   the	   modified	   phospholipid	  
glycophosphatidylinositol	  (GPI).	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The	   “Cellular	   Component”	   GO-­‐category	   result	   (Table	   4-­‐14)	   again	   showed	   that	   the	  majority	   of	   the	  
significantly	  enriched	  protein	  groups	  contained	  ER	  (GO:0044432	  	  endoplasmic	   reticulum	   part,	   …)	  
and/or	  Golgi-­‐localized	  proteins	  (GO:0044431	  Golgi	  apparatus	  part,	  GO:0000139	   Golgi	  membrane,	  …).	  
In	   addition,	   many	   enclosed	   membrane	   or	   membrane-­‐related	   proteins	   (GO:0016021	   integral	  
component	   of	   membrane,	   GO:0044425	   membrane	   part,	   GO:0098588	   bounding	   membrane	   of	  
organelle,	  GO:0031090	  organelle	  membrane,	  …).	  	  
Considering	  the	  above	  results,	  the	  inclusion	  of	  PFA-­‐crosslinking	  step	  again	  enabled	  the	  identification	  
of	   substantially	   more	   putative	   FA2H-­‐interacting	   proteins,	   when	   compared	   to	   the	   experiment	  
without.	  Moreover,	  while	  there	  was	  certainly	  some	  error	  due	  to	  extensive	  crosslinking	   leading	  to	  a	  
larger	  amount	  of	   false-­‐positive	   identifications,	   a	   significant	   amount	  of	   the	  enriched	  protein	  groups	  
were	  linked	  to	  lipid,	  especially	  sphingolipid,	  metabolism.	  
4.2.3.2 SILAC	  BioID-­‐FA2H-­‐assay	  
Analogous	   to	   the	   SILAC	   IP	   experiments,	   the	   identification	  of	  mFA2H	   interaction	  partners	  using	   the	  
BioID-­‐method	   (see	   3.2.4.1	   Proximity-­‐dependent	   protein	   biotinylation	   &	   identification	   (BioID),	   was	  
carried	  out	  in	  combination	  with	  SILAC-­‐labeling.	  Again,	  the	  addition	  of	  quantitative	  information	  should	  
help	  to	  distinguish	  true	  interacting	  from	  unspecific	  background-­‐binding	  proteins.	  Still,	  because	  of	  the	  
random	  biotinylation	  by	  the	  fused	  biotin	  ligase,	  this	  screening	  method	  will	  unavoidably	  also	  lead	  to	  
some	   false-­‐positive	   identifications.	   As	   for	   the	   PFA-­‐crosslinking,	   this	   bias	   has	   to	   be	   accepted	  when	  
aiming	  to	  capture	  also	  weak	  and	  transient	  interactions.	  
Thus,	   HEK293-­‐T	   cells	   grown	   in	   SILAC-­‐media	   were	   either	   transiently	   transfected	   with	   the	   plasmid	  
coding	   for	   biotin	   ligase	   BirA*	   alone	   (pcDNA3.1-­‐myc-­‐BioID)	   or	   the	   fusion	   protein	   BirA*-­‐mFA2H	  
(pcDNA3.1-­‐myc-­‐BioID-­‐mFA2H).	   BirA*-­‐transfected	   cells	   were	   grown	   in	   light	   and	   BirA*-­‐mFA2H-­‐
transfected	   in	   heavy	   SILAC-­‐medium.	   24h	   after	   transfection,	   biotinylation	   of	   proximal	   proteins	   by	  
BirA*	  was	  induced	  by	  the	  addition	  of	  biotin	  to	  the	  culture	  media	  followed	  by	  another	  24h-­‐incubation.	  
Thereafter,	   cells	   were	   harvested,	   lysed,	   protein	   amounts	   determined	   and	   NeutrAvidin-­‐affinity	  
purification	  performed.	  Subsequently,	  bound	  proteins	  were	  tryptically	  digested	  directly	  on	  the	  beads	  
and	   the	   resulting	   peptides	   solutions	   of	   each	   light	   BirA*-­‐sample	   combined	   with	   one	   heavy	   BirA*-­‐
mFA2H	  sample.	  The	  combined	  peptides	  were	  then	  desalted,	  fractionated	  by	  OFFGEL,	  analyzed	  by	  LC-­‐
MS/MS,	  and	  the	  raw	  data	  processed	  by	  MaxQuant.	  Finally,	  identified	  and	  quantified	  protein	  groups	  
were	  statistical	  evaluated	  by	  Perseus	  and	  GOrilla	   (see	  Figure	  4-­‐31,	  Table	  4-­‐16	  and	  Table	  4-­‐17).	  The	  
experiment	  was	  done	  in	  triplicates.	  
	   	  







Figure	  4-­‐31:	  Identification	  of	  FA2H-­‐interactors	  by	  the	  SILAC	  BioID-­‐FA2H-­‐assay.	  
(A)	  Workflow	  diagram	  of	   the	   SILAC	  BioID-­‐FA2H-­‐assay.	  Twelve	  15	  cm	  dishes	  of	  HEK293-­‐T	  each,	   labeled	  with	  
SILAC	   culture	   medium,	   were	   transfected	   with	   pcDNA3.1-­‐mycBioID	   (light)	   or	   pcDNA3.1-­‐mycBioID-­‐mFA2H	  
(heavy)	  respectively.	  24	  h	  later,	  biotinylation	  was	  induced	  by	  adding	  50	  µM	  biotin	  to	  the	  medium	  and	  the	  cells	  
grown	  for	  another	  24	  h.	  Then	  cells	  were	  harvested,	  thereby	  always	  pooling	  two	  dishes	  of	  equally	  labeled	  and	  
transfected	  cells.	  Thereafter,	   cells	  were	   lysed,	  protein	  amounts	  determined	  and	  biotinylated	  proteins	  affinity	  
purified	   from	   each	   lysate	   separately	   using	  NeutrAvidin.	   Afterwards,	   by	   adding	   trypsin	   directly	   to	   the	   beads,	  
proteins	   bound	   to	   the	   affinity	   matrix	   were	   digested	   overnight.	   Then	   the	   resulting	   peptide	   digests	   were	  
aspirated	  and	  remaining	  peptides	  reextracted	  with	  5%	  ACN	  0.1%	  FA.	  Subsequently,	  each	  light	  BirA*	  digest	  was	  
combined	  with	  one	  heavy	  BirA*-­‐mFA2H	  digest.	  Afterwards,	  the	  combined	  samples	  (n=3)	  were	  desalted	  using	  
Oasis	  HLB	  cartridges,	  followed	  by	  fractionation	  into	  12	  fractions	  via	  isoelectric	  focusing	  (OFFGEL).	  Finally,	  after	  
peptide	   desalting	   by	   C18-­‐StageTips,	   all	   fractions	   were	   analyzed	   by	   LC-­‐MS/MS,	   proteins	   identified	   (human	  
Uniprot	   database	   +mFA2H)	   and	   quantified	   by	  MaxQuant	   and	   statistical	   analysis	   performed	   by	   Perseus	   and	  
GOrilla.	   (B)	   Volcano	   plot	   of	   all	   protein	   groups	   identified	   in	   at	   least	   two	   replicates.	   The	   resulting	  –log10	  p-­‐
values	  of	  each	  protein	  group	  (one-­‐sample	  t-­‐test	  against	  0)	  were	  plotted	  against	  their	  log2-­‐transformed	  average	  
H/L-­‐ratio	  (log2	  fold	  change).	  Proteins	  exhibiting	  a	  log2	  fold	  change	  ≥	  0.585	  (fold	  change	  ≥	  1.5)	  and	  a	  –log10	  p-­‐
value	  >	  1.301	  (p-­‐value	  <	  0.05)	  are	  highlighted	  in	  red.	  
In	  this	  experiment,	  546	  protein	  groups	  were	  identified	  and	  quantified	  in	  at	   least	  two	  replicates.	   	  Of	  
these	  only	  a	  small	  number	  of	  24	  protein	  groups	  showed	  a	  significant	  enrichment	  (log2	  fold	  change	  ≥	  
0.585;	   –log10	   p-­‐value	   >	   1.301)	   for	   the	   BirA*-­‐mFA2H	   sample.	   These	   are	   given	   in	   Table	   4-­‐16.	   The	  
original	  unprocessed	  MaxQuant	  results	  can	  and	  the	  processed	  protein	  group	  list	  can	  be	  found	  on	  the	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Table	   4-­‐16:	   Significantly	   enriched	   protein	   groups	   in	   BirA*-­‐mFA2H	   sample.Depicted	   are	   all	   protein	   groups	  
identified	  in	  at	  least	  two	  replicates	  with	  a	  log2	  fold	  change	  ≥	  0.585	  and	  a	  –log10	  p-­‐value	  >	  1.301.	  Protein	  groups	  
are	  given	  by	   their	   respective	  gene	  names	  and	  sorted	  by	   their	   log2	   fold	  change	   in	  descending	  order.	  Proteins	  
groups	   associated	   with	   protein	   quality	   control	   processes	   are	   highlighted	   in	   red,	   and	   with	   (sphingo)lipid	  
metabolism	  in	  bold.	  	  














1	   Fa2h	   5.696	   4.273	   13	   SRPR	   1.393	   2.627	  
2	   CCDC47	   2.229	   2.650	   14	   LBR	   1.333	   1.866	  
3	   PGRMC2	   2.126	   3.036	   15	   STBD1	   1.353	   1.835	  
4	   PTPN1	   2.021	   3.186	   16	   SPTLC1	   1.310	   1.351	  
5	   TOR1AIP1	   1.867	   3.545	   17	   LRRC59	   1.144	   1.712	  
6	   SMPD4	   1.669	   2.166	   18	   LEMD3	   1.147	   1.686	  
7	   SRPRB	   1.835	   2.399	   19	   TMPO	   1.102	   2.112	  
8	   VAPA	   1.770	   2.988	   20	   NUP155	   0.902	   1.771	  
9	   VAPB	   1.740	   2.440	   21	   FAF2	   0.958	   1.952	  
10	   STIM1	   1.617	   1.638	   22	   NSDHL	   0.857	   1.678	  
11	   ALDH3A2	   1.643	   2.044	   23	   ESYT1	   0.888	   1.807	  
12	   CDKAL1	   1.350	   3.093	   24	   MTDH	   0.591	   1.382	  
	   	   	   	   	   	   	   	   	  
As	   expected,	   the	   bait	   protein	   FA2H	   itself	   showed	   the	   highest	   degree	   of	   enrichment	   (log2	   fold	  
change),	  thereby	  proving	  the	  assay	  principle.	   Inspecting	  the	  other	  protein	  groups	   in	  detail	   revealed	  
mainly	   groups	   linked	   to	   lipid	   metabolism	   processes.	   For	   example,	   the	   sphingolipid	   metabolizing	  
enzymes	  SMPD4	  and	  SPTLC1,	  as	  well	  as	  lipid	  transport	  (VAPA/B)	  and	  fatty	  acid	  metabolizing	  enzymes	  
(ALDH3A2).	  Moreover,	  LBR	  (Lamin	  B	  receptor),	  which	  has	  known	  cholesterol	  desaturase	  activity,	  and	  
PGRMC2,	   whose	   paralog	   PGRMC1	   is	   implicated	   in	   the	   activity	   regulation	   of	   various	   metabolic	  
enzymes,	  were	  also	  significantly	  enriched.	  In	  addition,	  two	  protein	  groups	  (~8%	  of	  all	  identifications)	  
related	  to	  protein-­‐quality	  control	  processes	  (CCD47,	  FAF2)	  were	  also	  present.	  This	   indicated	  that	  at	  
least	   parts	   of	   the	   transiently	   expressed	   BirA*-­‐FA2H	   fusion	   protein	   were	   processed	   by	   the	   protein	  
quality	  control	  machinery.	  
To	  additionally	  characterize	  these	  protein	  groups,	  GO-­‐term	  enrichment	  analysis	  was	  performed	  with	  
GOrilla	   comparing	   the	   25	   significantly	   enriched	   against	   the	   546	   identified	   proteins.	   The	  main	   GO-­‐
categories	   “Biological	   Process”	   and	   “Cellular	   Component”	   were	   assessed.	   The	   results	   are	   shown	  
below	  in	  Table	  4-­‐17	  and	  Table	  4-­‐18.	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Table	   4-­‐17:	   “Biological	   Process”	   GO-­‐enrichment	   analysis	   results	   for	   protein	   groups	   significantly	   in	   BirA*-­‐
mFA2H	   sample.	   The	   set	   of	   25	   significantly	   enriched	   protein	   groups	   (target	   list)	   was	   analyzed	   for	   GO-­‐term	  
enrichment	   by	   comparing	   it	   with	   the	   whole	   set	   of	   identified	   546	   protein	   groups	   (ID	   list)	   using	   GOrilla.	   As	  
identifier	  the	  first	  major	  gene	  name	  for	  each	  protein	  group	  was	  imputed	  into	  GOrilla.	  GOrilla	  could	  assign	  terms	  
to	  24	  (of	  25)	  and	  501	  (of	  546)	  gene	  names.	  Each	  terms	  degree	  of	  enrichment	  is	  given	  by	  an	  uncorrected	  p-­‐value	  
calculated	  by	  hypergeometric	  testing.	  The	  list	  is	  sorted	  by	  p-­‐values	  in	  ascending	  order.	  Entries	  with	  p-­‐values	  >	  
0.001	  were	  filtered	  out.	  
GO	  Term	   Description	   P-­‐value	  
GO:0006643	   membrane	  lipid	  metabolic	  process	   1.65E-­‐07	  
GO:0006665	   sphingolipid	  metabolic	  process	   1.65E-­‐07	  
GO:0006066	   alcohol	  metabolic	  process	   3.24E-­‐06	  
GO:0030148	   sphingolipid	  biosynthetic	  process	   4.10E-­‐06	  
GO:0046467	   membrane	  lipid	  biosynthetic	  process	   4.10E-­‐06	  
GO:1901615	   organic	  hydroxy	  compound	  metabolic	  process	   1.82E-­‐05	  
GO:0008610	   lipid	  biosynthetic	  process	   4.70E-­‐05	  
GO:0006629	   lipid	  metabolic	  process	   1.58E-­‐04	  
GO:0034976	   response	  to	  endoplasmic	  reticulum	  stress	   1.64E-­‐04	  
GO:0006984	   ER-­‐nucleus	  signaling	  pathway	   3.58E-­‐04	  
GO:0046165	   alcohol	  biosynthetic	  process	   3.76E-­‐04	  
GO:0044255	   cellular	  lipid	  metabolic	  process	   7.67E-­‐04	  
GO:1901617	   organic	  hydroxy	  compound	  biosynthetic	  process	   9.11E-­‐04	  
	   	   	  
Table	   4-­‐18:	   “Cellular	   Component”	  GO-­‐enrichment	   analysis	   results	   for	  protein	   groups	   significantly	   in	  BirA*-­‐
mFA2H	   sample.	   The	   set	   of	   25	   significantly	   enriched	   protein	   groups	   (target	   list)	   was	   analyzed	   for	   GO-­‐term	  
enrichment	   by	   comparing	   it	   with	   the	   whole	   set	   of	   identified	   546	   protein	   groups	   (ID	   list)	   using	   GOrilla.	   As	  
identifier	  the	  first	  major	  gene	  name	  for	  each	  protein	  group	  was	  imputed	  into	  GOrilla.	  GOrilla	  could	  assign	  terms	  
to	  24	   (of	  25)	  and	  501	   (of	  546)	  gene	  names.	  Each	   term’s	  degree	  of	  enrichment	   is	  given	  by	  an	  uncorrected	  p-­‐
value	   calculated	  by	  hypergeometric	   testing.	   The	   list	   is	   sorted	  by	  p-­‐values	   in	   ascending	  order.	   Entries	  with	  p-­‐
values	  >	  0.001	  were	  filtered	  out.	  
GO	  Term	   Description	   P-­‐value	  
GO:0016021	   integral	  component	  of	  membrane	   6.76E-­‐18	  
GO:0044425	   membrane	  part	   5.59E-­‐16	  
GO:0044432	   endoplasmic	  reticulum	  part	   1.73E-­‐12	  
GO:0005789	   endoplasmic	  reticulum	  membrane	   1.84E-­‐12	  
GO:0098589	   membrane	  region	   2.07E-­‐10	  
GO:0031090	   organelle	  membrane	   1.08E-­‐08	  
GO:0016020	   membrane	   1.69E-­‐07	  
GO:0098588	   bounding	  membrane	  of	  organelle	   2.02E-­‐07	  
GO:0005783	   endoplasmic	  reticulum	   4.46E-­‐05	  
GO:0005637	   nuclear	  inner	  membrane	   9.11E-­‐04	  
	   	   	  
The	  GO-­‐enrichment	  analysis	  further	  supported	  the	  observations	  made	  when	  manually	  evaluating	  the	  
enriched	  protein	  groups.	  The	  terms	  enriched	  within	  Biological	  Process	  category	  were	  mainly	  related	  
to	   lipid,	   especially	   sphingolipid,	   metabolism	   (GO:0006643	   membrane	   lipid	   metabolic	   process,	  
GO:0006665	  sphingolipid	  metabolic	  process,	  …)	  and	  to	  protein	  quality	  control	  (GO:0034976	  response	  
to	  endoplasmic	  reticulum	  stress).	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The	  Cellular	  Compartment	  category	  proved	  the	  assay	  functionality	  by	  showing	  a	  strong	  enrichment	  
of	  ER	  (GO:0044432	  endoplasmic	  reticulum	  part,	  GO:0005789	  endoplasmic	  reticulum	  membrane)	  and	  
membrane	   protein	   containing	   protein	   groups	   (GO:0016021	   integral	   component	   of	   membrane,	  
GO:0044425	   membrane	   part,	   …).	   Since	   FA2H	   is	   an	   ER-­‐membrane	   protein,	   the	   majority	   of	   its	  
interactors	  should	  be	  such	  proteins.	  
4.2.3.3 Comparison	  of	  the	  screening	  results	  
The	  different	  screening	  methods	  for	  protein	  interaction	  partners	  of	  FA2H	  revealed	  a	  large	  amount	  of	  
possible	   candidates.	   As	  mentioned	   before,	   PFA	   and	   BioID	   screenings	   inevitably	   lead	   to	   some	   false	  
positive	  identifications.	  Therefore,	  each	  candidate	  has	  to	  be	  verified	  by	  additional	  assays.	  Since	  this	  is	  
not	  feasible	  for	  all	  of	  the	  candidates,	  the	  results	  of	  the	  different	  approaches	  were	  compared	  to	  find	  
proteins	   identified	   in	   two	   or	   three	   approaches.	   Moreover	   those	   were	   also	   more	   likely	   true	  
interactors	  of	   FA2H.	   For	   this	   comparison,	   the	   list	   of	   significantly	   enriched	  protein	   groups	   from	   the	  
two	  PFA-­‐assisted	  Twin-­‐StrepTag	  pulldowns,	  transient	  (PFA	  PD	  transient)	  and	  stable	  (PFA	  PD	  stable),	  
and	  the	  BioID-­‐FA2H-­‐assay	  (BioID)	  were	  used.	  The	  results	  are	  depicted	  in	  the	  Venn	  diagram	  below.	  In	  
this	   a	   circle,	   whose	   size	   is	   proportional	   to	   the	   number	   of	   significantly	   enriched	   protein	   groups,	  
represents	  each	  experiment.	  Overlapping	  areas	  between	  the	  circles	  resemble	  the	  amount	  of	  protein	  
groups	  shared	  between	  experiments.	  Note	  that	  the	  two	  non-­‐PFA	  experiments	  were	  not	  considered,	  
because	  they	  showed	  only	  small	  numbers	  of	  putative	  interaction	  partners.	  
	  
	  
Figure	   4-­‐32:	   Venn	   diagram	   showing	   the	   overlap	   in	   protein	   group	   identifications	   between	   three	   mFA2H	  
interaction	   partner	   screenings.	   PFA	   PD	   transient	   =	   PFA-­‐assisted	   Twin-­‐Strep	   pulldown	   of	   transiently-­‐
overexpressed	  mFA2H;	  PFA	  PD	  stable	  =	  PFA	  assisted	  Twin-­‐Strep	  pulldown	  of	  stably	  transfected	  mFA2H;	  BioID	  
=	  BioID-­‐FA2H-­‐assay	  
The	  three	  mFA2H	  interaction	  partner	  screenings	  showed	  a	  good	  degree	  of	  congruency.	  Only	  in	  the	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in	   any	   of	   the	   other	   two	   experiments	   (338).	   But	   this	   was	   not	   surprising,	   since	   this	   experiment	  
exhibited	   a	   very	   high	   number	   of	   significantly	   enriched	   proteins	   (437)	   likely	   including	  many	   false-­‐
positives.	   Overall,	   17	   protein	   groups	   were	   consistently	   identified	   in	   all	   three	   experiments.	   In	  
addition,	  77	  protein	  groups	  were	  exclusively	  enriched	  in	  the	  two	  PFA-­‐experiments	  and	  4	  only	  in	  PFA	  
PD	   stable	   and	   BioID.	   A	   table	   containing	   the	   protein	   identifications	   corresponding	   to	   each	  
overlapping	  area	  of	  the	  Venn	  diagram	  is	  given	  in	  Table	  4-­‐19.	  	  
Table	   4-­‐19:	   Protein	   groups	   identified	   and	   significantly	   enriched	   in	   two	   or	   three	   screenings.	   The	   protein	  
groups,	  which	  were	  significantly	  enriched	  in	  two	  or	  three	  of	  the	  indicated	  screening	  approaches,	  PFA	  pulldown	  
transient	  (PT),	  PFA	  pulldown	  stable	  (PS)	  or	  BioID	  (B),	  are	  given	  by	  their	  respective	  gene	  and	  protein	  names.	  The	  
presence	  of	  a	  protein	  group	  in	  the	  respective	  screening	  is	  indicated	  by	  a	  plus	  sign.	  
Gene	  
names	  
Protein	  names	   PT	   PS	   B	  
	  
	   Gene	  
names	  
Protein	  names	   PT	   PS	   B	  
ACSL3	   Long-­‐chain-­‐fatty-­‐acid-­‐-­‐
CoA	  ligase	  3	  
+	   +	   	   PSMC5	   26S	  protease	  regulatory	  subunit	  8	   +	   +	   	  
ALDH3A2	   Fatty	  aldehyde	  
dehydrogenase	  
+	   +	   +	   PSMD2	   26S	  proteasome	  non-­‐ATPase	  
regulatory	  subunit	  2	  







+	   +	   	   PSMD6	   26S	  proteasome	  non-­‐ATPase	  
regulatory	  subunit	  6	  
+	   +	   	  
ATP2A2	   Sarcoplasmic/endoplas
mic	  reticulum	  calcium	  
ATPase	  2	  
+	   +	   	   PTPLAD1	   Very-­‐long-­‐chain	  (3R)-­‐3-­‐
hydroxyacyl-­‐[acyl-­‐carrier	  protein]	  
dehydratase	  3	  
+	   +	   	  
BCAP31	   B-­‐cell	  receptor-­‐
associated	  protein	  31	  
+	   +	   	   PTPN1	   Tyrosine-­‐protein	  phosphatase	  
non-­‐receptor	  type	  1	  
+	   +	   +	  
CANX	   Calnexin	   +	   +	   	   PTRH2	   Peptidyl-­‐tRNA	  hydrolase	  2,	  
mitochondrial	  
+	   +	   	  
CCDC47	   Coiled-­‐coil	  domain-­‐
containing	  protein	  47	  
+	   +	   +	   RAB11A;	  
RAB11B	  
Ras-­‐related	  protein	  Rab-­‐11A;	  
11B	  
+	   +	   	  
CKAP4	   Cytoskeleton-­‐
associated	  protein	  4	  
+	   +	   	   RAB13;	  
RAB8A;	  
RAB8B	  
Ras-­‐related	  protein	  Rab-­‐13;	  8A;	  
8B	  
+	   +	   	  
COPA	   Coatomer	  subunit	  alpha	   +	   +	   	   RAB14	   Ras-­‐related	  protein	  Rab-­‐14	   +	   +	   	  
CYB5R3	   NADH-­‐cytochrome	  b5	  
reductase	  3	  






+	   +	   	   RAB1B;	  
RAB1C	  
Ras-­‐related	  protein	  Rab-­‐1B;	  
1C	  
+	   +	   	  
DHCR7	   7-­‐dehydrocholesterol	  
reductase	  
+	   +	   	   RAB2A	   Ras-­‐related	  protein	  Rab-­‐2A	   +	   +	   	  
DNAJC7	   DnaJ	  homolog	  
subfamily	  C	  member	  7	  
+	   +	   	   RAB5C	   Ras-­‐related	  protein	  Rab-­‐5C	   +	   +	   	  
DPM1	   Dolichol-­‐phosphate	  
mannosyltransferase	  
+	   +	   	   RAB6A	   Ras-­‐related	  protein	  Rab-­‐6A	   +	   +	   	  
EMC2	   ER	  membrane	  protein	  
complex	  subunit	  2	  
+	   +	   	   RAB7A	   Ras-­‐related	  protein	  Rab-­‐7a	   +	   +	   	  
EMD	   Emerin	   +	   +	   	   RDH11	   Retinol	  dehydrogenase	  11	   +	   +	   	  
EPHX1	   Epoxide	  hydrolase	  1	   +	   +	   	   RPLP0;	  
RPLP0P6	  
60S	  acidic	  ribosomal	  protein	  P0;	  
P0-­‐like	  
+	   +	   	  




+	   +	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ESYT1	   Extended	  
synaptotagmin-­‐1	  




+	   +	   	  
Fa2h	   Fatty	  acid	  2-­‐
hydroxylase	  













+	   +	   	  
FAF2	   FAS-­‐associated	  factor	  2	   +	   +	   +	   SACM1L	   Phosphatidylinositide	  
phosphatase	  SAC1	  
+	   +	   	  
HMOX2	   Heme	  oxygenase	  2	   +	   +	   	   SCFD1	   Sec1	  family	  domain-­‐containing	  
protein	  1	  
+	   +	   	  
HSD17B12	   Estradiol	  17-­‐beta-­‐
dehydrogenase	  12	  
+	   +	   	   SDCBP	   Syntenin-­‐1	   +	   +	   	  
HSD17B7	   3-­‐keto-­‐steroid	  
reductase	  
+	   +	   	   SEC22B	   Vesicle-­‐trafficking	  protein	  SEC22b	   +	   +	   	  
HSPA1A	   Heat	  shock	  70	  kDa	  
protein	  1A/1B	  
+	   +	   	   SEC23A	   Protein	  transport	  protein	  Sec23A	   +	   +	   	  
HSPA5	   78	  kDa	  glucose-­‐
regulated	  protein	  
+	   +	   	   SLC27A4	   Long-­‐chain	  fatty	  acid	  transport	  
protein	  4	  
+	   +	   	  
HSPA6;	  
HSPA7	  
Heat	  shock	  70	  kDa	  
protein	  6;Putative	  heat	  
shock	  70	  kDa	  protein	  7	  
+	   +	   	   SMPD4	   Sphingomyelin	  phosphodiesterase	  
4	  
	   +	   +	  
HSPA8	   Heat	  shock	  cognate	  71	  
kDa	  protein	  
+	   +	   	   SND1	   Staphylococcal	  nuclease	  domain-­‐
containing	  protein	  1	  
+	   +	   	  
HYOU1	   Hypoxia	  up-­‐regulated	  
protein	  1	  
+	   +	   	   SPCS2	   Signal	  peptidase	  complex	  subunit	  
2	  
+	   +	   	  
KTN1	   Kinectin	   +	   +	   	   	   SPTLC1	   Serine	  palmitoyltransferase	  1	   +	   +	   +	  
LBR	   Lamin-­‐B	  receptor	   +	   +	   +	   SPTLC2	   Serine	  palmitoyltransferase	  2	   +	   +	   	  
LMAN1	   Protein	  ERGIC-­‐53	   +	   +	   	   SRPR	   Signal	  recognition	  particle	  receptor	  
subunit	  alpha	  
+	   +	  
LRRC59	   Leucine-­‐rich	  repeat-­‐
containing	  protein	  59	  
+	   +	   +	   SRPRB	   Signal	  recognition	  particle	  
receptor	  subunit	  beta	  
+	   +	   +	  
MTDH	   Protein	  LYRIC	   +	   +	   SSR4	   Translocon-­‐associated	  protein	  
subunit	  delta	  
+	   +	   	  
NAPA	   Alpha-­‐soluble	  NSF	  
attachment	  protein	  
+	   +	   	   STIM1	   Stromal	  interaction	  molecule	  1	   +	   +	   +	  













+	   +	   +	   SURF4	   Surfeit	  locus	  protein	  4	   +	   +	   	  
NSF	   Vesicle-­‐fusing	  ATPase	   +	   +	   	   TFRC	   Transferrin	  receptor	  protein	  1	   +	   +	   	  
NUP155	   Nuclear	  pore	  complex	  
protein	  Nup155	  
	   +	   +	   TMED9	   Transmembrane	  emp24	  domain-­‐
containing	  protein	  9	  
+	   +	   	  
OSBPL8	   Oxysterol-­‐binding	  
protein-­‐related	  protein	  
8	  
+	   +	   	   TMEM10
9	  
Transmembrane	  protein	  109	   +	   +	   	  
PDIA3	   Thioredoxin	   +	   +	   	   TMPO	   Lamina-­‐associated	  polypeptide	  2,	  
isoforms	  beta/gamma;	  
Thymopoietin;	  
+	   +	   +	  
PDIA3	   Protein	  disulfide-­‐ +	   +	   	   TMX1	   Thioredoxin-­‐related	   +	   +	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isomerase	  A3	   transmembrane	  protein	  1	  
PGRMC1	   Membrane-­‐associated	  
progesterone	  receptor	  
component	  1	  
+	   +	   	   TOLLIP	   Toll-­‐interacting	  protein	   +	   +	   	  
PGRMC2	   Membrane-­‐associated	  
progesterone	  receptor	  
component	  2	  
+	   +	   +	   TOR1AIP
1	  
Torsin-­‐1A-­‐interacting	  protein	  1	   +	   +	   +	  
PLD3	   Phospholipase	  D3	   +	   +	   	   VAPA	   Vesicle-­‐associated	  membrane	  
protein-­‐associated	  protein	  A	  
+	   +	   +	  
POR	   NADPH-­‐cytochrome	  
P450	  reductase	  
+	   +	   	   VAPB	   Vesicle-­‐associated	  membrane	  
protein-­‐associated	  protein	  B/C	  
+	   +	   +	  
PPIB	   Peptidyl-­‐prolyl	  cis-­‐trans	  
isomerase	  B	  
+	   +	   	   VCP	   Transitional	  endoplasmic	  
reticulum	  ATPase	  
+	   +	   	  
PSMC4	   26S	  protease	  regulatory	  
subunit	  6B	  
+	   +	   	   YIPF5	   Protein	  YIPF5	   +	   +	   	  
	  
	  
The	  majority	  of	  the	  protein	  groups	  concurrently	  identified	  and	  significantly	  enriched	  in	  two	  or	  three	  
assays	   are	   linked	   to	   lipid	   metabolism,	   protein	   folding	   and	   degradation,	   and	   cellular	   transport	  
process.	   Examples	   for	   lipid	   metabolism-­‐related	   proteins	   are:	   sphingolipid	   metabolism	   proteins	  	  
(SACM1L,	   SMPD4,	   SPTLC1,	   SPTLC2,	  VAPA,	  VAPB),	   electron	   transferring	  proteins	   (CYB5R3,	   POR),	   or	  
cholesterol	   metabolizing	   enzymes	   (DHCR7,	   HSD17B7,	   LBR,	   NSDHL).	   Furthermore,	   PGRMC1	   and	  
PGRMC2	  were	  identified	  repeatedly,	  which	  are	  both	  known	  to	  be	  involved	  in	  regulating	  the	  activity	  
of	   various	   metabolic	   enzymes.	   Enriched	   proteins	   linked	   to	   protein	   folding	   and	   degradation	  
machinery	  are	  proteasomal	  subsunits	   (PSMC5,	  PSMD6,	  PSMD6),	  ubiquitin	   (UBB,	  UBC),	  chaperones	  
(CANX,	  HSPA1A,	  HSPA6,	  HSPA7),	  olichyl-­‐diphosphooligosaccharide-­‐protein	  glycotransferase	  (DDOST,	  
RPN1,	   RPN2)	   and	   ERAD-­‐components	   (FAF2,	   ERLIN1,	   EMC2).	   Examples	   for	   proteins	   involved	   in	  
cellular	   transport	   processes	   are	   various	   Rab-­‐proteins	   (RAB1A,	   RAB1B,	   RAB5C,	   RAB7A),	   vesicular	  
transport	   proteins	   (COPA,	   SEC22B,	   SEC23A,	   SCFD1,	   STX18,	   TMED9),	   and	   ER-­‐protein	   import	  
components	  (SRPR,	  SRPRB,	  SSR4).	  	  
	  
4.2.4 Verification	  of	  FA2H	  interaction	  partners	  
With	   quite	   a	   large	   number	   of	   possible	   FA2H	   interaction	   partners	   identified	   in	   the	   different	   mass	  
spectrometry	   based	   screening	   approaches,	   a	   selection	   of	   promising	   candidates	  was	   tested	   by	   two	  
other	   assay	   methods.	   In	   the	   first	   method	   Twin-­‐Strep-­‐mFA2H	   was	   affinity	   purified	   after	   PFA-­‐
crosslinking	   as	   in	   the	   respective	   screenings,	   since	  most	   interactors	  were	  not	   identifiable	  without	   a	  
crosslinking	   step.	   Subsequently,	   the	   co-­‐precipitation	  of	   putative	   interactors	  was	   evaluated	   via	  WB.	  
For	   the	   second	  method	   bimolecular	   fluorescence	   complementation	   assays	   (BiFC)	  were	   conducted,	  
which	   allow	   the	   monitoring	   of	   protein	   interactions	   in	   living	   cells.	   In	   BiFC	   two	   fragments	   of	   a	  
fluorescent	   protein	   are	   fused	   to	   putative	   interacting	   proteins.	   Co-­‐expressed	   in	   the	   same	   cells	   the	  
interaction	  of	   the	   candidate	   proteins	   can	   lead	   to	   the	   complementation	  of	   a	   functional	   fluorescent	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protein,	  which	  can	  be	  visualized	  and	  quantified	  subsequently	  (see	  3.2.4.16	  Bimolecular	  fluorescence	  
complementation	  (BiFC)).	  
	  
4.2.4.1 TWIN-­‐StrepTag	  pulldown	  &	  Western	  blot	  
The	  interactions	  of	  FA2H	  with	  SACM1L,	  ACSL3,	  PGRMC1,	  ALDH3A2	  and	  SPTLC1	  were	  evaluated	  by	  Co-­‐
IP	  and	  WB.	  Thus,	  Twin-­‐Strep-­‐mFA2H	  was	  expressed	  in	  HEK293-­‐T	  cells	  (transient)	  or	  HEK293	  (stable).	  
Afterwards,	   PFA-­‐crosslinking	   was	   applied,	   the	   cells	   lysed	   and	   Twin-­‐Strep-­‐mFA2H	   precipitated	   by	  
StrepTactin-­‐affinity	   purification.	   The	   presence	   of	   putative	   interaction	   partners	   in	   the	   lysate	   (input)	  
and	   the	   eluate	   fraction	   was	   then	   tested	   by	  WB.	   For	   some	   proteins	   two	   additional	   fractions	   were	  
examined:	   unbound	   =	   lysate	   after	   bead	   incubation;	   beads	   =	   not-­‐eluted	   proteins.	   The	   WBs	   using	  
transiently	   transfected	  cells	  are	  shown	   in	  Figure	  4-­‐33	  and	   the	  WBs	  using	  stably	   transfected	  cells	   in	  
Figure	  4-­‐34.	  
	   	  











Figure	  4-­‐33:	  FA2H	  interaction	  partner	  verification	  by	  WB	  (transiently	  transfected	  cells).	  Either	  mock	  (pcDNA3)	  
or	   Twin-­‐Strep-­‐mFA2H	   (pESG-­‐IBA105-­‐mFA2H)	   plasmids	   were	   transfected	   into	   HEK293-­‐T	   cells	   (2x15	   cm	   plate	  
each).	  After	  48	  h,	  cells	  were	  harvested,	  thereby	  combining	  equally	  transfected	  cells.	  Then	  the	  cells	  were	  fixed	  
for	  20	  min	  with	  0.5%	  PFA,	  which	  was	  stopped	  by	  the	  addition	  of	   icecold	  1.25	  M	  glycine	  buffer.	  Cell	   lysis	  was	  
achieved	   in	  RIPA	  buffer	  followed	  by	  protein	  amount	  determination.	  A	  small	  amount	  of	  each	   lysate	  (1%	  (v/v))	  
was	   removed	   for	   later	   analysis	   (Input	   (1%))	   and	   the	   remaining	   lysate	   subjected	   to	   StrepTactin-­‐affinity	  
purification.	   Subsequently,	   each	   eluate	   was	   concentrated	   by	   CHCl3/MeOH-­‐precipitation,	   resuspended	   in	   2X	  
Laemmli	  buffer	  (Eluate).	  In	  some	  cases	  two	  additional	  samples	  were	  prepared.	  One,	  representing	  the	  proteins	  
not	  bound	   to	   the	  affinity	  matrix	   (Unbound	   (1%)),	   taken	   from	   the	   lysate	  after	   affinity-­‐purification.	   The	  other,	  
signifying	  non-­‐eluted	  proteins	  (Beads),	  was	  produced	  by	  boiling	  the	  beads	  in	  2X	  Laemmli	  after	  elution.	  Finally,	  
all	   samples	  were	  heated	   to	  95	   °C	   for	  10	  min,	   separated	  by	  SDS-­‐PAGE,	   transferred	   to	  a	  PVDF-­‐membrane	  and	  
analyzed	  by	  WB.	  Goat-­‐anti-­‐rabbit-­‐HRP	  was	  used	  as	  secondary	  antibody	  (dilution	  1:5000,	  1	  h,	  RT).	  (A)	  SACM1L	  
detected	   by	   anti-­‐SACM1L	   antibody	   incubation	   (dilution	   1:500,	   ON,	   4	   °C).	   (B)	   PGRMC1	   detected	   with	   anti-­‐
PGRMC1	   antibody	   (dilution	   1:1000,	   ON,	   4	   °C).	   (C)	   ALDH3A2	   detected	   with	   anti-­‐ALDH3A2	   antibody	   (dilution	  
1:1000,	  ON,	  4	  °C).	  
The	  SACM1L-­‐WB	  (Figure	  4-­‐33A)	  showed	  many	  proteins	  of	  different	  sizes	  with	  very	  prominent	  ones	  at	  
~30,	   ~60	   and	   ~110	   kDa,	   arguing	   against	   the	   antibodies	   specificity.	   According	   to	   the	   literature,	  
SACM1L	  should	  have	  given	  a	  protein	  signal	  corresponding	  to	  its	  molecular	  mass	  of	  67	  kDa.	  Thus,	  the	  
60	   kDa-­‐signal	   possibly	   represented	   SACM1L	   running	   a	   little	   lower	   than	   expected	   in	   the	   used	   gel	  
system.	   Accordingly,	   one	   could	   speculate	   that	   the	   larger	   protein-­‐band	   at	   ~110	   kDa	   represented	  
SACM1L-­‐dimers.	   But	   both	   signals	   were	   only	   present	   in	   the	   input	   and	   not	   in	   the	   eluate	   fractions	  
regardless	  of	  the	  presence	  of	  Twin-­‐Strep-­‐mFA2H.	  Therefore,	  the	  SACM1L-­‐FA2H	  interaction	  could	  not	  
be	  verified	  by	  WB	  with	  the	  used	  antibody.	  
SACM1L? 
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The	  PGRMC1-­‐WB	  (Figure	  4-­‐33B)	  showed	  a	  single	  band	  at	  ~25	  kDa	  corresponding	  with	   the	  proteins	  
predicted	   molecular	   weight	   (22	   kDa).	   This	   band	   was	   strongly	   visible	   in	   both	   input	   and	   unbound	  
fractions.	  Furthermore,	  a	  weaker	  PGRMC1	  signal	  was	  solely	  present	  in	  the	  +Twin-­‐Strep-­‐mFA2H,	  but	  
not	   in	   the	   mock	   eluate	   fraction,	   proving	   the	   specific	   interaction	   between	   FA2H	   and	   PGRMC1.	  
Together	  with	   the	   strong	  PGRMC1-­‐signals	   in	   the	  unbound	   fraction	   this	   further	   showed	   that	  only	   a	  
small	  fraction	  of	  PGRMC1	  is	   interacting	  with	  FA2H.	  Lastly,	  there	  was	  no	  PGRMC1-­‐signal	   in	  the	  bead	  






Figure	   4-­‐34:	   FA2H	   interaction	   partner	   verification	   by	   WB	   (stably	   transfected	   cells).	   HEK293	   cells,	  
untransfected	   (mock)	   or	   stably	   transfected	   with	   Twin-­‐Strep-­‐mFA2H	   (+Twin-­‐Strep-­‐mFA2H),	   were	   grown	   until	  
reaching	  confluence	  on	  two	  15	  cm	  plates	  each.	  Afterwards,	  cells	  were	  harvested,	  equal	  cells	  from	  two	  plates	  
combined,	   pellets	   fixed	   in	   0.5%	   PFA	   for	   20	  min	   and	   the	   fixation	   stopped	   by	   adding	   icecold	   1.25	  M	   glycine	  
solution.	  Cell	   lysis	  was	  achieved	  in	  RIPA	  buffer	  followed	  by	  protein	  amount	  determination.	  A	  small	  amount	  of	  
each	   lysate	   (1%	   (v/v))	   was	   removed	   for	   later	   analysis	   (Input	   (1%))	   and	   the	   remaining	   lysate	   subjected	   to	  
StrepTactin-­‐affinity	   purification.	   Subsequently,	   each	   eluate	   was	   concentrated	   by	   CHCl3/MeOH-­‐precipitation,	  
resuspended	  in	  2X	  Laemmli	  buffer	  (Eluate).	  Finally,	  all	  samples	  were	  heated	  to	  95	  °C	  for	  10	  min,	  separated	  by	  
SDS-­‐PAGE,	   transferred	   to	   a	   PVDF-­‐membrane	   and	   analyzed	   by	   WB.	   Anti-­‐rabbit-­‐HRP	   was	   used	   as	   secondary	  
antibody	  (dilution	  1:5000,	  1.5	  h,	  RT).	  For	  the	  detection	  of	  more	  than	  one	  protein	  the	  membrane	  was	  stripped	  
and	  reprobed.	  (A)	  SPTLC1	  was	  detected	  by	  incubating	  with	  the	  respective	  antibody	  (dilution	  1:2000,	  2	  h,	  RT).	  
(B)	  ACSL3	  detected	  with	  anti-­‐ACSL3	  antibody	  after	  membrane	  stripping	   (dilution	  1:1000,	  ON,	  4	   °C).	  Note	   the	  
very	  weak	  protein	  signal	  at	  55	  kDa,	  representing	  residual	  anti-­‐SPTLC1	  antibody	  not	  removed	  by	  the	  stripping	  
step.	  
The	  SPTLC1-­‐WB	  (Figure	  4-­‐34A)	  displayed	  one	  major	  signal	  at	  ~54	  kDa,	  fitting	  the	  expected	  molecular	  
weight	   of	   SPTLC1	   (53	   kDa),	   together	   with	   two	   very	   weak	   background	   bands	   of	   greater	   sizes.	   The	  
major	   band	   was	   visible	   within	   both	   input	   fractions,	   but	   just	   in	   the	   +Twin-­‐Strep-­‐mFA2H	   eluate	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higher	  in	  the	  input,	  than	  in	  the	  eluate	  fraction.	  Considering	  this	  difference	  in	  signal	  intensity	  and	  the	  
fact	  that	  only	  ~1%	  of	  the	  total	  lysate	  were	  analyzed,	  it	  became	  obvious	  that	  only	  a	  small	  fraction	  of	  
SPTLC1	  interacted	  with	  FA2H.	  
The	  ACSL3-­‐WB	  (Figure	  4-­‐34B)	  exhibited	  mainly	  one	  prominent	  protein	  band	  at	  ~75	  -­‐	  80	  kDa,	  which	  
was	   in	   line	  with	  ACSL3’s	  predicted	  molecular	  weight	   (80	  kDa).	  As	   for	  SPTLC1,	   it	  was	  present	  with	  a	  
high	  intesity	  in	  both	  input	  and	  with	  less	  intensity	  in	  the	  +Twin-­‐Strep-­‐mFA2H	  eluate	  fraction,	  thereby	  
verifying	  the	  interaction	  between	  FA2H	  and	  ACSL3.	   	  Furthermore,	  this	  difference	  in	  signal	   intensity,	  
together	   with	   the	   fact	   that	   only	   ~1%	   of	   the	   total	   lysate	   were	   analyzed,	   proved	   that	   only	   a	   small	  
fraction	  of	  ACSL3	  was	  interacting	  with	  FA2H.	  
In	   summary,	   PGRMC1,	   SPTLC1	   and	   ACSL3	   could	   be	   verified	   as	   FA2H	   interaction	   partners	   by	   WB,	  
showing	  a	  signal	  in	  the	  eluate	  fraction	  derived	  from	  the	  Twin-­‐Strep-­‐mFA2H	  sample,	  but	  not	  from	  the	  
control	   sample.	   In	   addition,	   it	   became	   clear	   for	   all	   three	   that	   that	   only	   a	   small	   fraction	   of	   each	  
protein	  was	  part	  of	  the	  interaction	  with	  FA2H.	  
4.2.4.2 Bimolecular	  fluorescence	  complementation	  
Verification	   of	   protein	   interaction	   in	   living	   cells	   was	   done	   using	   bimolecular	   fluorescence	  
complementation	   (BiFC)	   for	   the	   interactions	  with	   PGRMC1,	   CersS2,	   ACSL3	   and	   SPTLC1.	   Therefore,	  
cells	   were	   transiently	   transfected	   with	   plasmids	   coding	   for	   Split-­‐YFP-­‐tagged	   putative	   interaction	  
partners.	   The	   complementation	  of	   functional	   fluorescent	  proteins	  was	   then	  qualitatively	  evaluated	  
by	  fluorescence	  microscopy	  (Figure	  4-­‐35).	  As	  a	  positive	  control	  for	  successful	  BiFC,	  cells	  were	  also	  co-­‐
transfected	  with	  plasmids	  coding	  for	  cYFP1-­‐	  and	  YFP2-­‐tagged	  ER-­‐Golgi	  intermediate	  compartment	  53	  
kDa	   protein	   (ERGIC53),	   which	   is	   known	   to	   produce	   a	   strong	   BiFC-­‐signal	   due	   to	   protein	  
oligomerization.	  As	   a	  potential	   second	  positive	   control	  CerS2	   recently	  discovered	  dimerization	  was	  
also	  tested	  by	  BiFC	  (Laviad	  et	  al.	  2012).	  After	  this	   initial	  experiments,	  two	  interactions	  were	  further	  
assessed	   in	   quantitative	   competition	   assays	   using	   fluorescence	   intensity	  measurements	   in	   a	   plate	  
reader	  (Figure	  4-­‐36).	  	  
For	   the	   qualitative	   evaluation,	   BHK	   cells	   were	   seeded	   on	   coverslips	   and	   subsequently	   transfected	  
with	  the	  respective	  constructs.	  24	  h	  after	  transfection,	  the	  cells	  were	  PFA-­‐fixed,	  permeabilized,	  DAPI-­‐
stained	  and	  mounted	  on	   coverslides.	  Representative	   fluorescent	   images	  of	   each	   interaction	   tested	  
are	  shown	  below.	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Figure	   4-­‐35:	   Fluorescent	  microscopy	   of	   BiFC-­‐tested	   protein-­‐protein	   interactions.	  BHK	   cells	  were	   seeded	  on	  
glass	  coverslips	  in	  a	  24-­‐well	  plate.	  24h	  later	  they	  were	  transfected	  with	  1	  µg	  total	  plasmid	  DNA	  (0.5	  µg	  of	  each	  
BiFc-­‐plasmid)	   using	   TurboFect.	   (A)	   –	   (F)	   After	   another	   24	   h,	   the	   cells	   were	   washed,	   fixed	   with	   PFA,	  
permeabilized	  with	   TX-­‐100	   and	   nuclei	   stained	  with	  DAPI.	   Following	   subsequent	  washing	   steps,	   all	   coverslips	  
were	  mounted	  on	  coverslides	  and	  fluorescent	  microscopy	  performed	  using	  63X	  magnification	  and	   immersion	  
oil.	  Since	  no	  YFP-­‐filters	  were	  available,	  the	  constructs	  were	  visualized	  in	  the	  GFP-­‐channel.	  The	  YFP1-­‐ERGIC53-­‐
YFP2-­‐ERGIC	   dimerization	   was	   used	   as	   positive	   control.	   White	   arrowheads	   indicate	   cells	   exhibiting	   an	   ER	   &	  
Golgi-­‐like	   staining	   pattern.	   Unfilled	   arrowheads	   indicate	   cells	   with	   a	   circular	   staining	   pattern.	   Note	   that	   the	  
circular	  assemblies	  seem	  to	  be	  composed	  of	  smaller	  rounder	  structures.	  (G)	  Because	  of	  unstable	  YFP-­‐constructs	  
PFA-­‐fixation,	  permeabilization	  and	  DAPI-­‐staining	  were	  omitted.	  Living	  cells	  were	  mounted	  on	  coverslides	  in	  PBS	  
and	   directly	   visualized	   using	   the	   same	   microscope	   settings	   as	   above.	   Checkered	   arrowheads	   point	   at	   cells,	  
which	  exhibit	  an	  ER	  &	  Golgi-­‐like	  staining	  pattern	  in	  combination	  with	  strongly	  staining	  punctuate	  structures.	  
As	   expected,	   no	   GFP-­‐signals	   were	   visible	   in	   the	   negative	   control	   (mock),	   but	   strong	   signals	   in	   the	  
positive	   control	   (cYFP1-­‐ERGIC53	   +	   YFP2-­‐ERGIC53).	   The	   majority	   of	   the	   cells	   transfected	   with	   the	  
different	   interaction	   partner	   candidates	   showed	   signals,	   which	   varied	   in	   intensity	   and	   shape.	   The	  
oligomerization	   of	   ERGIC53	   showed	   strong	   signals	   with	   a	   typical	   ER	   &	   Golgi-­‐like	   staining	   pattern	  
(white	   arrowheads),	   corresponding	   with	   the	   expected	   protein	   localization.	   Interestingly,	   BiFC	   was	  
also	  able	   to	  verify	   the	   recently	  published	  oligomerization	  of	  CerS2,	   thus	   further	  demonstrating	   the	  
validity	  of	  the	  method.	  Moreover,	  while	  some	  cells	  co-­‐transfected	  with	  CerS2-­‐cYFP1	  and	  CerS2-­‐YFP2	  
also	  exhibited	  ER	  &	  Golgi-­‐like	  signals,	  many	  others	  showed	  a	  very	  different	  signal	  shape.	  In	  those	  the	  
fluorescent	  signal	  was	  observable	  as	  thin	  circular	  assemblies	  composed	  of	  smaller	  round	  structures	  
(unfilled	   arrowheads).	   The	   interaction	   of	   FA2H	   with	   PGRMC1	   was	   also	   observable	   by	   BiFC.	  
Intriguingly,	   it	   presented	   with	   the	   same	   two	   distinct	   staining	   patterns	   as	   the	   CerS-­‐dimerization.	  
Moreover,	   the	   FA2H-­‐CerS2	   interaction	   was	   verified	   by	   BiFC,	   showing	   an	   ER	   &	   Golgi-­‐like	   staining	  
pattern	   similar	   to	   the	   ERGIC53-­‐dimerization.	   In	   contrast,	   no	   signal	   was	   observable	   for	   the	   FA2H-­‐
ACSL3-­‐interaction.	  This	  was	  also	  the	  case	  when	  other	  YFP-­‐tag	  combinations,	  e.g.	  FA2H-­‐YFP1	  &	  ACSL3-­‐
YFP2,	  were	  used	   (data	  not	   shown).	  This	  negative	   result	  does	  not	  disprove	   the	   interaction,	  because	  
some	  protein-­‐protein	  interactions	  are	  not	  accessible	  by	  BiFC	  due	  to	  steric	  constraints.	  If	  the	  two	  YFP-­‐
fragments	  do	  not	   come	   into	  close	  contact,	  no	   functional	   fluorescent	  protein	   is	   complemented	  and	  
thus	   no	   signal	   measurable.	   Alternatively,	   the	   interaction	   may	   be	   indirect	   i.e.	   facilitated	   by	   an	  
additional	  protein	  and	  therefore	  not	  provable	  using	  BiFC.	  Lastly,	  the	  interaction	  of	  FA2H	  and	  SPTLC1	  
was	  also	  shown	  using	  BiFC.	  While	  the	  fluorescent	  signals	  were	  very	  weak,	  an	  ER	  &	  Golgi-­‐like	  staining	  
pattern	   in	   combination	   with	   strongly	   staining	   punctuate	   structures	   could	   still	   be	   discerned	  
(checkered	   arrowheads).	   In	   summary,	   the	   assay	   showed	   the	   complementation	   of	   functional	  
fluorescent	  proteins	  for	  three	  of	  the	  four	  putative	  FA2H	  interaction	  partners	  tested	  (PGRMC1,	  CerS2,	  
SPTLC1),	  thereby	  further	  supporting	  the	  validity	  of	  each	  interaction.	  	  
To	   further	   support	   the	   specificity	   of	   the	   interactions	   two	   of	   them,	   FA2H	   &	   PGRMC1	   and	   FA2H	   &	  
SPTLC1,	  were	  also	  assayed	  in	  BiFC	  competition	  assays.	  Accordingly,	  BHK	  cells	  were	  seeded	  in	  6	  well	  
plates,	   transiently	   transfected	   with	   the	   respective	   BiFC-­‐constructs	   and	   grown	   for	   48	   h.	   For	   the	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competition,	  samples	  were	  included	  in	  which	  untagged	  FA2H,	  PGRMC1	  or	  SPTLC1	  were	  co-­‐expressed	  
together	  with	   their	   BiFC-­‐counterparts.	   If	   the	   interactions	   are	   really	   specific	   the	   untagged	   proteins	  
should	  lead	  to	  a	  fluorescence	  intensity	  reduction,	  since	  complexes	  composed	  of	  tagged	  and	  untagged	  
protein	   are	   not	   fluorescent.	   Note	   that	   a	   complete	   reduction	   will	   not	   be	   achieved,	   since	   the	  
complemented	  fluorescent	  protein	  is	  very	  stable	  once	  it	  has	  been	  formed.	  Thus,	  the	  competitiors	  can	  
only	  sequester	  target	  proteins,	  which	  are	  not	  already	  interacting	  with	  their	  respective	  BiFC-­‐partner.	  
After	  transfection,	  the	  cells	  were	  harvested	  by	  trypsinization,	  washed	  and	  resuspended	   in	  PBS,	  and	  
finally	   transferred	   to	   a	   black	   96	  well	   plate.	   Subsequently,	   fluorescence	   intensities	   were	  measured	  
using	  a	  plate	  reader.	  For	  each	  interaction	  three	  independent	  experiments	  were	  conducted.	  Since	  the	  
measured	  absolute	  intensities	  differed	  strongly	  between	  independent	  experiments,	  due	  to	  variations	  
in	   transfection	   efficiency,	   all	   values	   were	   normalized	   to	   the	   dimerization	   of	   cYFP1-­‐ERGIC53	   with	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Figure	   4-­‐36:	   BiFC	   competition	   assay	   of	   the	   interaction	   FA2H-­‐PGRMC1	   and	   FA2H-­‐SPTLC1.	   BHK	   cells	   were	  
seeded	  in	  6	  well	  plates.	  24	  h	  later	  they	  were	  transfected	  with	  a	  total	  plasmid	  DNA	  amount	  of	  4	  µg	  (0.25	  µg	  of	  
each	  BiFC-­‐plasmids	  filled	  up	  to	  4	  µg	  total	  plasmid	  amount	  with	  pcDNA3).	  To	  further	  support	  the	  specificity	  of	  
the	   interaction,	  competition	  samples	  were	   included	  by	  co-­‐expressing	  high	  amounts	  of	  untagged	  FA2H	  or	   the	  
respective	  interaction	  partner	  (3.5	  µg	  of	  plasmid).	  The	  cYFP1-­‐ERGIC53	  +	  YFP2-­‐ERGIC53	  sample	  was	  included	  as	  
a	  positive	   control.	   Following	  a	  medium	  exchange	  24	  h	  after	   transfection,	   the	  cells	  were	  grown	  another	  24	  h	  
before	  harvesting	  by	  trypsinization.	  Subsequently,	  the	  cells	  were	  washed	  twice	  in	  1	  ml	  PBS,	  resuspended	  in	  200	  
µl	  PBS,	  transferred	  to	  a	  black	  96	  well	  plate	  and	  their	  fluorescence	  measured	  in	  a	  plate	  reader.	  Each	  experiment	  
was	  done	  in	  three	  replicates	  (n=3)	  and	  values	  are	  given	  as	  mean	  +/-­‐	  standard	  deviation.	  P-­‐values	  were	  obtained	  
by	   Student’s	   t-­‐test.	   To	   correct	   for	   intensity	   variations,	   caused	   by	   differences	   in	   transfection	   efficiency,	  
intensities	  are	  given	  relatively	  to	  the	  cYFP1-­‐ERGIC53	  +	  YFP2-­‐ERGIC53	  positive	  control	  (average	  sample/ERGIC53	  
RFU	   ratio).	   (A)	   FA2H-­‐PGRMC1	   interaction.	   Measured	   with	   Mithras	   LB	   940	   plate	   reader.	   (B)	   FA2H-­‐SPTLC1	  
interaction.	  Measured	  with	  Infinite	  200	  PRO	  plate	  reader.	  
The	  FA2H-­‐PGRMC1	  interaction	  was	  repetitively	  measurable	  by	  BiFC	  (Figure	  4-­‐36A).	  Furthermore,	  the	  
specificity	  of	  the	  interaction	  could	  be	  confirmed	  by	  competition	  samples,	  in	  which	  excess	  amounts	  of	  
non-­‐tagged	  hPGRMC1	  or	  mFA2H	  were	  co-­‐expressed	  with	  the	  BiFC-­‐partners.	  While	  the	  co-­‐expression	  
of	  hPGRMC1	  significantly	  reduced	  the	  average	  sample/ERGIC53	  RFU	  ratio	  by	  40%,	  co-­‐expression	  of	  
mFA2H,	   however,	   led	   only	   to	   a	   significant	   reduction	   of	   15%.	   The	   less	   efficient	   competition	   with	  
mFA2H	  might	  be	  explained	  by	  the	  observation	  made	  before,	  that	  FA2H	  may	  functions	  as	  a	  dimer	  (see	  
~80	   kDa	   complex	   in:	   4.2.2.1	   BlueNative	   PAGE	   and	   4.2.2.2	   PFA-­‐crosslinking).	   If	   FA2H-­‐PGRMC1	  
complexes	  also	   contained	   two	  FA2H	  molecules,	   a	   strong	  BiFC	   competition	  was	  only	  possible	  when	  
both	  FA2H-­‐molecules	  were	  replaced	  by	  untagged	  ones.	  Conversely,	   the	  competition	  with	  PGRMC1,	  
presumably	  present	  in	  the	  complex	  as	  a	  monomer,	  was	  much	  more	  efficient.	  
A	  similar	  result	  was	  apparent	  for	  the	  FA2H-­‐SPTLC1	  interaction	  (Figure	  4-­‐36B).	  This	  interaction	  could	  
be	  almost	  completely	  diminished	  by	  competing	  with	  untagged	  FA2H,	  thereby	  significantly	  reducing	  (p	  
=	   0.0107)	   the	   average	   sample/ERGIC53	   RFU	   ratio	   by	   70%.	   Unfortunately,	   the	   competition	   with	  
SPTLC1	   led	   to	   massive	   cell	   death,	   thereby	   not	   allowing	   a	   BiFC	   measurement.	   Thus,	   it	   should	   be	  
repeated	  with	  lower	  plasmid	  amounts	  of	  untagged	  SPTLC1.	  
Taken	   together,	   the	   competition	   experiments	   confirmed	   the	   specific	   interaction	   of	   FA2H	   with	  
PGRMC1	  and	  with	  SPTLC1.	  	  




5.1 Comparative	  quantitative	  myelin	  proteome	  analysis	  of	  FA2H-­‐KO	  mice	  
The	   first	   part	   of	   this	   thesis	   focused	   on	   the	   discovery	   of	   potential	   changes	   in	   the	   myelin	   protein	  
composition	  of	  FA2H-­‐KO	  in	  comparison	  to	  WT	  mice	  by	  mass	  spectrometry	  based	  proteomics.	  Finding	  
differences	  might	  help	  to	  explain	  the	  observed	  pathology.	  Interestingly,	  the	  initial	  analysis	  of	  young	  	  
(~5	  month)	  FA2H-­‐KO	  mice	  by	  WB	  showed	  no	  differences	   for	   some	  major	  CNS-­‐myelin	  proteins,	   like	  
MBP,	  CNP	  and	  L-­‐MAG	  (Zöller	  et	  al.	  2008).	  But	  this	  does	  not	  excludes	  that	  other	  myelin	  proteins	  are	  
changed.	   Moreover,	   some	   changes	   might	   be	   only	   minimal	   in	   young	   animals	   and	   become	   more	  
prominent	   over	   time.	   This	   would	   be	   in	   line	   with	   the	   late	   occurrence	   (~18	  month)	   of	   histological-­‐
observable	  myelin	  changes.	  Thus,	  a	  systematic	  and	  comprehensive	  evaluation	  of	  both	  CNS-­‐	  and	  PNS-­‐
myelin	   from	   animals	   of	   different	   ages	   should	   clarify	   the	   contribution	   of	   proteomic	   changes	   to	   the	  
myelin	  pathology.	  The	  general	  feasibility	  of	  a	  mass	  spectrometry	  based	  screening	  approach	  has	  been	  
shown	  before	  in	  other	  publications	  using	  mouse	  models	  of	  demyelination	  e.g.	  CGalT-­‐KO	  (Taylor	  et	  al.	  
2004),	  PLP-­‐KO	  (Werner	  et	  al.	  2007),	  CGalT-­‐KO	  and	  CST-­‐KO	  	  (Fewou	  et	  al.	  2010)	  and	  prion	  protein-­‐KO	  
(Prnp-­‐KO)	  mice	   (Patzig	  et	  al.	  2011).	  While	   the	   first	   three	  publications	  concentrated	  on	  CNS-­‐myelin,	  
the	   fourth	   one	   investigated	   PNS-­‐myelin.	   In	   all	   recent	   approaches,	   two	   dimensional	   differential	   gel	  
electrophoresis	   (2D	  DIGE)	   (Rozanas	  &	   Loyland	  2008)	  was	  used	   to	  measure	   the	  proteome	   changes.	  
While	   it	   is	   a	   well-­‐established	   method,	   by	   now	   it	   has	   been	   increasingly	   replaced	   by	   shotgun	  
proteomics	  in	  combination	  with	  label-­‐free	  or	  label-­‐based	  protein	  quantification	  (Lambert	  et	  al.	  2005;	  
Brewis	   &	   Brennan	   2010).	   In	   these	   approaches,	   proteins	   are	   digested	   to	   peptides,	   afterwards	  
separated	   by	   multidimensional	   liquid	   chromatography-­‐based	   systems,	   and	   subsequently	   directly	  
analyzed	   in	   a	   mass	   spectrometer.	   These	   systems	   are	   usually	   more	   sensitive,	   allowing	   a	   greater	  
number	  of	  peptide	  and	  protein	  identifications	  and	  are	  also	  better	  applicable	  for	  highly	  charged	  and	  
hydrophobic	   proteins,	   which	   present	   a	   challenge	   for	   gel-­‐based	   systems.	   In	   addition,	   the	   use	   of	  
certain	   labeling	   techniques,	   like	   the	   isobaric	   TMT	   or	   iTRAQ-­‐tags,	   allows	   for	   more	   complex	  
multiplexing	  (Wu	  et	  al.	  2006).	  While	  only	  up	  to	  three	  samples	  can	  be	  measured	  simultaneously	  with	  
DIGE,	  the	  newest	  generation	  of	  TMT-­‐tags	  permits	  the	  quantification	  of	  up	  to	  ten	  samples	  in	  one	  mass	  
spectrometric	  measurement	  (McAlister	  et	  al.	  2012).	  
CNS-­‐	  and	  PNS-­‐myelin	   from	  WT	  and	  KO-­‐animals	  of	   three	  different	  ages	   (6,	  13	  and	  17	  months)	  were	  
each	  compared	  using	  a	  gel-­‐free	  mass	  spectrometry-­‐based	  relative-­‐quantification	  approach,	  including	  
isobaric	   TMT	   6-­‐plex	   peptide	   labeling.	   Furthermore,	   the	   assays	   were	   conducted	   in	   three	   biological	  
replicates.	  Subsequently,	  a	  selection	  of	  changed	  proteins	  was	  independently	  verified	  by	  quantitative	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WBs	  in	  brain	  lysates	  and	  myelin	  obtained	  from	  another	  group	  of	  very	  old	  (21	  –	  23	  months)	  WT	  and	  
FA2H-­‐KO	  animals.	  
Initially,	   myelin	   was	   purified	   from	   both	   tissues	   using	   a	   well-­‐established	   density	   gradient	   method.	  
Afterwards,	  myelin	  purity	  and	  the	  consistency	  of	  purification	  were	  successfully	  confirmed	  by	  1D-­‐SDS-­‐
PAGE	  and	   silver	   staining.	  Moreover,	   it	   showed	  no	  obvious	  protein	  abundance	  differences	  between	  
KO	  and	  WT	  animals	  in	  both	  tissues.	  At	  the	  next	  step,	  the	  proteomic	  analyses	  were	  conducted.	  	  
5.1.1 CNS-­‐myelin	  
Considering	  CNS-­‐myelin,	  1682	  protein	  groups	  could	  be	  identified.	  This	  significantly	  exceeded	  (~30%)	  
the	   number	   of	   about	   1300	   proteins	   constituting	   the	   reference	   list	   compiled	   by	   de	   Monasterio-­‐
Schrader	  and	  colleagues	   from	  all	   articles	  published	  about	   the	  CNS-­‐myelin	  proteome	  until	  2012	   (de	  
Monasterio-­‐Schrader	  et	  al.	  2012).	  This	  was	  even	  more	  drastic	  considering	   that	   in	  each	  single	  study	  
comprising	  the	  compendium	  not	  more	  than	  ~1000	  proteins	  were	  reported.	  Nevertheless,	  about	  2/3	  
(829)	   of	   the	   reference	   CNS-­‐myelin	   proteins	   were	   also	   identified	   in	   this	   study.	   This	   is	   a	   very	   good	  
overlap	   and	   in	   agreement	   with	   observations	   made	   by	   the	   authors	   of	   the	   reference	   list,	   which	  
calculated	   that	   only	   52%	  of	  myelin	   proteins	  were	   found	   in	  more	   than	   one	   experiment,	  while	   48%	  
were	   identified	   once.	   The	   reasons	   for	   this	   are	   that	   each	   study	   differed	   in	   aspects	   like	   sample	  
preparation	   (myelin	  amount,	  delipidation,	  digestion	  method),	  protein	  and/or	  peptide	   fractionation,	  
the	   mass	   spectrometer	   (type,	   generation,	   settings)	   and	   the	   mode	   of	   data	   analysis	   (software,	  
database,	  stringency	  settings).	  Especially	  the	  availability	  of	  the	  newest	  generation	  of	  high	  resolution	  
and	  fast	  scanning	  MS-­‐devices	  allows	  for	  the	  identification	  of	  significantly	  more	  proteins	  than	  found	  in	  
older	  studies.	  Another	  aspect	  is	  data	  analysis	  search	  stringency.	  Some	  of	  the	  studies	  used	  a	  cutoff	  of	  
2	  unique	  peptides	  to	  deem	  an	  identification	  specific.	  In	  contrast,	  in	  this	  study	  a	  false	  discovery	  rate-­‐
based	  (FDR-­‐based)	  approach	  was	  used,	  taking	  even	  proteins	  with	  one	  razor	  peptide	  (peptide	  shared	  
by	   different	   proteins	   comprising	   a	   group)	   into	   account.	   The	   FDR	   is	   calculated	   by	   comparing	   the	  
peptide	  sequence	  information	  to	  a	  decoy	  database	  besides	  the	  normal	  database.	  The	  decoy	  database	  
is	  a	  sequence-­‐reversed	  version	  of	   the	  normal	  database	  and	  thus	  all	  peptides	   found	   in	  the	  reversed	  
database	   should	   be	   false	   positive	   identifications.	   Afterwards,	   the	   search	   algorithm	   dynamically	  
adjusts	   the	   peptide	   score	   significance	   threshold	   to	   a	   value,	   where	   a	   predefined	   amount	   of	   the	  
protein	  identifications	  are	  false	  positives	  (=FDR-­‐treshold).	  In	  this	  study	  this	  FDR-­‐threshold	  was	  set	  to	  
0.01	   (1%	  false	  positive	   identifications).	  But	  even	  when	   filtering	   this	  dataset	   for	   two	  razor	  peptides,	  
1233	  protein	  groups	  remain,	  which	  are	  still	  about	  20%	  more	  identifications	  than	  in	  any	  of	  the	  single	  
studies	   analyzing	  mouse	  myelin	   before.	   Furthermore,	  within	   the	   identified	   1682	   protein	   groups,	   a	  
significant	  amount	  of	  protein	  groups	  was	  present,	  which	  are	  not	  regarded	  “classical”	  myelin	  proteins.	  
This	  is	  expected	  and	  consistent	  with	  myelin	  proteome	  analyses	  published	  before,	  especially	  the	  most	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recent	  ones	  using	  more	   sensitive	  mass	   spectrometers	   (de	  Monasterio-­‐Schrader	   et	   al.	   2012).	   There	  
are	   always	   contaminations	   with	   mitochondria	   and	   synaptic	   vesicles,	   which	   are	   co-­‐purified	   in	   the	  
myelin	   preparation	   process.	   Besides,	   residual	   axonal	  membranes,	  which	   are	   directly	   bound	   to	   the	  
myelin	  sheath,	  are	  also	   inevitably	  co-­‐enriched.	  Still,	  since	  some	  reported	  protein	   locations	  found	   in	  
public	   database	   are	   incorrect	   and	   a	   protein	   may	   have	   more	   than	   one	   localization,	   these	  
identifications	  are	  usually	  not	  excluded	  (de	  Monasterio-­‐Schrader	  et	  al.	  2012).	  	  
As	  the	  next	  step,	  FA2H-­‐KO/WT	  ratios	  were	  calculated	  and	  the	  1682	  protein	  groups	  filtered	  in	  a	  way,	  
that	  only	   those	  remained,	  which	  had	  at	   least	   two	  expression	  ratios	  at	  one	   timepoint.	  This	   reduced	  
the	  list	  to	  1205	  protein	  groups,	  which	  were	  afterwards	  analyzed	  by	  a	  separate	  one-­‐sample	  t-­‐test	  for	  
each	  timepoint,	  to	  find	  protein	  groups	  significantly	  changed	  between	  both	  genotypes.	  Overall,	  there	  
were	  protein	  groups	  both	  up-­‐	  and/or	  downregulated	  at	  all	  three	  timepoints,	  together	  making	  up	  145	  
significant	   changes.	  None	  of	   the	  major	  CNS-­‐myelin	  proteins	  were	   significantly	   changed,	  which	   is	   in	  
line	  with	   the	  previous	  WB	  analyses	  of	  major	  myelin	  proteins	   (Zöller	  et	  al.	  2008).	  Only	   the	  data	   for	  
MBP	  was	   inconsistent,	   possibly	   because	   of	   the	   large	   amounts	   of	   different	  MBP-­‐isoforms.	   Thus,	   its	  
expression	  was	  further	  examined	  by	  WB	  in	  myelin	  and	  whole	  brain	  lysates	  of	  very	  old	  animals	  (21	  –	  
23	  months).	  The	  WB	  clarified	  that	  no	  expression	  difference	  existed	  for	  all	  detectable	  MBP-­‐isoforms	  in	  
brain	   myelin,	   which	   was	   consistent	   with	   the	   protein	   bands	   seen	   in	   the	   silver	   stained	   1D	   gel.	   In	  
contrast,	  MBP	  was	  significantly	  reduced	  in	  the	  whole	  brain	  of	  FA2H-­‐KO	  mice,	  which	  is	  contradictory	  
to	   the	   results	   of	   the	   initial	   FA2H-­‐KO	   mice	   characterization.	   But	   both	   experiments	   cannot	   be	  
compared	   completely,	   because	   the	   animals	   assessed	   back	   then	  were	  much	   younger	   (10	   days	   -­‐	   12	  
weeks).	   Furthermore,	   the	   previous	   quantification	   was	   based	   on	   an	   ECL-­‐WB,	   whereas	   an	   infrared	  
fluorescent	  WB	   (LICOR)	   was	   used	   in	   this	   study,	   whose	   quantification	   results	   are	  more	   reliable.	   In	  
summary,	  these	  results	  suggest	  that	  while	  the	  major	  composition	  of	  myelin	  was	  not	  changed,	  its	  total	  
amount	   became	   reduced	   in	   KO-­‐animals	   during	   aging.	   This	   is	   further	   supported	  by	   the	   observation	  
made	  in	  our	  group	  that	  the	  amount	  of	  compact	  myelin,	  obtained	  from	  FA2H-­‐KO	  animals,	  appeared	  to	  
be	   reduced	   by	   25	   –	   30%	   (Meixner	   2009).	   Furthermore,	   this	   has	   a	   general	   consequence	   for	   the	  
quantification	  of	  myelin-­‐protein	  changes	  in	  FA2H-­‐KO	  mice	  solely	  based	  on	  whole	  brain	  lysates.	  Total	  
brain	  lysates	  are	  usually	  normalized	  by	  loading	  the	  same	  protein	  amounts,	  but	  the	  lysates	  from	  KO-­‐
mice	   contain	   less	   myelin.	   Hence,	   protein	   upregulations	   will	   be	   reduced	   or	   even	   masked,	   while	  
protein	  downregulations	  will	  be	  exaggerated.	  
Analyzing	  the	  145	  significantly	  changed	  protein	  groups	  there	  was	  an	   interesting	  observation.	  While	  
the	  number	  of	  upregulated	  protein	  groups	  increased	  (15	  -­‐>	  11	  -­‐>	  61),	  the	  number	  of	  downregulated	  
decreased	   (35	   -­‐>	   19	   -­‐>	   10)	   over	   time.	   In	   addition,	   only	   a	   small	   number	   of	   protein	   groups	   were	  
constantly	   significantly	   changed.	   In	   detail,	   considering	   the	   upregulated	   proteins,	   some	   permanent	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changes	   existed,	   which	   appeared	   already	   at	   6	   months	   or	   13	   months	   of	   age.	   In	   contrast,	   the	  
downregulated	  proteins	  were	  less	  consistently	  changed,	  with	  many	  reverting	  back	  to	  WT-­‐levels	  in	  17-­‐
month-­‐old	   KO-­‐animals.	   Only	   when	   considering	   not	   significant	   changes,	   a	   small	   number	   of	   protein	  
groups	  seemed	  to	  display	  a	  persistent	  change.	  Nevertheless,	  for	  some	  protein	  groups	  this	  seemingly	  
not	  permanent	  change	  was	  possibly	  just	  a	  result	  of	  a	  high	  biological	  variability.	  One	  has	  to	  consider	  
that	   using	   18	   mice	   varying	   in	   their	   genetic	   background	   purity	   certainly	   caused	   a	   high	   degree	   of	  
biological	  variability.	  This	  in	  turn	  resulted	  in	  higher	  p-­‐values,	  which	  were	  filtered	  out	  by	  the	  applied	  
significance	  threshold.	   In	  summary,	  these	  results	   indicated	  that	  the	  pathology	  of	  FA2H-­‐deficiency	   is	  
aggravating	   over	   time	   with	   more	   proteins	   becoming	   upregulated	   in	   KO-­‐mice.	   Furthermore,	   they	  
suggested	  that	  many	  protein	  changes	  were	  strongly	  compensated	  by	  the	  KO-­‐animals	  organism,	  thus	  
restoring	  the	  amounts	  of	  affected	  proteins	  to	  WT	  levels.	  
The	   145	   significantly	   changed	   protein	   groups	  were	   also	   analyzed	   by	   an	   automated	  GO-­‐annotation	  
analysis,	   which	   gave	   inconclusive	   results.	   The	   protein	   groups,	   up-­‐	   and	   downregulated	   in	   FA2H-­‐KO	  
mice,	   had	   very	   diverse	   cellular	   localizations	   and	   functions.	   The	   only	   striking	   observation	   was	   the	  
considerably	   large	  number	   of	   upregulated	  protein	   groups	   at	   each	   timepoint,	  which	  were	   linked	   to	  
the	  cytoskeleton	  or	  the	  immune	  system.	  Moreover,	  the	  number	  of	  proteins	  found	  in	  both	  categories	  
increased	  over	  time.	  
Since	   the	   strongest	  CNS-­‐myelin	  proteome	  changes	  were	  upregulations	  at	   timepoint	  17M,	   involving	  
mainly	  cytoskeletal	  and	  immune	  system-­‐related	  protein	  groups,	  a	  selection	  of	  these	  were	  studied	  in	  
more	  detail	  by	  WBs.	  Upregulated	  cytoskeletal-­‐related	  proteins	  were	  microtubule-­‐associated	  protein	  
tau	   (MAPT),	   glial	   fibrillary	  acidic	  protein	   (GFAP)	  and	  neurofilament	  heavy	   (NF-­‐H).	   Furthermore,	   the	  
immunological	  complement	  proteins	  C1qb	  and	  C4b,	  the	  cholesterol-­‐transport	  protein	  apolipoprotein	  
E	   (ApoE),	  which	   is	   also	   involved	   in	   immunological	   processes,	   and	   the	   structural	  myelin	  membrane	  
protein	  Opalin	  were	  analyzed.	  All	  of	  these	  seven	  protein	  groups	  had	  at	  least	  a	  ~2-­‐fold	  upregulation	  at	  
timepoint	   17M	   according	   to	   the	   mass	   spectrometric	   analysis.	   Moreover,	   except	   for	   Opalin,	   all	   of	  
these	  are	  often	  not	  considered	  classical	  myelin	  proteins.	  Still,	  they	  have	  all	  been	  identified	  repeatedly	  
in	   systematic	   myelin	   analyses	   (de	   Monasterio-­‐Schrader	   et	   al.	   2012).	   Cytoskeletal	   proteins	   for	  
example	  are	  often	  closely	  linked	  to	  cell	  membranes	  of	  neural	  and	  glial	  origin	  and	  become	  co-­‐purified	  
during	  myelin	  preparation.	  Thus,	  a	  measured	  upregulation	  in	  myelin	  might	  reflect	  an	  upregulation	  in	  
the	   whole	   brain.	   Accordingly,	   the	   WB	   analyses	   were	   conducted	   on	   myelin,	   but	   also	   whole	   brain	  
lysates,	  of	  another	  group	  of	  old	  WT	  and	  FA2H-­‐KO	  mice	  (21	  –	  23	  month).	  	  
Microtubule-­‐associated	   protein	   tau	   is	   a	   cellular	   protein,	   binding	   to	   microtubule	   and	   thereby	  
stabilizing	   them.	   While	   it	   is	   usually	   considered	   a	   neuronal	   protein	   being	   responsibly	   for	   axonal	  
tubulin	  stabilization,	   it	  has	  also	  been	  shown	  to	  be	  expressed	  and	  function	   in	  other	  neural	  cells	  e.g.	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oligodendrocytes	  (LoPresti	  et	  al.	  1995;	  LoPresti	  2002).	  Interestingly,	  in	  oligodendrocytes	  it	  showed	  a	  
similar	   cellular	   distribution	   as	   MBP,	   suggesting	   a	   role	   in	   myelination	   (LoPresti	   et	   al.	   1995).	  
Furthermore,	   under	   certain	   circumstances,	   tau	   can	   become	   hyperphophorylated	   and	   forms	  
intracellular	  fibrillary	  tangle	  aggregates	  in	  a	  still	  not	  fully	  discovered	  process.	  These	  aggregates	  have	  
been	  first	  described	  in	  Alzheimer’s	  disease	  (MIM	  104300),	  but	  by	  now	  they	  have	  also	  been	  found	  in	  a	  
variety	   of	   other	   neurodegenerative	   diseases,	   which	   are	   therefore	   collectively	   called	   tauopathies	  
(MIM:	  157140)	  (Spillantini	  &	  Goedert	  2013).	  Excitingly,	  in	  many	  tauopathies,	  brain	  iron	  accumulation	  
has	  been	  observed	  as	  well	   (Haraguchi	  et	  al.	  2011;	  Lei	  et	  al.	  2012),	  which	   is	  a	   feature	  also	   found	   in	  
some	   FA2H-­‐deficient	   patients	   (Schneider	   &	   Bhatia	   2010).	   Intriguingly,	   the	   mass	   spectrometric	  
analysis	  showed	  a	  ~2-­‐fold	  increase	  of	  microtubule-­‐associated	  protein	  tau	  in	  myelin	  of	  FA2H-­‐KO	  mice,	  
which	  could	  be	  verified	  by	  WB	  (~3-­‐fold).	  In	  contrast,	  the	  total	  tau	  amount	  in	  the	  whole	  brain	  seemed	  
was	  not	  statistically	  significantly	  changed.	  The	  meaning	  of	  the	  myelin-­‐restriced	  increase	  of	  tau	  cannot	  
be	   explained	   conclusively,	   but	   it	   might	   reflect	   a	   relocalization	   of	   oligodendrocyte-­‐expressed	   tau.	  
Thus,	   the	   strong	  overexpression	  of	  myelin-­‐associated	   tau	   in	  FA2H-­‐KO	  animals	  opens	   the	  possibility	  
that	  FA2H	  deficiency	  is	  a	  tauopathy.	  But	  to	  clarify	  this	  issue,	  an	  aggregation	  of	  tau	  in	  FA2H-­‐KO	  mice	  
has	  to	  be	  shown	  first.	  If	  such	  an	  aggregation	  exists,	  it	  might	  explain	  some	  of	  the	  neurodegenerative	  
features	  seen	  in	  FA2H-­‐deficient	  patients.	  Moreover,	  since	  tau	  has	  also	  been	  implicated	  to	  be	  involved	  
in	  myelination	  (LoPresti	  et	  al.	  1995)	  and	  oligodendrocyte	  maturation	  (LoPresti	  2002),	  the	  increase	  in	  
tau	  may	   indicate	  remyelination	   in	  FA2H-­‐KO	  mice.	  Alternatively,	   the	   larger	   tau	  amounts	   in	  FA2H-­‐KO	  
myelin	  might	  have	  been	  only	  a	  consequence	  of	   the	  axon	  and	  myelin	  sheath	  degeneration	   found	   in	  
FA2H-­‐KO	   animals.	   The	   degeneration	   potentially	   led	   to	   increased	   amounts	   of	   cellular	   debris,	  which	  
might	  had	  been	  co-­‐purified	  in	  the	  myelin	  preparation,	  becoming	  evident	  in	  higher	  amounts	  of	  certain	  
cellular	  proteins.	  	  
Glial	   fibrillary	   acidic	   protein	   (GFAP)	   is	   not	   a	   classical	  myelin	   protein,	   but	   usually	   co-­‐purified	   during	  
myelin	  purification	  (de	  Monasterio-­‐Schrader	  et	  al.	  2012).	  Thus,	  it	  can	  be	  considered	  a	  contamination	  
of	   myelin	   with	   astroglial	   cellular	   material.	   GFAP	   is	   one	   of	   the	   major	   cytoskeletal	   intermediate	  
filament	   proteins	   of	   astrocytes,	   thought	   to	   be	   important	   for	  maintaining	  mechanical	   strength,	   cell	  
shape	   and	   motility	   (Middeldorp	   &	   Hol	   2011).	   Still,	   its	   precise	   functions	   are	   largely	   unknown.	  
Furthermore,	  increased	  levels	  of	  GFAP	  are	  a	  marker	  for	  astrogliosis,	  the	  strong	  increase	  in	  activated	  
and	  reactive	  astrocytes,	  following	  different	  types	  of	  CNS	  injury.	  The	  activated	  astrocytes	  proliferate	  
and	  secrete	  various	  factors	  to	  repair	  the	  tissue	  damage	  (Karimi-­‐Abdolrezaee	  &	  Billakanti	  2012).	  But	  if	  
the	   CNS	   damage	   is	   extremely	   severe,	   the	   effects	   caused	   by	   the	   activated	   astrocytes	   can	   be	  more	  
detrimental	   than	   helpful,	   leading	   to	   neuronal	   death	   and	   eventually	   glial	   scaring.	   Accordingly,	  
astrogliosis	   is	   a	   feature	  of	  many	  neuroinflammatory	   and	  neurodegenerative	   diseases,	   like	  multiple	  
sclerosis,	  prion	  associated	  spongiform	  encephalopathies,	  Alzheimer’s	  disease	  and	  Parkinson's	  disease	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(Kurz	  et	  al.	  2012;	  Nagele	  et	  al.	  2004;	  Eng	  &	  Ghirnikar	  1994;	  Linker	  et	  al.	  2009).	  Interestingly,	  the	  GFAP	  
signal	   was	   more	   prominent	   in	   FA2H-­‐KO	   myelin,	   as	   became	   evident	   by	   the	   mass	   spectrometric	  
analysis,	  showing	  a	  ~2.5-­‐fold	  upregulation	  of	  GFAP.	  This	   indicated	  that	  astrogliosis	  was	  occurring	   in	  
brains	  of	  FA2H-­‐KO	  mice,	  becoming	  evident	   in	  higher	  amounts	  of	  co-­‐purified	  GFAP.	  Presumably,	  the	  
axonal	   and	   myelin	   sheath	   degeneration	   led	   to	   brain	   tissue	   lesions,	   which	   were	   populated	   by	  
proliferating	   astrocytes.	   Interestingly,	   this	   expands	   the	   pathology	   of	   FA2H	   deficiency,	   for	   which	  
astrogliosis	  has	  not	  been	  described	  before.	  To	  verify	  this	  assumption,	  quantitative	  WB-­‐analyses	  were	  
performed	  on	  myelin	  and	  whole	  brain	  lysates	  of	  very	  old	  (21	  –	  23	  month)	  WT	  and	  FA2H-­‐KO	  animals.	  
The	   WB-­‐analyses	   successfully	   confirmed	   the	   astrogliosis,	   showing	   even	   a	   ~6-­‐fold	   higher	   GFAP-­‐
amount	  in	  myelin	  and	  a	  ~2-­‐fold	  GFAP-­‐upregulation	  in	  the	  whole	  brain.	  The	  stronger	  GFAP-­‐increase	  in	  
myelin	  in	  the	  WB-­‐analysis	  compared	  to	  the	  mass	  spectrometric	  analysis	  might	  be	  explained	  by	  fact,	  
that	  the	  animals	  use	  for	  the	  WB-­‐analysis	  were	  4	  –	  6	  months	  older	  than	  the	  ones	  measured	  by	  mass	  
spectrometry.	  Consequently,	  it	  could	  be	  speculated	  that	  the	  proposed	  astrogliosis	  is	  aggravating.	  	  
Neurofilament	  proteins	  are	  not	  classical	  myelin	  proteins,	  but	  usually	  co-­‐purified	  probably	  because	  of	  
their	   association	   with	   axonal	   membranes.	   Neurofilament	   heavy	   (NF-­‐H)	   is	   the	   largest	   of	   the	   three	  
major	  neuronal	   intermediate	   filaments.	   Largely	  abundant	   in	  axons,	   they	  are	   responsible	   for	  axonal	  
structural	   integrity	   and	   transport	   (Collard	   et	   al.	   1995).	   In	   addition,	   NF-­‐H	   seems	   to	   be	   especially	  
important	   for	   the	   development	   of	   large-­‐caliber	   myelinated	   axons	   (Elder	   et	   al.	   1998).	   Intriguingly,	  
neurofilaments	   are	   linked	   to	   various	   neurodegenerative	   diseases	   e.g.	   amyotrophic	   lateral	   sclerosis	  
(ALS),	   Charcot-­‐Marie-­‐Tooth	   (CMT)	   disease,	   neurofilament	   inclusion	   disease	   (NFID),	   giant	   axonal	  
neuropathy	   (GAN),	   diabetic	   neuropathy	   and	   spastic	   paraplegia	   (Yuan	   et	   al.	   2012;	   Szaro	   &	   Strong	  
2010).	  Consequently,	  the	  ~2-­‐fold	  increase	  of	  NF-­‐H,	  measured	  by	  mass	  spectrometry	  in	  17-­‐month-­‐old	  
FA2H-­‐KO,	  might	  capitulate	  the	  late	  occurring	  axonal	  degeneration.	  To	  confirm	  this,	  NF-­‐H’s	  expression	  
was	   also	   analyzed	   by	  WB-­‐analyses	   of	   total	   brain	   and	  myelin.	   But	   both	  WBs	   showed	   no	   significant	  
difference	   in	   the	   protein’s	   expression	   between	   both	   genotypes.	   This	   implies	   that	   NF-­‐H	   has	   to	   be	  
considered	   a	   contamination,	   becoming	   co-­‐purified	   during	   myelin	   purification	   in	   an	   inconsistent	  
manner.	  
Besides	  cytoskeletal	  proteins,	  two	  immune-­‐related	  proteins	  showed	  an	  upregulation	  according	  to	  the	  
mass	   spectrometric	   analysis:	   C1qb	   (~4-­‐fold)	   and	   C4b	   (~5-­‐fold).	   Both	   are	   components	   of	   the	  
complement	   cascade	   system	   and	   thus	   major	   mediators	   of	   inflammatory	   responses.	   C1q	   is	   a	   key	  
component	   of	   the	   multiprotein	   C1-­‐complex,	   mediating	   the	   first	   step	   in	   the	   classical	   component	  
activation	  cascade	   in	   the	  context	  of	  an	  antibody-­‐mediated	  response.	   In	  contrast,	  C4b	   is	  part	  of	   the	  
C4-­‐complex,	  which	  itself	  becomes	  activated	  through	  proteolytic	  cleavage	  by	  the	  C1-­‐complex,	  thereby	  
representing	   the	  second	  step	   in	  classical	  component	  activation	  (Kindt	  et	  al.	  2007).	  Accordingly,	   the	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proteins’	   upregulation	   in	   FA2H-­‐KO	   mice	   points	   at	   a	   previously	   unknown	   involvement	   of	   aberrant	  
neuroinflammatory	   processes	   in	   the	   pathogenesis	   of	   FA2H	   deficiency.	   Since	   no	   pathogens	   or	  
autoimmune	  response	  are	  known	  to	  be	  involved	  in	  FA2H	  deficiency,	  this	  result	  was	  rather	  surprising.	  
But	   there	   is	   an	   increase	   in	   research,	   documenting	   a	   antibody-­‐independent	   activation	   of	   the	  
complement	  system	  in	  other	  CNS-­‐pathologies	  like	  Alzheimer’s	  disease	  (Aiyaz	  et	  al.	  2012;	  Shen	  et	  al.	  
2013)	   and	   brain	   or	   spinal	   cord	   injury	   (Qiao	   et	   al.	   2006;	   Pasinetti	   et	   al.	   1992).	   Remarkably,	   in	  
Alzheimer’s	  disease	  it	  seems	  that	  aggregating	  Aβ-­‐itself	  binds	  and	  activates	  the	  C1-­‐complex	  (Rogers	  et	  
al.	  1992),	  and	   there	   is	  also	  evidence	  showing	   the	  same	   for	   tau	   (Shen	  et	  al.	  2001).	  As	   for	   the	  other	  
candidates,	  C1q’s	  expression	  was	  also	  evaluated	  by	  WB-­‐analyses	  in	  myelin	  and	  whole	  brain.	  Besides	  
the	   expected	   C1q-­‐signal,	   the	   used	   antibody	   produced	   a	   strong	   additional	   and	   probably	   unspecific	  
signal,	  which	  did	  not	  correspond	  to	  the	  proteins	  normal	  size.	  Therefore,	  the	  whole	  antibody	  might	  be	  
unspecific,	   casting	  doubt	  on	   the	  quantification	  results.	  While	  a	  significant	  ~2-­‐fold	  upregulation	  was	  
observable	   in	   myelin,	   no	   significant	   change	   was	  measurable	   in	   the	   whole	   brain.	   Accordingly,	   C1q	  
should	  be	  verified	  with	  another	  antibody	  to	  be	  sure	  of	  its	  upregulation.	  Alternatively,	  the	  expression	  
of	  other	  complement	  factors	  could	  be	  examined	  to	  clarify	  the	  contribution	  of	  neuroinflammation	  to	  
the	  pathology	  of	   FA2H	  deficiency.	  Moreover,	   in	   the	  myelin	  WB-­‐analysis	   the	  measured	   change	  was	  
only	  ~2-­‐fold	  and	  thus	  substantially	  smaller	  than	  in	  the	  MS-­‐analysis	  (~4-­‐fold).	  Since	  the	  animals	  used	  
in	   the	  WB	   were	   significantly	   older,	   the	   opposite	   result	   had	   been	   expected.	   Older	   animals	   should	  
show	  at	   least	  a	  similar	  or	  even	  a	  higher	  degree	  of	  neuroinflammation.	  An	  explanation	  may	  be	  that	  
the	  neuroinflammation	  is	  occurring	  in	  episodes,	  and	  thus	  the	  C1q-­‐level	  is	  fluctuating	  over	  time.	  
In	  accordance	  with	  the	  upregulation	  of	  complement	  proteins,	  apolipoprotein	  E	  (ApoE)	  exhibited	  an	  
increase	   (~2-­‐fold)	   in	   FA2H-­‐KO	   myelin	   as	   well.	   This	   protein,	   being	   the	   essential	   apolipoprotein	   of	  
chylomicrons	  and	  very	   low-­‐density	   lipoproteins,	  has	  been	  known	  and	  studied	  extensively	  regarding	  
its	   role	   in	   cholesterol	   transport.	   In	   addition,	   by	   now	   it	   has	   been	   proven	   to	   play	   roles	   in	  
neurodegenerative	  diseases	  like	  Alzheimer’s	  disease	  (Kim	  et	  al.	  2009;	  Kanekiyo	  et	  al.	  2014).	  Likewise,	  
ApoE	  is	  also	   involved	  in	   immunoregulation	  processes	  as	  has	  been	  shown	  in	  Alzheimer’s,	  but	  also	   in	  
other	   diseases	   like	  multiple	   sclerosis	   and	  Guillain-­‐Barré	   syndrome	   (Zhang	   et	   al.	   2011;	   Zhang	   et	   al.	  
2010).	  Intriguingly,	  ApoE	  seems	  to	  modulate	  microglial	  and	  macrophage	  activation	  by	  switching	  them	  
from	   a	   pro-­‐	   to	   an	   anti-­‐inflammatory	   state	   (Baitsch	   et	   al.	   2011).	   For	   the	   FA2H-­‐KO	   mice	   the	  
upregulation	  of	  ApoE	  therefore	  strengthens	  the	  observation	  that	  neuroinflammation	  was	  present	  in	  
the	  diseased	  animals	  brains.	  Presumably,	  the	  organism	  tried	  to	  attenuate	  this	  neuroinflammation	  by	  
increasing	   its	   ApoE	   amounts.	   Again,	   the	   upregulation	   of	   ApoE	   found	   in	   the	   mass	   spectrometric	  
screening	  could	  also	  be	  verified	  by	  WB	  in	  whole	  brain	  and	  myelin.	  While	  a	  similar	  increase	  of	  ~2-­‐fold	  
could	  be	  measured	  and	  quantified	  in	  the	  whole	  brain,	  the	  myelin	  WB	  result	  allowed	  no	  quantitative	  
evaluation.	  Nevertheless,	   because	  ApoE	  became	  visible	  with	   a	   strong	  protein	   signal	   in	   all	   four	   KO-­‐
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animals,	   but	  with	   a	  weak	   signal	   in	   only	   a	   single	  WT-­‐animal,	   its	   upregulation	   in	  myelin	   of	   FA2H-­‐KO	  
mice	  was	  clearly	  verified.	  
Lastly,	   the	   mass	   spectrometric	   analysis	   also	   revealed	   the	   ~2-­‐fold	   upregulation	   of	   the	   myelin	  
membrane	  protein	  Opalin,	  for	  which	  only	  a	  small	  amount	  of	  information	  is	  available.	  Moreover,	  the	  
upregulation	  could	  also	  be	  verified	  using	  quantitative	  WBs	   in	  myelin	   (~5-­‐fold)	  and	  whole	  brain	  (~3-­‐
fold).	   Initially,	   Opalin,	   also	   called	   transmembrane	   protein	   10	   (Tmem10),	   was	   discovered	   in	   a	  
chromosome	   locus	   associated	   with	   temporal	   lobe	   epilepsy	   and	   spastic	   paraplegia	   (Nobile	   et	   al.	  
2002).	   Later	   research	   revealed	   Opalin	   to	   be	   an	   oligodendrocyte	   specific	   transmembrane	  
sialylglycoprotein,	  which	  starts	  being	  expressed	  during	  early	  myelination	  and	  becoming	  later	  mainly	  
located	  in	  myelin	  paranodal	  loops.	  There	  it	  is	  speculated	  to	  have	  an	  intermembranous	  connective	  or	  
signaling	  function	  (Aruga	  et	  al.	  2007;	  Kippert	  et	  al.	  2008;	  Golan	  et	  al.	  2008;	  Yoshikawa	  et	  al.	  2008).	  
Furthermore,	   recent	   research	   results	   showed	   that	   it	   is	   largely	   found	   in	   mature	   oligodendrocytes,	  
becoming	  expressed	  after	  the	  typical	  early	  myelin	  proteins	  MBP	  and	  MAG	  (Jiang	  et	  al.	  2013).	  In	  the	  
same	   article,	   the	   authors	   further	   showed	   that,	   Opalin	   was	   reduced	   in	   a	   hypomyelination	   mouse	  
model.	  This	  is	  in	  line	  with	  an	  earlier	  publication,	  which	  revealed	  a	  reduced	  expression	  of	  Opalin	  and	  
other	  major	  myelin	  proteins	   like	  myelin-­‐associated	  glycoprotein	  (MAG)	  and	  myelin	  and	   lymphocyte	  
protein	  (MAL)	   in	  a	  canine	  model	  of	  the	  lysosomal	  storage	  disease	  fucosidosis	  (Fletcher	  et	  al.	  2011).	  
On	   the	   contrary,	   in	   a	   Parkinson’s	   disease	   related	   LRRK2-­‐KO	  mouse	  model	  Opalin	  was	   found	   to	   be	  
increased	   significantly	   (Dorval	   et	   al.	   2014).	   Furthermore,	   my	   own	   results	   also	   showed	   an	  
upregulation	  of	  Opalin	  in	  myelin	  and	  whole	  brain	  of	  FA2H-­‐KO	  mice.	  Since	  Opalin	  may	  have	  a	  function	  
in	   myelin	   stability	   maintenance,	   the	   upregulation	   could	   explain	   the	   long-­‐term	   myelin	   instability	  
caused	   by	   FA2H	   deficiency.	   Moreover,	   the	   higher	   amounts	   of	   Opalin	   in	   FA2H-­‐KO	   myelin	   can	   be	  
explained	   by	   different	   mechanisms.	   First,	   Opalins	   transport	   may	   be	   dependent	   on	   2-­‐OH	  
sphingolipids.	  Since	  these	  lipids	  are	  missing	  in	  FA2H-­‐KO	  mice,	  the	  protein	  may	  become	  mislocalized	  
from	   its	   normal	   localization,	   the	   paranodes,	   to	   compact	   myelin.	   Potentially,	   the	   cells	   try	   to	  
counteract	  this	  by	  producing	  higher	  amounts	  of	  the	  protein,	  thereby	  leading	  to	  an	  overall	  increase	  of	  
Opalin	  in	  the	  whole	  brain.	  Alternatively,	  the	  transport	  of	  Opalin	  is	  not	  affected.	  Instead	  the	  protein’s	  
increase	   in	   myelin	   might	   reflect	   a	   stronger	   gene	   expression	   of	   Opalin.	   But	   to	   clarify	   this,	   further	  
studies	  have	  to	  be	  conducted.	  
5.1.2 PNS-­‐myelin	  
Besides	   CNS-­‐myelin,	   PNS-­‐myelin	   derived	   from	   the	   same	   animals	   was	   analyzed	   as	   well.	   While	   the	  
protein	   composition	   of	   FA2H-­‐KO	   PNS-­‐myelin	   has	   not	   been	   investigated	   so	   far,	   the	   PNS-­‐pathology	  
observed	  in	  some	  very	  old	  (~18	  month)	  mice	  argues	  for	  a	  systematic	  evaluation	  (Zöller	  et	  al.	  2008).	  
Thus,	   PNS-­‐myelin	  was	   analyzed	  by	   the	   same	   analytical	   setup,	   leading	   to	   the	   identification	   of	   1309	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protein	   groups.	   This	   largely	   extended	   the	   currently	   known	   PNS-­‐myelin	   proteome	   (550	   PNS-­‐myelin	  
proteins	  (Patzig	  et	  al.	  2011))	  by	  ~160%.	  While	  at	  the	  first	  glance	  this	  number	  seems	  to	  be	  extensively	  
large,	   one	   has	   to	   consider	   that	   the	   reference	   study	   was	   actually	   the	   first	   systematic	   mass	  
spectrometry	   study	   conducted	  on	  PNS-­‐myelin	   so	   far.	   Comparatively,	   in	   CNS-­‐myelin	   the	   number	   of	  
identifications	  was	  also	   increasing	  with	  every	  new	  publication,	   starting	  with	  about	  100	   in	   the	  2004	  
publication	  by	  Taylor	  and	  colleagues	  (Taylor	  et	  al.	  2004)	  and	  reaching	  ~1000	  in	  the	  recent	  publication	  
by	  Gopalakrishnan	   and	   colleagues	   (Gopalakrishnan	  et	   al.	   2013).	   The	   reasons	   for	   this	   increase	  over	  
time	  are	  the	  same	  discussed	  for	  the	  CNS-­‐myelin	  above	  e.g.	   improved	  sample	  preparation	  and	  mass	  
spectrometry	   instrumentation.	   But	   for	   the	   same	   reasons	   it	   also	   has	   to	   be	   assumed	   that	   a	   certain	  
amount	   of	   the	   newly	   identified	   proteins	   are	   contaminants,	   becoming	   detactable	   by	   the	   more	  
sensitive	  instruments.	  Nevertheless,	  a	  comparison	  of	  the	  1309	  identifications	  with	  the	  550	  previously	  
reported	   identifications	   supported	   the	   validity	   of	   this	   study	   by	   showing	   a	   huge	   congruency.	   387	  
(~70%)	  of	  the	  previously	  identified	  proteins	  were	  present	  in	  our	  study	  as	  well.	  	  	  
Afterwards,	  analogous	  to	  the	  CNS-­‐myelin	  analysis,	  FA2H-­‐KO/WT	  ratios	  were	  calculated	  for	  the	  three	  
timepoints.	  Subsequently	  the	  protein	  groups	  were	  filtered	  in	  a	  way	  that	  only	  those	  remained,	  which	  
exhibited	  at	  least	  two	  expression	  ratios	  at	  one	  timepoint.	  This	  reduced	  the	  protein	  list	  to	  830	  entries.	  
Thereafter,	   significantly	   changed	   protein	   groups	   were	   calculated	   by	   one-­‐sample	   t-­‐tests,	   which	  
resulted	   in	   a	   list	   of	   95	   protein	   groups	   being	   significantly	   changed	   at	   at	   least	   one	   timepoint.	  
Interestingly,	   none	   of	   the	  major	   PNS-­‐myelin	   proteins	  were	   part	   of	   the	   significant	   changes,	   except	  
periaxin.	  Because	  of	   the	  mixed	  genetic	  background	  of	   the	  analyzed	  mice,	   it	  was	  unclear	   if	  periaxin	  
was	  upregulated	  in	  17-­‐month-­‐old	  FA2H-­‐KO	  animals.	  Therefore,	  periaxin’s	  expression	  status	  had	  to	  be	  
additionaly	   clarified	   by	   WB.	   This	   analysis	   showed	   that	   periaxin,	   like	   the	   other	   major	   PNS-­‐myelin	  
proteins,	  was	  not	  significantly	  changed	  between	  WT	  and	  FA2H-­‐KO	  animals.	  	  
Moreover,	  when	  considering	  all	  95	  significantly	  changed	  protein	  groups,	  most	  were	  not	  consistently	  
changed.	  Overall,	  the	  majority	  of	  these	  changes	  were	  found	  in	  the	  17-­‐month-­‐old	  animals,	  which	  is	  in	  
line	  with	   the	  observed	   late	   on-­‐set	   of	   the	   PNS-­‐pathology.	   In	   addition,	  when	   looking	   at	   the	   average	  
FA2H-­‐KO/WT	  ratios	  regardless	  of	  their	  significance,	  the	  expression	  of	  many	  varied	  strongly	  between	  
the	   three	   timepoints,	   indicating	   a	   high	   degree	   of	   biological	   variability.	   Still,	   a	   few	   protein	   groups	  
might	  have	  been	  altered	  more	  constantly,	  having	  similar	  average	  expression	  ratios	  at	  more	  than	  one	  
timepoint.	  Accordingly,	  about	  20	  protein	  groups	  existed,	  which	  were	  significantly	  changed	  exclusively	  
at	   timepoint	   13	   or	   17M,	   but	   had	   a	   second	   expression	   value	   at	   the	   other	   timepoint	   that	   was	   not	  
significant.	   Therefore,	   to	   confirm	   these	   potential	   consistent	   changes,	   the	   experiment	   should	   be	  
repeated	   with	   additional	   animals.	   Besides,	   complementary	   experiments,	   like	   WBs	   or	  
immunofluorescence	   stainings,	   should	   be	   done	   as	  well.	   Furthermore,	   it	   has	   to	   be	   considered	   that	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some	  protein	  alterations	  may	  manifest	  at	  late	  stages	  of	  the	  disease	  progression	  and	  thus	  cannot	  be	  
measured	   in	   young	   animals.	   Consequently,	   the	   mass	   spectrometry	   screening	   should	   be	   also	  
conducted	  with	  old	  animals	  starting	  at	  ~17	  month	  of	  age.	  Likewise,	  it	  should	  be	  mentioned	  that	  the	  
PNS-­‐pathology	  in	  general	  is	  very	  variable	  between	  individual	  mice	  regarding	  onset	  and	  severity.	  From	  
observations	   made	   in	   our	   group	   (not	   published),	   this	   seems	   to	   be	   particularly	   affected	   by	   the	  
animals’	   genetic	   background.	   While	   many	   of	   the	   initially	   analyzed	   very	   old	   mixed-­‐background	  
(129Ola/C57BL/6)	  mice	  developed	  a	  progressing	  hindlimb	  paralysis,	  this	  was	  not	  the	  case	  for	  a	  small	  
number	   of	   the	   animals	   backcrossed	   to	   a	   C57BL/6	   background.	   Thus,	   it	   would	   be	   an	   option	   to	  
selectively	   analyze	   only	   FA2H-­‐KO	  mice,	  which	   have	   already	   developed	   the	   paralysis,	   to	   get	   clearer	  
results.	  
Still,	   the	   potentially	   changed	   protein	   groups	   contained	   some	   promising	   proteins.	   Considering	   the	  
upregulated	  protein	  groups	  the	  most	  interesting	  changes	  were	  upregulations	  of	  CD36	  and	  galectin	  3.	  
CD36	   is	   an	   integral	   plasma	  membrane	   scavenger	   receptor,	  which	   has	   been	   shown	   to	   bind	   various	  
ligands,	  e.g.	  anionic	  phospholipids,	  collagen,	  oxidized	  low-­‐density	  lipoproteins	  and	  thrombospondin.	  
Moreover,	   it	   is	   involved	   in	   the	   binding	   and	   transport	   of	   long-­‐chain	   fatty	   acids.	   Accordingly,	   it	   has	  
been	  described	   to	   be	   involved	   in	   various	   processes,	   like	   angiogenesis,	   atherosclerosis,	  metabolism	  
and	  immunity.	  For	  example,	   it	  has	  been	  shown	  to	  promote	  adipocyte	  differentiation	  (Christiaens	  et	  
al.	   2012).	   In	   this	   regard	   a	   captivating	   link	   exist	   to	   FA2H.	   In	   a	   cell	   culture	   model	   of	   adipocyte	  
differentiation	   the	   siRNA-­‐mediated	   knock-­‐down	   of	   FA2H	   inhibited	   the	   differentiation	   and	   led	   to	  
decreased	   levels	   of	   CD36	   mRNA	   (Guo	   et	   al.	   2010).	   Moreover,	   studies	   using	   CD36-­‐KO	   mice	   have	  
shown,	  that	  its	  presence	  on	  the	  surface	  of	  macrophage	  is	  important	  for	  the	  phagocytosis	  of	  degraded	  
myelin	   after	   nerve	   injury	   (Eto	   et	   al.	   2003).	   Thus,	   CD36-­‐KO	  mice	   exhibited	   a	   delayed	   clearance	   of	  
myelin	  debris,	  which	   in	  turn	   led	  to	  a	  delayed	  remyelination.	  As	  a	  consequence,	  the	  upregulation	   in	  
PNS-­‐myelin	  indicates,	  that	  the	  demyelination	  observed	  in	  FA2H-­‐KO	  mice	  is	  potentially	  accompanied	  
by	  myelin	  phagocytosis	  and	  remyelination.	  	  
The	   also	   upregulated	   lectin	   galectin	   3	   (Lgals3)	   is	   involved	   in	   similar	   processes.	   Galectin	   3	   binds	   to	  
various	  oligosaccharide	   chains	  of	   glycosylated	  PM	  or	   extracellular	  matrix	  proteins.	   The	  protein	  has	  
been	   shown	   to	   play	   an	   important	   role	   in	   inflammatory	   diseases.	   For	   example,	   galectin	   3	   is	  
upregulated	   in	   experimental	   autoimmune	   encephalomyelitis	   and	   it’s	   KO	   drastically	   reduces	   the	  
disease	   severity	   (Jiang	   et	   al.	   2009).	   Moreover,	   in	   the	   CNS	   it	   has	   been	   shown	   to	   promote	  
oligodendrocyte	   differentiation,	   which	   is	   needed	   for	   myelination.	   Accordingly,	   Lgals3-­‐KO	   mice	  
showed	  signs	  of	  demyelination	  (Pasquini	  et	  al.	  2011).	  In	  the	  PNS	  it	  has	  been	  shown	  to	  be	  upregulated	  
in	   Schwann	   cells	   after	   PNS	   injury	   and	   inhibits	   the	   cells’	   proliferation	   (Gustavsson	   et	   al.	   2007).	  
Therefore,	  its	  upregulation	  in	  myelin	  of	  old	  FA2H-­‐KO	  mice	  might	  represent	  similar	  processes.	  	  
5	  Discussion	  -­‐	  Comparative	  quantitative	  myelin	  proteome	  analysis	  of	  FA2H-­‐KO	  mice	  
	  
149	  
Regarding	  the	  downregulated	  protein	  groups,	  the	  potentially	  most	  interesting	  one	  was	  prion	  protein	  
(Prnp).	  Prion	  protein	  is	  a	  glycosylphosphatidylinositol-­‐anchored	  membrane	  glycoprotein	  targeted	  to	  
lipid	  rafts	  (Taylor	  et	  al.	  2009).	  It	  can	  exist	  in	  different	  isoforms,	  most	  notably	  the	  normal	  cellular	  PrPC	  
and	   the	  misfolded	   and	   aggregating	   PrPSC.	   The	   later	   is	   the	   disease-­‐causing	   agent	   in	   so-­‐called	   prion	  
diseases,	   like	   Creutzfeldt-­‐Jakob	   disease,	   bovine	   spongiform	   encephalopathis	   or	   scrapie	   (OMIM:	  
176640).	   The	   normal	   functions	   of	   PrpC	   are	   still	   not	   completely	   understood,	   but	   it	   seems	   to	   be	  
involved	   in	   a	   couple	   of	   processes	   e.g.	   iron	   uptake	   and	   homeostasis	   (Singh	   et	   al.	   2009),	   neuronal	  
development	   (Steele	   et	   al.	   2006),	   synaptic	   plasticity	   (Laurén	   et	   al.	   2009),	   and	   PNS	   myelin	   sheath	  
maintenance	   (Bremer	   et	   al.	   2010).	   Evidence	   for	   the	   last	   function	   came	   from	   studies	  with	   PrPC-­‐KO	  
mice.	  The	  animals	  developed	  a	  chronic	  demyelinating	  polyneuropathy	  (CDP)	  in	  the	  PNS.	  Intriguingly,	  
similar	  to	  FA2H-­‐KO	  mice,	  the	  PrPC-­‐KO	  animals	  had	  a	  normal	  initial	  myelin	  development,	  but	  its	  long-­‐
term	  stability	  was	  impaired.	  Furthermore,	  CDP	  only	  occurred	  if	  the	  gene	  was	  deleted	  in	  neurons,	  but	  
not	   in	   Schwann	   cells.	   This	   suggests	   that	   neuronal	   PrPC	   is	   involved	   in	   the	   directed	   communication	  
between	   axons	   and	   Schwann	   cells	   and	   this	   communication	   seems	   to	   be	   essential	   for	  maintaining	  
myelin	  stability.	  Hence,	  the	  reduction	  of	  PrPC	  in	  PNS-­‐myelin	  of	  FA2H-­‐KO	  mice	  may	  explain	  the	  long-­‐
term	  myelin	  instability.	  A	  possible	  mechanism	  could	  be	  that	  the	  loss	  of	  2-­‐OH	  sphingolipids	  from	  lipid	  
rafts	   is	   interfering	   with	   PrPC’s	   localization.	   But	   to	   clarify	   this	   assumption,	   further	   experiments	   are	  
needed.	  First	  of	  all	  the	  mass	  spectrometry	  result	  should	  be	  confirmed	  by	  WB.	  Afterwards,	  a	  potential	  
PrPC-­‐mislocalization	   could	   be	   confirmed	   by	   immunostainings	   in	   isolated	   nerves	   and	   cell	   culture	  
models	  of	  FA2H	  deficiency.	  
Another	  downregulated	  protein	  group	  contained	   the	   small	  VCP/p97-­‐interacting	  protein	   (Svip).	   Svip	  
was	   initially	   identified	   as	   a	   cofactor	   of	   the	   ATPase	   VCP,	   which	   is	   an	   essential	   component	   of	   ER-­‐
associated	  degradation	  (ERAD)	  (Nagahama	  et	  al.	  2003).	  Further	  studies	  showed	  that	  it	  functions	  as	  a	  
negative	  regulator	  of	  ERAD	  (Ballar	  et	  al.	  2007)	  and	  that	  its	  expression	  is	  largely	  restricted	  to	  the	  CNS	  
and	   PNS,	   where	   it	   co-­‐localizes	   with	   VCP	   in	   neuronal	   cell	   bodies	   (Wang	   et	   al.	   2011).	   Intriguingly,	  
recent	   findings	   showed	   that	   it	   is	   also	   localized	   to	   compact	  myelin	   independent	   of	   VCP	   (Wu	   et	   al.	  
2013).	   There	   it	   might	   be	   important	   for	   myelin	   compaction,	   because	   of	   certain	   structural	  
characteristics	  similar	  to	  MBP,	  as	  the	  authors	  of	  this	  study	  suggested.	  As	  a	  consequence,	  it	  could	  be	  
speculated	   that	   its	   reduction	   leads	   to	   the	   long-­‐term	  myelin	   instability	   observed	   in	   FA2H-­‐deficient	  
mice.	  
5.1.3 Conclusion	  
In	   summary,	   the	   proteomic	   analysis	   of	   CNS-­‐	   and	   PNS-­‐myelin	   of	   FA2H-­‐KO	   mice	   revealed	   some	  
interesting	  protein	  changes,	  of	  which	  some	  may	  be	  essential	  in	  understanding	  the	  pathology	  of	  FA2H	  
deficiency.	   In	  the	  CNS	  the	  most	  prominent	  ones	  were	  upregulations	  of	  C1qb,	  C4b,	  ApoE,	  GFAP	  and	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tau,	   hinting	   at	   previously	   unknown	   roles	   of	   inflammation,	   astrogliosis	   and	   tau	   aggregation	   in	   the	  
pathology	  of	  FA2H	  deficiency.	  Moreover,	  Opalin,	  a	   structural	  myelin	  membrane	  protein	  potentially	  
involved	  in	  myelin	  stability	  maintenance,	  was	  also	  upregulated.	  Accordingly,	  it	  might	  account	  for	  the	  
long-­‐term	   myelin	   instability	   found	   in	   FA2H-­‐KO	   mice,	   but	   this	   has	   to	   be	   verified	   by	   further	  
experiments.	   In	   the	   PNS	   the	   analysis	   results	  were	   less	   consistent,	   but	   there	  was	   still	   evidence	   for	  
some	  noteworthy	  protein	  changes.	  For	  example,	  CD36	  and	  galectin	  3	  seem	  to	  be	  upregulated,	  which	  
is	  indicative	  of	  processes	  like	  myelin	  debris	  clearance	  and	  remyelination.	  In	  addition,	  there	  seemed	  to	  
be	  a	  reduction	  of	  PrPC	  ans	  Svip	  in	  FA2H-­‐KO	  myelin.	  Similar	  to	  Opalin	  in	  the	  CNS,	  both	  proteins	  may	  be	  
been	  necessary	  for	  myelin	  stability	  and	  thus	  might	  explain	  the	  long-­‐term	  PNS-­‐myelin	  instability.	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5.2 Interaction	  partners	  of	  FA2H	  
The	  second	  part	  of	   this	   thesis	   focused	  on	  the	  discovery	  of	  protein	   interactions	  partners	  of	  mFA2H.	  
Identifying	  them	  might	  give	  insights	  into	  the	  regulation	  of	  sphingolipid	  metabolism	  and	  possibly	  the	  
pathology	  of	  FA2H	  deficiency,	  which	  may	  not	  only	  be	  caused	  by	  loss	  of	  2-­‐OH	  sphingolipids	  synthesis,	  
but	   the	   loss	   of	   certain	   protein	   interactions	   of	   FA2H.	   Evidence	   for	   this	   assumption	   is	   given	   by	   the	  
observation	  that	  some	  FA2H	  mutations	  found	  in	  SPG35	  patients	  retained	  high	  or	  WT-­‐levels	  of	  FA2H	  
activity	   (Dick	  et	  al.	   2010;	  Kruer	  et	  al.	   2010).	   For	   the	  discovery	  of	   interaction	  partners	   two	   types	  of	  
affinity	  tag-­‐based	  Co-­‐IP	  experiments	  were	  done	  in	  combination	  with	  quantitative	  mass	  spectrometry.	  
The	  two	  affinity	  systems	  used	  were	  the	  Twin-­‐StrepTag-­‐StrepTactin	  system	  and	  the	  BioID-­‐system.	   In	  
the	   first	   system	   interactors	   were	   directly	   co-­‐purified	   with	   recombinantly	   expressed	   Twin-­‐Strep-­‐
mFA2H.	   In	   contrast,	   in	   the	   second	   system	   a	   fusion	   protein	   of	   a	   biotin-­‐ligase	   and	   mFA2H	   was	  
expressed,	  leading	  to	  the	  biotinylation	  of	  proteins	  proximal	  to	  FA2H.	  These	  were	  then	  purified	  using	  
biotin-­‐specific	  NeutrAvidin-­‐affinity	  purification.	  Furthermore,	  quantitative	  mass	  spectrometry,	  using	  
SILAC-­‐labeling,	  was	  included	  to	  reduce	  the	  number	  of	  false	  interaction	  partner	  identifications,	  caused	  
by	  proteins	  unspecifically	  bound	  to	  the	  affinity-­‐matrix	  material.	  
5.2.1 Initial	  detection	  of	  FA2H-­‐containing	  protein	  complexes	  
In	   the	   beginning,	   mFA2H	   was	   cloned	   into	   expression	   vectors	   for	   both	   systems.	   Afterwards,	   the	  
expression	   of	   constructs	   and	   functionality	   of	   both	   systems	   could	   be	   verified	   in	   initial	   experiments	  
using	  immortalized	  human	  cell	  lines	  (HeLa	  and	  HEK293-­‐T).	  These	  cell	  lines	  were	  chosen,	  because	  they	  
allow	  the	  efficient	  transfection	  of	  large	  cell	  numbers	  needed	  for	  the	  affinity	  purification	  process	  and	  
thus	  have	  been	  often	  used	   in	   similar	   studies.	   Since	   FA2H	   is	   highly	   conserved	  between	  human	  and	  
mouse,	  with	   the	  murine	  enzyme	  being	  active	   in	  human	  cells,	   this	   should	  not	   reduce	  validity	  of	   the	  
Co-­‐IP	   experiments.	   At	   the	   next	   step,	   the	   presence	   of	   a	   FA2H-­‐containing	   complex	   was	   tested	   by	  
BlueNative	   PAGE	   and	   PFA-­‐crosslinking	   in	   conjunction	   with	   anti-­‐StrepTag-­‐WB,	   using	   Twin-­‐Strep-­‐
mFA2H	  transiently	  expressed	  in	  HEK293-­‐T	  cells.	  The	  BlueNative	  PAGE	  showed	  the	  presence	  of	  three	  
FA2H-­‐containing	   complexes	   of	   ~80,	   ~750	   –	   900	   and	   >1000	   kDa.	   The	   PFA-­‐crosslinking	   experiments	  
revealed	  four	  major	  complexes	  at	  ~60,	  ~80	  and	  two	  more	  at	  >170	  kDa.	  Whether	  these	  two	  were	  the	  
same	   as	   the	   ones	   seen	   in	   the	   BlueNative	   experiment	   could	   not	   be	   determined.	   In	   a	   follow	   up	  
experiment,	  showing	  the	  applicability	  of	  StrepTactin-­‐affinity	  purification	  after	  PFA-­‐crosslinking,	  only	  
the	  ~60	  and	  ~80	  kDa	  complexes	  were	  still	  visible	  in	  the	  eluate.	  Interestingly,	  the	  80	  kDa	  signal	  might	  
resemble	  FA2H	  homodimers,	  since	  FA2H	  itself	  has	  a	  molecular	  weight	  of	  about	  40	  kDa.	  Potentially,	  
such	  a	  dimerization	  could	  be	  a	  prerequisite	   for	  FA2H	  to	  be	  fully	   functional,	  as	   it	   is	   for	  example	  the	  
case	  for	  CerS-­‐enzymes	  (Laviad	  et	  al.	  2012).	  Thus,	  additional	  experiments	  should	  be	  done	  to	  clarify	  the	  
identity	  of	  the	  80	  kDa	  signal.	  In	  summary,	  the	  results	  showed	  that	  only	  the	  relatively	  small	  complexes	  
containing	   crosslinked	   FA2H	   could	   be	   enriched	   by	   affinity	   purification.	   Following	   this	   initial	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experiments,	   the	  affinity	   tag-­‐based	  SILAC	  Co-­‐IP	  experiments	   including	  mass	   spectrometric	  analyzes	  
were	  conducted.	  
5.2.2 Identification	  of	  FA2H	  interacting	  proteins	  by	  mass	  spectrometry	  
The	  first	  attempt	  of	  identifying	  interaction	  partners	  of	  FA2H	  after	  StrepTactin-­‐affinity	  purification	  did	  
only	   lead	   to	   the	   identification	   of	   a	   few	   co-­‐purified	   proteins.	   While	   FA2H	   itself	   was	   significantly	  
enriched,	  thereby	  proving	  a	  successful	  and	  efficient	  SILAC-­‐IP,	  only	  two	  other	  protein	  groups	  showed	  
a	   significant	   co-­‐purification.	   The	   proteins	   corresponding	   to	   the	   groups	   were	   components	   of	   the	  
proteasome	   (PSMD2;	   PSMC6).	   Even	  when	   lowering	   the	   threshold	   for	   a	   significant	   enrichment,	   the	  
majority	  of	  groups	  (45%)	  contained	  manly	  other	  proteins	  related	  to	  protein	  quality	  control	  processes,	  
for	   example	   chaperones,	   ubiquitin,	   ubiquitin	   ligases	   etc.	   This	   indicated	   that	   the	   overexpression	   of	  
FA2H	   was	   probably	   too	   strong.	   Since	   the	   ER’s	   capacity	   is	   limited,	   probably	   the	   majority	   of	   the	  
transiently	   expressed	   FA2H	  was	   targeted	   and	   processed	   by	   the	   ER-­‐associated	   protein	   degradation	  
(ERAD)	  machinery.	  	  
In	   parallel,	   the	   same	   experiment	   was	   conducted	   with	   the	   inclusion	   of	   a	   PFA-­‐crosslinking	   step	   to	  
strengthen	   weak	   interactions	   normally	   lost	   during	   sample	   processing	   and	   possibly	   also	   capture	  
transient	   interactions.	   This	   enlarged	   the	   number	   of	   significantly	   enriched	   protein	   groups	   to	   125.	  
Manual	   inspection	   and	   an	   automated	   GO-­‐term	   enrichment	   analysis	   revealed,	   that	   many	   of	   the	  
enriched	  proteins	  had	  a	  putative	  ER	  and/or	  membrane	  localization.	  Since	  FA2H	  itself	  is	  an	  ER	  protein,	  
its	  interaction	  partners	  are	  expected	  to	  be	  ER	  or	  ER-­‐associated	  proteins.	  In	  addition,	  the	  GO	  analysis	  
also	  proved	  an	  enrichment	  of	  Golgi	  apparatus-­‐related	  protein	  groups,	  but	  since	  the	  ER	  and	  the	  Golgi	  
apparatus	  are	  closely	  linked,	  with	  many	  proteins	  shuttling	  between	  both	  compartments,	  this	  was	  not	  
unexpected.	  Regarding	  protein	  function,	  many	  of	  the	  125	  protein	  groups	  were	  again	  linked	  to	  protein	  
quality	  control	  processes,	  but	  their	  amount	   in	  regard	  to	  all	   identifications	  was	  only	  ~20%.	   In	  detail,	  
components	  of	  the	  protein	  folding	  system	  as	  well	  as	  the	  ERAD	  machinery	  (Christianson	  et	  al.	  2012)	  
were	  present.	  Significantly	  enriched	  ERAD	  subcompenents	  for	  example	  were:	  EMC2,	  which	  is	  part	  of	  
the	   ER	  membrane	   complex,	   ERLIN1	   and	   ERLIN2,	  which	   are	   involved	   in	   ubiquitin	   ligation	   and	   VCP,	  
which	   is	  needed	   for	   the	  extraction	  of	  proteins	   from	   the	  ER.	  Overall,	   this	   result	  was	  not	   surprising,	  
since	   the	   expression	   conditions	   of	   FA2H	   were	   not	   different	   from	   the	   ones	   used	   in	   the	   other	  
experiment.	  Nonetheless,	   now	   additional	   protein	   groups,	  mainly	   associated	  with	   cellular	   transport	  
and	   lipid	  metabolism,	   were	   identified	   as	   FA2H	   interaction	   partners	   as	   well.	   The	   cellular	   transport	  
processes	  included	  direct	  protein	  transport	  as	  well	  as	  general	  vesicular	  transport	  processes.	  In	  detail,	  
these	   were	   parts	   of	   the	   ribosome-­‐ER	   protein	   translocation	   complex,	   like	   ribosomal	   structural	  
components	   (RPL7,	   RPL13	   and	   RPL14)	   or	   the	   signal	   recognition	   particle	   receptor	   B	   (SRPRB).	   Since	  
newly	   synthesized	   FA2H	  had	   to	   be	   inserted	   into	   the	   ER,	   finding	   such	   interaction	   partners	  was	   not	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surprising.	  In	  addition,	  many	  protein	  groups	  involved	  in	  vesicular	  transport,	  for	  example	  RAB-­‐proteins	  
(RAB7A,	   RAB5C),	   SNARE-­‐proteins	   (SEC22B,	   SEC23A),	   a	   vesicle-­‐fusing	   ATPase	   (NSF)	   and	   a	   coatomer	  
subunit	  (COPA),	  were	  present.	  However,	  because	  some	  are	  highly	  abundant	  ER-­‐proteins,	  it	  cannot	  be	  
excluded	  that	  some	  were	  just	  randomly	  crosslinked	  to	  FA2H	  and	  thus	  not	  real	   interaction	  partners.	  
Last	  but	  not	   least,	  a	   significant	  number	  of	  enriched	  protein	  groups	  was	   linked	   to	   lipid	  metabolism.	  
Among	  these	  were	  protein	  groups	   involved	   in	   fatty	  acid	   (PTPLAD1,	  ALDH3A2,	  ACSL3),	  phospholipid	  
(PLD3),	   sphingolipid	   (SPTLC1	  and	  SPTLC2),	  as	  well	  as	  cholesterol	  metabolism	  (HSD17B12,	  HSD17B7,	  
DHCR7,	   NSDHL,	   LBR).	   Others	   are	   responsible	   for	   lipid	   transport	   processes	   (VAPA,	   VAPB,	   OSBPL8,	  
SLC27A4)	  and	  the	  regulation	  of	  lipid	  metabolism	  (SACM1L).	  Furthermore,	  two	  reductases,	  shown	  to	  
be	   involved	   in	   lipid	  metabolism	   (POR,	  CYB5R3),	   and	   the	   cytochrome	  b5	   (cytb5)-­‐containing	  proteins	  
PGRMC1	   and	   PGRMC2,	   which	   are	   implicated	   in	   regulating	   the	   activities	   of	   various	   metabolic	  
enzymes,	  were	  present.	  	  
Although	   the	   inclusion	   of	   PFA-­‐crosslinking	   allowed	   the	   identification	   of	   more	   and	   other	   than	   just	  
protein	   quality	   control-­‐related	   FA2H	   interaction	   partners,	   both	   experiments	  were	   repeated	  with	   a	  
stable	  cell	  line.	  According	  to	  the	  literature	  (Gibson	  et	  al.	  2013),	  stable	  cell	  lines,	  expressing	  the	  gene	  
of	   interest	   at	   near-­‐physiological	   levels,	   should	   be	   chosen	   in	   favour	   of	   transient	   transfected	   ones,	  
because	  overexpression	  can	  cause	  various	  unwanted	  effects.	  Normally,	   the	  amount	  of	  a	  protein	   in	  
different	  complexes	  within	  a	  cell	   is	  tightly	  regulated	  and	  balanced.	  Large	  amounts	  of	  a	  protein	  may	  
perturb	   stoichiometric	   balances	   within	   complexes,	   lead	   to	   wrong	   cellular	   localization,	   induce	  
unspecific	   non-­‐natural	   occurring	   interactions	   and	   cause	   protein	   misfolding	   and	   aggregation.	  
Furthermore,	  transient	  transfections	  often	  show	  a	  high	  variance	  in	  efficiency	  between	  experiments.	  
Last	  but	  not	   least,	   the	  expression	  of	   FA2H	  at	   lower	   levels	  might	  allow	   for	   the	   identification	  of	   less	  
abundant	   proteins,	   which	  may	   have	   been	   lost	   due	   to	   a	   displacement	   by	   quality	   control	   proteins.	  
Besides	   the	  mode	  of	   transfection,	   the	  experimental	   sample	  processing	  was	   also	   slightly	   altered	  by	  
performing	   the	   sample	   mixing	   step	   of	   control	   and	   Twin-­‐Strep-­‐mFA2H	   samples	   after	   the	   affinity-­‐
purification	  step.	  The	  intention	  for	  this	  was	  to	  prevent	  protein	  exchanges	  between	  complexes	  from	  
differentially	   labeled	   cells.	   Such	   exchanges	   can	   lead	   to	   the	   loss	   of	   high	  H/L-­‐ratios,	   thereby	  making	  
some	  interaction	  partners	  undetectable.	  
When	  looking	  at	  the	  results	  of	  the	  Co-­‐IP	  of	  stably	  expressed	  Twin-­‐Strep-­‐mFA2H	  without	  crosslinking,	  
only	  a	  small	  number	  (27)	  of	  the	  total	  number	  of	  identified	  protein	  groups	  was	  significantly	  enriched	  
including	   FA2H.	   Nevertheless,	   these	   were	   substantially	   more	   compared	   to	   the	   experiment	   with	  
transiently	  transfected	  cells.	  GO-­‐term	  enrichment	  analysis	  showed	  that	  they	  were	  largely	  related	  to	  
endocytosis	   processes	   and	   the	   regulation	   of	   protein	   complex	   assembly.	   For	   example,	   vesicular	  
adaptor	  proteins	  (AP2A2,	  AP2S1),	  a	  motor	  protein	  (MYO1E),	  a	  membrane-­‐curvature	  inducing	  protein	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(EPN1)	   and	  parts	  of	   the	   actin-­‐polymerization	  machinery	   co-­‐purified	   (ARPC1A,	  ARPC2,	  ARPC3)	  were	  
present,	   which	   are	   known	   to	   facilitate	   vesicular	   budding	   processes.	   The	   identification	   of	   such	  
proteins	   very	   likely	   reflects	   FA2H	   transport	   between	   the	   ER	   and	   early	   Golgi	   system.	   As	   an	   ER-­‐
membrane	   protein,	   FA2H	   is	   also	   partly	   transported	   to	   the	   early	   Golgi	   apparatus.	   From	   there	   it	   is	  
transported	   back	   by	   retrograde	   transport	   processes,	   involving	   its	   C-­‐terminal	   ER-­‐retention	   signal.	  
Besides	   the	   transport	   related	   protein	   goups,	   the	   sphingolipid	   metabolizing	   enzyme	   SPTLC1,	  
previously	   identified	   in	   the	   Co-­‐IP	   from	   transiently-­‐transfected	   and	   PFA-­‐crosslinked	   cells,	   was	   also	  
identified	  as	  FA2H	  interaction	  partner.	  In	  addition,	  despite	  the	  use	  of	  stable	  transfection,	  20%	  of	  all	  
protein	  groups	  were	  still	  related	  to	  protein	  quality	  control.	  While	  this	  amount	  was	  drastically	   lower	  
compared	  to	  the	  experiment	  with	  transiently	  transfected	  cells,	  it	  was	  of	  a	  similar	  magnitude	  as	  seen	  
in	   the	  PFA-­‐assisted	  pulldown	  experiment.	  This	   implied	   that	   the	   improvement	  described	  above	  was	  
mainly	  caused	  by	   the	  postponement	  of	   the	  sample	  mixing	  step	  and	   likely	  not	   the	  mode	  of	  protein	  
expression.	   Obviously,	   the	   expression	   of	   FA2H	   was	   still	   too	   high,	   thus	   causing	   the	   enzyme’s	  
degradation	  by	  the	  ERAD	  machinery.	  	  
Repeating	  the	  PFA-­‐assisted	  Co-­‐IP	  with	  stably	  expressed	  Twin-­‐Strep-­‐mFA2H	  led	  to	  the	  identification	  of	  
437	   significantly	  enriched	  protein	  groups.	   Thus,	  with	  1062	   identifications	   in	   total,	   about	  41%	  were	  
putative	   interaction	   partners.	   Together	   with	   the	   observation,	   that	   only	   ~47%	   of	   the	   identified	  
proteins	  were	  background	  proteins	  (log2	  fold	  change	  between	  0.58	  and	  -­‐0.58),	  compared	  to	  ~85%	  in	  
the	   PFA-­‐crosslinking	   experiment	  with	   transiently	   transfected	   cells,	   this	   pointed	   at	   an	   experimental	  
error.	   Very	   likely,	   the	   stopping	   of	   the	   crosslinking	   reaction	   was	   incomplete,	   thereby	   resulting	   in	  
excessive	   crosslinking.	   Accordingly,	   some	   of	   the	   potential	   interaction	   partners	   may	   just	   be	   false	  
positive	  identifications	  and	  the	  results	  of	  this	  analysis	  should	  be	  interpreted	  with	  caution.	  But	  since	  
this	   experiment	   was	   only	   intended	   to	   be	   a	   large	   screening	   approach	   and	   interesting	   interaction	  
partners	   were	   later	   confirmed	   in	   detail	   by	   follow-­‐up	   experiments,	   its	   results	   were	   still	   taken	   into	  
account.	   	   Interestingly,	   they	   were	   quite	   similar	   to	   the	   results	   obtained	   with	   the	   transiently	  
transfected	   and	   PFA-­‐treated	   cells.	   First,	   the	   majority	   of	   the	   potential	   interaction	   partners	   had	   a	  
known	  ER	  and/or	  Golgi	   apparatus	   localization,	   thereby	   suggesting	   the	   correct	   targeting	  of	   the	  bait	  
protein.	   Second,	   GO-­‐analyses	   again	   revealed	   an	   enrichment	   of	   protein	   groups	   related	   to	   cellular	  
transport	   processes,	   like	   protein,	   vesicular	   and	   ion	   transport.	   Third,	   proteins	   involved	   in	   lipid	  
metabolism	  were	  present,	  with	  a	  strong	  focus	  on	  sphingolipid-­‐related	  proteins.	  Fourth,	  the	  amount	  
of	   significantly	   enriched	   protein	   quality	   control-­‐related	   protein	   groups	   was	   again	   about	   20%.	   As	  
discussed	  above,	  this	  repeatedly	  proved	  that	  changing	  the	  mode	  of	  transfection	  had	  not	   led	  to	  the	  
expected	   reduction	   in	   FA2H’s	   degradation.	   Last,	   unlike	   before,	   the	   GO	   analysis	   proved	   the	  
enrichment	  of	  protein	  groups	  linked	  to	  GTP-­‐metabolism	  and	  small	  GTPase	  signaling.	   	  But	  inspecting	  
them	  closely	  revealed	  that	  these	  were	   largely	  RAB-­‐proteins	   facilitating	  cellular	   transport	  processes.	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Obviously,	   while	   some	   of	   them	   were	   also	   identified	   in	   the	   assays	   before,	   their	   abundance	   was	  
especially	  high	  in	  this	  experiment.	  
Using	   the	   BioID-­‐method,	   24	   protein	   groups	   were	   significantly	   enriched.	   As	   expected,	   the	   highest	  
enrichment	  was	  observed	  for	  the	  bait	  protein	  itself,	  thus	  proving	  its	  strong	  biotinylation	  by	  the	  fused	  
biotin	   ligase.	   Moreover,	   manual	   inspection	   and	   GO-­‐analyses	   showed	   that	   the	   majority	   of	   the	  
identified	  protein	  groups	  had	  known	  ER	  and/or	  membrane-­‐localization,	  again	  hinting	  at	  the	  correct	  
targeting	   of	   the	   bait	   protein.	   Further,	   the	   enriched	   protein	   groups	   were	   largely	   linked	   to	   lipid,	  
especially	   sphingolipid	   metabolism,	   but	   some	   were	   also	   associated	   with	   protein	   quality	   control	  
processes.	   In	   detail,	   there	   was	   a	   significant	   enrichment	   of	   the	   sphingolipid	  metabolizing	   enzymes	  
SMPD4	   and	   SPTLC1,	   as	   well	   as	   lipid	   transport	   (VAPA/B)	   and	   fatty	   acid	   metabolizing	   enzymes	  
(ALDH3A2).	  Moreover,	  LBR	  (Lamin	  B	  receptor),	  which	  has	  known	  cholesterol	  desaturase	  activity	  and	  
PGRMC2,	   which,	   similar	   to	   its	   paralog	   PGRMC1,	   is	   implicated	   in	   the	   activity	   regulation	   of	   various	  
metabolic	  enzymes	  (Wendler	  &	  Wehling	  2013),	  were	  enriched	  as	  well.	  	  
5.2.3 Comparison	  of	  the	  FA2H	  interaction	  partner	  screening	  results	  	  
In	  summary,	  the	  different	  screening	  experiments	  allowed	  insights	  into	  the	  largely	  unknown	  protein-­‐
protein	   interaction	   network	   of	   mammalian	   FA2H.	   While	   the	   initial	   experiment	   with	   transiently	  
expressed	  Twin-­‐Step-­‐mFA2H	  resulted	  only	  in	  the	  identification	  of	  a	  few	  interaction	  partners,	  all	  other	  
experiments	   revealed	   significantly	  more.	  Many	  of	   these	  were	  either	  proteins	   involved	   in	   the	   same	  
metabolic	   context	   as	   FA2H	   i.e.	   lipid	   metabolism,	   or	   in	   cellular	   transport	   processes.	   In	   addition,	  
because	   FA2H	  was	   probably	   present	   in	   larger	   amounts	   than	   under	   physiological	   conditions,	   there	  
was	   a	   significant	   amount	   (~20%)	   of	   protein	   quality	   control	   related	   proteins	   identified	   as	   well.	  
Consequently,	  the	  expression	  level	  of	  FA2H	  should	  be	  further	  lowered	  to	  a	  near-­‐physiological	  level	  by	  
changing	  the	  transfection	  method.	  Methods	  to	  achieve	  such	  a	  near-­‐physiological	  expression	  are	  for	  
example	   possible	   by	   bacterial	   artificial	   chromosome	   transfection	   or	   direct	   genetical	   manipulation	  
methods	   (CRISPR/Cas9-­‐system,	   TALE-­‐system,	   ...).	   Alternatively,	   an	   antibody	   has	   to	   be	   generated,	  
which	  is	  capable	  of	  precipitating	  endogenous	  FA2H,	  thereby	  omitting	  the	  need	  for	  any	  kind	  of	  cellular	  
manipulation.	  
Nevertheless,	   some	   interesting	   and	   likely	   FA2H	   interaction	   partner	   candidates	   were	   identified.	   Of	  
these,	   especially	   the	   ones	   found	   multiple	   times	   had	   a	   higher	   probability	   to	   be	   true	   interactors.	  	  
Therefore,	   a	   comparison	   of	   the	   three	   experiments	   with	   the	   most	   interaction	   partners,	   both	   PFA-­‐
assisted	   and	   the	   BioID-­‐experiment,	   was	   conducted.	   The	   comparison	   showed	   16	   protein	   groups	  
besides	   FA2H	   itself,	   which	   were	   constantly	   significantly	   enriched.	   Furthermore,	   there	   were	   81	  
protein	   groups	   shared	   between	   two	   experiments	   only.	  Not	   surprisingly,	   as	   seen	   in	   each	   individual	  
assay,	   many	   of	   these	   are	   linked	   to	   the	   same	   biological	   process	   FA2H	   is	   involved	   in	   i.e.	   lipid	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metabolism.	   Thus,	   a	   selection	  of	   the	  most	   interesting	   interaction	  partners,	   identified	   in	   2	   or	  more	  
screenings,	  are	  discussed	  in	  more	  detail	  below.	  It	  should	  be	  noted,	  that	  not	  all	  these	  have	  to	  interact	  
functionaly	  with	  FA2H,	  because	  for	  some	  proteins	  the	  interaction	  may	  only	  be	  physical.	  
Most	   notably,	   the	   serine	   palmitoyl	   transferases	   1	   and	   2	   (SPTLC1	   and	   SPTLC2)	   were	   identified	  
repeatedly,	  which	  are	   the	  essential	   components	  of	   the	   serine	  palmitoyl	   transferase	   (SPT)	   complex.	  
Importantly,	  SPTLC1	  was	  also	  identified	  by	  SILAC-­‐IP	  without	  PFA-­‐crosslinking.	  This	  suggested	  that	  the	  
interaction	   with	   FA2H	   is	   first	   relatively	   strong,	   and	   second	   not	   an	   artifact	   of	   unspecific	   protein	  
crosslinking.	   The	   SPT-­‐complex	   catalyzes	   the	   first	   step	   of	   sphingolipid	   synthesis	   (Hornemann	   et	   al.	  
2007).	   This	   is	   especially	   interesting,	   because	   the	   product	   of	   this	   reaction,	   dihydrosphingosine,	   and	  
the	   product	   of	   FA2H,	   2-­‐OH	   fatty	   acids,	   are	   used	   by	   ceramide	   synthases	   (CerS)	   to	   form	   ceramides	  
(Mizutani	  et	  al.	  2008).	  Intriguingly,	  CerS2,	  specific	  for	  generating	  very	  long-­‐chain	  ceramides,	  was	  also	  
identified	   in	  one	   screening	  assay.	   In	   addition,	   the	   repeatedly	  discovered	  acyl-­‐CoA	   synthetase	   long-­‐
chain	   3	   (ACSL3)	   also	   fits	   into	   this	   process,	   because	   CerS-­‐enzymes	   need	   activated	   fatty	   acids	   as	  
substrates.	   Hence,	   the	   interaction	   of	   ACSL3	   and	   FA2H	   potentially	   ensures	   that	   alpha-­‐hydroxylated	  
fatty	  acids	  are	  directly	  activated	  after	  synthesis	  and	  thus	  efficiently	   incorporated	  into	  sphingolipids.	  
Excitingly,	  the	  fatty	  acid	  elongase	  ELOVL5,	  which	  is	  involved	  in	  the	  generation	  of	  long	  and	  very	  long	  
fatty	  acids	  (Leonard	  et	  al.	  2000),	  was	  also	  discovered	  once.	  Taken	  together,	  these	  findings	  hint	  at	  a	  
functional	  coupling	  of	  the	  proteins	  involved	  in	  the	  early	  steps	  of	  2-­‐OH	  sphingolipid	  synthesis,	  possibly	  
allowing	  an	  efficient	  substrate	  transfer	  and	  interregulation	  of	  the	  enzymes	  involved.	  	  
Likewise,	  there	  were	  other	  identified	  proteins,	  which	  are	  known	  to	  be	  involved	  in	  additional	  areas	  of	  
sphingolipid	  metabolism.	  One	  has	  to	  keep	   in	  mind	  that	   it	   is	  not	  clear,	   if	  all	  of	   them	  are	  truly	  direct	  
interaction	   partners	   of	   FA2H.	   Since	   many	   proteins	   are	   part	   of	   relatively	   large	   protein	   complexes,	  
some	   interactions	   may	   just	   be	   indirect.	   One	   such	   protein	   was	   aldehyde	   dehydrogenase	   3A2	  
(ALDH3A2),	  which	  links	  sphingolipid	  synthesis	  to	  sphingolipid	  degradation	  (Nakahara	  et	  al.	  2012).	  The	  
enzyme	   catalyzes	   the	   oxidation	   of	   hexadecenal	   to	   hexadecenoic	   acid,	   which	   is	   generated	   during	  
breakdown	   of	   sphingosine	   1-­‐phosphate	   (S1P)	   by	   S1P-­‐lyase.	   Hexadecenoic	   acid	   is	   then	   further	  
converted	  to	  palmitoyl-­‐CoA	  involving	  an	  activation	  step	  by	  ACSL-­‐enzymes.	  The	  generated	  palmitoyl-­‐
CoA	   could	   subsequently	   be	   reused,	   for	   example	   by	   the	   SPT-­‐complex.	   Since	   ALDH3A2	   works	   on	   a	  
sphingolipid	   degradation	   product,	   whose	   N-­‐linked	   fatty	   acid	   chain	   has	   been	   removed	   already,	   a	  
direct	   functional	   relationship	  with	   FA2H	   seems	   unlikely.	   Presumably	   ALDH3A2	   is	   rather	   associated	  
with	   ACSL-­‐enzymes,	   and	   thus	   was	   co-­‐purified	   with	   them.	   Similarly,	   the	   repeatedly	   identified	  
sphingomyelin	   phosphodiesterase	   4	   (SMPD4),	   which	   hydrolyses	   sphingomyelin	   to	   ceramide	   and	  
phosphocholine,	  may	  have	  been	  soley	  co-­‐purified	  because	  of	  an	  interaction	  with	  CerS-­‐enzymes.	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Other	   identified	   interactors,	   like	   vesicle-­‐associated	  membrane	  protein-­‐associated	  proteins	  A	   and	  B	  
(VAPA/B)	  and	  oxysterol	  binding	  protein-­‐like	  8	  (OSBPL8),	  are	  involved	  in	  lipid	  transport	  processes	  and	  
the	   interplay	   between	   cholesterol	   and	   sphingolipid	  metabolism.	   The	   ER-­‐resident	   proteins	   VAPA/B	  
facilitate	  ER-­‐Golgi	   trafficking	  of	  proteins,	  but	  also	  non-­‐vesicular	   lipid	   transport.	  The	   later	  process	   is	  
thought	   to	  be	  achieved	  by	   recruiting	   transport	  proteins	   like	  CERT	  and	  OSBPs	   to	  VAPs	  via	  a	   specific	  
FFAT-­‐peptide	  motif	  present	   in	  both	  protein	  types	  (Hanada	  et	  al.	  2007;	  Raychaudhuri	  &	  Prinz	  2010).	  
While	  CERT	   is	  responsible	  for	  sphingolipid	   intermembrane	  transfer,	  OSBPs	  probably	  facilitate	  sterol	  
transport	  processes.	   In	  addition,	  OSBP	  seems	  to	  be	  able	  to	  facilitate	  CERTs	  binding	  to	  VAP,	  thereby	  
activating	  ceramide	  transfer	  from	  ER	  to	  the	  Golgi	  apparatus	  and	  finally	  leading	  to	  an	  upregulation	  of	  
sphingomyelin	   synthesis	   (Perry	   &	   Ridgway	   2006).	   Surprisingly,	   the	   OSBP	   found	   as	   potential	   FA2H	  
interaction	   partner,	   OSBPL8,	   misses	   the	   FFAT-­‐motif	   needed	   for	   VAP-­‐binding.	   One	   could	   therefore	  
speculate	   that	   this	   interaction	   represents	   a	   previously	   unknown	   direct	   linkage	   between	   2-­‐OH	  
sphingolipid	  synthesis	  and	  sterol	  metabolism.	  Intriguingly,	  evidence	  for	  a	  co-­‐regulation	  between	  both	  
pathways	  has	  already	  been	  discovered	  in	  the	  analyses	  of	  yeast	  mutants	  (Swain	  et	  al.	  2002;	  Guan	  et	  
al.	  2009).	  Alternatively,	  these	  interactions	  might	  be	  less	  specific	  than	  assumed,	  since	  VAPA,	  VAPB	  and	  
OSBPL8	  have	  recently	  been	  identified	  as	  parts	  of	  the	  mammalian	  ERAD	  network	  (Christianson	  et	  al.	  
2012).	   Therefore,	   finding	   them	   in	   a	   complex	   with	   FA2H	   may	   solely	   be	   caused	   by	   the	   enzyme’s	  
overexpression.	  
The	   potential	   interaction	   partner,	   SACM1L,	   is	   a	   known	   regulator	   of	   sphingolipid	   synthesis.	   This	  
protein	   is	   called	   suppressor	  of	  actin	  mutations	  1-­‐like	  protein	   (SACM1L)	  after	   its	   initially	  discovered	  
yeast	   homolog	   SAC1.	   It	   is	   a	   phosphoinositide	   phosphatase	   that	   primarily	   dephosphorylates	  
phosphatidylinositol	   4-­‐phosphate	   (PI4P),	   the	  predominant	  phosphoinositide	  of	   the	  Golgi	   apparatus	  
(Hughes	  et	  al.	  2000;	  Foti	  et	  al.	  2001).	   In	  yeast	   it	  has	  been	  shown	  to	  be	  part	  of	  the	  SPOTS-­‐complex,	  
whose	   other	   major	   components	   are	   the	   yeast	   serine	   palmitoyltransferase	   (LCB1	   and	   2),	   the	  
regulatory	  Orm	   proteins	   (ORM1	   and	  ORM2),	   the	   accessory	   protein	   TSC3	   and	   SAC1	   (Breslow	   et	   al.	  
2010).	   Remarkably,	   the	   Orm	   proteins	   and	   SAC1	   both	   seem	   to	   negatively	   regulate	   serine	  
palmitoyltransferase.	   This	   was	   shown	   in	   yeast	   mutant	   of	   both	   protein	   types,	   which	   exhibited	   a	  
significant	   increase	   in	  cellular	   sphingoid	  base	  amounts	   (Breslow	  et	  al.	  2010).	  Also	   interesting	   is	   the	  
fact,	   that	   SACM1L’s	   substrate	   PI4P	   further	   presents	   a	   link	   to	   the	   regulation	   of	   lipid	   transport	  
processes.	  This	  is	  the	  case,	  because	  lipid	  transport	  proteins	  like	  CERT,	  FAPP2	  and	  most	  OSBPs	  contain	  
a	  PI4P-­‐binding	  pleckstrin	  homology	  (PH)	  domain,	  which	  targets	  them	  to	  the	  Golgi	  apparatus	  (Breslow	  
&	  Weissman	  2010).	  But	  how	  SACM1L,	  which	   is	  an	  ER-­‐membrane	  protein,	  acts	  on	  the	  mainly	  Golgi-­‐
localized	   PI4P	   is	   still	   an	   open	   question.	   Attractively,	   there	   is	   also	   evidence	   for	   a	   functional	  
relationship	   between	   yeast	   FA2H	   (SCS7)	   and	   SACM1L	   ,	   as	   shown	   by	   Tani	   and	   Kuge	   (Tani	   &	   Kuge	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2010).	  Obviously,	  yeast	  double-­‐deficient	  for	  SCS7	  and	  SAC1,	  but	  not	  for	  SAC1	  alone,	  exhibit	  a	  severe	  
growth	  defect.	  
The	  two	  endoplasmatic-­‐localized	  oxidoreductases,	  cytochrome	  b5	  reductase	  3	  (CYB5R3)	  and	  NADPH-­‐
cytochrome	   P450	   reductase	   (POR),	   were	   also	   identified.	   Both	   are	   responsible	   for	   the	   transfer	   of	  
electrons	   from	   reduction	   equivalents,	   NADH	   (CYB5R3)	   or	   NADPH	   (POR),	   to	   metabolic	   enzymes.	  
CYB5R3,	   as	   it	   name	   implies,	   reduces	   cytb5	   and	   cytb5-­‐domain	   containing	  proteins.	   POR,	   in	   contrast,	  
transfers	   electrons	  mainly	   to	   P450	   enzymes,	   but	   it	   can	   also	   supply	   them	   to	  heme	  oxygenases	   and	  
cytb5.	   Interestingly,	   POR	   is	   also	   the	   reductase	   used	   in	   in-­‐vitro	   fatty	   acid	   2-­‐hydroxylation	   assays	  
(Alderson	  et	  al.	  2004;	  Alderson	  et	  al.	  2005).	  Since	  FA2H	  needs	  a	  supply	  of	  electrons	  for	  hydroxylating	  
fatty	   acids,	   identifying	   both	   in	   the	   interaction	   partner	   screenings	   strengthens	   the	   validity	   of	   the	  
assays	  functionality.	  
Two	   other	   enzymes,	   identified	   as	   potential	   FA2H	   interaction	   partners,	   were	   the	   highly	   sequence-­‐
homologous	   membrane-­‐associated	   progesterone	   receptor	   component	   1	   and	   2	   (PGRMC1	   and	  
PGRMC2).	  Both	  proteins	  contain	  a	  cytb5	  heme-­‐binding	  domain	  similar	  to	  FA2H’s.	  Furthermore,	  there	  
is	   a	   large	   amount	   of	   research,	   proving	   that	   PGRMC1	   binds	   and	   regulates	   the	   activity	   of	   various	  
cytochrome	  P450,	   including	   sterol	   synthesizing,	   enzymes	   (Hughes	   et	   al.	   2007;	  Debose-­‐Boyd	   2007).	  
Interestingly,	   the	   regulation	   can	   be	   negative	   and	   positive	   depending	   on	   the	   respective	   binding-­‐
partner.	   Taken	   together,	   this	   hints	   at	   a	   potential	   regulatory	   interaction	   between	   FA2H	   and	   the	  
PGRMC	   proteins.	   In	   addition,	   PGRMC1	   is	   also	   involved	   in	   other	   processes,	   like	   tumor	   growth	  
regulation	   (Peluso,	   Liu,	   et	   al.	   2008;	   Crudden	   et	   al.	   2005;	   Ahmed	   et	   al.	   2010)	   and	   progesterone	  
signaling	   (Meyer	   et	   al.	   1996;	   Peluso,	   Romak,	   et	   al.	   2008).	  Moreover,	   PGRMC1	   has	   been	   shown	   to	  
interact	  with	   insulin-­‐induced	   gene	  1	  protein	   (Insig1)	   and	   sterol	   regulatory	   element-­‐binding	  protein	  
cleavage-­‐activating	  protein	  (SCAP),	  important	  regulators	  of	  cholesterol	  homeostasis	  (Suchanek	  et	  al.	  
2005).	   Stimulatingly,	   Insig1	   has	   just	   lately	   been	   shown	   to	   facilitate	   ERAD	   of	   the	   sphingolipid	  
synthesizing	  enzyme	  CGalT	  in	  collaboration	  with	  the	  sigma-­‐1	  receptor	  chaperone	  (Sig-­‐1R)	  in	  a	  sterol-­‐
dependent	  matter	  (Hayashi	  et	  al.	  2012)	  to	  regulate	  the	  cellular	  enzyme-­‐amount.	  Together	  with	  the	  
observation	  that	  PGRMC1	  has	  been	  proven	  to	  be	  the	  elusive	  sigma-­‐2	  receptor,	  this	  strongly	  argues	  
for	   a	   similar	   ERAD-­‐function	  of	   PGRMC1	   (Xu	  et	   al.	   2011).	   Regarding	   the	   interaction	  with	   FA2H,	   this	  
opens	   the	   possibility	   that	   PGRMC1	   negatively	   regulates	   FA2H’s	   activity	   by	   inducing	   the	   protein’s	  
degradation.	  But	  this	  remains	  to	  be	  proven	  experimentally.	  Moreover,	   it	  also	  hints	  at	  a	  close	  cross-­‐
regulation	  between	  sterol	  and	  sphingolipid	  metabolism.	  Considering	  PGRMC2,	  much	  less	  is	  known	  so	  
far,	  but	  recent	  research	  showed	  that	   it	  shares	  PGRMC1’s	  binding	  to	  cytochrome	  enzymes	  (Albrecht	  
et	  al.	  2012)	  and	  therefore	  may	  have	  similar	  regulatory	  function.	  Fittingly,	  it	  was	  recently	  identified	  as	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part	   of	   the	   mammalian	   ERAD	   system	   in	   a	   complex	   systematic	   approach	   combining	   proteomics,	  
functional	  genomics	  and	  transcriptional	  data	  (Christianson	  et	  al.	  2012).	  
In	  regard	  to	  the	  ERAD	  system,	  two	  other	  of	  its	  components,	  ER	  lipid	  raft	  associated	  1	  and	  2	  (ERLIN1	  
and	  ERLIN2),	  were	  identified	  as	  well.	  While	  ERLIN1	  was	  identified	  in	  two	  screenings,	  ERLIN2	  was	  just	  
identified	  once.	  Henceforth,	  they	  were	  initially	  dismissed	  as	  specific	  FA2H	  interaction	  partners.	  While	  
their	   association	   with	   FA2H	   may	   solely	   be	   an	   artifact	   of	   FA2H’s	   overexpression,	   the	   fact	   that	  
mutations	   in	   both	   genes	   can	   cause	   hereditary	   spastic	   paraplegias	   (ERLIN1	  è	   SPG18;	   ERLIN2	  è	  
SPG62)	  hints	  at	  a	  more	  specific	  connection.	  Functionally,	  both	  proteins	  form	  a	  complex	  with	  various	  
target	  proteins,	  thereby	  initializing	  their	  degradation	  by	  the	  ERAD	  pathway	  (Pearce	  et	  al.	  2009;	  Jo	  et	  
al.	  2011;	  Christianson	  et	  al.	  2012).	  Intriguingly,	  they	  also	  seem	  to	  interact	  with	  and	  regulate	  proteins	  
of	  the	  cholesterol-­‐sensing	  machinery,	  like	  Insig1,	  SCAP	  and	  sterol	  regulatory	  element	  binding	  protein	  
(SREBP).	  Moreover,	  it	  was	  shown	  that	  both	  ERLINs	  also	  interact	  directly	  with	  cholesterol	  (Huber	  et	  al.	  
2013).	  In	  summary,	  analogous	  to	  PGRMC1	  and	  PGRMC2,	  FA2H’s	  interaction	  with	  ERLIN1	  and	  ERLIN2	  
suggests,	  that	  FA2H	  and	  thus	  2-­‐OH	  sphingolipid	  synthesis	  may	  be	  negatively	  regulated	  by	  the	  ERAD	  
system.	   In	   addition,	   it	   seems	   to	   be	   closely	   linked	   to	   cholesterol	   metabolism,	   which	   apparently	   is	  
regulated	  by	  the	  same	  protein	  degradation	  machinery.	  In	  this	  regard	  it	  could	  be	  speculated	  that	  the	  
spastic	   paraplegias,	   linked	   to	  mutations	   in	   both	   ERLIN-­‐genes,	   are	   potentially	   caused	  by	   the	   loss	   of	  
FA2H’s	  protein	  level	  regulation.	  	  
5.2.4 Verification	   of	   FA2H	   interaction	   partners	   by	   Western	   blot	   and	   bimolecular	  
fluorescence	  complementation	  
To	   confirm	   some	   of	   the	   discovered	   potential	   interaction	   partners,	   the	   interactions	   of	   FA2H	   with	  
ACSL3,	  ALDH3A2,	  CerS2,	  SACM1L,	  SPTLC1	  and	  PGRMC1	  were	  afterwards	  tested	  by	  Co-­‐IP	  +	  WB	  and/or	  
BiFC	  experiments.	  PGRMC1,	  ACSL3	  and	  SPTLC1	  could	  be	  verified	  as	  FA2H-­‐interactors	  by	  Co-­‐IP	  +	  WB	  
(including	   PFA-­‐crosslinking).	   In	   contrast,	   ALDH3A2	   and	   SACM1L	   could	   not,	   because	   the	   antibodies	  
used	  seemed	  not	  be	  specific.	  Therefore,	  the	  assays	  should	  be	  repeated	  with	  different	  antibodies.	  In	  
addition,	  both	  assays	  should	  then	  further	  be	  conducted	  with	  the	  stable	  cell	  line,	  to	  exclude	  potential	  
overexpression	   artifacts	   affecting	   the	  WB.	  Regarding	  BiFC,	   the	   interactions	  of	   FA2H	  with	  PGRMC1,	  
SPTLC1	  and	  CerS2	  could	  be	  confirmed	  also	  in	  living	  cells.	  Additionally,	  BiFC	  competition	  experiments,	  
employing	  co-­‐expressed	  untagged	  versions	  of	   the	   interaction	  partners	  as	  competitors,	   lend	   further	  
credibility	   to	   the	   interactions	   of	   FA2H	  with	   PGRMC1	   and	  with	   SPTLC1.	   Only	   the	   competition	  with	  
untagged	  SPTLC1	  was	  not	  successful	  and	  should	  be	  repeated	  with	  lower	  plasmid	  amounts,	  because	  
the	   protein’s	   overexpression	   caused	   massive	   cell	   death.	   In	   contrast,	   the	   ACSL3-­‐FA2H	   interaction	  
could	   not	   be	   validated	   with	   BiFC.	   This	   can	   be	   attributed	   to	   the	   fact	   that	   not	   all	   protein-­‐protein	  
interactions	  are	  accessible	  by	  BiFC-­‐assays,	  because	  certain	  steric	  constraints	  can	  impair	  the	  formation	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of	  functional	  fluorescent	  protein.	  In	  many	  cases	  this	  can	  be	  solved	  by	  varying	  the	  attachment	  site	  (N-­‐	  
or	   C-­‐terminal)	   of	   the	   fluorescent	   fragments	   and	   trying	   all	   possible	   combinations	   of	   both	   putative	  
interactions	  partners	  (Kerppola	  2008).	  For	  ACSL3	  this	  still	  led	  to	  no	  measurable	  BiFC-­‐signal	  (data	  not	  
shown).	  But	  since	  FA2H’s	  termini	  are	  both	  located	  in	  the	  cytosol	  and	  ACSL3’s	  N-­‐terminus	  in	  the	  ER-­‐
lumen,	  not	  all	  interaction	  partner	  combinations	  could	  be	  experimentally	  tested	  using	  this	  approach.	  
Furthermore,	   even	   if	   all	   combinations	   are	   available,	   steric	   constraints	  may	   still	   exist.	   In	   conclusion	  
this	  generally	  emphasizes	  an	  inherent	  disadvantage	  of	  BiFC.	  While	  a	  positive	  BiFC-­‐result	  is	  indicative	  
of	   a	   protein-­‐protein	   interaction,	   a	   negative	   result	   neither	   proves	   nor	   disproves	   it.	   An	   alternative	  
explanation	   for	   the	   negative	   BiFC-­‐results	   lies	   in	   the	   fact	   that	   some	   protein-­‐protein	   interactions,	  
identified	   with	   the	   used	   screening	   approaches,	   may	   be	   indirect,	   i.e.	   facilitated	   by	   an	   additional	  
protein.	  Accordingly,	  the	  fluorescent	  fragments	  cannot	  come	  in	  the	  close	  contact	  needed	  for	  BiFC.	  
	  
5.2.5 Conclusion	  
In	   summary,	   the	   conducted	   analysis	   revealed	   a	   substantial	   number	   of	   potential	   FA2H	   interaction	  
partners	   of	   which	   many	   were	   linked	   to	   sphingolipid	   metabolism.	   Thus,	   a	   pathway	   diagram	   of	  
sphingolipid	  metabolism	  can	  be	  generated,	  in	  which	  the	  identified	  proteins	  are	  highlighted	  in	  color.	  
Moreover,	  proteins	  additionaly	  identified	  with	  another	  method	  (Co-­‐IP	  +	  WB	  or	  BiFC),	  are	  indicated	  in	  
bold	   (Figure	   5-­‐1).	   The	   pathway	   diagram	   shows	   that	   the	  majority	   of	   these	   interaction	   partners	   are	  
either	   potentially	   involved	   in	   the	   alpha-­‐hydroxylation	   of	   fatty	   acids,	   like	   the	   reductases	   POR	   or	  
CYB5R3,	   or	   in	   other	   early	   steps	   of	   sphingolipid	   synthesis.	   The	   most	   notable	   identifications	   were	  
subunits	   of	   the	   SPOTS-­‐complex,	   which	   catalyzes	   the	   initial	   step	   of	   sphingolipid	   synthesis,	   ACSL3,	  
which	  activates	   fatty	   acid	   chains,	   and	  CerS2,	  which	   incorporates	   fatty	   acyl-­‐CoAs	   into	   sphingolipids.	  
Therefore,	   it	   seems,	   that	   the	   early	   sphingolipid	   synthesizing	   enzymes	   are	   part	   of	   a	   multiprotein	  
complex,	   implying	   a	   tight	   coupling	   of	   the	   enzymatic	   reactions.	   Accordingly,	   products	   of	   one	  
enzymatic	  reaction	  can	  be	  easily	  transported	  from	  one	  enzyme	  to	  the	  next,	  allowing	  a	  very	  efficient	  
and	  potentially	  fast	  synthesis	  of	  sphingolipids.	  In	  addition,	  the	  coupling	  also	  opens	  up	  the	  possibility	  
of	  efficient	  interregulation	  between	  the	  different	  synthesis	  steps.	  	  
Interestingly,	   SMPD4	   and	   ALDH3A2	   were	   also	   identified,	   which	   might	   suggest	   that	   sphingolipid	  
synthesis	   and	   degradation	   are	   closely	   linked,	   thereby	   open	   up	   the	   possibility	   of	   interregulation	  
between	  both	  pathways.	  Furthermore,	  the	  identification	  of	  lipid	  transport	  proteins,	  like	  VAPA,	  VAPB	  
and	  OSBBPL,	  connects	  sphingolipid	  metabolism	  and	  lipid	  transport.	  Last	  but	  not	  least,	  PGRMC1	  and	  
PGRMC2	  were	  repeatedly	   identified.	  So	  far,	  both	  proteins	  have	  not	  been	  connected	  to	  sphingolipid	  
metabolism,	   but	   since	   they	   are	   known	   to	   regulate	   the	   activity	   of	   various	   enzymes,	   they	  might	   are	  
regulators	  of	  FA2H’s	  activity.	  





Figure	  5-­‐1:	  Discovered	  putative	  FA2H	  interaction	  partners	  and	  their	  position	  in	  sphingolipid	  metabolism.	  
Colored	   boxes	   highlight	   proteins	   discovered	   in	   screenings	   as	   potential	   FA2H	   interaction	   partners,	   while	   all	  
other	   important	   proteins	   are	   depicted	   in	   grey	   boxes.	   Proteins	   verified	   in	   another	   assay	   besides	   mass	  
spectrometry	  (WB,	  BiFC)	  are	  highlighted	  in	  bold.	  3-­‐KR	  =	  3-­‐keto-­‐dihydrosphingosine	  reductase;	  ACSL3	  =	  acyl-­‐CoA	  
synthetase	   long-­‐chain	   3;	   ALDH3A2	   =	   aldehyde	   dehydrogenase	   3	   A2;	   CerS2	   =	   ceramide	   synthase	   2;	   CDase	   =	  
ceramidase;	  CERT	  =	  ceramide	  transfer	  protein;	  CYB5R3	  =	  cytochrome	  b5	  reductase	  3;	  DES	  =	  desaturase;	  FA2H	  =	  
fatty	   acid	   2-­‐hydroxylase;	   OSBP(L)	   =	   oxysterol	   binding	   protein	   like;	   PGRMC1/2	   =	   progesterone	   receptor	  
membrane	   component	   1/2;	   SK	   =	   sphingosine	   kinase;	   SACM1L	   =	   suppressor	   of	   actin	   mutations	   1-­‐like	   (S.	  
cerevisiae);	  SMS	  =	  sphingomyelin	  synthase;	  SMPD4	  =	  sphingomyelin	  phosphodiesterase	  4;	  SPL	  =	  sphingosine	  1-­‐
phosphate	  lyase;	  SPOTS	  =	  SPTLC,	  Orm1/2,	  Tsc3,	  Sac1;	  SPP	  =	  sphingosine	  1-­‐phosphate	  phosphatase;	  SPTLC1/2	  =	  
serine	   palmitoyltransferase	   1/2;	   TSC3	   =	   temperature-­‐sensitive	   CSG2	   supressor	   (S.	   cerevisiae)	   (existence	   of	  
human	  homolog	   in	  SPOTS-­‐complex	  unknown);	  ORMDL	  =	  Orm1-­‐like	   (S.	  cerevisiae);	  POR	  =	  NADPH-­‐cytochrome	  
P450	  reductase;	  VAP	  =	  vesicle-­‐associated	  membrane	  protein	  (consists	  of	  VAPA	  and	  VAPB).	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ACN	   acetonitrile	   	   MBP	   myelin	  basic	  protein	  
ACSL3	   	   acyl-­‐CoA	  synthetase	  long-­‐chain	  3	   	   MCFD2	   multiple	  coagulation	  factor	  deficiency	  2	  
ALDH3A2	  	   aldehyde	  dehydrogenase	  3	  family,	  
member	  A2	  
	   mFA2H	   murine	  fatty	  acid	  2-­‐hydroxylase	  
ApoE	   apolipoprotein	  E	   	   NF-­‐H	   neurofilament	  heavy	  
BHK	   	   baby	  hamster	  kidney	  cells	   	   MS	   mass	  spectrometry	  
BiFC	   bimolecular	  fluorescence	  
complementation	  
	   ON	   overnight	  
BioID	   proximity-­‐dependent	  protein	  
biotinylation	  and	  identification	  
	   P0	   myelin	  protein	  P0	  
BirA*	   constitutively	  active	  E.coli	  biotin	  ligase	   	   PAGE	   polyacrylamide	  gel	  electrophoresis	  
C1qb	   complement	  C1q	  subcomponent	  
subunit	  B	  
	   PBS	   phosphate	  buffered	  saline	  
C4b	   complement	  4-­‐B	   	   PCR	   polymerase	  chain	  reaction	  
Cer	   ceramide	   	   PFA	   paraformaldehyde	  
CerS	   ceramide	  synthase	   	   PGRMC1	   progesterone	  receptor	  membrane	  
component	  1	  
CERT	   ceramide	  transfer	  protein	   	   PLP	   myelin	  proteolipid	  protein	  
CHO	   chinese	  hamster	  ovary	  cells	   	   PM	   plasma	  membrane	  
CGT	   ceramide	  galactosyl	  transferase	   	   PMP2	   myelin	  P2	  protein	  
CNP	   2',3'-­‐cyclic-­‐nucleotide	  3'-­‐
phosphodiesterase	  
	   PNS	   peripheral	  nervous	  system	  
CNS	   central	  nervous	  system	   	   PrpC	   prion	  protein	  
ddH2O	   double	  destilled	  water	   	   PPI	   protein-­‐protein	  interaction(s)	  
DAPI	   4',6-­‐diamidino-­‐2-­‐phenylindole	   	   PRX	   periaxin	  
DMEM	   Dulbecco’s	  modified	  Eagle's	  medium	   	   PVDF	   polyvinylidene	  fluoride	  
DMSO	   dimethyl	  sulfoxide	   	   RT	   room	  temperature	  
DTT	   dithiothreitol	   	   SACM1L	   SAC1	  suppressor	  of	  actin	  mutations	  1-­‐like	  
(yeast)	  
EDTA	   ethylenediaminetetraacetic	  acid	   	   SAG	   Schwann	  cell	  membrane	  glycoprotein	  
ER	   endoplasmic	  reticulum	   	   SDS	   sodium	  dodecyl	  sulfate	  
ERAD	   ER-­‐associated	  degradation	   	   SILAC	   stable	  isotope	  labeling	  by	  amino	  acids	  in	  cell	  
culture	  
ERGIC53	   ER-­‐Golgi	  intermediate	  compartment	  
53	  kDa	  protein	  
	   SPE	   solid	  phase	  extraction	  
FA	   formic	  acid	   	   SM	   sphingomyelin	  
FA2H	   fatty	  acid	  2-­‐hydroxylase	   	   SMPD	   sphingomyelin	  phosphodiesterase	  
FCS	   fetal	  calf	  serum	   	   SN	   supernatant	  
GalCer	   galactosylceramide	   	   SPTLC	   serine	  palmitoyltransferase	  
GFAP	   glial	  fibrillary	  acidic	  protein	   	   StageTips	   stop-­‐and-­‐go-­‐extraction	  tips	  
GlcCer	   	   glucosylceramide	   	   TAE	   Tris-­‐acetate-­‐EDTA	  buffer	  
GSL	   glycosphingolipid	   	   TBS	   TRIS	  buffered	  saline	  
HEK	   human	  embryonic	  kidney	  cells	   	   TBS-­‐T	   TRIS	  buffered	  saline	  +	  Tween	  20	  
HeLa	   	   Henrietta	  Lacks	  cells	  (immortal	  cell	  
line)	  
	   TEAB	   triethylammonium	  bicarbonate	  buffer	  
IP	   immunoprecipitation	   	   TFA	   trifluoroacetic	  acid	  
KO	   knock-­‐out	   	   TMT	   tandem	  mass	  tag	  
LB	   lysogeny	  broth	   	   TOF	   time	  of	  flight	  
MAG	   myelin-­‐associated	  glycoprotein	   	   ULCFA	   ultra	  long-­‐chain	  fatty	  acids	  
MALDI	   matrix-­‐assisted	  laser	  
desorption/ionization	  
	   VLCFA	   very	  long-­‐chain	  fatty	  acids	  










	   	  
	  









	   	  




10.2 Amino	  acid	  sequences	  	  
	  








MA P A P P P AA S F T P A E VQR R L AAGACWVR RGA S L YD L T S F VRHHPGG EQL L L AR AGQD I S AD LDG P PHRH S
80 100 120 140
DNAR RWL E QY YVG E L R ADPQDP T E NGAVA S A E TQKTDP A L E PQ F KVVDWDKD L VDWQK P L LWQVGH LG E K
160 180 200
YDEWVHQP VAR P I R L FH SD L I E A F S KT VWY S V P I I WV P L V L Y L SWS Y YR T L TQDN I R L F A S L T R E Y SMMM
220 240 260 280
P E S V F I G L F V LGML FWT F V E YV I HR F L FHMK P P SN SHY L I MLH F VMHGQHHKAP FDG S R L V F P P V P A S L V
300 320 340
I A F F YV F L R L I L P E T VGG I I F AGG L LG YV L YDMTHY Y LH FG S P HKG S Y L YNMKAHHVKHH F E YQK SG FG I
360










MAA E DVVATGADP SD L E SGG L LH E I F T S P LN L L L LG L C I F L L YK I V RGDQP AA SGD SDDDE P P P L P R L KR
80 100 120 140
RD F T P A E L R R FDGVQDP R I LMA I NGKV FDVT KGR K F YG P E G P YGV F AGRDA S RG L AT F C LDK E A L KDE YD
160 180















MLQT L YDY FWWE R LWL P VN L TWAD L E DKDGR V YAKA SD L Y I T L P L A L L F L V I R Y F F E L YVAT P L AA L LNV
80 100 120 140
K E KT R L R A P PNAT L E H F YQT SGKQP KQV E VD L L S RQSG L SGRQV E RWF R R R RNQDR P S L L KK F R E A SWR F
160 180 200
T Y Y L I A F VAGMAVT VDK PWF YD L R KVWE GY P I Q S I I P SQYWY YM I E L S F YWS L L F S I A SDVKR KD F K E Q I
220 240 260 280
I HHVAT I I L L C F SWF ANYVR AGT L I MA LHDA SDY L L E S AKMFNYAGWKNTCNN L F I V F A I V F I I T R L V I M
300 320 340
P FW I LHCTM I Y P L E L Y P A F FG Y Y F FN FMMAV LQMLH I FWAY F I L RMAHK F I TGK L I E DE R SDR E E T E S S E
360 380






















MATAT E QWV L V EMVQA L Y E A P AYH L I L E G I L I LW I I R L L F S KT YK LQE R SD L T VK E K E E L I E EWQP E P L
80 100 120
V P P V P KDHP A LNYN I V SG P P SHKT VVNGK E C I N F A S FN F LG L LDNP R VKAAA L A S L KK YGVGTCG P RG F
160 180 200
YGT FDVH LD L E DR L AK FMKT E E A I I Y S YG F AT I A S A I P A Y S KRGD I V F VDRAAC F A I QKG LQA S R SD I K
220 240 260
L F KHNDMAD L E R L L K E QE I E DQKNP R KAR VT R R F I VV E G L YMNTGT I C P L P E L VK L K YK YKAR I F L E E S
300 320 340
L S FGV LG E HGRGVT E HYG I N I DD I D L I S ANMENA L A S I GG F CCGR S F V I DHQR L SGQGYC F S A S L P P L L
360 380 400
AAAA I E A LN I ME E NPG I F AV L K E KCGQ I HKA LQG I SG L KVVG E S L S P A FH LQL E E S TG S R E QDVR L LQE
420 440 460























MNNHV S S K P S TMK L KHT I N P I L L Y F I H F L I S L YT I L T Y I P F Y F F S E S RQE K SNR I KAK P VN S K PD S AYR S
80 100 120 140
VN S LDG L A S V L Y P GCDT LDKV F T YAKNK F KNKR L LGT R E V LNE E DE VQPNGK I F KKV I LGQYNWL S Y E DV
160 180 200
F VR A FN FGNG LQMLGQK P KTN I A I F C E T R A EWM I AAQAC FMYN FQL VT L YAT LGG P A I VHA LNE T E VTN I
220 240 260 280
I T S K E L LQT K L KD I V S L V P R L RH I I T VDGK P P TWS E F P KG I I VHTMAAV E A LGAKA SME NQPH S K P L P SD
300 320 340
I AV I MYT SG S TG L P KGVM I SH SN I I AG I TGMAE R I P E LG E E DV Y I G Y L P L AHV L E L S A E L VC L SHGCR I G
360 380 400 420
Y S S PQT L ADQS S K I KKG S KGDT SML K P T LMAAV P E I MDR I YKNVMNKV S EMS S FQRN L F I L A YNYKMEQ I
440 460 480
S KGRNT P L CD S F V F R KVR S L LGGN I R L L L CGGAP L S AT TQR FMN I C F CC P VGQGYG L T E S AGAGT I S E VW
500 520 540 560
DYNTGR VGAP L VCC E I K L KNWE E GGY FNTDK PHP RG E I L I GGQS VTMGY YKNE AKT KAD F F E DE NGQRWL
580 600 620
CTGD I G E F E P DGC L K I I DR KKD L VK LQAG E YV S LGKV E AA L KN L P L VDN I CAYAN S YH S YV I G F VV PNQK
640 660 680 700
E L T E L AR KKG L KGTWE E L CN S C EME NE V L KV L S E AA I S A S L E K F E I P VK I R L S P E PWT P E TG L VTDA F K L
720





10.3 Data	  files	  (DVD)	  
In	  the	  printed	  version	  of	  this	  thesis	  an	  envelope	  containing	  optical	  data	  media	  (DVDs)	  should	  be	  
found	  here.	  They	  contain	  the	  following	  supplemental	  data	  files:	  	  
• Unprocessed	  MaxQuant	  result	  text	  files	  (txt-­‐format)	  
• Processed	  protein	  groups	  lists	  (xxls-­‐format)	  
• Annotation	  analysis	  result	  lists	  (xxls-­‐format)	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